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Thesis summary 
Parkinson’s disease (PD) is commonly treated with L-DOPA. Long-term treatment is 
associated with the development of motor side effects such as L-DOPA induced dyskinesia 
(LID), and pathological changes in the striatal circuitry. However, while this circuitry is 
implicated in both motor and non-motor behaviour, little is known about the effects of long-
term L-DOPA treatment on non-motor function. This thesis used a rat model of PD and LID 
to test the hypothesis that long-term L-DOPA treatment also affects non-motor behaviour.  
Pharmacological studies typically utilise albino rats, while pigmented rats are 
preferred for operant studies. To guide later methodological decisions, Experiment 1 
compared pigmented Listed Hooded and albino Sprague Dawley rats’ motor, dyskinetic, or 
operant response to L-DOPA. As there were no gross strain differences, and Lister Hooded 
rats are preferred in operant studies, they were used in later experiments measuring both LID 
and operant behaviour. Experiment 2 aimed to identify appropriate lesion screening tests. 
Success of unilateral 6-OHDA lesions is commonly measured using amphetamine-induced 
rotations. However, amphetamine interferes with goal-directed behaviour. The ability of 
amphetamine-induced rotations and four non-pharmacological motor tests to accurately 
identify lesion rats was therefore compared. The non-pharmacological spontaneous rotations 
and cylinder tests were identified as robust screening tests and used in later experiments.  
L-DOPA competes with dietary amino acids for transport across the blood-brain 
barrier, and chronic L-DOPA treatment sensitises dopamine receptors. It was therefore 
hypothesised that food restriction and chronic L-DOPA would both decrease the L-DOPA 
dose required to alleviate motor symptoms in the rat 6-OHDA model. Chapter 4 describes 
two dose response curves testing the effect of food restriction and chronic L-DOPA on the 
motor response to acute L-DOPA in rats with intra-striatal or MFB lesions. Chronic L-DOPA 
increased the motor response to acute L-DOPA in the MFB, but not intra-striatal, lesion 
model. Conversely, food restriction increased the motor response to acute L-DOPA in the 
intra-striatal, but not MFB, lesion model. Chapter 5 used microdialysis to test the hypothesis 
that the increased motor response following food restriction was caused by an increased 
influx of L-DOPA to the striatum. The data did not support the hypothesis but suggested that 
food restriction affects baseline neurotransmitter levels in the 6-OHDA lesion rat.  
Chapter 6 tested the hypothesis that LID onset, by disrupting cortico-striatal synaptic 
plasticity which is implicated in motor skill learning, impairs acquisition of novel motor skills 
by measuring rats’ performance on the staircase task. While an initial experiment suggested 
that chronic LID onset impaired lesion rats’ acquisition of the task, the phenomenon could 
not be replicated. Chapters 7 and 8 further explored the effect of chronic L-DOPA on non-
motor function using a lateralized choice reaction time task reliant on the striatal system. 
Chronic L-DOPA exacerbated a lesion induced accuracy deficit that has been hypothesised to 
reflect extinction. This deficit was linked to LID onset, rather than L-DOPA exposure per se. 
The data therefore expand on current knowledge by suggesting that the effects of chronic             
L-DOPA extends beyond inducing motor side effects to also affect non-motor function. 
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1. Introduction 
1.1 Overview of the general introduction 
Parkinson‟s disease (PD) is a movement disorder which, on a neurological level, is 
characterised by a gradual loss of dopaminergic neurons in the substantia nigra pars compacta 
(SNc) and abnormal alpha synuclein inclusions. Behaviourally, PD is characterised by motor 
symptoms including tremor, rigidity, akinesia, and postural instability as well as non-motor 
symptoms such as hyposomia and constipation. On a cognitive level, PD has been suggested 
to impair functions such as learning dependent on positive reinforcement and attention 
processes. This introduction will provide an overview of the history, symptoms, and 
neuropathology of PD, as well as known risk factors for developing the disease. It will 
thereafter describe common preclinical models and behavioural tests that are used to study 
PD and anti-parkinsonian drugs in the preclinical setting. Finally, the introduction will 
provide an overview of pharmacological treatments available to treat PD symptoms and 
common side effects of these.  
Particular emphasis will be placed on describing levodopa (L-DOPA) which is the 
gold standard treatment in PD. The introduction will describe the effects of acute L-DOPA on 
motor and non-motor function. Furthermore, it will describe how long-term treatment gives 
rise to motor complications in the majority of PD patients. It will thereafter describe how the 
onset of L-DOPA induced dyskinesia (LID), a common motor complication arising from 
long-term L-DOPA treatment, is associated with changes to striatal dopamine receptors and 
cortico-striatal synaptic plasticity.  
Whereas many studies have explored the effects of acute L-DOPA on both motor and 
non-motor function, the majority of studies exploring the effects of the long-term L-DOPA 
have focused solely on the motor side effects. However, LID onset is associated with 
pathological changes in the striatum, which is implicated in both motor function and non-
motor function. This suggests that the abnormal changes associated with the onset of LID 
may not only disrupt motor function, but also affect non-motor functions dependent on the 
same circuitry. This thesis project therefore tested whether long-term L-DOPA treatment 
impacts on non-motor behaviour mediated by the striatum using a rat model of PD.  
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1.2. History and disease overview 
The first comprehensive description of PD was provided by James Parkinson in his 1817 
monograph “An Essay on the Shaking Palsy”. Parkinson‟s description was based on six case 
studies and stated that patients exhibited:  
 
“Involuntary tremulous motion, with lessened muscular power, in 
parts not in action and even when supported; with a propensity to 
bend the trunk forwards, and to pass from a walking to a running 
pace: the senses and intellects being uninjured” (Parkinson, 1817, p.1) 
  
Parkinson (1817) further described how the first symptom patients recalled was a “slight 
sense of weakness”. As the disease progressed, patients began experiencing tremor in one 
limb, usually a hand or an arm, which spread to other muscle groups, usually the contralateral 
limb, within 12 months. The disease was furthermore associated with a sense of fatigue, a 
hunched posture, and a spread of the tremor. As the tremor and postural instability worsened, 
Parkinson (1817) noted that patients also began exhibiting difficulties walking, and an 
increased risk of falling. In addition, Parkinson (1817) noted an occurrence of non-motor 
symptoms such as disrupted sleep and hypo-functional bowels movements. Crucial for the 
scientific understanding of the disease, Parkinson (1817) hypothesised that the characteristic 
tremors were caused by dysfunction of the central nervous system rather than the muscles.  
The motor symptoms described by Parkinson (1817) are similar to what are now 
considered the cardinal symptoms of PD: involuntary tremor, rigidity, akinesia or 
bradykinesia, and postural instability (e.g. Jankovic, 2008). In addition, PD also causes a 
range of non-motor symptoms including REM sleep disruptions, fatigue, excessive daytime 
sleepiness, hypoactive bowel movements, bladder dysfunction, pain, autonomic dysfunction, 
dysphagia, and an impaired sense of smell (Siddiqui et al, 2002; Chaudhuri et al, 2006; 
Haehner et al, 2009; Ziemssen & Reichmann, 2010a,b; Chaudhuri et al, 2011). These non-
motor symptoms of PD often occur prior to the onset of motor impairments (reviewed in 
Chaudhuri et al, 2006; Hawkes et al, 2010) and are perceived by patients as directly 
decreasing their quality of life (Politis et al, 2010).  
In addition, PD also affects psychological and cognitive functions. PD is associated 
with a higher prevalence of anxiety, apathy, depression, and dementia than observed in the 
general population (Slaughter et al, 2001; Chaudhuri et al, 2006; van der Hoek et al, 2011). 
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In addition, PD patients show deficits related to frontal lobe dysfunction. These include 
impaired performance on tasks measuring executive function, such as the Wisconsin Card 
Sorting Task and reversal learning tasks; which both depend on patients‟ ability to alter their 
response strategies according to external feedback (Cooper et al, 1991; Swainson et al, 2000; 
Chaudhuri & Schapira, 2009; Kehagia et al, 2010). The Wisconsin Card Sorting Task relies 
on the prefrontal cortex, the parietal lobe, and the striatum (Berman et al, 1995: Shafritz et al, 
2005). Similarly, reversal learning has been shown to rely in the prefrontal cortex, striatum, 
and orbito-frontal cortex (Kehagia et al, 2010). Hence, in addition to the motor symptoms 
traditionally associated with PD the disease also disrupts higher functions reliant on the 
frontal-striatal circuitry. 
1.3. The basal ganglia 
1.3.1. The healthy basal ganglia 
PD is presently considered predominantly a basal ganglia disorder. The following section will 
provide an overview of the basal ganglia circuitry in a healthy brain before describing how 
the system is affected by PD in section 1.3.2. 
The basal ganglia are a group of interconnected nuclei located in the midbrain that 
share connections with the cortex, thalamus, and brainstem. The main components are the 
caudate putamen complex (known as the striatum in rodents), the globus pallidus internal 
(GPi) and external (GPe) segments, the subthalamic nucleus (STN), the SNc, and the 
substantia nigra pars reticulata (SNr; Alexander & Crutcher, 1990).  
The complex interconnections of the basal ganglia are commonly described using the 
classic direct/indirect pathway model (Figure 1.1). While more complex versions of the 
model have been developed since the original model, the classic direct/indirect pathway 
model has remained valuable in describing the basic structure and function of the basal 
ganglia and is therefore still in use. According to the classic model, the striatum receives 
excitatory glutamatergic input from the cortex, along with modulatory, dopaminergic input 
from the SNc. Information is then relayed to the GPi and SNr, the basal ganglia output 
centres, via either the direct or the indirect pathway.  
In the direct pathway, GABAergic neurons containing dynorphin and substance P and 
expressing D1-type (i.e. D1 and D5) dopamine receptors relay information directly from the 
striatum to the GPi and SNr (the basal ganglia‟s output centre) via inhibitory projections. The 
GPi and SNr are connected to the thalamus via inhibitory GABAergic projections. The 
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thalamus, in turn, is connected with the motor cortex via excitatory glutamatergic neurons. 
Activation of the direct pathway results in inhibition of the GPi and SNr. This stops the 
inhibitory effect these structures otherwise exert on the thalamus, thereby increasing the 
thalamic input to the motor cortex. Hence, the net effect of direct pathway activation is an 
increased activity in the motor cortex and increased motor behaviour (Alexander & Crutcher, 
1990; Gerfen et al, 1990; Smith et al, 1998). 
In the indirect pathway, inhibitory projections consisting of GABAergic, enkephalin 
containing neurons expressing D2-type (i.e. D2, D3, and D4) dopamine receptors project 
from the striatum to the GPe. The GPe, in turn, projects to the STN via further inhibitory, 
GABAergic projections. Finally, the STN sends an excitatory glutamatergic projection to the 
GPi and SNr. Activation of the indirect pathway inhibits neuronal activity in the GPe. By 
decreasing the inhibitory effect that the GPe otherwise exerts on the STN, this ultimately  
 
 
Figure 1.1. A graphical representation of the direct and indirect pathway of the basal 
ganglia in a healthy brain. GPe=Globus pallidus external segment, GPi=Globus pallidus 
internal segment, SNc=Substantia nigra pars compacta, SNr=Substantia nigra pars 
reticulata, STN=Subthalamic nucleus. 
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causes disinhibition of the STN. When disinhibited, the STN exerts an excitatory 
glutamatergic influence on the GPi and SNr. Increasing the activity of the GPi and SNr in 
turn increases the inhibitory effect these structures exert on the thalamus - which in turn 
decreases the excitatory input the thalamus exerts on the cortex. Ultimately, this results in 
decreased activity in the motor cortex and reduced motor behaviour. The direct and indirect 
pathways thus work in parallel, causing excitation and inhibition of motor cortex respectively 
(Alexander & Crutcher, 1990; Gerfen et al, 1990; Smith et al, 1998). 
1.3.2. The basal ganglia in Parkinson’s Disease 
PD is characterised by a progressive loss of dopaminergic neurons in the SNc (Ehringer & 
Hornykiewicz, 1960). By the time motor symptoms appear approximately half of the 
dopaminergic SNc neurons have degenerated, a decrease which correlates with symptom 
severity and is significantly greater than would be expected in normal ageing (Scatton et al, 
1983; Fearnley & Lees, 1991). The SNc forms an integral part of the basal ganglia network 
and the dopamine loss that occurs in PD disrupts the balance that otherwise exists between 
the direct and indirect pathways. The following section will provide an overview of these 
pathological changes and their involvement in PD motor symptoms.  
Dopamine modulates striatal GABA transmission via D1 and D2 receptor binding. 
Binding to D1 type receptors excites, whereas binding to D2 type receptors inhibits striatal 
neurons (Girault et al, 1986; Yamamoto & Davy, 1992). The extensive dopamine loss 
occurring in PD decreases D2 mediated inhibition of GABA transmission, which in turn 
results in over-activity in the D2 expressing indirect pathway (Emir et al, 2012; Lindefors et 
al, 1989). Simultaneously, the decreased dopamine levels observed in PD decreases binding 
to D1 receptors, which leads to reduced activity in the D1 expressing direct pathway of PD 
patients (Obeso et al, 2000). Together, these changes in the activity in the direct and indirect 
pathway increase excitation of the SNr and GPe. This in turn enhances their inhibition of the 
thalamus, and, ultimately, reduces the excitatory input to the motor cortex. These changes, 
and their ultimate inhibitory effect on the motor cortex, are believed to underlie the impaired 
motor function observed in PD (Figure 1.2; Wichmann & DeLong, 1996; Obeso et al, 2000; 
Blandini et al, 2000). Support for the hypothesis of an imbalance between the direct and 
indirect pathways in PD is provided, for example, by data demonstrating decreased levels of 
the direct pathway peptide substance P, and increased mRNA levels of the indirect pathway 
peptide enkephalin in the caudate of PD patients (Fernandez et al, 1992; Nisbeth et al, 1995). 
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Whilst the classic direct and indirect pathway model has been highly influential in the 
field of PD research, it should be noted that the model has been criticised for being over- 
simplistic. For example, contrary to the model, some striatal neurons are believed to co-
express D1 and D2 receptors and a subpopulation of them also appears to project to both 
pathways. This challenges the view that the direct and indirect pathways are anatomically and 
chemically distinct (Parent et al, 2000). Neither does the classical model incorporate the more 
recently identified hyperdirect pathway. This is a cortico-subthalamic pathway that is 
believed to exert similar excitatory effects on the GPi and SNr as the indirect pathway, but 
the effects of which occur faster as the hyperdirect pathway acts directly on the GPi/SNr 
instead of being diverted via the striatum and GPe (Wichmann et al, 2011).  
 
 
Figure 1.2. The basal ganglia in Parkinson‟s disease. Shadowed lined represent a PD 
induced increase in the strength of a connection and dotted lines a PD induced decrease 
in the strength of a connection. GPe=Globus pallidus external segment, GPi=Globus 
pallidus internal segment, SNc=Substantia nigra pars compacta, SNr=Substantia nigra 
pars reticulata, STN=Subthalamic nucleus. 
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1.4. Alpha-synuclein pathology 
In addition to an imbalance between the direct and indirect pathways, PD patients also 
present with Lewy body pathology. Lewy bodies contain abnormal alpha synuclein 
aggregations as well as abnormally phosphorylated neurofilaments and ubiquitin, and are 
found in multiple locations in PD patients‟ central nervous system (Spillantini et al, 1998; 
Braak et al, 2003; Braak & Braak, 2000). Since the discovery of Lewy bodies in PD, these 
have gained increasing attention and it has been proposed that PD progression can be rated 
according to the spread of Lewy body pathology (Braak et al, 2003). The proposed rating 
scale divides PD progression into six steps with Lewy body pathology being restricted to the 
medulla oblongata in step 1, and spreading to the pontine tegmentum, the midbrain, basal 
procephalon & mesocortex, and neocortex in steps 2-6 respectively (Braak et al, 2003). This 
proposed model is supported by clinical data showing that alpha-synuclein pathology is 
capable of spreading from affected to healthy neurons (Hawkes et al, 2007; Li et al, 2008; 
Hansen et al, 2011). This ability of Lewy bodies to spread from affected to healthy neurons 
has also raised the question of whether or not PD is a prion disease. However, it should be 
mentioned that this hypothesis has been contested based on differences in the manner in 
which the alpha synuclein pathology spreads in PD and acknowledged prion diseases (Hiker 
et al, 2011).  
The precise mechanisms underlying Lewy body formation and their involvement in 
dopaminergic cell death are still unknown. It has been suggested that the alpha-synuclein 
aggregations interact with dopamine and mitochondrial activity to increase reactive oxygen 
species, which in turn leads to cell death (Perez et al, 2002; Maguire-Zeiss et al, 2005).  A 
causal role of Lewy bodies in cell death has been suggested by preclinical data showing 
impaired motor function, decreased striatal dopaminergic terminals, and Lewy Body 
resembling inclusions in the cortex, hippocampus, and SNc of transgenic mice over-
expressing alpha synucein (Masliah et al, 2000). However, with later publications failing to 
replicate these findings (Matsuoka et al, 2011; Rathke-Hartlieb et al, 2001), it has yet to be 
determined whether the Lewy bodies observed in PD are indeed causal for the dopaminergic 
cell death, secondary to another pathological feature of the disease, or part of the central 
nervous system‟s protective response (Maguire-Zeiss et al, 2005; Ross & Poirier, 2005).  
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1.5. Risk factors for Parkinson’s disease 
1.5.1. Genetic risk factors 
PD is not considered to be a monogenetic disorder. However, current data suggest that 
mutations to parkin, and PTEN-induced putative kinase 1 (PINK1), and leucine-rich repeat 
kinase 2 (LRRK2) all increase the risk for developing PD (Mata et al, 2006; Lücking et al, 
2000; Valente et al, 2004a).  
The parkin gene, first described by Kitada and colleagues (1998), has been associated 
with early onset PD. One cohort study identified a parkin mutation in 18% of participants 
diagnosed with PD, and in 49% of non-diagnosed relatives. Amongst the PD patients 
included in the study, the parkin mutation was most common in individuals with young-onset 
PD (Lücking et al, 2000). Parkin is believed to contribute to PD via its involvement in the 
cellular response to mitochondrial damage (Narendra et al, 2008) and the ubiquitin 
proteasome system (UPS) (Sherman & Goldberg, 2001; Betarbet et al, 2005). Post-mortem 
data have demonstrated that the UPS system is impaired in the SNc of PD patients 
(McNaught et al, 2003). Parkin interacts with the UPS system by ubiquinating damaging 
proteins, such as misfolded alpha synuclein, that are targeted for UPS-mediated degradation 
and thereby aids their removal (Sherman & Goldberg, 2001; Betarbet et al, 2005). Following 
UPS inhibition, in vitro data have shown increased alpha synuclein inclusions in ventral 
mesencephalic neurons and decreased survival of dopaminergic neurons (McNaught et al, 
2002). Together, the data therefore suggest that mutations to parkin may increase 
predisposition to PD both by impairing mitochondrial function and by inducing dysregulation 
of protesome function, which may ultimately contribute to the alpha synuclein pathology and 
dopaminergic cell loss that is characteristic of PD (Spillantini et al, 1998; Braak & Braak 
2000).  
Parkin is believed to act downstream of another gene also associated with PD; PINK1 
(Clarke et al, 2006). Like parkin, PINK1 is associated with early onset PD with one study 
demonstrating PINK1 mutations in 7% of patients diagnosed prior to the age of 50 (Valente 
et al, 2004a). The gene is believed to be part of the cellular response to stress, with cells 
expressing the mutation showing mitochondrial dysfunction and apoptosis when exposed to 
oxidative stress (Valente et al, 2004b).  
PD is also associated with mutations to LRRK, which interacts with the parkin gene 
(Smith et al, 2005). LRRK2 mutations are believed to be present in 6-40% of familial and 
approximately  3% of sporadic PD cases, depending on ethnicity (Mata et al, 2006), and are 
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predominantly associated with late onset PD (Zimprich et al, 2004). Mutations to the gene 
have been shown to increase the percentage of human neuroblastma SH-SY5Y cells 
undergoing apoptosis in response to cellular stress, a phenomenon which is believed to be 
caused by a LRRK2 interaction with the caspase 3, mitochondria dependent, apoptosis 
pathway (Iaccarino et al, 2007). Furthermore, data from aged LRRK2 knockout mice have 
shown that loss of LRRK increases the levels of ubiquinated proteins and alpha synuclein in 
the kidneys, which are known to have high concentration of LRRK2 mRNA relative to other 
organs (Tong et al, 2010). This has led to the hypothesis that LRRK2 mutations, like Parkin 
mutations, contribute to the alpha synuclein pathology observed in PD patients by disrupting 
the UPS system (Tong et al, 2010). 
Whilst only a minority of individuals expressing LRRK2, parkin, or PINK1 mutations 
develop PD, the cited studies suggest that mutations affecting mitochondrial function and the 
UPS system may increase the risk of developing PD.  
1.5.2. Environmental risk factors 
In addition to genetic predispositions, clinical and preclinical studies have also identified a 
range of environmental risk factors that are believed to increase the risk for PD. The most 
prominent environmental risk factor is exposure to specific herbicides or insecticides (Gorell 
et al, 1998). Two toxins that have received particular attention are rotenone and paraquat. 
Systemic administration of the pesticide rotenone has been shown to cause mitochondrial 
complex I inhibition, impair protosomal function, induce alpha-synuclein inclusions in 
dopaminergic neurons, cause loss of dopamine neurons, and cause  motor deficits in rats 
(Betarbet et al, 2000; Derek & Patel, 2008). Similarly, systemic administration of the 
herbicide paraquat has been shown to decrease survival of dopaminergic neurons and impair 
locomotor activity, as well as inducing alpha-synuclein aggregations in mice (Brooks et al, 
1999; Manning-Bog et al, 2002).  
The studies cited in this and the previous (1.5.1) section demonstrates the presence of 
both genetic and environmental risk factors for PD. With neither being able to account for all 
cases of PD, the cause of the disease remains unknown. Instead, it is yet to be determined 
whether PD arises from an interaction between genetic and environmental factors, or if 
genetic and environmental risk factors give rise to different subtypes of the disease. 
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1.6 Experimental models of Parkinson’s Disease 
Whilst PD is not known to occur spontaneously in other species, aspects of its pathology may 
be mimicked in preclinical models. Commonly used models capture the alpha synuclein 
pathology observed in PD, genetic mutations linked to the disease (e.g. LRRK2, PINK1, and 
Parkin), or induce dopamine loss via administration of pharmacological agents or 
neurotoxins. While there is a range of preclinical models of PD available (reviewed in e.g. 
Duty & Jenner, 2011), the following sections will describe some of the most common 
preclinical models before focusing on the 6-hydroxy-dopamine (6-OHDA) rat model which 
was used in this thesis project, and its use in dyskinesia research. 
1.6.1. Models of alpha-synuclein pathology 
In addition to SNc dopamine loss, PD is characterised by the presence of Lewy bodies. 
Findings of alpha-synuclein aggregations within Lewy bodies (Spillantini et al, 1997), and an 
association between mutations to the alpha synuclein gene and familial PD (Polymeropoulos 
et al, 1997) encouraged the development of preclinical models mimicking the alpha synuclein 
pathology observed in PD. In 2000, Mashlia and colleagues demonstrated that over-
expression of wild-type human alpha-synuclein in mice caused a loss of striatal dopamine 
and motor deficits. Unfortunately, the effect on motor function has not always been 
replicable, limiting the use of this specific model in studies on the effect of alpha synuclein 
on motor function (Matsuoka et al, 2011; Rathke-Hartlieb et al, 2001). However, in addition 
to motor deficits, a separate line of research has found that transgenic mice over-expressing 
alpha-synuclein exhibit hyposmia (Fleming et al, 2008), an important non-motor symptom of 
the disease (Haehner et al, 2009; Politis et al, 2010). Hence, transgenic models of alpha 
synuclein over-expression may be useful for studying the effect of alpha synuclein inclusions 
on certain non-motor symptoms of PD. 
As an alternative to transgenic models, the alpha-synuclein pathology observed in PD 
may also be mimicked by stereotactic infusion of viral vectors expressing mutated alpha-
synuclein. This has been shown to induce alpha-synuclein aggregations, loss of dopaminergic 
neurons, and impaired motor performance in rats with a SNc dopamine loss of approximately 
60% (Lo-Bianco et al, 2002; Kirik et al, 2002). Whilst not widely used, infusion of vectors 
carrying human alpha-synuclein has also been combined with rotenone exposure to produce a 
model exhibiting greater motor impairments (Mulcahy et al, 2012). . 
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1.6.2. Models of genetic risk factors 
As described in section 1.5.1, the LRRK2, parkin, and PINK1 genes have all been linked to 
PD. These genes have been studied in a range of preclinical models, including transfected cell 
lines (e.g. Iaccarino et al, 2007; Narendra et al, 2008; Valente et al, 2004b), drosophila (e.g. 
Liu et al, 2008; Poole et al, 2008; Yang et al, 2006), and mice (e.g. Li et al, 2009; Itier et al, 
2003; Gispert et al, 2009).  
Over-expressing LRRK2 in drosophila affects mitochondria function, as indicated by 
an increased sensitivity to the mictochondria complex I inhibitor rotenone (Ng et al, 2009). 
Furthermore, over-expression of human and mutant LRRK2 in drosophila causes a loss of 
dopaminergic neurons and motor deficits such as reduced climbing ability and spontaneous 
locomotor activity (Ng et al, 2009; Liu et al, 2008). The climbing deficit can be alleviated by 
acute administration of the dopamine precursor L-DOPA (Liu et al, 2008), suggesting that 
the LRRK2 drosophila may be used for screening antiparkinsonian drugs. LRRK2 has also 
been oveexpressed in transgenic mouse models, where it has been shown to increase alpha 
synuclein aggregation, induce neuronal loss in the prefrontal cortex and dorsal striatum, and 
decrease spontaneous activity and rearing behaviour (Lin et al, 2009). Similar to the 
drosophila model, the reduced spontaneous motor activity in transgenic mice has been shown 
to improve following acute L-DOPA treatment (Li et al, 2009).  
The PINK1 gene has also been studied in transgenic models of PD. In drosophila, 
inactivation of PINK1 impairs mitochondrial activity, induces loss of dopaminergic neurons, 
and reduces flight ability (Yang et al, 2006: Park et al, 2006).  Mitochondrial dysfunction has 
also been observed in a PINK1 transgenic mouse model (Gispert et al, 2009). While, unlike 
the drosophila, these transgenic mice did not show a loss of dopaminergic neurons, they 
exhibited decreased striatal dopamine levels and a reduction in their spontaneous locomotor 
activity - changes which were hypothesised to be caused by disrupted dopamine 
neurotransmission (Gispert et al, 2009). It is uncertain whether the motor symptoms 
expressed by PINK1 transgenic mice can be reversed or ameliorated by L-DOPA, as is the 
case in other transgenic models (Dawson et al, 2010), although there are indications that      
L-DOPA treatment may restore abnormal spontaneous GABA currents that are observed in 
PINK1 knockout mice (Dehorter et al, 2012). 
Transgenic models of parkin have also been developed. In drosophila, loss of parkin 
function reduces dopamine levels, and causes a climbing deficit which can be ameliorated by 
acute L-DOPA administration (Cha et al, 2005). Conversely, over-expressing parkin in 
drosophila may alleviate or rescue the detrimental effects of other PD related mutations. For 
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example, in transgenic LRRK2 drosophila, co-expression of parkin reduces both the LRRK2 
induced degeneration of dopaminergic neurons and the neurodegenerative effect of rotenone 
exposure (Ng et al, 2009). Similarly, in transgenic drosophila with inactivated PINK1, over-
expression of parkin rescues mitochondria function, reduces the otherwise observed loss of 
dopaminergic neurons, and reverses the flies‟ climbing deficit (Yang et al, 2006: Park et al, 
2006). 
The effect of parkin on PD symptoms has also been modelled in knock-out mice. 
Whilst not showing a loss of dopaminergic neurons, parkin knock-out mice exhibit changes 
indicative of disruptions to the dopaminergic system such as an increase in limbic dopamine 
levels without an associated change in dopamine turnover, and decreased DAT and VMAT 
levels (Itier et al, 2003). Similar findings have been reported by other groups, who have 
shown that parkin knock-out mice have higher striatal dopamine levels than wildtype controls 
(Goldberg et al, 2003). These data have been suggested to reflect impaired control of 
dopamine release from nigral neurons (Itier et al, 2003; Goldberg et al, 2003). On a 
behavioural level, transgenic mice show impaired motor function, such as reduced 
spontaneous motor activity, making more slips than controls when walking across an elevated 
beam, and somatosensory impairments (Itier et al, 2003; Goldberg et al, 2003), as well as a 
decreased motor response to acute amphetamine administration (Itier et al, 2003).  
1.6.3. The MPTP model 
Neurotoxins are commonly used in the preclinical setting to induce a dopamine loss 
resembling the decreased dopamine levels observed in PD. One of the most commonly used 
toxins is MPTP.  
In the late 1970‟s and early 1980‟s, a number of American drug addicts were found 
with severe movement disruptions. Whilst the symptoms resembled those observed in PD, 
their rapid onset and the young age of the patients were uncharacteristic of idiopathic PD. 
Instead, it became apparent that the patients had previously self-administered what they had 
believed to be the recreational drug 1-Methyl-4-phenyl-4-propionoxypiperidine (MPPP) but 
which had, due to poor synthesis, in fact been its precursor MPTP. Within one week of 
MPTP administration, the patients began exhibiting akinesia, rigidity, and difficulties 
speaking (Langston et al, 1983). Improvement of the symptoms following administration of 
the anti-Parkinsonian drug L-DOPA and a D2 agonist suggested that the akinesia was caused 
by a dopamine deficiency, something which was confirmed by PET imaging and post-
mortem examination (Davis et al, 1979; Langston et al, 1983).  
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It is now known that MPTP is taken up by astroglia, where it is converted into 1-
methyl-4-phenyl-2,3-dihydropyridinium cation (MDPD+) and ultimately 1-methyl-4-
phenylpyridinium ion (MPP+) by monoamine oxidase (MAO). MPP+ is taken up by 
dopaminergic nerve terminals where it accumulates. Once inside the neurons, the toxin is 
believed to induce cell death by inhibiting mitochondrial activity, as well as by increasing 
intraneuronal calcium to toxic levels (Gerlach et al, 1991). In line with the case studies 
presented by Langston and colleagues (1983), systemic administration of MPTP has been 
shown to induce profound loss of dopamine, its metabolites, and serotonin in experimental 
settings (Gerlach et al, 1991; Johnston et al, 2010a; Lundblad et al, 2005). 
Today, MPTP is widely used in preclinical PD research. It is most commonly used to 
induce dopamine loss in mice and primates. It is not typically used in rats, where the central 
nervous system is able to clear MPTP and its metabolites more rapidly than in mice (Pileblad 
et al, 1985; Johannessen et al, 1985), and the effect of MPTP is therefore more variable. The 
MPTP induced motor symptoms may be alleviated by acute L-DOPA administration 
(Johnston et al, 2010a; Lundblad et al, 2005). Furthermore, long-term L-DOPA exposure in 
MPTP lesion mice and primates causes the onset of LID, a common side effect of long-term 
L-DOPA treatment in patients that is further described in section 1.8.3. In MPTP models, 
LID may be reduced by the clinically available anti-dyskinetic drug Amantadine (Blanchet et 
al, 1998; Lundblad et al, 2005), suggesting MPTP models are valid preclinical model of LID. 
In addition to motor symptoms, MPTP has been used to mimic non-motor symptoms of PD 
such as reduced REM sleep (Barraud et al, 2009), constipation (Natale et al, 2010), hyper-
reflexive bladders that result in more frequent spontaneous emptying of bladders than in 
healthy animals (Albanese et al, 1988), and cognitive deficits in the form of impaired delayed 
alternation (Schneider & Kovelowski, 1990).  
Whether MPTP administration can mimic the alpha synuclein pathology observed in 
PD remains under debate with such inclusions being reported in some but not all MPTP 
studies and, when present, being qualitatively different from human Lewy bodies (Meredith 
et al, 2002; Vila et al, 2000; Shimoji et al, 2005).  
1.6.4. The 6-hydroxy-dopamine model 
In rats, PD motor symptoms are most commonly induced by infusing the neurotoxin             
6-OHDA along the nigrostriatal pathway: typically the SNc, striatum, or the medial forebrain 
bundle (MFB). The applicability of 6-OHDA to PD research was first recognised in the late 
1960‟s, when Ungerstedt (1968) discovered that infusion of the toxin into dopamine rich 
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regions caused dopaminergic and noradrenergic cell death. 6-OHDA is believed to induce 
cell death via at least two separate routes. First, inhibition of complex I disrupts the 
mitochondrial respiratory chain, which in turn is believed to disrupt the mitochondrial 
membrane potential and increase reactive oxygen species (ROS). Second, it is believed that 
further interaction between 6-OHDA and MAO causes auto-oxidation of the toxin, as well as 
generating damaging ROS (Glinka & Youdim, 1995; Blum et al, 2001).   
6-OHDA is unable to cross the blood brain barrier and is therefore delivered to the 
neural region of interest via stereotaxic surgery. 6-OHDA lesions are commonly only induced 
unilaterally, as bilateral dopamine denervation is associated with aphagia, adipsia, and weight 
loss (Zigmond & Stricker, 1972; Sakai & Gash, 1994). Following unilateral infusion to the 
dopaminergic system a hemi-Parkinsonian model is created, where akinesia is predominantly 
exhibited in the limbs contralateral to the lesion (e.g. Whishaw et al 1997, Olsson et al, 
1995). The 6-OHDA lesion has also been used to study non-motor effects of dopamine 
denervation such as sensorimotor functions and the accuracy with which lesion rats respond 
to a conditioned stimulus (CS) in a lateralised choice-reaction time task (Carli et al, 1985;  
Dowd & Dunnett, 2004, 2007), which is further described in section 1.6.7.1.  
The akinesia exhibited in the 6-OHDA model can be alleviated by common 
antiparkinsonian drugs such as L-DOPA, dopamine agonists, and MAO inhibitors (Lundblad 
et al, 2002; Marin et al, 2007; MacInnes & Duty, 2004; Olsson et al, 1995; Lindgren et al, 
2007). As described in the following section, the model is also widely used to study LID. 
1.6.5. Modelling dyskinesia in the 6-hydroxy-dopamine model 
PD motor symptoms are commonly treated by acute administration of the dopamine 
precursor L-DOPA. However, as further discussed in section 1.8.3, long-term L-DOPA 
treatment often leads to onset of the motor side effect LID. LID may also be induced in        
6-OHDA lesion rats, where the dyskinetic movements are referred to as abnormal involuntary 
movements (AIMs). 
Repeated administration of L-DOPA causes a gradual development of AIMs in the 
majority of rats with extensive 6-OHDA lesions to the dopaminergic system (Winkler et al, 
2002). The AIMs manifest themselves when lesion rats are on L-DOPA, and their magnitude 
plateau after approximately 2 weeks of daily injections, depending on dose (e.g. Lundblad et 
al, 2002; Winkler et al, 2002). The dyskinetic movements exhibited in the rat model include 
axial AIMs characterised by a twisting of the torso towards the side contralateral to the 
lesion, that in severe cases causes a loss of balance (Figure 1.3A), forelimb AIMs that are 
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manifested in the form of purposeless movements of the forelimb contralateral to the lesion 
(Figure 1.3B), and orolingual AIMs which include either a chewing motion or in more severe 
cases protrusions of the tongue (Figure 1.3C ; Cenci et al, 1998; Winkler et al, 2002).  
 
 
Figure 1.3. Stillshots of a rat with a unilateral 6-OHDA lesion exhibiting axial (a), forelimb 
(b), and orolingual (c) AIMs following an acute injection of L-DOPA. AIMs=Abnormal 
involuntary movements. Reprinted from Winkler et al (2002).  
 
The AIMs expressed by rats with unilateral 6-OHDA lesions can be measured using 
different rating scales (Breger et al, 2013). The original rat AIMs scoring protocol was 
developed by Cenci and colleagues (1998) and classified movements as “abnormal” if they 
were (i) L-DOPA induced, (ii) affected the side of the body contralateral to the 6-OHDA 
lesion, and (iii) were repetitive, purposeless, and not exhibited in the normal rat behavioural 
repertoire. Cenci et al (1998) scored rats for 1 min, every 20 min, and rated axial, forelimb, 
and orolingual AIMs on a scale from 0 to 4 depending on the length of time the AIM was 
exhibited during each 1 min scoring point (0=never, 1=less than 50% of the time, 2=more 
than 50% of the time, 3=continuously but could be interrupted by sudden noises, 
4=continuously and could not be interrupted by sudden noises; Cenci et al, 1998). In 
addition, Cenci and colleagues (1998) rated locomotive AIMs, classified as an increased 
locomotive behaviour towards the contralateral side, using the same point scale. However, 
since the original scale was described, later publications have queried the validity of the 
locomotive AIMs. Locomotive AIMs are not reduced by drugs that have anti-dyskinetic 
effects in the clinic, and that reduce other rat AIMs subtypes (Lundblad et al, 2002), thus 
suggesting that they are not a good model for human LID. The original rating scale has also 
been extended by Winkler and colleagues (2002) to score AIMs according to their severity as 
well as the duration, thereby increasing the sensitivity of the scale.  
Since its development, the validity of the 6-OHDA rat dyskinesia model has been 
supported by data showing that (i) just as in human LID, rat AIMs are induced by L-DOPA 
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but not D2 agonists, (ii) just as in human LID, there is a correlation between AIMs and 
FosB/ΔFosB upregulation, and (iii) that AIMs decrease following administration of the only 
clinically available anti-dyskinetic drug, Amantadine (Lundblad et al, 2002; Andersson et al, 
1999; Lindgren et al, 2011; Breger et al, 2013).  
1.6.6. Testing motor function in the unilateral 6-OHDA lesion model 
To provide a background to the experimental chapters presented in this thesis, the following 
sections will provide an overview of behavioural tests that were used in the thesis project to 
study motor and non-motor function in the unilateral 6-OHDA rat model of PD. Further 
information on the manner in which the tests were conducted is provided in Chapter 2. 
1.6.6.1. Rotational bias as a measurement of dopamine denervation 
When first describing the effect of 6-OHDA infusion on dopaminergic cells, Ungerstedt 
(1968) reported that rats with unilateral lesions to the dopaminergic system spontaneously 
turned towards the side of the lesion. The degree of turning behaviour was related to the 
extent of dopaminergic denervation, and driven by asymmetry between dopamine levels in 
the intact and lesion striata (Ungerstedt, 1968). The finding was replicated in a subsequent 
study which also demonstrated that the rotational bias could be enhanced by acute 
administration of amphetamine (Ungerstedt & Arbuthnott, 1970); a drug which causes release 
of presynaptic dopaminergic vesicles whilst inhibiting DAT activity and thus increases 
striatal dopamine levels (Sulzer et al, 2005). Following unilateral 6-OHDA lesions, fewer 
dopaminergic terminals are present in the lesion than the intact striata, which causes the vast 
majority of amphetamine induced dopamine release to occur in the intact striata. This 
exacerbates the dopamine imbalance between the hemispheres, and thereby enhances the 
ipsilateral rotational bias that is observed following unilateral dopamine depletion 
(Ungerstedt, 1968; Ungerstedt & Arbuthnott, 1970). Acute amphetamine may induce a 
rotational bias in rats with a striatal dopamine loss as low as 50% relative to the intact striata, 
although not all lesion rats rotate at this level of depletion (Hefti et al, 1980). Amphetamine 
induced rotations are commonly used post-lesion to assess the success of 6-OHDA lesions, 
with pre-determined cut-off points often being applied to identify rats with extensive 
dopamine loss (Fornaguera et al, 1994). The test has been used to screen lesion success 
following unilateral 6-OHDA lesions to the SNc (e.g. Ungerstedt & Arbuthnott, 1970), the 
striatum (e.g. Barneoud et al, 2000), and the MFB (e.g. Torres et al, 2011).  
However, despite its widespread use, the amphetamine induced rotational bias does 
not correlate well with fine motor function (Metz & Whishaw, 2002). Whilst the reason for 
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this poor correlation has not been firmly concluded, it has been suggested that the SNc is 
organised in a somatotopographical manner and that lesions affecting e.g. skilled forelimb 
motor function do not affect whole body rotational behaviour (Metz & Whishaw, 2002). 
Therefore, crude pharmacological tests, such as amphetamine induced rotations, that are 
sensitive to large dopamine denervation might not be suitable for predicting skilled motor 
function and are of limited use when wishing to balance experimental groups in studies 
assessing finer motor skills. Further concerns regarding the value of amphetamine induced 
rotations as a lesion screening tool stem from findings that amphetamine exposure alters, for 
example, c-fos mRNA levels which are implicated in learning (Cadet et al, 2010), that it 
affects later neurochemical and motor responses to dopaminergic drugs (Vanderschuren et al, 
1999), and that it predisposes animals to acquire habitual rather than goal-directed behaviour 
when tested on operant tasks (Nelson & Kilcross, 2006; Nordquist et al, 2007).  
Other anti-parkinsonian drugs such as L-DOPA and dopamine agonists have also 
been shown to induce a rotational bias in the unilateral 6-OHDA model (e.g. Hefti et al, 
1980; Barneoud et al, 2000; Lundblad et al, 2002). The lesion striatum is less able to store the 
dopamine which is synthesised from L-DOPA than the intact striatum, and acute L-DOPA 
administration therefore causes greater extracellular dopamine levels in the lesion than intact 
striata, resulting in a contralateral rotational bias (Smith et al, 2010). Dopamine agonists such 
as apomorphine and bromocriptine cause contralateral turning by binding to postsynaptic 
receptors which are sensitised in the lesion but not the intact striatum (Hefti et al, 1980; 
Barneoud et al, 2000; Lundblad et al, 2002). However, despite their ability to induce a 
rotational bias post-lesion, the use of L-DOPA and dopamine agonists is not without its 
limitations when screening for 6-OHDA lesions. Repeated L-DOPA administration induces 
LID in the majority of 6-OHDA lesion rats (e.g. Winkler et al, 2002), and L-DOPA induced 
rotations are therefore inappropriate as a screening tool for studies comparing the behaviour 
of L-DOPA treated and drug naive rats, such as the experiments reported in Chapters 6-8. 
Apomorphine, the dopamine agonist most commonly used to screen 6-OHDA lesion success 
sensitises dopamine receptors (Gancher et al, 1995), and is not sensitive to dopamine loss 
<90% (e.g. Heft et al, 1980). The latter makes it an inappropriate screening method for 
lesions inducing a lesser depletion, such as the intrastriatal 6-OHDA lesions reported in 
Chapters 4 and 5. 
24 
 
1.6.6.2. Testing motor function in the unilateral 6-OHDA rat 
Following unilateral 6-OHDA lesions, the lesion induced motor impairments predominantly 
manifest themselves in limbs contralateral to the lesion. The discrepancy in ipsilateral and 
contralateral motor ability can be measured using a range of behavioural tests. Commonly 
used tests of motor asymmetry include the cylinder test, the adjusting step test, the vibrissae 
test, and the staircase test. 
The cylinder test (section 2.4.4) measures rats‟ spontaneous use of their ipsilateral and 
contralateral forelimbs when exploring a novel environment consisting of a transparent 
cylinder. During explorative behaviour, rats often rear up against the wall of the cylinder and, 
when doing so, commonly use their forelimbs to support themselves. Intact rats will use both 
their forelimbs to an equal extent, while lesion rats predominantly support themselves using 
their ipsilateral forelimb (Schallert et al, 2000). By measuring the extent to which rats use 
their ipsilateral and contralateral forelimbs during explorative behaviour, the cylinder test 
provides a measurement of the motor asymmetry induced by a unilateral lesion. While the 
test is sensitive to dopaminergic treatments such as L-DOPA and the D2 agonist 
bromocriptine (Lundblad et al, 2002), it is dependent on spontaneous explorative behaviour. 
This explorative behaviour may decrease following repeated exposure to the cylinder which 
limits the number of times the test can be used in the same animal.  
This problem is overcome in tests where movement is directly encouraged by the 
experimenter. Examples of such tests are the adjusting step (section 2.4.3) and vibrissae tests 
(section 2.3.8), which measure forelimb motor function and sensorimotor function 
respectively (Olsson et al, 1995; Woodlee et al, 2005). Both tests involve gentle restraint of 
the rat, followed by tactile stimulation of a forelimb or vibrissae, and recording of the 
behavioural response this stimulation evokes. In the adjusting step test the experimenter 
restrains either the ipsilateral or contralateral forelimb while simultaneously ensuring that the 
free forelimb is in gentle contact with a flat tabletop surface. The rat is then moved along the 
tabletop surface and the number of stepping motions the rat initiates using its free forelimb is 
measured. The same procedure is repeated following restriction of the other forelimb, and the 
number of adjusting steps a rat makes using the forelimb ipsilateral and contralateral to the 
lesion are compared (Woodlee et al, 2005).  
As in the adjusting step test, the vibrissae test also involves restraint of the forelimb 
ipsilateral or contralateral to the lesion by the experimenter. The rat is then moved in an 
upwards direction parallel to a bench top, so as to cause the rat‟s ipsilateral or contralateral 
whiskers to brush against the bench top. The test measures rats‟ ability to respond to whisker 
25 
 
stimulation by placing their free forelimb on the bench, and compares the number of 
responses made following stimulation of their ipsilateral and contralateral whiskers (Olsson 
et al, 1995).   
The above tests offer a measurement of crude motor function. Other behavioural tasks 
may be used in instances where finer motor skills are measured. These include qualitative 
rating of animals‟ movements (reviewed in Klein et al, 2012), and the staircase test (Montoya 
et al, 1991). The latter measures rats‟ and mice‟ ability to grasp and retrieve sucrose pellets in 
so called „staircase boxes‟ when using the forelimb ipsilateral or contralateral to the lesion 
(section 2.4.7). Unlike handtests, such as the adjusting step test and the vibrissae tests, or 
subjective rating scales, the staircase test holds the advantage of being free from experimenter 
bias. The movement sequence involved in picking up an object using a forelimb is highly 
similar between rats and people (Sacrey et al, 2009), suggesting that drug-induced 
improvement on the staircase and other reaching tasks may predict therapeutic relief in the 
clinic. 
1.6.7. Testing operant behaviour in the unilateral 6-OHDA lesion model 
Operant boxes are commonly used to measure cognitive functions in preclinical rat models as 
they remove experimenter bias, are capable of recording a range of parameters 
simultaneously, and may be programmed to be used for a variety of paradigms. A range of 
operant boxes are commercially available, including the nine-hole box (section 2.7.2; 
Robbins et al, 1993) where animals may respond to visual or auditory stimuli by nose-poking 
into an array of holes, and the two-lever „Skinner box‟ chamber (section 2.7.1, e.g. Döbrössy 
& Dunnett, 1997) where animals respond to visual or auditory stimuli by pressing lateralised 
levers.  
The majority of operant box tasks are designed for either intact rats, or rats with 
bilateral lesions. However, this thesis project used a unilateral 6-OHDA rat model of PD. To 
study the effects of acute and chronic dopaminergic medication on motor and non-motor 
function, it was therefore necessary to identify an operant paradigm which was (i) suitable for 
rats with unilateral lesions and (ii) able to dissociate between the effects dopamine 
denervation on motor and non-motor behaviour. One such task is the lateralised choice 
reaction time (LCRT) task which takes place in nine-hole operant boxes and is described in 
more detail below. 
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1.6.7.1. The lateralised choice reaction time task 
The lateralised choice reaction time (LCRT) task (section 2.7.2.2) was originally developed 
by Carli and colleagues (1985) to distinguish between visual neglect, movement initiation, 
and movement execution. The task requires rats to respond to illumination of a central hole 
by making, and maintaining, a centralised nose poke until a visual CS is presented on either 
the ipsilateral or contralateral side (Carli et al, 1985). In response to the CS, rats must make a 
lateralised nose poke to gain a pellet reward (Carli et al, 1985). Depending on the version of 
the LCRT task that is used, this response is either directed to the same hole in which the CS 
was presented („same‟ version) or the opposite lateralised hole („opposite‟ version; Figure 
1.4).  
 
 
Figure 1.4. A schematic overview of a nine-hole operant box with only three response 
holes are exposed as is the case in the LCRT task (A), and an example of correct 
responding in the „same‟ (B) and „opposite‟ (C) versions of the LCRT task. The rats are 
rewarded for responding to a central light cue by making a sustained nose poke in the 
central hole until the onset of a lateralised CS, upon which they must either respond in 
the same response hole the CS was presented in („same‟ version, B) or in the opposite 
response hole („opposite‟ version, C). Adapted from Dowd & Dunnett, 2005. 
CS=Conditioned stimulus; LCRT=Lateralised choice reaction time 
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The task provides four main outcome measures: usable trials, reaction time, 
movement time, and accuracy. „Usable trials‟ refer to the proportion of trials that rats 
complete by executing a lateralised nose poke in response to the lateralised CS. „Reaction 
time‟ refers to the time elapsed between the onset of a lateralised CS and discontinuation of 
the central nose poke. „Movement time‟ refers to the time elapsed between discontinuation of 
a central nose poke and the completion of a subsequent lateralised nose poke. Finally, 
„accuracy‟ refers to the proportion of usable trials in which rats direct their lateralised 
responses into the correct lateral hole following presentation of a lateralised CS. 
Using the LCRT task, Carli and colleagues (1985) found that rats that had been pre-
trained on the task prior to unilateral 6-OHDA lesions to the striatum exhibited increased 
reaction time and decreased accuracy when required to respond to contralateral CS by 
making contralateral nose pokes („same‟ version of the task). No deficit was observed when 
rats were required to respond to ipsilateral CS by making ipsilateral nose pokes (Carli et al, 
1985). A reaction time and accuracy deficit did, however, show when rats were tested on the 
„opposite‟ version of the task which required them to respond to contralateral CS by making 
ipsilateral nose pokes and vice versa. In this version of the test, the deficit manifested itself 
when rats were required to execute contralateral responses to ipsilateral cues. Hence, the 
deficit was not related to the position of the visual stimulus but rather the direction of the 
required motor response. Furthermore, when altering the task so that the rats‟ response to a 
visual cue consisted of making a full turn and pressing the panel on the opposite wall, thus 
allowing them to respond to contralateral cues by either an ipsilateral or a contralateral turn, 
the accuracy deficit that had previously been observed following 6-OHDA lesions 
disappeared (Carli et al, 1985). Together, the data suggested that the deficit was not due to an 
inability to detect the lateralised CS, but an impaired ability to initiate or execute contralateral 
movements following 6-OHDA lesions (Carli et al, 1985).  
The neurobiology of the deficit was explored in a subsequent study which compared 
the effects of 6-OHDA lesions to the nucleus accumbens (NAcc) and the striatum on 
performance on the „same‟ version of the LCRT task (Carli et al, 1989). The previous 
findings of a 6-OHDA induced deficit in contralateral reaction time and accuracy (Carli et al, 
1985) were replicated in rats with intrastriatal lesions but not in the NAcc lesion group (Carli 
et al, 1989). This led the authors to hypothesise that dorsal striatal dopamine is essential for 
rats‟ ability to initiate contralateral movements (Carli et al, 1989).  
 Based on the findings of Carli et al (1985, 1989), the LCRT task was later employed 
by Dowd & Dunnett (2004) as a means of studying the behavioural effects of ventral 
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mesencephalic tissue transplants on rats with unilateral 6-OHDA lesions to the MFB. In line 
with Carli and colleagues‟ original findings (1985, 1989), dopamine depletion impaired 
reaction time and accuracy when rats responded to contralateral cues by making contralateral 
responses („same‟ version). In addition, there was a bilateral increase in movement time that 
had not previously been reported. The appearance of a movement time deficit may have been 
due to the greater dopamine depletion induced by MFB lesions, relative to the intra-striatal 
lesions used by Carli and colleagues (1985, 1989). It may also have been due to the distance 
between the centre hole and the lateralised hole in which rats‟ responded to a CS, which was 
greater in Dowd & Dunnett‟s (2004) than in Carli and colleagues‟ (1985, 1989) experiments.  
Dowd & Dunnett‟s (2004) publication also differed from Carli and colleagues‟ (1985, 
1989) in the manner in which they illustrated the post-lesion behaviour. Whereas the 
publications by Carli and colleagues (1985, 1989) presented bar graphs showing the post-
lesion performance averaged across a block of testing, Dowd & Dunnett (2004) used line 
graphs to show the post-lesion behaviour as a function of time. When presenting the 
contralateral accuracy using a line graph it became apparent that the contralateral accuracy 
deficit manifested itself gradually (Dowd & Dunnett, 2004). Specifically, the lesion group 
was able to accurately respond to contralateral stimuli on the first day of post-lesion testing 
but thereafter displayed a gradual decrease in contralateral accuracy over the subsequent four 
days of testing. Interestingly, following a break from testing and reintroduction to the task 
eight weeks post-lesion, the accuracy of contralateral responding on the first day of testing 
returned to the initial post-lesion levels. Similar to what had previously been observed a 
gradual decline in contralateral performance was then observed over the following four days 
of testing. This phenomenon could not be explained by a continued loss of striatal dopamine 
since the lesion was complete at the time of testing. Furthermore, if the deficit was purely 
motor mediated the impairment would be expected to have been stable from the outset of 
post-lesion testing. Hence, the accuracy deficit could not be explained by Carli and 
colleagues‟ (1985, 1989) original hypothesis of an impaired ability to initiate contralateral 
movements (Carli et al, 1989; Brown & Robbins, 1989) 
The finding of a gradual decline in performance rather than a stable impairment was 
replicated in a subsequent experiment which compared the effects of unilateral 6-OHDA 
intra-striatal and MFB lesions on performance on the „same‟ version of the LCRT task 
(Dowd & Dunnett, 2005a). Both lesions caused a gradual impairment in contralateral reaction 
time, movement time, and accuracy when tested two weeks post-lesion, although the 
accuracy deficit was more pronounced in the MFB lesion group. When re-tested four months 
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post-lesion the intra-striatal lesion group seized showing a deficit in their reaction time, 
movement time, and accuracy while the MFB lesion group continued being impaired on all 
parameters. Interestingly, in line with previous findings, the contralateral accuracy of the 
MFB lesion returned to initial post-lesion testing levels on the first day of testing after which 
a second gradual decline in performance was observed (Dowd & Dunnett, 2005a). A follow-
up experiment, including rats with MFB or intra-striatal lesions, was conducted in which the 
„opposite‟ version of the LCRT task was used, i.e. where rats were required to respond to 
ipsilateral CS by making a contralateral response and vice versa. In this version of the task, 
both the MFB and intra-striatal lesion groups exhibited impaired accuracy when required to 
respond to ipsilateral stimuli by making a contralateral response (Dowd & Dunnett, 2005b). 
In contrast to the earlier findings, which were obtained using the standard „same‟ version of 
the task (Dowd & Dunnett, 2005a), this accuracy deficit remained stable in both lesion 
groups when re-tested four months post-lesion (Dowd & Dunnett, 2005b).  
From a methodological perspective, the described studies suggest that the standard 
„same‟ version of the LCRT task is appropriate for long-term experiments including rats with 
lesions to the MFB, but not to the striatum The difference between the two lesions‟ effect on 
LCRT task performance may be due to the extent of dopamine denervation they induce in the 
SNc or VTA, which is greater following a MFB than intra-striatal lesion, or the ability of the 
MFB lesions to also affect prefrontal dopamine levels (Dowd & Dunnett, 2005a).  
From a theoretical perspective, the most notable difference between Carli and 
colleagues‟ (19895, 1989) and Dowd & Dunnett‟s (2004, 2005a,b) publications was the 
demonstration of a gradually emerging contralateral accuracy deficit in the latter publications. 
In Dowd & Dunnett‟s (2004, 2005a,b) publications, this deficit disappeared on the first day 
of re-testing rats following a three months test-free interval. Dowd & Dunnett (2007) noted 
that this re-emergence of contralateral responding resembled „spontaneous recovery‟ of 
contralateral accuracy. „Spontaneous recovery‟ is one of the hallmarks of extinction. It refers 
to the tendency of a conditioned response (CR) to reappear in animals that have undergone 
extinction when these animals are reintroduced to the same task following a period of not 
being tested. In addition to „spontaneous recover‟, extinction is also associated with 
„reinstatement‟ and „renewal‟. „Reinstatement‟ refers to the re-appearance of a CR in animals 
exposed to the US between extinction and retention testing. „Renewal‟ refers to the tendency 
of a CR to reappear in animals that have undergone extinction when retested in a different 
environment (Myers & Davis, 2002). Based on the gradual decline in contralateral accuracy, 
which was similar to what occurred when physically removing the sucrose pellet reward 
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following a correct contralateral response (Dowd & Dunnett, 2007), and the „spontaneous 
recovery‟ like re-emergence of responding that was observed when lesion rats were retested 
after a test-free interval, Dowd and Dunnett (2007) hypothesised that the contralateral 
accuracy deficit observed in lesion rats represented extinction. This was hypothesised to be 
driven by an ablation of the dopaminergic reward signal that otherwise occur following 
presentation of a US (Schultz, 2010) in the lesion rats.  
The LRCT task data reviewed above demonstrate the presence of motor deficits in the 
form of increased reaction and movement times following unilateral 6-OHDA lesions, as well 
as non-motor deficits that may reflect extinction (Carli et al, 1985, 1989; Dowd & Dunnett, 
2004, 2007). The LCRT task may thus be used to measure deficits to both motor and non-
motor function. This made it an appropriate task when conducting experiments designed to 
dissociate between the effect of dopaminergic drugs on motor and non-motor behaviour in 
rats with unilateral 6-OHDA lesions as part of this thesis project.  
1.7. Pharmaceutical treatments for Parkinson’s Disease 
The following section will provide an overview of pharmacological treatments for PD, and 
some common side effects associated with them before explaining the relevance of these side 
effects for the overall hypothesis the thesis project tested.  
1.7.1. Anti-cholinergic drugs 
The first effective pharmaceutical treatments for PD were anticholinergic drugs, which were 
introduced in the late 19
th
 century. These anticholinergic compounds were extracted from the 
plant Atropa Belladonna, until the 1950‟s, when synthetic compounds became available. 
Unfortunately, whilst long being the only pharmacological therapy showing clinical 
effectiveness, anticholinergic drugs offer limited relief when given as a monotherapy and are 
associated with severe side effects, including impaired psychosis, poor concentration, and 
memory disruptions (Katzenschlager et al, 2003; Smith et al, 2012; Sawada et al, 2013).  
1.7.2. L-DOPA 
Today, the most commonly prescribed pharmacological treatment for PD is the dopamine 
precursor L-DOPA. Being unable to cross the blood-brain barrier by passive diffusion,        
L-DOPA requires active transport via the LAT1 transport system (reviewed in del Amo et al, 
2008). Once in the brain it is converted into dopamine by neurons containing the enzyme 
DOPA decarboxylase (Figure 1.5; Flatmark et al, 2000). L-DOPA is predominantly taken up 
by dopaminergic neurons where it is converted into dopamine and released into the synaptic 
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cleft, thereby temporarily restoring extracellular dopamine levels. In addition, it is known that 
some L-DOPA is taken up and converted into dopamine by serotonergic neurons which also 
contain DOPA decarboxylase, and other yet unidentified sources (Tanaka et al, 1999; 
Flatmark et al, 2000; Cenci & Lundblad, 2006; Lindgren et al, 2010).  
L-DOPA‟s anti-Parkinsonian effects were first discovered in the late 1950‟s when the 
now Nobel laureate Arvid Carlsson showed that it reversed the akinetic effects of reserpine, a 
compound which blocks the vesicular monoamine transporter responsible for transporting 
cytoplasmic dopamine to presynaptic terminals (Carlsson et al, 1957). Based on Carlsson and 
colleagues‟ (1957) work, Birkmayer and Hornykiewicz (1961) administered L-DOPA to PD 
patients where it was shown to offer dose-dependent improvements of motor symptoms, and 
enable patients who had previously been restricted to sitting or lying positions to yet again 
stand and walk by their own accord (Birkmayer & Hornykiewicz, 1961, 1998). In line with 
their initial findings, acute administration of L-DOPA is now known to relieve the akinesia, 
bradykinesia, ridigity, and to a lesser extent also the tremor associated with PD (Birkmayer & 
Hornykiewicz, 1998; Miyasaki et al, 2002). While being superior to other 
pharmacological treatments in alleviating the motor symptoms of PD, L-DOPA is however 
associated with the onset of motor complications as further described in section 1.8.3 which 
limits its use. 
 
1.7.3. Dopamine Agonists 
Dopamine agonists act on postsynaptic receptors, where they mimic the actions of the 
dopamine that is lost in PD. Dopamine receptors are divided into D1-like (D1 and D5 
receptors) and D2-like (D2, D3, and D4 receptors) receptors (Jaber et al, 1996). PD patients 
are not prescribed D1 agonists as these are implicated in the development of LID (e.g. Mela 
et al, 2012), but are instead prescribed D2 type agonists. Dopamine agonists are used either 
as a monotherapy or in conjunction with L-DOPA, which allows medical practitioners to 
reduce the dose of the latter. While D2 agonists are less effective than L-DOPA in treating 
the motor symptoms of PD they hold the advantage of inducing no, or only mild, LID if 
administered as a first-line treatment (Pearce et al, 1998). Agonist treatment is therefore 
commonly recommended in early PD (National Institute for Health and Clinical Excellence, 
2006). Furthermore, late-stage PD patients have been shown to benefit from continuous 
infusion of the non-selective agonist apomorphine, as continuous delivery of dopaminergic 
medication instead of short-acting doses of L-DOPA is able to improve motor function while 
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Figure 1.5. A representation of the synthesis and relationship between L-DOPA, 
dopamine, and their derivates. Neurotransmitters and their precursors are shown in the 
blue boxes. The enzymes responsible for their conversion are listed above the arrows, 
which show the point at which each enzyme is involved in the synthesis. Adapted from 
Flatmark et al (2000).  
 
also increasing the therapeutic window of dopaminergic medication and reducing dyskinesias 
(Garcia Ruiz et al, 2008).  
1.7.4. Enzyme inhibitors 
In addition to dopaminergic drugs, common PD treatments also include the administration of 
catechol-o-methyl transferase (COMT) and MAO enzyme inhibitors.  
COMT inhibitors prevent the metabolism of L-DOPA, and thereby increase the 
bioavailability of L-DOPA in the brain. Co-administering COMT inhibitors with L-DOPA 
reduces motor fluctuations by increasing patients‟ “on time” and reducing their “off time” 
(1.8.3), offers symptomatic relief, and enables a reduction of patients‟ L-DOPA dose (Goetz 
et al, 2005; Talati et al, 2090; Deane et al, 2009; Stowe, 2011). However, despite preclinical 
data suggesting that COMT inhibitors can reduce dyskinesia in MPTP lesion monkey by 
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allowing a reduction of the L-DOPA dose necessary to achieve therapeutic effect (Huot et al, 
2013), a meta-analysis of clinical trial data has suggested that COMT inhibitors administered 
as per current clinical practise may increase dyskinesias in patients (Talati et al, 2009). Based 
on available data, official UK prescription guidelines therefore recommend COMT inhibitors 
for reduction of motor fluctuations in late stage PD but not for purpose of reducing LID 
(National Institute for Health and Clinical Excellence, 2006). 
MAO-inhbitors prevent the degradation of extracellular dopamine and therefore 
improve motor symptoms by prolonging the time that dopamine can act on post-synaptic 
receptors (Rascol et al, 2005). In the UK, official guidelines recommend MAO-B inhibitors 
as a monotherapy to achieve symptomatic relief in early PD, or in conjunction with L-DOPA 
in late PD (National Institute for Health and Clinical Excellence, 2006). MAO-inhibitors have 
been shown to increase the quality of patients‟ motor function as assessed by the Unified 
Parkinson‟s Disease Rating Scale, prolong the alleviating effects of L-DOPA on PD motor 
symptoms, and allow a 30-40% reduction in patients‟ L-DOPA dose (Gerlach et al, 1996; 
Rascol et al, 2005; Stowe, 2011). While MAO inhibitors improve motor side effects by 
reducing the daily time patients spend in “off” periods, their impact on dyskinesia is still 
under debate. Whilst single studies have reported that MAO-B inhibitors increase the time 
patients can spend on L-DOPA without experiencing disabling dyskinesias (Waters et al, 
2004; Rascol et al, 2005), other studies have reported an increase in dyskinesias when co-
administering MAO-B inhibitors with L-DOPA (Talati et al, 2009). Based on the available 
data, the most recent official UK guidelines recommend MAO-B inhibitors for the control of 
L-DOPA induced motor fluctuations but not for dyskinesia (National Institute for Health and 
Clinical Excellence, 2006).  
In addition to the positive effects of MAO inhibition on PD motor symptoms, one 
commonly used MAO-B inhibitor, selegiline, has also been suggested to have a 
neuroprotective function. It is believed that this effect is due to inhibition of MAO-B 
mediated dopamine degradation, which reduces the formation of toxic compounds that would 
otherwise damage dopaminergic neurons (Gerlach et al, 1996). However, based on currently 
available clinical data, current official UK guidelines do not recommend administration of 
MAO-B inhibitors to PD patients for neuroprotective purposes unless tested as part of a 
clinical trial (Gerlach et al, 1996; National Institute for Health and Clinical Excellence, 
2006). 
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1.8. Side effects of dopaminergic medication  
1.8.1. Non-motor effects of acute L-DOPA administration 
Administration of acute L-DOPA or dopamine agonists improve motor function in PD 
patients and animal models of PD (Birkmayer & Hornykiewicz, 1998; Miyasaki et al, 
2002; Pearce et al, 1998; Stern, 2000; Miyasaki et al, 2002). However, in addition to 
relieving motor deficits these drugs also affect non-motor function.  
For example, in primate MPTP lesion primates, L-DOPA doses that alleviate motor 
symptoms have been demonstrated to also impair performance on a delayed response task 
with high attentional demands (Schneider et al, 2009, 2013). Interestingly, the impaired 
performance on this delayed response task was ameliorated by co-administering nicotine, 
which increases dopamine clearance via its interaction with the dopamine transporter. The 
data have therefore been taken to suggest that increased cortical dopamine levels, as 
occurring following acute L-DOPA administration, disrupt attention (Decamp et al, 2009). 
Acute L-DOPA has also been shown to improve PD patients‟ accuracy on task-
switching and probabilistic learning tasks when patients are required to learn from positive 
feedback, while simultaneously impairing accuracy when patients‟ are required to learn from 
negative feedback (Cools et al, 2003; Frank et al, 2004). It has been suggested that acute     
L-DOPA administration mediates learning from positive feedback because the elevated 
dopamine levels that result from acute administration resemble the phasic dopamine signal 
that is typically observed following delivery of a US (Frank et al, 2004; Cools, 2006; Schultz, 
2010). Simultaneously, the increase in dopamine levels following acute L-DOPA has been 
hypothesised to mask the depression in dopamine activity that typically follows the absence 
of an expected reward – thereby impairing learning that would otherwise result from absence 
of positive reinforcement (Frank et al, 2004; Cools, 2006; Schultz, 2010). Data from fMRI 
studies support the notion that acute L-DOPA affects the dopaminergic circuits implicated in 
feedback based learning. While healthy participants show activation in the cortico-striatal 
loop (the prefrontal cortex, caudate, thalamus, and the supplementary motor area) during 
positive feed-back mediated set-shifting, this activation is absent in PD patients tested off    
L-DOPA and partly restored following acute L-DOPA administration (Au et al, 2012).  
Acute L-DOPA also affects impulsive behaviour such as gambling. This has been 
demonstrated by, for example, Cools and colleagues (2003) using a gambling task where the 
probabilities of winning could be calculated by the participant before placing a bet. Whilst   
L-DOPA did not affect the accuracy with which patients placed their bets, patients on          
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L-DOPA placed larger bets than patients tested off L-DOPA (Cools et al, 2003). The 
impulsive betting strategies are believed to be mediated by the ventral striatum which is less 
affected by the dopamine denervation observed in PD than the dorsal striatum (Cools et al, 
2003). It is believed that L-DOPA doses that are able to offer relief of motor symptoms 
(reliant on dorsal striatal dopamine levels) simultaneously over-stimulate the less affected 
ventral striatum, and thereby enhance behaviours mediated by the ventral striatum such as 
impulsive behaviour (Cools et al, 2006). 
1.8.2. Non-motor effects of acute dopamine agonist administration   
Non-motor side effects have also been observed following dopamine agonist treatment. D2 
agonists have been implicated in the development of impulse control disorders (ICDs), which 
one large cohort study estimated to affect approximately 14% of PD patients (Weintraub et 
al, 2010). ICDs are defined in the American Psychiatric Association‟s Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV) as being characterised by an inability, or 
severe difficulty, in resisting impulses that will result in negative consequences. ICDs 
associated with dopamine agonist use in PD include pathological gambling, hypersexuality, 
and dopamine dysregulation syndrome (Weintraub et al, 2010; Voon & Fox, 2007). These 
ICDs have been linked to the fronto-striatal and limbic-striatal circuitries (Voon & Fox, 
2007) where, for example, there is increased release of ventral striatal dopamine when PD 
patients with ICDs engage in gambling (Steeves et al, 2009). Interestingly, while activity in 
healthy controls‟ ventral striatum shows stronger correlation with activity in the prefrontal 
cortex than in the insular during placebo conditions, acute D2/3 agonist administration causes 
the ventral striatum to instead show stronger correlation with activity in the insula. This has 
led to the suggestion that D2/3 agonists decrease top-down control over impulsive behaviour 
(mediated by prefrontal cortex) in favour of increased emotional influence on decision 
making (mediated by the insula) (Ye et al, 2011). On a behavioural level this has been 
suggested to cause overestimation of potential reward and an underestimation of potential 
risk, resulting in ICDs in a subset of PD patients (Camara, 2009). 
1.8.3. Motor complications following chronic L-DOPA  
L-DOPA‟s ability to offer greater symptomatic relief of PD motor symptoms than other 
pharmacological treatments for PD has made it the gold standard treatment in PD (Miyasaki 
et al, 2002). Unfortunately, the beneficial effects of L-DOPA on motor function are 
compromised by the development of adverse motor side effects following long-term use. The 
most notable side effect is LID, which affects approximately half of all patients after 5 years 
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of L-DOPA treatment (Nutt, 2001). L-DOPA induced dyskinesias are abnormal involuntary 
movements exhibited when patients are on L-DOPA treatment and consist of choreas and 
dystonia. The former are abrupt, hyperkinetic, movements of body limbs, whereas dystonia 
refers to slow, twisting, cramp-like movements of limbs (Cenci, 2007; Deane et al, 2009; 
Khan, 2012). Currently, the only clinically available treatment for the reduction of LID is the 
NMDA antagonist Amantadine (National Institute for Health and Clinical Excellence, 2006). 
Co-administering Amantadine with L-DOPA has been shown to reduce dyskinesia scores by 
approximately 60% without impacting on L-DOPA‟s beneficial effect on motor function 
(Verhagen et al, 1998).  
In addition to LID, long-term L-DOPA treatment is associated with an increase in the 
duration of patients‟ so called “off” periods. These are periods during which the last L-DOPA 
dose has lost its effect but the next has not yet become effective. Hence, patients experiencing 
an “off period” no longer benefit from the drug‟s therapeutic effects and instead transiently 
return to an akinetic state (Marsden & Parkes, 1977; Khan, 2012).  
1.8.4 Receptor changes following LID onset 
Following initial dopamine loss, there is a sensitisation of D1-type receptors, and an 
upregulation of D2-type receptors, mGlu5, and NMDA receptors (Aubert et al, 2005; 
Sanchez-Pernaute et al, 2008; Ouattara et al, 2011; Wullner et al, 1994; Marti et al, 1999; 
Turjanski et al 1997; Ulas et al, 1994). LID onset further affects striatal receptors by 
increasing the binding to D1 receptors in MPTP lesion monkeys, whereas monkeys that 
remain non-dyskinetic following L-DOPA treatment show a normalisation of D1 binding 
(Table 1.1; Aubert et al, 2005). LID onset also enhances the upregulation of striatal mGlu5 
receptors that occurs in MPTP lesion monkeys and PD patients (Sanchez-Pernaute et al, 
2008; Ouattara et al, 2011). Furthermore, LID affects NMDA receptors, with PET imaging 
studies showing greater striatal NMDA receptor activity in dyskinetic than in non-dyskinetic 
patients when the patient cohorts were tested on, but not off, acute L-DOPA (Ahmed et al, 
2011). 
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Table 1.1. An overview of changes to striatal receptors occurring following dopamine 
denervation and subsequent L-DOPA treatment, in dyskinetic and non-dyskinetic animals 
and patients. The table also shows whether the change was observed in patients, non-
human primates, or rodents. If data was obtained uding a preclinical model, the toxin 
used to mimick the dopamine loss observed in PD is indicated. References are displayed 
below the table.  
 Dopamine loss Chronic L-DOPA 
  Dyskinetic Non-dyskinetic 
D1 Sensitised  
(MPTP primates1) 
Further sensitization 
(MPTP primates1) 
Normalised 
(MPTP primatess1) 
D2 Upregulated
 
(MPTP primates1) 
Increased binding 
(Patients2) 
No change in receptors 
(MPTP primates1, patients2)  
 
No change 
(Patients2) 
mGlu5 Upregulated 
(MPTP primates3) 
Further upregulation 
(Patients and MPTP primates4) 
Less binding than in 
dyskinetic 
animals/patients 
(Patients and MPTP primates4) 
NMDA Sensitised  
& upregulated 
(6-OHDA rat5,6) 
 
Increased NMDA binding  
(Patients7) 
Increased binding relative 
to non-dyskinetic patients 
when on L-DOPA 
(Patients8) 
 
1: Aubert et al (2005); 2: Turjanski et al (1997); 3: Sanchez-Pernaute et al (2008); 4: Ouattara et al (2011); 5: Wullner et al (1994); 6: Marti 
et al (1998); 7: Ulas et al (1994); 8: Ahmed et al (2011) 
1.8.5. Changes in synaptic plasticity following chronic L-DOPA 
In addition to receptor level changes, LID has also been linked to changes in synaptic 
plasticity. Synaptic plasticity includes the three mechanisms long-term potentiation (LTP), 
long-term depression (LTD), and depotentiation.  
LTP refers to the long-lasting potentiation of the synaptic strength between two 
neurons as the result of a previous short, but intense, synaptic activation and agonism of 
specific receptors (Bliss, 2003).  LTP has been induced in cortico-striatal fibers in vitro by 
applying high frequency stimulation (HFS) whilst activating NMDA receptors by removing 
magnesium from the bathing solution the tissue is kept in (Calabresi et al, 1992, 2007; 
Centonze et al, 2003; Picconi et al, 2003). The success of the LTP induction can be 
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demonstrated by recording the excitatory post-synaptic potentials (EPSPs) elicited in the 
post-synaptic neuron following later application of HFS stimulation. The magnitude of 
EPSPs is greater post- than pre-LTP induction (Picconi et al, 2003). 
LTD refers to a long lasting decrease in the synaptic strength between two neurons. 
LTD has been induced in cortico-striatal fibers in vitro by applying HFS to the tissue while 
NMDA receptors are inactivated by adding external magnesium to the bathing solution the 
tissue is kept in (Centonze et al, 2003). Like LTP, the presence of LTD may be measured by 
recording EPSPs or field potentials. Following LTD induction these are of lower magnitude 
than before induction (Bliss et al, 2003; Pisani et al, 2005; Calaresi et al, 1992a,b).  
Following successful striatal LTP induction in cortico-striatal fibres, the potentiated 
response can be reversed in vitro by applying LFS to the presynaptic neuron. This process is 
known as depotentiation. Unlike LTD it does not represent a shift away from the baseline 
synaptic strength, but instead a reversal of the LTP induced potentiation (Picconi et al, 1992; 
Bliss et al, 2003; Pisani et al, 2005: Huang et al, 2010). 
In vitro experiments have enabled a greater understanding of the induction of cortico-
striatal LTP and LTD. Both forms of plasticity are blocked in cortico-striatal tissue from rats 
that have undergone 6-OHDA lesions (Calabresi et al, 1992a; Kerr & Wickens, 2001), 
suggesting a role of dopamine in both forms of plasticity. By using pharmacological blockade 
paradigms further insight into the receptors implicated in plasticity has been gained. Cortico-
striatal LTP has been shown to depend on co-activation of mGlu1 & mGlu5 receptors 
(Gubellini et al, 2003), NMDA receptors (Calabresi et al, 1992b), and D1 or D5 receptors ( 
Table 1.2; Kerr & Wickens, 2001). Cortico-striatal LTD formation, on the other hand, 
has been shown to be dependent on activation of mGlu1 receptors, D5 receptors, and D2-type 
receptors ( 
Table 1.2; Calabresi et al, 1992a; Gubellini et al, 2001; Centonze et al, 2003). 
Cortico-striatal depotentiation has been induced in vitro in the absence of magnesium 
(Picconi et al, 2003) which suggests that its induction involves NMDA activation. 
Furthermore, depotentiation has also been shown to require activation of protein phosphates 1 
and 2A, and to be inhibited by D1 agonism (Picconi et al, 2003). 
While cortico-striatal LTP and LTD are typically blocked in tissue from rats that have 
received 6-OHDA lesions (Calabresi et al, 1992a; Kerr & Wickens, 2001), in vitro data have 
demonstrated restored ability for LTP formation in tissue from lesion rats that were 
chronically treated with L-DOPA prior to culling (Picconi et al, 2003). Interestingly, the data 
demonstrated a difference in the ability for cortico-striatal plasticity in tissue from lesion rats 
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that did and did not develop LID in response to chronic L-DOPA treatment. Specifically, 
depotentiation of LTP could be induced in cortico-striatal tissue from L-DOPA treated non- 
dyskinetic rats, but not in tissue from rats that developed LID in response to the L-DOPA 
treatment (Picconi et al, 2003). This is believed to be due to the increased phosphorylation of 
 
Table 1.2. An overview of the receptors that have been implicated in the induction of 
cortico-striatal long-term potentiation (LTP) and long-term depression (LTD).  
 
mGlu1 mGlu5 NMDA D1  D5 D2 type 
LTP x x x x x  
LTD x    x X 
 
DARPP-32 that is associated with LID (e.g. Santini et al, 2007). Data obtained from sham 
lesion rats have shown that phosphorylation of DARPP-32, which is induced by D1 receptor 
activation, inhibits phosphatase 1 which is required for cortico-striatal depotentiation to occur 
(Picconi et al, 2003). Hence, the phosphorylation of DARP32 that is known to occur in LID 
may underlie the loss of cortico-striatal depotentiation observed in tissue from lesion rats that 
have developed LID (Picconi et al, 2003).  
Clinical data suggest that the disrupted synaptic plasticity observed in preclinical 
models may translate to the PD patients. In the clinic, LTP like plasticity may be induced in 
the motor cortex using protocols involving transmagnetic stimulation (TMS). One such 
protocol is the paired associative stimulation (PAS) method in which TMS applied over the 
motor cortex is paired with median nerve stimulation at the wrist. Changes in the amplitude 
of motor evoked potentials (MEPs) at the abductor pollicis brevis is then used as an indicator 
of potentiated responses. Using this protocol, Morgante and colleagues (2006) demonstrated 
a loss of LTP like plasticity in Parkinsonian patients tested off-medication. This plasticity 
was restored by acute administration of dopaminergic medication in non-dyskinetic, but not 
in dyskinetic, patients (Morgante et al, 2006). In line with preclinical findings (e.g. Picconi et 
al, 2003) the data thus demonstrated a requirement for dopamine for LTP like plasticity to 
occur in the cortico-striatal circuitry. However, the findings reported by Morgante and 
colleagues (2006) differed from preclinical data (Picconi et al, 2003) by being unable to 
induce LTP-like plasticity in dyskinetic participants. One possible reason for the discrepancy 
is the protocols used: whereas preclinical experiments (e.g. Picconi et al, 2003) study LTP 
directly in cortico-striatal tissue, Morgante and colleagues‟ (2006) protocol only measured 
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LTP indirectly by measuring the effects of TMS on motor MEPs. There was thus a difference 
both in the methodology used and the specific brain structures being studied. 
A later study readdressed the issue using a new protocol that had been demonstrated 
to be more consistent in its ability to induce LTP like effects in PD patients (Huang et al, 
2010, 2011). With this protocol, it was also possible to study both LTP like and 
depotentiation like plasticity (Huang et al, 2010, Huang et al, 2011). In their study, Huang 
and colleagues (2011) were able to induce LTP like potentiation in both dyskinetic and non-
dyskinetic patients when these received their full L-DOPA dose. Furthermore, in line with 
preclinical data (Picconi et al, 2003) only the non-dyskinetic group was found to have 
retained the ability for depotentiation. The data from Huang and colleagues (2011) therefore 
suggested that preclinical findings of disrupted synaptic plasticity in a model of PD (Picconi 
et al, 2003) may translate to the clinic. The data further suggested that the failure of an earlier 
study (Morgante et al, 2006) to demonstrate LTP like plasticity in dyskinetic PD patients may 
have been due to the methodology used.  
The hypothesis that subtle differences in methodology and patients medication have a 
large impact on the ability to induce LTP like plasticity using PAS protocol is supported by 
data from other clinical experiments. In the previously described study, Huang and colleagues 
(2011) were able to induce LTP like plasticity in PD patients receiving their full L-DOPA 
dose. However, they failed to induce LTP like plasticity when patients received half their 
dose (Huang et al, 2011). This is consistent with data from other studies where LTP-like 
plasticity could not be induced in patients receiving a low L-DOPA dose prior to testing 
(Suppa et al, 2011). Together, these studies show that the ability for inducing LTP like 
potentiation in patients is highly sensitive to not only the protocol (Morgante et al, 2006, 
Hunag et al, 2010, 2011) but also the dose of medication the participants receive (Suppa et al, 
2011, Huang et al, 2011). 
A weakness of the clinical studies described above (Morgante et al, 2006; Huang et 
al, 2010, 2011; Suppa et al, 2011) is that they only measured LTP and depotentiation 
indirectly - unlike in vitro studies which are able to directly measure the effect of potentiation 
on post-synaptic responses. One instance in which synaptic plasticity can be measured 
directly in the clinic is during deep-brain stimulation (DBS) implantation, a surgical therapy 
aimed to relieve PD symptoms by implantation of electrodes to the basal ganglia (Starr et al, 
1998). During such implantation, Prescott and colleagues (2009) were able to record field 
evoked potentials (fEP) following HFS in the SNr of patients that were either on or off        
L-DOPA medication at the time of surgery. Prescott and colleagues (2009) demonstrated that 
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LTP could only be induced in patients who were on L-DOPA at the time of testing. Whilst 
recording from the SNr (Prescott et al, 2009) rather than cortico-striatal tissue as in the 
previously described preclinical study (Picconi et al, 2003), the data offer further support for 
findings of a disruptive effect of PD on basal ganglia plasticity, and the need for dopamine 
for successful LTP induction in the basal ganglia network, as well as suggesting that the 
abnormal plasticity associated with PD may affect multiple parts of the basal ganglia 
circuitry. 
Whilst further work is required to understand the precise effect of PD and acute and 
chronic L-DOPA on basal ganglia synaptic plasticity, the cited studies suggest a long-term 
effect on synaptic plasticity on basal ganglia plasticity. These changes, together with the 
receptor changes also associated with L-DOPA and LID onset, could both be hypothesised to 
affect non-motor behaviour mediated by the striatum. In addition to motor function, the 
striatum is known to mediate non-motor functions such as motor learning, and goal-directed, 
and habitual behaviour (e.g. Wächter et al, 2010; Yin et al, 2004, 2005; Reynolds et al, 2001; 
Luft et al, 2004; Okulski et al, 2002). Therefore, further to the already known effect of 
chronic L-DOPA on the development of LID and motor fluctuations (Marsden & Parkes, 
1977), chronic exposure to the drug may impact on non-motor functions. 
1.9 Thesis aims 
In the 1960‟s, the reported link between dopamine loss and akinesia led to the dopamine 
precursor L-DOPA being introduced as a pharmacological treatment for PD motor symptoms 
(Ehringer & Hornykiewicz, 1960; Birkmayer & Hornykiewicz, 1961). The therapeutic relief 
provided by L-DOPA made it the gold standard treatment for PD, However, it is now 
recognised that L-DOPA affects a wider range of behaviours than initially realised. Acute    
L-DOPA administration is known to affect both motor function (Birkmayer & Hornykiewicz, 
1961) and cognition (e.g. Cools, 2006). Conversely, while long-term L-DOPA is known to 
induce motor side effects (Marsden  & Parkes, 1977), little is known about the effects of 
long-term L-DOPA treatment on non-motor function. This is in spite of data showing that 
chronic L-DOPA exposure and LID onset are associated with receptor and plasticity changes 
to the striatal system (e.g. Aubert et al, 2005; Picconi et al, 2003; Prescott et al, 2009; Huang 
et al, 2011), and knowledge that this system is implicated in non-motor functions such as 
motor learning, goal-directed behaviour, and habitual behaviour (Wächter et al, 2010; Yin et 
al, 2004, 2005). The purpose of this thesis was to address the gap in the current scientific 
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understanding by exploring whether the effects of long-term L-DOPA exposure and LID 
onset extended beyond motor side, to also affect non-motor behaviour.  
The main aims of the thesis were: 
 To determine whether the chronic L-DOPA impairs motor learning and non-motor 
function in the 6-OHDA rat model of PD.  
 To compare the effect of chronic L-DOPA and a D2 agonist, which does not induce 
LID, on motor learning and non-motor function in the 6-OHDA rat model of PD. 
 To, once a deficit had been identified, dissociate the effects of chronic L-DOPA and 
the development of LID on said deficit. 
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2. Methods 
2.1 Rats 
2.1.1 Animal husbandry 
Experiments were conducted in the School of Biosciences, Cardiff University, with the 
exception of Experiment 5 which was conducted at Eli Lilly & Co Ltd, Windlesham, Surrey, 
UK. For this reason, there were minor differences in the animal husbandry in Experiment 5 
relative to the other experiments, as specified below.  
Rats were housed in groups of 1-4 rats per cage in all experiments apart from in 
Experiment 5, where they were housed in groups of 1-5. The holding room light was set to a 
14:10 h light/dark cycle in all experiments apart from Experiment 5, in which a 12:12 h 
light/dark cycle was used.  
In accordance with Home Office regulations, the room temperature was kept between 
19°C and 23°C and the humidity at 55% ± 10%. The cage floor was covered by sawdust, and 
basic enrichment provided in the form of a cardboard tunnel and wooden chewing sticks in 
all experiments apart from Experiment 5, where rats were given a plastic nest ball and 
wooden chewing sticks. Rats were given ad libitum access to water and, when not on food 
restriction, food chow. The diet consisted of Teklad Global 14% Protein Rodent Maintenance 
Diet (Harlan Laboratories, UK) in all experiments apart from that Experiment 5, where 
Tekland Global 16% Protein Rodent Maintenance Diet (Harlan Laboratories, UK) was used.  
2.1.2. Rats used & suppliers 
All Lister Hooded rats were obtained from Charles River (UK). Sprague Dawley rats were 
obtained from Harlan (UK), apart from the Sprague Dawley cohort included in Experiment 5 
which was obtained from Charles River (UK). 
2.1.3. Food restriction 
Food restriction, when used in this thesis, refers to the practise of restricting rats‟ food intake 
from ad libitum to being fed once daily in such volumes that the rats‟ weights are maintained 
at between 85% and 90% of their baseline weight.  
In instances where rats were food restricted prior to reaching adulthood their target 
weights were adjusted to allow for further growth. Based on growth curves provided by the 
animal suppliers, adulthood was considered reached when female rats weighed ≥250 g, and 
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male rats weighed ≥350 g. For rats that were not considered to have reached adulthood, the 
minimum target weight was set to 85% of baseline weight and the maximum target weight 
was set to 90% of baseline weight during their first week of food restriction. In subsequent 
weeks, the upper and lower targets weights were increased by 5 g per week until the rats were 
fully grown.  
2.2. Surgery 
2.2.1. General surgery procedures 
Rats that had previously been food restricted were given ad libitum access to food for a 
minimum of two days prior to surgery. 
Prior to surgery, 1g 6-OHDA containing ascorbic acid (cat no H116, Sigma-Aldrich) 
was mixed with 0.8 ml 0.9% saline. This caused the final solution to have a free base 
concentration of 5.14 mg/ml. The 6-OHDA solution was pipetted into eight aliquots, 
containing 100 µl solution each, immediately after the saline and 6-OHDA had been mixed. 
The aliquots were wrapped in tin foil to protect them from light and stored at -20°C. On the 
day of surgery, one aliquot at the time was taken to surgery where it was kept in an ice filled 
polystyrene box, with the lid kept on at all times to prevent exposure to light. The colour of 
the toxin was closely monitored and an aliquot was discarded and replaced as soon as the     
6-OHDA started turning pink.  
Rats were anaesthetised in induction chambers using 2-4% isoflurane with NO2 and 
O2 simultaneously administered at a 2:1 ratio. Once unconscious and no longer showing a 
response to pinching of the tail tip or hindlimb digit the rats were moved to stereotaxic frames 
(Kopf) where anaesthesia was maintained using the same isoflurane, NO2 and O2 
concentrations as during induction. Blunt ear bars were used to stabilise the head. An incision 
was made across the skull above bregma using a sharp scalpel. The exposed skull surface was 
thereafter cleared using the scalpel blade and cotton buds. Forceps were used to prevent the 
skin from closing the wound during surgery.   
Lesion coordinates were calculated from bregma, which was identified using a 
surgery microscope. Once the coordinates had been identified, a small hole was drilled 
through the skull, and 6-OHDA was infused using a 30 gauge cannula. A syringe pump and a 
Hamilton syringe, connected to the cannula by polyethylene tubing, were used to infuse the 
toxin at a speed of 1 µl/min. Following infusion and diffusion of the toxin, the rats received a 
5 ml subcutaneous injection of 0.9% saline (AnimalCare, UK) to prevent dehydration and the 
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wound on the skull was stitched together using vicryl sutures. Rats were thereafter placed in 
heated recovery cages until they were awake and alert enough to be returned to the holding 
room. Once recovered from anaesthesia, rats were returned to clean cages, prepared as 
described previously (2.1.1) but including nesting material for warmth for the first two nights 
post surgery. Rats were checked daily for a minimum of three days, with special attention 
paid to their weights, the healing of the wound, and alertness.  
Because of changes in the standard practises in the School of Biosciences, Cardiff 
University, and because one of the experiments (Experiment 5) was conducted in a different 
location (Eli Lilly & Co Ltd, Windlesham, Surrey) and under a different project licence there 
were differences in the post surgery analgesics used in different experiments. In the 
experiments described in Chapters 3 and 4, analgesic was provided in the form of 
paracetamol dissolved in their drinking water upon return to the home cages. Paracetamol 
was administered for two days post-surgery. In the experiment described in chapter 5 
analgesic was provided by a s.c. injection of 0.15 ml buprenorphine (Vetergesics, UK)  
administered after infusion of 6-OHDA. In the experiments described in Chapters 6-8, 
analgesic was provided by a s.c. injection of 30µl Metacam (Boehringer Ingelheim, UK) after 
infusion of 6-OHDA.  
2.2.2. Medial forebrain bundle lesions 
Lesions to the MFB were conducted by infusing 6-OHDA into AP -4.0, ML -1.3 from 
bregma, and DV -7.0 below dura mater. The tooth bar was set to -4.5mm. The toxin was 
infused for 3 min at a rate of 1 µl/min, causing 15.42 µg of freebase 6-OHDA to be infused. 
The cannula was left in place a further 2 min before removal, to allow for diffusion around 
the infusion site.  
2.2.3. Intra-striatal lesions 
Intra-striatal lesions were conducted by infusion of 6-OHDA across eight sites. The tooth bar 
was set to -4.5mm. Four holes were drilled at AP +1.0, ML-2.0; AP +0.4, ML -2.8; AP -0.2, 
ML -3.6; and AP -0.8, ML -4.4 relative to bregma. Infusion took place at two depths. First, 
the cannula was lowered to DV -5.5 below dura mater and 6-OHDA was infused for 1 min 
The cannula was then retracted to DV -4.5 below dura mater and 6-OHDA was infused for 1 
more min at a speed of 1 µl/min. The cannula was thereafter left at DV-4.5 for 2 min to allow 
for diffusion around at the infusion site before retracting the cannula. 
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2.3. Drug preparation & administration 
2.3.1. Bromocriptine 
Bromocriptine was stored in a 4°C fridge. During preparation, it was mixed with an equal 
weight of tartaric acid and placed in a sonicator where 1-2 drops of ethanol was added. Once 
the solution had dissolved, distilled water was added to create the desired concentration. The 
drug was administered i.p. at a volume of 2 ml/kg.   
2.3.2. L-DOPA 
L-DOPA was stored in a -20°C freezer. During drug preparation, benserazide hydrochloride 
was added to the weighed out L-DOPA and both drugs were dissolved in 0.9% saline. 
Benserazide hydrochloride was always administered at a concentration of 15 mg/kg. The      
L-DOPA solution was prepared immediately before administration and injected at a volume 
of 1 ml/kg. L-DOPA was always administered via s.c. injections to the scruff, as s.c. 
administration has been demonstrated to produce less variable plasma levels of the drug than 
i.p. injections (Lindgren et al, 2007).When administered on a daily basis, care was taken to 
alternate the site of injection between the right, left, and central scruff to avoid soreness.  
2.3.3. Met-amphetamine 
Met-amphetamine was stored in room temperature. The drug was dissolved in 0.9% saline 
immediately before administration and injected i.p. at a concentration of 2.5 mg/kg and a 
volume of 1 ml/kg.  
2.3.4. Raclopride tartrate 
Raclopride tartrate was weighed out and dissolved in sterile 0.9% saline immediately before 
injection. The drug was administered i.p. at a volume of 1 ml/kg.  
2.4. Motor behavioural tests 
2.4.1. The 100 pellets test 
Food restricted rats were placed in empty transparent activity cages (section 2.4.4). The 
bottom of the activity cages measured 20 cm wide and 36 cm long, whilst the top measured 
26 cm wide and 41.5 cm long. The height was 18.5 cm. A metal grid cage lid was placed on 
top of the cage during testing to ensure the rats‟ remained inside. The lid was made of 30 
grids running across the length of the cage, located 1 cm apart from each other, and 11 grids 
running across the width of the cage, located 4 cm apart from each other.  
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In the beginning of a testing session, disposable plastic drug weigh boats containing 
100 sucrose pellets (AIN-76A Rodent Tablet, TestDiet, UK) were placed in the cage. Using a 
count-up timer, the time taken for rats to eat the available pellets was measured. There was no 
upper time limit and all tested rats consumed the available sucrose pellets.  
2.4.2. Activity cages 
Activity cages from TMed Associates Inc. (Vermont, USA) were made of transparent 
Plexiglas and positioned on a metal rack. On either side of the cage were three continuous 
laser beams going across the bottom of the cage. Perservative and non-persevative beam 
breaks were recorded and used as an indicator of rats‟ activity levels.   
The bottom of the activity cages measured 20 cm wide and 36 cm long, whilst the top 
measured 26 cm wide and 41.5 cm long. The height was 18.5 cm. A metal grided cage lid 
was placed on top of the cage during testing. It consisted of 30 grids running across the length 
of the cage, 1 cm apart, and 11 grids running across the width of the cage, 4 cm apart.  
 2.4.3. Adjusting step test 
The adjusting step test was first described by Olsson et al (1995) to measure forelimb 
akinesia in the hemi-Parkinsonian rat and is known to be sensitive to both dopamine 
denervation and anti-Parkinsonsian drugs. The test was conducted in accordance with the 
previously published protocol (Olsson et al, 1995). Rats were restrained in such way that they 
could only use one forelimb, and thereafter moved along a 1 m flat surface while ensuring 
that the free forelimb was in constant contact with the surface. To ensure all rats were 
constrained at a consistent distance from the table top during testing they were held in such a 
way that the experimenters‟ knuckles were always in contact with the table top whilst 
restraining the rats.  
Rats were moved in the forehand and backhand direction across the 1 m distance three 
times during testing of the ipsilateral and contralateral forelimb, respectively. The average 
number of adjusting steps the made using the paw ipsilateral and contralateral to the lesion 
was recorded and used as an indicator of forelimb akinesia.  
2.4.4. The Cylinder Test 
Background 
The cylinder test was developed by Schallert and colleagues (2000) as a measurement of 
forelimb motor function in the laboratory rat. The cylinder test is a non-invasive test which 
draws on rats‟ inquisitive nature. It measures rats‟ use of their right and left forelimb whilst 
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exploring a novel cylinder environment. Whilst intact rats use both forelimbs to an equal 
extent, rats with unilateral 6-OHDA lesions or hemispinal damage preferentially use their 
unaffected forelimb when exploring the cylinder (Schallert et al, 2000). Dopaminergic drugs 
have previously been demonstrated to reduce the ipsilateral bias exhibited by rats with 
unilateral 6-OHDA lesions making it a useful tool in preclinical PD research (Lundblad et al, 
2002). 
Apparatus 
The cylinder (in-house manufacturing) was made of transparent plexiglas and had diameter of 
25 cm and a height of 43 cm. Two mirrors were placed behind the cylinder to allow 
observation of paw placements made whilst rats were turned away from the experimenter.  
Testing 
Each session was filmed using a 3.1 mega pixel Panasonic NV-GS330 cam recorder that was 
mounted on a tripod. Each session began when a rat was placed in the cylinder by the 
experimenter. The rat remained in the cylinder until the experimenter, who used a clicker to 
count the number of paw placements made, had observed a minimum of 15 paw placements. 
A paw placement was defined as a weight bearing placement of either forelimb against the 
wall of the cylinder. The first ten paw placements were used in the analysis, where they were 
recorded as being made by either the ipsilateral or contralateral paw. If it was unclear whether 
or not a paw placement had been made, a note was made by the experimenter and the video 
recording was used to confirm the number of ipsilateral and contralateral paw placements that 
had been executed.  
2.4.5. Elevated body swing 
The elevated body swing test has previously been described by Borlongan & Sanberg (1995) 
who demonstrated an ipsilateral bias in rats with unilateral 6-OHDA lesions, and a positive 
correlation between rats‟ ipsilateral bias on the elevated body swing test and the ipsilateral 
bias of their apomorphine induced rotations. Testing began with rats being picked up from a 
flat table surface by the base of their tails. Care was taken to ensure that the rat‟s trunk was 
not bent in either direction when they were picked up by the experimenter. Rats were then 
held approximately 20 cm above the table top surface until they lifted their bodies by more 
than 30° in either direction at which point the movement was recorded as being to either the 
ipsilateral or contralateral side of the lesion and the rat was returned to the surface. Rats were 
tested three times, with a short break in between each trial during which they were allowed to 
walk freely on the table top to ensure they remained calm during testing. 
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2.4.6. Rotometer testing 
A schematic representation of the rotometers is provided in Figure 2.1. The rotometers and 
the control unit were both manufactured by Med Associates Inc, USA. Prior to commencing 
testing the rats were tethered using an elastic band, with the exception of Chapter 5 where 
plastic, self-locking cable ties were used. Rats were thereafter placed in cylindrical rotometer 
pots (dimensions specified below). The rats‟ harnesses (i.e. the elastic bands or cable ties) 
were connected to a suspended, elastic cord via a hook. The cord was attached to a 
mechanical rotation sensor which rotated when the rats did. Rotation of the sensor was 
recorded by the software. The settings were adjusted to record partial/ 90° turns per count, in 
1 min time bins, with 8° retrace. 
Rats were placed in bowls during testing. All experiments, apart from Experiment 5, 
were conducted at the School of Biosciences, Cardiff University where the bowls were made 
of transparent plastic and had an upper diameter of 30 cm, and a bottom diameter of 15 cm 
(Whitefurze, UK). The bowls were placed inside transparent, plastic cylinders that acted as 
walls and ensured that the rats‟ remained within the rotometer bowls. Fresh sawdust was 
placed in the bowl prior to each testing session. Experiment 5 was conducted at Eli Lilly & 
Co Ltd, Windlesham, Surrey, where different pots were used. These pots were made of metal 
and had a height of 45 cm and a diameter of 45.5 cm, and were surrounded by non-
transparent plastic walls.   
 
 
Figure 2.1. A schematic representation of an automated rotometer. 
 
2.4.6.1. Amphetamine induced rotations 
When developing the 6-OHDA rat model of PD, it was noted that unilateral lesions caused 
rats to spontaneously turn towards the side of the lesion (Ungerstedt, 1968). It was also 
shown that the ipsilateral bias in rats‟ locomotion could be enhanced following acute 
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administration of amphetamine, which causes release of dopamine from dopaminergic 
terminals whilst also preventing dopamine reuptake (Ungerstedt & Arbuthnott, 1970). 
Amphetamine induced rotations have since been used as a time-efficient method for 
screening lesion extent in following unilateral 6-OHDA lesions to the dopaminergic system.  
When amphetamine induced rotations were used in this thesis project, rats were 
placed in the rotomers, their harnesses were attached, and the rats were then given an i.p 
injection of 2.5 mg/kg met-amphetamine at a volume of 1 ml/kg immediately before the 
recording started. Rotational behaviour was recorded for 90 min post-injection.  
2.4.6.2. Spontaneous rotations 
Recording of rats‟ spontaneous rotations was conducted after 7pm as rats are more active 
close to, and during, their dark cycle which began at 8pm in the experiments where 
spontaneous rotations were recorded. The light in the rotometers room was switched off 
throughout testing to increase the rats‟ activity levels. In each spontaneous rotation session, 
rats were placed in the rotometers one at the time and their rotational behaviour recorded for 
10 min. To ensure maximal activity, no habituation period was provided. Instead, the 
software started recording immediately after each rat was placed in her rotometer pot. 
 
2.4.7. The Staircase Test 
Background 
The staircase test was developed by Montoya and colleagues (1991) as a means for 
measuring fine motor skills. It takes place in so called staircase boxes where it measures food 
restricted rodents‟ ability to collect sucrose pellets using their ipsilateral and contralateral 
forelimb respectively. The retrieval of sucrose pellets requires successful advancement of the 
forelimb towards the pellet, pronation of the digits, grasping of the pellet by closing the digits 
around it, and finally moving the grasped pellet back to rat‟s head for consuming. Whilst 
intact rats readily collect sucrose pellets using both paws, unilateral 6-OHDA lesions impair 
rats‟ ability to retrieve pellets using the forelimb contralateral to the lesion (Montoya et al, 
1991). The movement sequence involved in reaching for, and grasping an object has been 
shown to be highly similar between rats and people which adds to the clinical validity of the 
test (Sacrey et al, 2009). 
Apparatus 
A picture of a staircase box is shown in Figure 2.2. The staircase boxes consisted of three 
parts; a main box with a lid on top into which the rats were initially placed, an extension 
51 
 
containing a platform supporting the rats‟ bodies during testing, and a removable staircase 
that was inserted into the extension during testing. At the bottom of the main box was a metal 
grid, where grids placed 1cm apart ran across the width of the box. The lid on the main box 
and the extension were made of transparent Plexiglas, the platform and the staircase were 
both made of non-transparent plastic, and the walls of the main box were made of either non-
transparent plastic or metal. 
The main box was 11.5 cm wide, 20 cm long, and had a height of 20 cm. The 
extension was 16.5 cm long, 6 cm wide, and had a 6 cm gap between the platform and the 
ceiling. The steps on the staircase were 1.9 cm long, 1.5 cm wide and had an indentation in 
the middle into which sucrose pellets (AIN-76A Rodent Tablet, TestDiet, UK) were placed. 
The indentation was 0.5 cm deep and had a diameter of 1.7 cm. The staircase was 4.32 cm 
high, with the lowest step being located 0.5 cm above the ground.  
 
 
Figure 2.2. Picture of a rat staircase box. Picture modified from Campden Instrument‟s 
website. 
 
Testing procedure 
Prior to testing, a staircase baited with 45 mg sucrose pellets (AIN-76A Rodent Tablet, 
TestDiet, UK) was inserted into the staircase box. The number of pellets placed on each step 
was either 3 or 4, as detailed in the individual experiment methods sections. Following 
baiting of the staircase, food restricted rats were placed in the staircase box by the 
experimenter who thereafter did not interact with the rats until the end of the session. Rats 
were allowed 15 min in the staircase boxes after which they were returned to their home 
cages.  
At the end of each testing session, the number of pellets remaining on each step was 
counted to provide a measurement of ipsilateral and contralateral forelimb use. In addition, 
the number of displaced pellets was counted as an indicator of attempted but failed retrievals. 
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A displaced pellet was defined as a pellet that was known to have been pushed from one step 
to a lower step. For example, if a step had been baited with 3 pellets, but 5 pellets were 
located on it at the end of staircase testing, two of these pellets must have been pushed there 
from an above step and were therefore defined as displaced. Based on the collected data, it 
was also possible to determine the furthest away step the rats had been able to access, which 
was used as an indicator of reaching ability.  
2.4.8. The Vibrissae Test 
The vibrissae test was first described by Woodlee et al (2005). It is used to measure 
sensorimotor reflex in the hemi-Parkinsonian rat and has been shown to be sensitive to both 
6-ODHA lesions and antiparkinsonian drugs (Woodlee et al, 2005; Pinna et al, 2010).  
During testing rats were restrained in such a way that they only had free use of one 
forelimb. Rats were held just below a bench top with their bodies parallel to the bench 
surface and then lifted in an upwards direction so that the whiskers on the same side of the 
body as the unrestricted forelimb gently brushed against the side of the table top. An intact rat 
responds to this stimulation by placing their corresponding paw on the bench top. Rats with 
unilateral 6-OHDA lesions, however, make fewer responses following stimulation of their 
contralateral whiskers than following stimulation of their ipsilateral whiskers. 
A score of 1.0 was given if the rats responded to the stimulation by raising their 
unrestricted paw and placing it on the table top. A score of 0.5 was given of the rats 
responded to the stimulation by raising their unrestricted paw but failed to place it on the 
table top. The procedure was repeated ten times before turning the rat round and repeating on 
the other side.  
2.5. Dyskinesia Scoring 
Abnormal involuntary movements (AIMs) were defined as affecting the side of the body 
contralateral to the lesion, being atypical, and not serving any observable purpose. While the 
original AIMs scoring protocol (Cenci et al, 1998) rated four subtypes of AIMs (axial 
turning, locomotion, orolingual movements, and forelimb AIMs) on a scale from 0 to 4 
depending on the time per scoring session the AIMs were present, the scoring protocol has 
since been modified to also include scoring of AIMs severity (Winkler et al, 2002). The 
refined scoring scale is as such more sensitive, and it has been demonstrated that scores 
obtained using the refined scale correlate significantly with molecular markers of LID 
(Winkler et al, 2002).  
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This thesis project scored AIMs using Winkler et al‟s (2002) scale, as scoring both 
duration and severity of AIMs was considered to enhance the sensitivity of the scores. In 
addition, hindlimb dystonia which is considered to mimic the dystonia that forms part of 
human LID (Steece-Collier et al, 2003) and has also been reported by other researchers 
(Breger et al¸ 2013) was scored. Locomotor AIMs were not reported these have been 
demonstrated to not be reduced following administration of a clinically available anti-
dyskinetic drug (Lundblad et al, 2002), which questions the validity of locomotor AIMs as a 
model for human LID.  
As such, four AIMs subtypes were scored affecting the forelimbs, hindlimbs, axial 
angle, and orolingual function respectively. All AIMs were given both duration and severity 
scores.  Duration scores ranged from 0 to 4 (Table 2.1). A score of 0 indicated that no AIM 
was observed; 1 that it was present < 50% of the time; 2 that it was present > 50% of the time 
but not continuous; 3 that the movement was continuous but could be interrupted by a sudden 
noise or movement; and 4 that the movement was continuous and could not be interrupted by 
sudden noises or movements. Severity scores ranged from 0-2 for orolingual AIMs, and 0-4 
for all other AIMs as detailed in Table 2.2.  
The rats‟ AIMs were scored for 1 min every 20 min for a total duration of 2 h 
following drug administration in Chapter 4, and for 3 h following drug administration in all 
other experiments. When calculating the overall score for each time point, the duration and 
severity scores for each subtype were multiplied and the products added together to produce a 
final, cumulative AIMs score. The maximum score a rat could obtain at one scoring point 
was 32. In a 2h scoring session the maximum achievable score was 192, and in a 3h scoring 
session the maximum achievable score was 288. 
A rat was classified as non-dyskinetic if it never exhibited a severity score >1 on the 
axial, forelimb, or orolingual AIMs subtype at any scoring session. This cut-off has 
previously been shown to distinguish between rats with high and low striatal levels 
dyskinesia markers such as phosphorylated ERK1/2 (Westin et al, 2007). FosB, and PDyn 
mRNA (Andersson et al, 1999). In addition, following acute L-DOPA administration, rats 
classified as non-dyskinetic using this cut-off have lower levels of extracellular DOPA in the 
SNc and striatum than dyskinetic controls (Lindgren et al, 2010) and, unlike dyskinetic rats, 
do not show an angiogenic response to L-DOPA treatment (Westin et al, 2006).  
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Table 2.1. The scoring criteria used to determine duration for AIMs. 
 
 
Table 2.2. The scoring criteria used to determine the severity of AIMs. 
 
 
2.6. Microdialysis 
2.6.1. Probe implantation 
Prior to surgery polyethylene tubing was attached to each probe‟s inlet and outlet. Rats were 
anaesthetised and prepared for surgery as described in section 2.2.1.  
The bilateral implantation sites were located AP ±0.1, ML ±3.2 from bregma, and 
DV-5.0 from dura mater. Prior to inserting the probe, two screws were mounted caudally of 
the drill holes at such depths that they were securely attached to the skull without penetrating 
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it. A stereotaxic frame with two manipulator arms was used to lower the probes into the 
implantation sites.  
During implantation, artificial cerebrospinal fluid (aCSF; 77.78% pure water with 
10.10% 141 mM NaCl, 10.10% 5mM KCl, 1.01% 1.5mM CaCl2, and 1.01% 0.8mM MgCl2) 
was pumped through the probes‟ inlet tubes at a speed of 5 µl/min using a Hamilton syringe 
pump. In intact probes the aCSF flows unhindered through the probe and out via its outlet 
tube. Disrupted flow indicates damage to the probe membrane. Therefore, if flow became 
disrupted while the probe was lowered, the probe was retracted and replaced.  
Once both probes were in the correct position and the experimenter had ensured a 
constant, unhindered flow of aCSF through the probes, dental cement was used to attach the 
probes to the screws and the skull. Care was taken to ensure the exposed skull was clean and 
dry prior to applying the dental cement. Once the dental cement had dried, the tubing 
connected to the probes‟ inlets and outlets were sealed using a soldering iron to prevent air 
and dust from entering the system. The rat was then given a s.c. injection of 0.15 ml 
buprenorphine (Vetergesics, UK) in the scruff and placed in a heated recovery chamber until 
fully recovered from surgery. Rats were monitored closely for a minimum of 2 h post 
implantation. They were thereafter housed individually and checked for a minimum of 3 
times/day for 48 h following implantation.  
The micodialysis probes were custom made from Microbiotech (Sweden) and had 7 
mm guide shafts and 3 mm membranes. The membrane was a 6000 Dalton cut-off 
cuprophane membrane, stabilised with glycerol, and with an outer diameter of 0.24 mm.  
2.6.2. Dialysis 
Dialysis took place in a designated room where lights were kept dimmed throughout the 
dialysis session. Rats were weighed and then placed in cylindrical, non-transparent 
cylindrical pots that contained sawdust from their respective home cages. The pots were 30 
cm tall and had a diameter of 35 cm. All rats were given a hydrogel (Harlan, UK) in their 
pots to prevent dehydration. Ad libitum rats also had food pellets placed in their pots.  
During testing, rats wore a harness in the form of a plastic electrical tie loosely fitted 
beneath their forelimbs. The harness was attached to an elastic wire by a clip. The wire was 
suspended from a lever attached to the top of the pot via a rotatable swirl, which allowed the 
rats to move freely in the pot without disrupting the system. 
Dialysis samples consisted of a D sample, a P sample, and 16 experimental samples. 
The D sample was collected prior to connecting the rat to the dialysis system, by running the 
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artificial CSF through the tubing system for 5 min using an automated Hamilton pump with 
the rate set to 5 µl/min. After collecting the D sample, and prior to collecting the P sample, 
the soldered tip of the polyethylene tubes attached to each probe‟s inlet and outlet were cut 
with a scalpel and connected to two polyethylene tubes which ran via the inside of the elastic 
wire to the dialysis syringe pump and sample vial respectively. Following connection of the 
tubing, the P sample was collected over a 1 h period with the pump set to 2 µl/min. The 
following 16 experimental samples were collected every 15 min, with the flow rate 
maintained at 2 µl/min. Rats were administered a s.c. injection of 5 mg/kg L-DOPA, to the 
scruff at the beginning of the sixth sample.  
2.6.3. HPLC 
All HPLC was conducted by Jane Cooper at Eli Lilly & Co Ltd (Windlesham, Surrey) who 
also analysed the chromatograms and provided the author of this thesis with the numerical 
data.  
The mobile phase was made up by 100 mM NaH2PO, 1.6 mM OSA, and 14% MeOH 
with the pH set to 3.2. An autosampler (Spark Triathalon) injected 20 µl of the sample into 
the mobile phase. The pump (JASCO) then moved the mobile phase and sample past the 
column (BDS Hypersil C18, 150x3 mm, 3u particles) at a rate of 400 µl/min. The column 
oven (JASCO) was kept at 30°C. Standards were in the range of 0.1-100 ng/ml and were run 
in duplicate before and after samples to ensure correct calibration. Data was stored and 
processed using Empower (Waters) from which it was exported into Microsoft Excel. An 
example of a chromatogram with the peaks representing DOPA, DOPAC, 5HIAA, dopamine, 
and HVA may be found in Figure 2.3. In accordance with Lilly's protocols, the additional 
peaks observed in the chromatograms were not identified once it had been established that 
they did not interfere with the primary analytes.  
2.7. Operant tests 
2.7.1. Testing in two lever boxes 
Apparatus 
The two lever operant boxes were manufactured by Paul Fray Ltd (Cambridge, UK). The 
boxes were equipped with a house light in the ceiling, and two retractable levers. Pellets were 
delivered into a food hopper which was covered by a hinged Plexiglas panel positioned 
between the two levers. Behind the panel was a light which could be switched on to indicate 
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Figure 2.3. An example of a chromatogram from the microdialysis study described in Chapter 5. The graph shows the DOPA, DOPAC, 
5HIAA, DA, and HVA peaks in the intact (A-B) and lesion (C-D) striata of a rat with a unilateral, 6-OHDA, MFB lesion before (A+C) and 
after (B+D) s.c. administration of 5 mg/kg L-DOPA. As explained in section 2.6.3, the additional peaks observed in the chromatograms 
were not characterised. The chromatograms were supplied by Jane Cooper at Eli Lilly & Co Ltd, Windlesham, Surrey. 5HIAA=5-
Hydroxyindoleacetic acid, DA=dopamine, HVA=Homovanillic acid, s.c.=subcutaneous 
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the presence of a sucrose pellet. In addition, there were stimulus lights above each lever as 
well as the panel (Figure 2.4). 
The boxes were 25 cm wide, 25 cm deep and 22 cm high. The panel measured 4.5 x 
4.5 cm. The food hopper behind the panel was 4 cm deep and had a slight indentation in the  
 
 
Figure 2.4. A photograph of a two lever operant box, with arrows indicating the location 
of the retractable levers, the food hopper from which sucrose pellets were delivered 
following a correct trial, and the sucrose pellet dispenser. A stimulus lights was located at 
the back of the Plexiglas panel covering the front of the food hopper (not visible in 
photo). The picture was provided by Cambridge Instruments (UK).  
 
middle which caused the sugar pellets to naturally roll into the middle of the food hopper. 
The distance between the levers and the panel was 3 cm. The floor consisted of a metal grid 
which was located above a litter tray. The grids were placed 1 cm apart from each other. 
2.7.2.1.  Simple discrimination task 
Task overview 
Simple discrimination testing was conducted in two-lever operant chambers (Figure 2.4) with 
the house light turned on during testing. A normal session consisted of five blocks, each 
block consisting of ten trials each. On so called reversal days, rats were tested on six blocks, 
again consisting of ten trials each. 
The rats initiated a trial by making a panel press, upon which both levers were 
presented. If a rat did not press either lever within 15 s, they received a “time-out” during 
which both levers retracted and the house and panel lights were turned off for 3 s. If the rat 
pressed the correct lever within the set time the panel light was switched on and a sucrose 
pellet (AIN-76A Rodent Tablet, TestDiet, UK) was delivered into the food hopper. If the 
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incorrect lever was pressed the rat received a time-out and no sucrose pellet was delivered. 
Following either lever press, both levers retracted as soon as the rat released pressure from 
the chosen lever. Both a correct response and a time-out was followed by a 2 s intertrial 
interval during which the house light was turned on.   
The rats were rewarded for pressing one pre-determined lever for three days in a row 
after which they were tested on a so called reversal day. On the reversal day, rats were 
rewarded for pressing the same lever as previously in the first block, while the remaining five 
blocks rats rewarded rats for pressing the opposite (i.e. previously incorrect) lever. After the 
reversal day, rats were given three days of being rewarded for pressing the new “correct” 
lever. Accuracy was calculated as the number of correct trials over total trials and expressed 
as a percentage. Movement time was defined as the time elapsed between termination of a 
panel press and initiation of a lever press.   
A normal session terminated after 25 min or 50 trials, whichever occurred first. On 
reversal days, i.e. when the contingencies changed, the session terminated after 30 min or 60 
trials, whichever occurred first.  
2.7.1.2.2. Pre-lesion training 
Pre-lesion training was conducted in the same two lever boxes that were used for the simple 
discrimination task. Prior to commencing training, rats were food restricted for 1 week and 
exposed to sucrose pellets twice in their home cages to avoid neophobic reactions. During 
their first exposure to the operant boxes, the house and panel lights were both turned on and 
30 sucrose pellets were automatically delivered into the food hopper after the rat had been 
placed there. Rats were allowed 30 min to consume the pellets and thereafter removed from 
the boxes.  
On the second day of pre-lesion training, the house and panel lights were turned on 
and one single sucrose pellet was delivered into the hopper after the rat had been placed in 
the box. Whenever a rat entered the panel, another pellet was delivered thereby encouraging 
the rats to continue the panel pressing. Rats could obtain a maximum of 50 pellets during a 25 
min session.  
Once the rats panel pressed for 50 pellets in the 25 min session, lever press training 
commenced. During lever press training, the house light remained turned on but the panel 
light was only turned on following the delivery of a sucrose pellet. Pressing the panel caused 
one of the levers to be presented. The levers were presented in a pseudo-randomised order. 
Pressing the presented lever was always rewarded with the delivery of a sucrose pellet and 
illumination of the panel light. Once the rat collected the sucrose pellet, the panel light was 
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switched off. The session was terminated after either 50 lever presses or 25 min, whichever 
occurred first.  
 
 
2.7.1.2.3. Sucrose consumption test 
During the sucrose consumption test, which took place in the same two lever boxes as the 
simple discrimination task, one pellet was automatically delivered into the food hopper and 
the panel light was turned on after the rat was placed in the box. When the rat pressed the 
panel to enter the hopper and retrieve the pellet, the panel light was switched off and a 0 s or 
5 s (depending on which version of the task that was being run) intertrial interval (ITI) 
commenced. Panel presses made during the 5 s ITI did not result in the delivery of further 
sucrose pellets but were recorded as perservative presses. At the end of the 5 s ITI, the panel 
light was turned back on and a panel press was again rewarded by delivery of another sucrose 
pellet. As before, delivery of a sucrose pellet was followed by a 0 s or 5 s ITI. The cycle 
continued for 25 min. The maximum number of pellets rats could obtain was set to 1000 but 
no rat reached this limit.  
2.7.2. Testing in nine-hole operant boxes 
Apparatus 
The nine-hole operant boxes were manufactured by Paul Fray Ltd (Cambridge, UK). All 
boxes were fitted with a house light in the ceiling, and nine-holes into which the rats could 
poke. Sucrose pellets were delivered into a food hopper which was covered by a hinged 
Plexiglas panel and positioned on the wall opposite to the nine-holes. Behind the panel was a 
light which could be switched on to indicate the presence of a sucrose pellet (Figure 2.5). The 
holes that were not used were covered by plastic dummies.  
The inside length of the boxes was 26 cm. The inside width of the boxes was  25 cm 
in the middle of the box, and 22.5 cm on either short side of the side of the box. The inside 
height of the boxes was 26 cm. The stimulus holes measured 2.3x2.3 cm, and were 3 cm 
deep. All stimulus holes were positioned 3 cm apart. The sensors detecting nose pokes into 
the stimulus holes were positioned 0.5 cm into the holes. The panel measured 8x8 cm, and 
the food hopper located behind the panel was 3.5 cm deep with a slight indentation in the 
middle that caused the sucrose pellets (AIN-76A Rodent Tablet, TestDiet, UK) to naturally 
roll into the middle of the food hopper. The floor consisted of a metal grid which was located 
above a litter tray. The grids were placed 1 cm apart from each other.  
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All hardware and software controlling the boxes was manufactured by Cambridge 
Cognition (Cambridge, UK). 
 
Figure 2.5. A photograph of a nine-hole operant box, with arrows indicating the location 
of the stimulus holes in which rats responded during testing, the food hopper from which 
sucrose pellets were delivered following a correct trial, and the sucrose pellet dispenser. 
Stimulus lights were located in the end of each stimulus hole and at the back of the 
Plexiglas panel covering the front of the food hopper (not visible in photo). The picture is 
modified from Camden Instruments‟ website. 
 
2.7.2.1. Lateralised Choice Reaction Time task 
Task overview  
During LCRT task testing, only three of the stimulus holes in the nine-hole boxes were 
exposed and the house light was by default turned on. Each trial began with the automatic 
illumination of the central stimulus light. The rats were required to maintain a nose poke into 
the illuminated hole for a variable length of time (200, 400, 600, or 800 ms) until either of the 
two lateral stimulus holes lit up for 50 ms. If the rat responded into the recently illuminated 
stimulus hole, the panel light was turned on and a sucrose pellet was delivered. If the rat 
terminated the nose poke before the end of the hold, responded into the incorrect hole, or 
neglected to make a response within 10 s, a “time-out” occurred during which the house light 
was turned off for 2 s. Following both time-outs and correct responses, a 2 s long intertrial 
period commenced after which another trial was automatically generated. Each session lasted 
for 30 min. There was no limit to the number of trials a rat could complete in one session. 
A usable trial was defined as a trial where the rats maintained the hold into the central 
stimulus hole for the required length. Reaction time was defined as the time elapsed between 
the illumination of the lateral stimulus light and the discontinuation of the central nose poke. 
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Movement time was defined as the time elapsed between the discontinuation of a nose poke 
in the central hole and execution of a nose poke into a lateral stimulus hole. Only reaction and 
movement times following correct responses were reported.  
2.7.2.2.4. Pre-lesion training 
Prior to training, rats were food restricted to between 85% and 90% of their baseline weights. 
In instances where rats had not reached adulthood, their target weights were adjusted as 
previously described (2.1.3). To avoid neophobic reactions, rats were exposed to sucrose 
pellets twice in their home cages prior to pre-lesion training. Sucrose pellets were placed on 
the floor of their home cages in the evening and the cages were checked the following 
morning to confirm that the sucrose pellets had been consumed. During their first exposure to 
the operant boxes, rats were allowed one 15 min habituation session in the boxes. During this 
session, sucrose pellets were left in the three stimulus holes that were used in the LCRT task 
to encourage explorative behaviour, while the other holes were covered by plastic dummies.  
During their second exposure to the boxes the rats completed a magazine training 
session, during which a sucrose pellet was automatically dropped into the illuminated food 
hopper in the beginning of the session and another pellet was dropped following each panel 
entry. During magazine training, the house light was kept on but all stimulus lights were off. 
Magazine training sessions were 15 min long.  
After rats had learned to enter the magazine for sucrose pellets, central nose poke 
training commenced. During such training, the central stimulus hole was automatically 
illuminated in the beginning of each trial. Following a nose poke into the lit hole, the stimulus 
light was switched off, a sucrose pellet dropped into the panel and the panel light illuminated.  
A new trial was automatically generated when the rats‟ entered the food hopper. Central nose 
poke training sessions were 30 min long and followed by general nose poke training, where 
rats were trained to respond to any illuminated hole regardless of its location. General nose 
poke training sessions followed the same format as central nose poke training, but also 
included the use of the two lateral stimulus lights. At the beginning of a trial, one of the three 
stimulus lights was chosen by the software in a pseudo-randomised order, and automatically 
illuminated. Responding into the illuminated hole resulted in the delivery of a sucrose pellet 
as described previously.  
Once the nose poke training was completed the rats were trained on the LCRT task. 
Initially, there was no minimum time the rats‟ had to maintain their response to the central 
stimulus light and the lateral lights were illuminated for 2 s. As the rats learned the task, the 
time which they had to maintain the central hold prior to onset of a lateral light cue was 
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gradually increased, and the length of time the lateral stimulus lights were switched on for 
was decreased. At the end of training, rats had to maintain their central nose pokes for 200, 
400, 600, or 800 ms, and the lateral lights were only illuminated for 50 ms. The length of 
time rats had to maintain their central nose poke was determined by the software in a pseudo-
randomised order, to ensure that lateralised nose pokes were made in response to the 
presentation of a visual cue and not merely executed following a pre-learned time interval. 
2.8. Perfusion 
Rats were deeply anaesthetised by i.p. administration of 1 ml Euthathal. Perfusion began once 
the rat had lost consciousness and no longer reacted to a tail pinch, toe pinch, or exhibited a 
blink reflex in response to gentle stimulation of the area around the eye. A cut was made 
across the rat‟s chest and rib case. Forceps were used to move the rib case thereby exposing 
the heart. Thereafter, the descending aorta was clamped, a needle attached to a motorised 
pump via a plastic tube was inserted into the apex of the heart, and a small incision was made 
to the top right atria to allow release of blood and PBS fluids. 1M PBS was then pumped 
though the circulatory system at a rate of 60 ml/min for 2 min. If there was still visible blood 
in the PBS leaving the system via the incision in the right atria following 2 min, PBS 
continued being pumped through the system until the fluids leaving the system were clear. 
The motorised pump was thereafter used to pump 1.5% paraformaldehyde (PFA) in 1 M PBS 
through the cardiovascular system for 4 min. If the limbs were not stiff by the end of the 4 
min, further time was allowed until stiffness of the limbs was observed.  
Once perfusion was complete, the brain was removed and placed in 1.5% PFA in 1M 
PBS overnight after which it was placed in 25% sucrose in 1M PBS and stored in a 4ºC 
fridge. 
2.9. Culling and collection of fresh striata 
Rats were deeply anaesthetised by i.p. administration of 1 ml Euthathal. The procedure began 
once the animal had lost consciousness and no longer reacted to a tail pinch, toe pinch, or 
exhibited a blink reflex in response to light stimulation of the eye. Rats were decapitated 
using a rat guillotine, the brain removed and quickly placed on an ice-cooled petri dish to 
cool it. The brain was cut coronally at the level of the optical nerve using a razor blade and 
the hindbrain post-fixed in 4% PFA overnight after which it was transferred to sucrose. The 
cortex was peeled off the remaining brain, thereby exposing the striata. Fine point dissection 
forceps were used to cut around the striatum, which was then removed with the help of 
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curved dissection forceps. The ipsilateral and contralateral striata were placed in separate 
eppendorfs and immediately placed in dry ice. The tissue was then stored at -80°C until used. 
2.10. Immunohistochemistry: Tyrosine Hydroxylase staining 
The fixed brains were cut in 40 µm thick coronal sections using a freezing stage sledge 
microtome. Sections were stored in TBZ (0.1M TBS with 0.02% sodium azide) at 4°C until 
commencing immunohistological staining. 
1 in every 6 sections was taken for histological staining. Following washes in 0.1M 
TBS the sections were incubated in quench (3% hydrogen peroxide, 10% methanol, in 
distilled H20) for 5 min before further TBS washes were conducted. Non-specific binding 
was blocked for 1 h using TBS with 0.1% Triton x-100 (Sigma-Aldrich, UK) and 3% horse 
(cat no 1650) or goat (cat no 16210) serum (both Invitrogen, UK). Sections were then 
incubated in TBS with 3% serum, 0.1% triton X-100, and 1:2000 primary anti-TH antibody 
(MAB318 or MAB318, Millipore, UK). Sections were left to incubate on a shaker, overnight 
in room temperature. The following day, sections were washed in TBS before incubated for   
2 h in TBS with serum and 1:200 secondary antibody (BA9010 or BA1000, Vector, UK). The 
incubation was conducted on a shaker in room temperature. Sections were then washed in 
TBS before incubation in ABC kit (DAKO, UK) solution (0.5% solution A, 0.5% solution B, 
1% goat serum in 1M TBS). Following a 2h incubation, sections were given further TBS 
washes, followed by 2x5min washes in 0.05M TNS, pH 7.4. The section bound antibody was 
visualised using 3-3‟-diaminobenzadine (DAB, Vector Laboratories). During visualisation, 
the sections were incubated in TNS and 0.5% DAB with 3% of 30% hydrogen peroxide 
(VWR) added to initiate the reaction. The reaction was stopped by washing the sections in 
TNS. The stained sections were hand-mounted on gelatinised microscope slides, allowed to 
air-dry overnight, dehydrated in ascending concentrations of alcohol (75-100%, Fisher 
Scientific), cleared in xyelene (VWR), and finally cover-slipped using DPX mountant.  
An illustrative example of a nigra stained for tyrosine hydroxylase using the protocol 
described above in provided in Figure 2.6. 
2.11. Cell counting 
Anatomical structures were defined according to Paxinos & Watson (1986). Distinction 
between the SNc and VTA was made by defining the VTA as the TH+ cell body containing 
area medial to the MT tract and lateral to the fasciculus retroflexus. Cell bodies staining  
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Figure 2.6. Example of an intact nigra stained for tyrosine hydroxylase using the protocol 
described in section 2.10. MT=Medial terminal nucleus, SNc=Substantia nigra pars 
compacta, VTA=Ventral tegmental area. 
 
positive for TH in the SNc and VTA were manually counted using a microscope with a 10 x 
magnification at the level where the mammillotegmental tract separated the two regions. One 
section was counted per rat, All TH+ cell bodies in the SNc and VTA of the section were 
counted, and the cell bodies in the ipsilatereal side were expressed as a percentage of the 
intact side. It is recognised that the method does not provide an absolute number of cell 
bodies such as stereotactic counting would. However, in the experiments reported in this 
thesis cell counting was conducted to confirm presence of a lesion and expressing dopamine 
loss as a percentage of intact side was therefore sufficient. Rats with <90% dopamine loss in 
the ipsilateral SNc following a MFB lesion were considered not to have full lesions. These 
were therefore excluded from further analysis with the exception of (i) Experiment 2 where 
data from rats with <90% dopamine loss in the SNc was included as the aim of the 
experiment was to compare motor performance of rats with <90% and ≥90% SNc dopamine 
loss and (ii) Experiment 3 which used intra-striatal lesions that are known to induce less 
pronounced loss of dopaminergic cell bodies (Yuan et al, 2005) and where no cut-off was 
used.  
2.12. Optical density 
Optical density was used to measure striatal dopamine denervation in Experiments 3, 4, 5 and 
9. Optical density was measured from one section per rat. Pictures showing both the 
ipsilateral and contralateral striata were taken using a Leica DFC420 camera and Leica 
application v3.6 software. Photos were converted into black-and-white 8-bit format and 
optical density in the striatum measured using Image J v1.42 software (National Institute of 
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Health, U.S.A.). A grey scale was used to convert grey scale measurements into arbitrary 
optical density measures. The optical density of the corpus callosum was subtracted from the 
optical density values of the ipsilateral and contralateral striatum. The normalised optical 
density measures were then used for measuring the percentage loss of striatal optical density 
and for subsequent statistical analyses. 
2.13. Western blot 
All Western blot analysis reported in this thesis was conducted in Dr. Fabrizio Gardoni‟s 
(Department of Pharmacology, Milan University, Italy) lab who also quantified the Western 
blot data and provided the author of this thesis with numerical data for statistical analysis. 
Subcellular fractionation of striatal tissue was performed as described in Gardoni et al 
(2006) with minor modifications. Striata were homogenized in ice-cold sucrose 0.32 M 
containing 1 mM Hepes,1 mM MgCl2, 1 mM EDTA, 1 mM NaHCO3, 0. mM PMSF, at pH 
7.4. The homogenized tissue was centrifuged at 1000 g for 5 min. The resulting supernatant 
was centrifuged at 13000 g for 15 min to obtain a crude membrane fraction. The pellet was 
resuspended in buffer containing 75 mM KCl and 1% Triton X-100 and centrifuged at  
100 000 g for 1 h. The final pellet, referred to as TIF, was homogenized in a glass-glass 
potter in 20 mM Hepes and stored at -80°C until processing. TIF was used instead of the 
classical Post-Synaptic Density, because the amount of the starting material was very limited. 
All purifications were performed in presence of a complete set of protease (Complete) and 
phosphatase (PhosSTOP) inhibitors (Roche Diagnostics, Basel, Switzerland). Protein content 
of the samples was quantified using the Bio-Rad (Hercules, CA, USA) protein assay. After 
measuring protein concentration, all samples were standardized at 1 µg/ul concentration and 
20 µg/sample loaded in each lane. Western Blot analysis was performed on the TIF using 
monoclonal antibodies raised against N-Methyl-D-aspartic acid (NMDA) glutamate receptor 
subunits NR2A (Zymed, San Francisco, USA) and NR2B (NeuroMab, Davis, USA). 
Quantification of Western blotting analysis was performed by means of computer-assisted 
imaging (Quantity-One® System; Bio-Rad) after normalization on tubulin levels. 
2.14. Statistical analysis 
All statistical analysis was conducted using SPSS v21.0. In instances of missing values, these 
were replaced using the series mean. Details on statistical tests are specified in the method 
section of each experiment.  
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3. Strain Differences & Lesion Screening 
Background: The chapter describes two experiments that informed methodological decision 
making in later thesis experiments. 
 
Aim: Two experiments were conducted to determine (i) whether Lister Hooded rats could be 
used in experiments studying the behavioural effects of LID onset, (ii) whether lesion rats 
that had been chronically treated with L-DOPA could be tested in operant chambers 
following acute L-DOPA administration without the presence of disabling AIMs, and (iii) 
whether non-pharmacological behavioural tests could be used to predict lesion success in the 
unilateral 6-OHDA MFB rat. 
 
Methods: Experiment 1 compared Lister Hooded and Sprague Dawley rats in terms of their 
AIMs following chronic L-DOPA treatment, their motor response to acute L-DOPA, and 
their performance on a simple discrimination task following acute administration of L-DOPA 
or saline. Experiment 2 used behavioural and histological data from a pilot experiment to 
determine the relationship between dopamine loss in the SNc and VTA and performance on 
non-pharmacological motor tests. These findings were compared with behavioural and 
histological data collected in later thesis experiments. 
 
Results: Data from Experiment 1 suggested that (i) Lister Hooded rats can be used in          
L-DOPA experiments instead of the more commonly used Sprague Dawley strain, and (ii) 
lesion rats that have received chronic L-DOPA treatment can be tested in operant chambers 
following acute administration of a low (1 mg/kg) L-DOPA dose without disabling 
dyskinesias interfering with operant performance. Data from Experiment 2 suggested that the 
non-pharmacological cylinder test is preferable to amphetamine induced rotations when 
screening lesion success in psychopharmacological experiments.  
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3.1. Introduction 
3.1.1. Pigmented versus albino rat strains 
A primary aim of this thesis project was to test the effect of acute and chronic L-DOPA on 
non-motor function in the 6-OHDA rat model of PD. This was planned to be accomplished, 
in part, by using the operant LCRT task (section 2.7.2.2). The dyskinetic and motor effects of 
L-DOPA are typically studied using albino rat strains, such as the Sprague Dawley rat (e.g. 
Monville et al, 2005, Breger et al, 2013). However, pigmented strains such as the Lister 
Hooded rat have better vision (Prusky et al, 2002) and are therefore preferred in operant 
paradigms reliant on the presentation of visual cues such as the LCRT task (e.g. Carli et al, 
1985).  
There are known differences between pigmented and albino rats‟ spontaneous activity 
levels and their performance on behavioural tests such as object discrimination, spatial 
learning, and autoshaping (Andrews et al, 1995; Nakagawara et al, 1997). Rat strains also 
differ in a range of parameters that could affect the response to dopaminergic treatment such 
as basal levels of dopamine, dopamine transporter (DAT), and the expression of striatal D1 
and NMDA receptors (Sziraki et al, 2001; Zamudio et al, 2005; Lei et al, 2009) which are 
implicated in LID (Mela et al, 2012; Gardoni et al, 2012; Sawada et al, 2010). Whilst it is 
unknown whether there are strain differences in cortico-striatal plasticity, which is also 
implicated in LID (Picconi et al, 2003), Lister Hooded rats are known to differ from the 
albino Wistar strain in e.g. hippocampal plasticity (Manahan-Vaughan & Schwegler, 2011).  
Because of the behavioural and physiological differences between albino and 
pigmented rat strains, the possibility that they may also differ in their motor and dyskinetic 
response to L-DOPA could not be excluded. The LCRT task, where rats respond to visual 
stimuli (Carli et al, 1985) and where a high level of visual acuity is required, was to be 
utilised in later experiments. The pigmented Lister Hooded strain has previously been used in 
in-house LCRT task experiments (e.g. Dowd & Dunnett, 2004), and would because of their 
higher visual acuity (Prusky et al, 2002) be preferable to albino strains in LCRT task studies. 
However, Lister Hooded rats are not typically used in L-DOPA studies. Previous in-house 
experiments on L-DOPA and LID have instead utilised Sprague Dawley rats (e.g. Monville et 
al, 2005, Breger et al, 2013). Therefore, before proceeding with psychopharmacological 
experiments where L-DOPA was administered to Lister Hooded rats before LCRT task 
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testing, it was desirable to test whether there were gross strain differences in Sprague Dawley 
and Lister Hooded rats‟ dyskinetic, motor, and operant response to L-DOPA.  
3.1.2. Pharmacological versus non-pharmacological lesion screening tests 
Another issue which warranted further study was the way in which lesion extent would be 
assessed following recovery from unilateral 6-OHDA lesions. A successful unilateral lesion 
causes marked asymmetry in the dopamine levels of the intact and lesion striata, which is 
reflected in an ipsilateral bias of rats‟ movement (Ungerstedt, 1968). The bias may be 
enhanced pharmacologically, using apomorphine or amphetamine (e.g. Matsuda et al, 1995; 
Ungerstedt & Arbuthnott, 1970). The dopamine agonist apomorphine induces a contralateral 
rotational bias, as 6-OHDA lesions are associated with sensitisation of dopamine receptors in 
the lesion striatum. Amphetamine, on the other hand, causes dopamine release from 
dopaminergic terminals whilst simultaneously blocking dopamine reuptake. This increases 
the already existent dopamine asymmetry between the lesion and intact striata of rats with 
unilateral 6-OHDA lesions and enhances their ipsilateral rotational bias (Ungerstedt & 
Arbuthnott, 1970; Costall et al, 1976; Carboni et al, 1989). The ability to pharmacologically 
enhance unilaterally lesion rats‟ rotational bias has led to apomorphine and amphetamine-
induced rotations being commonly used to assess lesion extent in research utilizing the rat     
6-OHDA model of PD (Smith et al, 2010). 
 However, there are limitations to using apomorphine- and amphetamine-induced 
rotations as lesion screening tests. Apomorphine exposure induces a long-lasting sensitisation 
of apomorphine-induced rotations (Klug & Norman, 1993) and has been shown to increase 
the magnitude of later AIMs (Delfino et al, 2004). As it alters both later motor behaviour and 
AIMs, it was not considered appropriate for use in experiments exploring the effects of LID 
onset on motor and non-motor function. Furthermore, while apomorphine causes a robust 
rotational response in rats with >90% striatal dopamine loss, it does not detect less 
pronounced lesions (Hefti et al, 1980) and is therefore not suitable for e.g. the intra-striatal 
lesion model utilised in Chapter 4. Acute amphetamine does cause a turning bias in rats with 
<90% striatal dopamine loss (Hefti et al, 1980). Unlike apomorphine, the net rotational bias 
observed following acute amphetamine also correlates significantly with striatal dopamine 
loss (Hudson et al, 1993). However, recent data has queried whether the long-term effects of 
the drug make it an inappropriate lesion screening method for cognitive and 
psychopharmacological experiments.  
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 For example, when Nelson & Killcross (2006) investigated the effect of amphetamine 
on habit formation, rats that were exposed to d-amphetamine (2 mg/kg for seven days) were 
found to conduct more magazine entries and lever presses when tested on a random-interval 
schedule post-satiation than saline treated controls did. As such, the data suggested that 
amphetamine exposure made rats prone to revert to habitual responses, rather than exhibiting 
goal-directed behaviours (Nelson & Killcross, 2006). This hypothesis was supported by a 
study conducted by a separate group in which rats that had been exposed to d-amphetamine 
(2.5 mg/kg for five days) prior to training on a random interval schedule failed to show a 
decrease in lever presses following devaluation, again suggestive of an amphetamine-driven 
switch from goal directed to habitual behaviour (Nordquist et al, 2007). In addition, 
Nordquist and colleagues (2007) observed that, prior to satiation, amphetamine-treated rats 
made more presses on the reinforced lever than saline controls did on a random ratio task 
without differing in their lever presses on a non-reinforced lever. It was suggested that this 
phenomenon represented an increase in the motivational value of the sucrose reward 
following amphetamine priming (Nordquist et al, 2007). Together, the studies by Nelson & 
Killcross (2006) and Nordquist and colleagues (2007) suggest a replicable effect of repeated 
amphetamine exposure on habit formation.  
There is also reason to believe that even a single amphetamine exposure may have 
long-term effects on the dopaminergic system. Rats that have been exposed to one injection 
of 5 mg/kg amphetamine show an increased locomotive response to later injection of 1 mg/kg 
amphetamine (Vanderschuren et al, 1999). Relative to saline controls, these rats also show 
increased locomotor response to acute cocaine, and a trend (p=0.06) towards an increase in 
their locomotor response to a D2 agonist (Vanderschuren et al, 1999). Furthermore, in vitro 
data show that a single exposure to amphetamine (i) increases the levels of electrically 
evoked dopamine and acetylcholine release in vitro from tissue slices obtained from the 
striatum, NAcc, and prefrontal cortex (Vanderschuren et al, 1999), (ii) increases the striatal 
5-HIAAV/5-HT ratio (Cadet et al, 2010), and (iii) alters the expression of a range of genes in 
the intact as well as the dopamine denervated striata, including an increase in c-Fos (Cadet et 
al, 2010).  
Together, the abovementioned studies imply that repeated administration of 
amphetamine as part of lesion screening could affect subsequent non-motor behaviour and 
potentially confound data obtained from operant tasks, particularly in paradigms based upon 
stimulus-response associations. Furthermore, even a single exposure to amphetamine could 
affect later neurochemical or behavioural responses to dopaminergic drugs. For these reasons, 
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amphetamine was considered inappropriate for screening lesions in experiments testing the 
effect of L-DOPA on subsequent motor and non-motor behaviour. Therefore, Experiment 2 
analysed histological and behavioural data gathered from a pilot experiment in order to 
identify non-pharmacological screening tests that could be used in later thesis experiments.  
3.2. Experiment 1: Assessing Strain Differences in L-DOPA Response 
3.2.1. Introduction 
The primary purpose of the experiment was to determine whether Lister Hooded rats could be 
used in place of Sprague Dawley rats in later experiments including both LID induction and 
operant testing. However, the opportunity was seized to simultaneously test whether (i) it was 
possible to administer acute L-DOPA to lesion rats that had previously been chronically 
treated with L-DOPA prior to testing in operant boxes without AIMs interfering with operant 
behavioural output, (ii) if acute L-DOPA impacted on lesion rats‟ performance on a simple 
discrimination and reversal learning task. 
LID is associated with a range of changes to the dopaminergic system, including 
sensitization of D1 receptors (Aubert et al, 2005) which are implicated in the expression of 
AIMs (e.g. Mela et al, 2012). Following LID onset, animals will exhibit AIMs following 
subsequent acute L-DOPA administration. If such AIMs were to occur during testing in 
operant chambers they could interfere with purposeful motor actions, confound the data, and 
increase the risk of injuries. It was therefore necessary to determine if a low dose of acute     
L-DOPA could induce sufficient motor activation so as to be functional in rats with previous 
history of chronic L-DOPA treatment, without inducing severe AIMs.  
When testing whether it was possible to conduct operant testing following acute 
administration of a low L-DOPA dose, a simple discrimination and reversal learning task 
which was hypothesized to rely on the dopaminergic system was utilised. The task took place 
in two-lever boxes and rewarded rats for pressing one, over the other, lever. Following three 
days of testing, the contingencies were changed so as to reward rats for pressing the opposite 
lever. Simple discrimination and reversal learning both depend on striatal function, but recruit 
different part of the striatal system. Lesions to the dorsolateral striatum, which is connected to 
prefrontal motor cortex, disrupt acquisition of a simple discrimination task (Featherstone et 
al, 2004; Robbins et al, 1990). Conversely, reversal learning is believed to be reliant on the 
ventral striatum and ventral prefrontal cortex (Clarke et al, 2004). Based on previously 
published data suggesting a disruptive effect of dopamine depletion on performance on a 
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discrimination task (e.g. Robbins et al, 1990) it was hypothesised that lesion rats would be 
impaired relative to intact controls when acquiring the simple discrimination task utilised in 
this experiment. Moreover, because the lesions were unilateral it was further hypothesized 
that the deficit would only manifest itself when lesion rats were reinforced for responding on 
the lever contralateral to the lesion.  
Following dopamine loss, it has been suggested that performance on simple 
discrimination and reversal learning tasks is affected by acute L-DOPA (Cools, 2006). Acute 
L-DOPA administration has been shown to reinstate the ability to acquire a simple 
discrimination task in dopamine deficient mice which were otherwise unable to learn the task 
(Robinson et al, 2007). Conversely, acute L-DOPA also impairs accuracy on reversal 
learning tasks (Clarke et al, 2004; Cools, 2001). The disparity in the effect of acute L-DOPA 
on simple discrimination and reversal learning has been suggested to relate to the drug‟s 
ability to mimic the neural “reward signal”, a signal consisting of phasic dopamine release 
that typically occurs following delivery of a US (Schultz, 2010). By mimicking the reward 
signal, which is lost or attenuated following dopamine denervation, acute L-DOPA has been 
suggested to enhance learning dependent on positive reinforcement in PD patients (Cools, 
2006). However, the elevated striatal dopamine levels that follow acute L-DOPA 
administration have been suggested to simultaneously mask the depression in dopamine 
activity that typically occur following omission of an expected reward (Frank et al, 2004; 
Schultz, 2010; Cools, 2006). Based on current literature, it was therefore hypothesised that 
acute L-DOPA administration would restore the dopamine reward signal that was expected to 
be lost or reduced when lesion rats performed correct contralateral responses, while 
simultaneously masking the depression in dopamine activity that should occur when an 
expected reward following a correct response was omitted (i.e. when switching 
contingencies). Hence, during operant testing it was hypothesized that acute L-DOPA would 
(i) improve lesion rats‟ performance when lesion rats were rewarded for making contralateral 
responses, and (ii) impair lesion rats‟ reversal learning.  
As previously stated, excitotoxic lesions to the ventral striatum have been shown to 
impair reversal learning (Clarke et al, 2004). In addition, dopamine loss in the NAcc (which 
forms part of the ventral striatum) also reduces responding for food pellets in progressive 
ratio tasks, which are commonly used to measure rats‟ motivation to work for food or drug 
rewards (e.g. Hamill et al, 1999). MFB lesions decrease dopamine levels in both the dorsal 
and ventral striatum (Deumens et al, 2002). It was therefore possible that the MFB 6-OHDA 
lesions used in this experiment would decrease rats‟ motivation to work for sucrose pellets. 
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Acute L-DOPA could further affect motivation, as the L-DOPA doses required to offer 
therapeutic relief of motor symptoms (mediated by the dorsal striatum) are believed to 
simultaneously over stimulate the less denervated ventral striatum (Cools, 2006; Hamill et al, 
1999). Therefore, at the end of the simple discrimination task, the current experiment also 
tested whether there was an effect of 6-OHDA MFB lesions, and acute L-DOPA on the 
number of sucrose pellets consumed by rats in a sucrose pellet test. 
3.2.1.1. Aims 
The aim of the experiment was to (i) test for strain differences in Sprague Dawley and Lister 
Hooded rats‟ motor and dyskinetic response to acute L-DOPA, (ii) confirm whether lesion 
rats that had been chronically treated with L-DOPA treatment could be tested in operant 
chambers following a low dose of acute L-DOPA without the interference of AIMs, and (iii) 
test whether a low dose of acute L-DOPA affected learning on a simple discrimination and 
reversal learning task or (iv) the number of freely available sucrose pellets consumed by 
lesion rats.  
3.2.2. Methods 
3.2.2.1. Experimental design 
A subgroup of Lister Hooded and Sprague Dawley rats was given unilateral 6-OHDA lesions 
to the MFB and then chronically treated with L-DOPA until stable AIMs developed. 
Following a three day wash-out period, the effect of acute L-DOPA on the vibrissae and 
adjusting step tests, as well as on rats‟ spontaneous activity levels, was measured. Rats were 
then tested on a simple discrimination task, and a pellet consumption test following acute 
administration of saline or 1 mg/kg L-DOPA (Figure 3.1).  
3.2.2.2. Procedure 
Female Lister Hooded (n=21) and Sprague Dawley (n=20) rats were food restricted for 1 
week before undergoing magazine and lever press training in two-lever operant boxes 
(2.7.2.2.4). All rats completed training within 14 days.  
Subgroups of the Lister Hooded (n=13) and Sprague Dawley (n=12) rats were given 
unilateral 6-OHDA MFB lesions using 6-OHDA (section 2.2.2), leaving the remaining Lister 
Hooded (n=8) and Sprague Dawley (n=8) rats as intact controls. Following recovery, lesion 
extent was assessed using amphetamine-induced rotations (section 2.4.6.2). All lesion rats 
were then administered 10 mg/kg L-DOPA daily for two weeks during which period they 
were scored for AIMs (section 2.5). At the end of the chronic L-DOPA treatment an 
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Figure 3.1. A graphical representation of the experimental design of Experiment 1. The 
figure specifies both the duration of the individual testing phases, and the overall number 
of days in the experiment. Ad lib=Ad libitum, AIMs=Abnormal involuntary movements, 
Amphet.=Amphetamine, FR=Food restriction, MFB=Medial forebrain bundle, s.c.= 
subcutaneous, SD=Simple discrimination 
 
additional AIMs scoring session was conducted. In this session, AIMs were recorded 
following administration of 1 mg/kg L-DOPA. At the same time, the effect of 1 mg/kg         
L-DOPA on activity levels was measured using activity cages (section 2.4.2). Rats were 
allowed a 30 min habituation period in the activity boxes before s.c. L-DOPA administration, 
after which the number of beam breaks made was automatically recorded by the system for 
60 min. Note that the purpose of the test was to determine whether or not the chosen            
L-DOPA dose would induce a behavioural effect in lesion rats. For this reason, and due to a 
restricted number of available activity cages, only lesion rats were tested. Furthermore, to 
better understand the effect of 1 mg/kg L-DOPA on motor function, lesion rats‟ performance 
on the adjusting step and vibrissae tests (2.4.3 and 2.4.8) was measured following 
administration of L-DOPA (“on” condition) or saline (“off” condition).  
Intact and lesion rats were then food restricted for one week and tested on a simple 
discrimination task in two-lever operant boxes (section 2.7.1) where their ability to 
discriminate between a reinforced and non-reinforced lever was measured. Approximately 
half of the lesion Lister Hooded (n=7) and Sprague Dawley rats (n=5) were injected s.c. with 
1 mg/kg L-DOPA 20 min prior to testing. The remaining lesion rats and all intact rats were 
given a s.c. saline injection of 1 ml/kg. At the end of the operant testing rats were tested in 
two versions of a pellet consumption test, in a counter balanced order. The pellet test took 
place in the same two-lever operant boxes as before and is further described in section 
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2.7.1.2.3. Briefly, pressing the illuminated panel resulted in the delivery of a sucrose pellet 
and the extinction of the panel light. Following an inter-trial interval (ITI), the panel was re-
illuminated and the rats could panel press to obtain another sucrose pellet. Presses made 
during the ITI did not produce a sucrose pellet. The two versions differed in the length of the 
ITI, which was either 0 s or 5 s. Previous observation of lesion rats had suggested that they 
could consume one sucrose pellet in less than 5 s. Therefore, a 5 s ITI was hypothesized to be 
less sensitive to an effect of 6-OHDA lesions on motor function than a 0 s ITI. Specifically, 
in the 0 s ITI version, it was expected that if both groups continuously panel pressed for 
sucrose pellets as fast as they could, the lesion induced motor impairment would still cause 
the lesion cohort to obtain overall fewer sucrose pellets than the intact group. Therefore, if 
lesion rats were to perform worse than intact rats on the 0 s ITI but not the 5 s ITI version of 
the task it could be hypothesized that the difference between lesion and intact rats was driven 
by a motor deficit.  
At the end of testing, rats were perfused (section 2.8) and their brains used for TH 
immunohistochemistry (section 2.10). Lesion extent was determined by counting the 
surviving TH+ cell bodies in the SNc and VTA (section 2.11).  
3.2.2.3. Statistical Analysis 
Neither SNc nor VTA dopamine denervation data showed a normal distribution. Whereas the 
VTA denervation data showed normal distribution after the data values were converted into 
the square root of the original values, it was not possible to transform the SNc dopamine 
denervation data to meet normal distribution. Therefore, the transformed VTA dopamine 
denervation data were analysed using a one-way ANOVA whereas the SNs dopamine 
denervation data were analysed using a non-parametric Kruskal Wallis test. Both tests 
compared the four experimental groups‟ (Sprague Dawley or Lister Hooded rats administered 
acute L-DOPA or saline during motor and operant tests) degree of dopamine denervation 
expressed as a percentage of the intact side. Striatal optical density was analysed in two 
separate non-parametric tests. First, the raw optical density measures from the ipsilateral 
versus contralateral striatum were compared using a Wilcoxon test to confirm that the lesion 
had reduced TH+ staining in the lesion striata. Second, a Kruskal-Wallis test was used to test 
whether the experimental groups differed in the percentage loss of ipsilateral striatal TH+ 
immunoreactivity induced by the lesion. 
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AIMs scores were analysed using a repeated measures ANOVA with Strain as 
between subject factor and Dose as a within subject factor.  
Baseline activity data were calculated as the average activity recorded during the 
habituation period and analysed using a one-way ANOVA. The effect of L-DOPA on 
spontaneous locomotion was analysed including all time points and using a repeated 
measures ANOVA with Strain as between subject factor, and Time Point as a within subjects 
factor.  
Data from the motor behaviour tests were analysed using a repeated measures 
ANOVA with Strain as a between subject factor, and Drug and Side as within subjects 
factors. As previously described, this data set only included data from lesion rats (n=25). 
Data from the simple discrimination task were analysed using a repeated measures 
ANOVA with Strain, Lesion, and Drug as between subject factors, and Side, Day, and Block 
as within subject factors. Block referred to a set of 10 consecutive trials, and was used as an 
indicator of within-session learning. Each trial consisted of 5 blocks, i.e. 50 trials.  
Pellet consumption data were analysed using a repeated measures ANOVA with 
Strain, Lesion, and Drug as between-subject variables, and the length of the ITI as a within-
subject variable.  
3.2.3. Results 
3.2.3.1. Lesion extent 
When counting the number of dopaminergic cell bodies, (described in section 2.11), a median 
of 118 (1
st
 and 3
rd
 quartile = 107 and 135) and 120 (1
st
 and 3
rd
 quartile = 103 and 152) TH 
positive cell bodies were counted in the intact SNc and VTA respectively (numbers from one 
brain section). These numbers are in line with what has been observed in other in-house 
studies using the same immunohistological protocol, and the same histological and 
microscope equipment (unpublished data). 
 The lesion induced a profound loss of TH positive cells bodies in both the ipsilateral 
SNc (Figure 3.2A) and the ipsilateral VTA (Figure 3.2B). A further analysis comparing the 
percentage loss in the ipsilateral relative to the contralateral hemisphere demonstrated that  
the four groups (Lister Hooded/Sprague Dawley tested on/off acute L-DOPA during motor 
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and operant testing) did not differ significantly in their denervation of the ipsilateral SNc 
(H=4.72, df=3, n.s.) or VTA (F3,24=1.57, n.s.).  
In addition to SNc and VTA denervation, the lesion also produced a significant 
decrease in the optical density measured in the lesion relative to the intact striatum (Figure 
3.2C; Z=-4.37, p<0.001). A further analysis based on the percentage decrease in ipsilateral 
optical density showed that the striatal denervation did not differ significantly between the 
groups (H=7.71, df=3, n.s.). 
 
 
Figure 3.2. The median surviving TH+ cell bodies in the ipsilateral SNc (A) and VTA (B), 
and the mean striatal optical density (C), all shown as a percentage of the intact side, of 
the lesion Lister Hooded (n=13) and lesion Sprague Dawley (n=12) cohorts. The photos 
show the striatum (D), the SNc, and the VTA (E) of a lesion rat included in the 
experiment. “On” and “off” refers to groups administered 1 mg/kg acute L-DOPA (“on”) 
or 1 mg/kg saline (“off”) prior operant testing. The box plots show the median and 
interquartile ranges, and circles represent outliers. LH=Lister Hooded, SD=Sprague 
Dawely, SNc=Substantia nigra pars compacta, TH=Tyrosine hydroxylase, VTA=Ventral 
tegmental area. 
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3.2.3.2. Dyskinetic response to L-DOPA 
Following chronic L-DOPA, all lesion rats developed LID. As expected, AIMs scores were 
significantly lower following administration of 1 mg/kg, than 10 mg/kg, L-DOPA (Figure 
3.3; Dose: F1,23=9.26, p<0.001). Lister Hooded rats showed significantly higher AIMs than 
Sprague Dawley rats, especially following administration of 10 mg/kg L-DOPA (Strain: 
F1,23=7.89, p<0.05; Dose x Strain: F1,23=6.28, p<0.05; Simple Effect:F1,23=7.56, p<0.05). 
 
 
Figure 3.3. The average cumulative AIMs scores of the lesion Lister Hooded (n=13) and 
lesion Sprague Dawley (n=12) group following administration of 10 mg/kg and 1 mg/kg 
L-DOPA. The error bars show the standard error of the mean. AIMs=Abnormal 
involuntary movements.*Effect of Dose; ⱡEffect of Strain, ⱡp<0.05, *p<0.05  
 
3.2.3.3.Effect of acute L-DOPA on motor function 
The two strains‟ locomotor response to 1 mg/kg acute L-DOPA was measured both by 
comparing their average baseline activity levels (one-way ANOVA) and by analysing the 
number of beam breaks made at all testing time points before and after L-DOPA injection 
(repeated measures ANOVA). There was no significant difference between the baseline 
number of beam breaks made by the Lister Hooded and Sprague Dawley strains (Figure 
3.4A; F1,23=0.30, n.s.). Neither was there a significant difference in locomotor activity when 
comparing all the beam breaks made during the session (Strain: F1,23=0.30, n.s.). Both strains 
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showed a a significant change in the number of beam breaks made at different times of 
testing (Time point: F21,483=9.74, p<0.001; Time point x Strain: F21,483=0.67, n.s.). However, 
visual inspection of the data did not reveal a clear increase in activity levels post L-DOPA 
injection. Instead the fluctuations related to the increased locomotion displayed by rats when 
first placed in the chambers, which likely reflected explorative behaviour of a novel 
environment. 
Rats‟ forelimb motor function was tested using the adjusting step test. Lesion Sprague 
Dawley and Lister Hooded rats demonstrated a similar contralateral impairment on the 
adjusting step test (Figure 3.4B; Side: F1,23=31.08, p<0.001; Strain: F1,23=1.62, n.s.; Side x 
Strain: F1,23=2.19, n.s.).  
 
 
Figure 3.4. Mean locomotor activity before and after acute L-DOPA administration (A), 
together with the mean performance on the adjusting step (B), and vibrissae (C) tests of 
lesion Lister Hooded (n=13) and Sprague Dawley (n=12) rats that had previously 
received chronic L-DOPA treatment and were tested following acute administration of 1 
mg/kg L-DOPA or saline. The error bars show the standard error of the mean. 
*Significant difference between ipsilateral and contralateral performance in rats tested 
off L-DOPA, #Significant difference between responses made when tested on versus off 
L-DOPA, ǂSignificant difference between Lister Hooded and Sprague Dawley rats‟ 
performance. ǂp<0.05, ***p<0.001, ### p<0.001.. ǂ p<0.05, ***p<0.001, ### 
p<0.001. 
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Acute administration of 1 mg/kg L-DOPA increased the number of adjusting steps lesion rats 
made with both the ipsilateral and contralateral forelimb, with no significant difference 
observed between the two strains (Drug: F1,23=70.70, p<0.001; Drug x Side: F1,23=0.33, n.s.; 
Drug x Strain: F1,23=0.07, n.s.). 
Sensorimotor function was tested using the vibrissae test. While lesion rats in both 
strains exhibited a contralateral deficit in the test (Figure 3.4C; Side: F1,23=47.85, p<0.001), 
this deficit was significantly more pronounced in the Sprague Dawley than in the Lister 
Hooded cohort (Side x Strain: F1,23=6.19, p<0.05; Simple Effect of Strain on Side: F1,23=5.11, 
p<0.05). Administration of 1 mg/kg acute L-DOPA significantly increased the number of 
contralateral responses made by both strains (Side x Drug: F1,23=10.51, p<0.05; Simple Effect 
of Drug on Contralateral Side: F1,23=47.08, p<0.001). The overall magnitude of the L-DOPA 
induced improvement was significantly greater in the Sprague Dawley than in the Lister 
Hooded cohort. However, while there was a trend towards a greater response exclusively on 
the contralateral side this did not reach statistical significance (Strain x Drug: F1,23=6.19, 
p<0.05; Simple Effect of Strain on L-DOPA condition: F1,23=5.63, p<0.05; Strain x Drug x 
Side: F1,23=3.67, p=0.067). Visual inspection of the data together with the statistically 
significant strain difference during the saline condition suggested that the overall difference 
between the effect of L-DOPA in the two strains may have been driven by a more 
pronounced contralateral baseline deficit in the Sprague Dawley cohort (Figure 3.4C). 
3.4.3.4. Simple discrimination task 
Whilst the unilateral lesion was shown to induce contralateral impairments in hand-tests of 
simple motor function, there was no overall effect of the lesion on contralateral accuracy in 
the simple discrimination task (Figure 3.5A-B; Lesion: F1,35=1.71, n.s.). However, relative to 
intact rats, lesion rats were more accurate on the second day of ipsilateral CS testing (Day x 
Side x Lesion: F8,280=3.17, p<0.05; Simple Effect of Lesion on Day: F1,35=7.72, p<0.001).  
While there was no overall difference between the strains (Strain: F1,35=2.93, n.s.), the 
performance of Lister Hooded rats differed significantly from that of Sprague Dawley rats on 
days 1 and 3 of each side of testing (Day x Strain x Lesion: F8,280=2.21, p<0.05; Simple 
Effect: min.F1,35=4.87, p<0.05). However, while Lister Hooded rats were significantly more 
accurate on the first days of contralateral and ipsilateral testing, and had a significantly 
overall lower performance than Sprague Dawley rats on the third day of contralateral and 
ipsilateral testing it should be noted that there were a lot of noise in the data which limits the 
conclusions that can be drawn from this statistical significance.   
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Figure 3.5. The performance of Lister Hooded (A) and Sprague Dawley (B) rats on a simple discrimination task where half the lesion rats 
were administered 1 mg/kg L-DOPA prior to testing while the remaining rats were administered 1 ml/kg saline. Each continuous line 
represents one day‟s performance, broken down into 5 blocks of 10 trials each. In total, rats were tested over 18 days. Half of these days, 
rats were rewarded for pressing the lever contralateral to the lesion and the remaining half rats were rewarded for pressing the lever 
ipsilateral to the lever (labelled „Contralateral CS‟ and „Ipsilateral CS‟, respectively, on the x-axis). The line charts show the mean and the 
error bars show the standard error of the mean. CS=Conditioned stimulus, Rev.= Reversal to ipsilateral/contralateral CS.  
* Effect of L-DOPA, ǂ Effect of Lesion, # Effect of Strain. *p<0.05, ǂ p<0.05, # p<0.05 
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Performance between blocks (i.e. sets of ten consecutive trials) was analysed 
to provide a measurement of learning occurring within daily testing sessions. All rats‟  
performance improved within each daily testing session (Figure 3.5; Block: 
F4,140=89.51, p<0.001). Lesion rats performance differed significantly from that of 
intact rats in the first block of testing (Block x Lesion: F4,140=6.87, p<0.01; Simple 
Effect of Lesion on Block:  F1,35=6.87, p<0.05). Whilst Lister Hooded rats tended to 
show overall greater within-session learning than Sprague Dawley rats (Block x 
Strain: F4,140=4.62, p<0.01), there was no difference in the effect which a lesion had 
on within-session learning in the two strains (Block x Strain x Lesion: F4,140=0.48, 
n.s.).  
Acute L-DOPA administration did not induce an overall improvement in 
accuracy (Figure 3.5; Drug: F1,35=1.66, n.s.), nor was there a difference in the effects 
of acute L-DOPA administration on the two strains (Side x Strain x Drug: F1,35=1.66, 
n.s; Strain x Drug: F1,35=0.16, n.s.), or an effect of acute L-DOPA on within-session 
performance (Block x Drug: F4,140=0.75, n.s.; Block x Strain x Drug: F4,140=0.83, n.s.). 
L-DOPA did, however, mildly impair performance on the third and fourth day of 
testing (Day x Drug: F8,280=3.12, p<0.01; Simple Effect of Drug on Day: 
min.F1,35=6.63, p<0.05; Side x Day x Drug: F8,280=1.37, n.s.). 
 
Sucrose Pellet Consumption Tests. Two versions of the sucrose consumption test, 
using a   0 s and 5 s ITI respectively, were conducted to assess rats‟ motivation to 
consume sucrose pellets in the same operant boxes that had been used in the simple 
discrimination task. All rats consumed more pellets in the 0 s ITI, than the 5 s ITI, 
version of the task (Figure 3.6; ITI: F1,35=98.95, p<0.001). There was no difference in 
the number of sucrose pellets consumed by Lister Hooded and Sprague Dawley rats 
(Strain: F1,35=0.02, n.s.; ITI x Strain: F1,35=0.30, n.s.), nor between lesion and intact 
rats (Lesion: F1,35=2.79, n.s.; ITI x Lesion: F1,35=0.21, n.s.), or rats administered acute 
L-DOPA or saline prior to testing  (Drug: F1,35=0.64, n.s.; ITI x Drug: F1,35=0.01, 
n.s.).  
3.2.4. Discussion 
The primary aim of the experiment was to determine whether (i) Lister Hooded rats 
could be used in the place of Sprague Dawley rats in L-DOPA and dyskinesia 
experiments, and (ii) whether lesion rats that had received chronic L-DOPA treatment 
 83 
 
could be tested in operant chambers following acute administration of a low dose of 
acute L-DOPA without the presence of disabling dyskinesias. To this end, lesion rats 
from the two strains were chronically treated with L-DOPA and compared in their 
AIMs and motor response to a low dose of acute L-DOPA. In addition, their 
performance on a simple discrimination and reversal learning task following acute 
administration of either L-DOPA or saline was compared. Based on the data  
 
Figure 3.6. The mean number of sucrose pellets obtained by Lister Hooded (n=21) 
and Sprague Dawley (n=20) rats on a sucrose pellet consumption test allowing 
rats to panel press for new pellets with a 0 s (A) or 5 s (B) ITI. “On” and “off” 
refer to lesion rats administered 1 mg/kg acute L-DOPA (“on”) or 1 ml/kg saline 
(“off”) prior to testing. The error bars show the standard error of the mean. 
ITI=Intertrial interval. 
 
presented in this section, it was concluded that (i) lesion Lister Hooded rats could be 
used in dyskinesia experiments, and (ii) that it was possible to administer a low        
L-DOPA dose to lesion rats that had previously received chronic L-DOPA treatment 
testing in operant chambers without inducing AIMs of such magnitude so as to 
interfere with operant performance. 
Following chronic L-DOPA treatment, acute administration of 10 or 1 mg/kg            
L-DOPA induced AIMs in lesion rats of both strains. Interestingly, Lister Hooded rats 
exhibited more pronounced AIMs than Sprague Dawley rats when administered acute          
L-DOPA post chronic treatment. The onset of LID and expression of AIMs have both 
been linked to sensitisation and activation of D1 type receptors (Aubert et al, 2005; 
Mela et al, 2012). Previous studies have suggested that rat strains differ in regard to 
their dopamine receptor and dopamine transporter binding (Zamudio et al, 2005). 
While strain differences between Lister Hooded and Sprague Dawley rats‟ D1 
receptors have not, to my knowledge, been specifically explored, Lister Hooded rats 
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show a greater locomotor response to amphetamine than Sprague Dawley rats, a 
phenomenon which has been speculated to be due to differences in the two strains‟ 
dopamine receptor sensitivity (McDermott & Kelly, 2008). Hence, whereas it was 
beyond the scope of the current experiment to determine the reasons for the strain 
difference in AIMs scores, it may be speculated that is was due to differences in Lister 
Hooded and Sprague Dawley rats‟ D1 receptor sensitivity.   
A primary aim of the experiment was to determine whether Lister Hooded rats 
could be used in L-DOPA and dyskinesia experiments instead of Sprague Dawley 
rats, which are more common in such studies (e.g. Monville et al, 2005; Breger et al, 
2013). Although the strains differed in the magnitude of their AIMs scores, LID was 
successfully induced in all lesion L-DOPA treated rats. Previous studies on rats and 
humans have shown between-species consistency in the mechanisms underlying LID 
(e.g. Andersson et al, 1999; Lindgren et al 2011; Verhagen et al, 1998; Breger et al, 
2013). Thus, while there were strain differences in the magnitude of AIMs expression 
these are unlikely to reflect differences in the mechanisms underlying LID and AIMs 
in Lister Hooded versus Sprague Dawley rats. For this reason, and because Lister 
Hooded rats are preferred in operant studies where high visual acuity is necessary, it 
was considered valid to use Lister Hooded rats in lieu of Sprague Dawley rats in later 
experiments where LID onset and operant behaviour were explored simultaneously. 
Because later experiments would administer acute L-DOPA to lesion rats who 
had developed LID prior to operant testing, the current experiment also tested whether 
a low dose of acute L-DOPA could improve motor function in lesion rats that had 
developed LID without simultaneously causing dyskinesias of such magnitude as to 
interfere with operant performance. In line with previous data (e.g. Lindgren et al, 
2007) it was demonstrated that decreasing the acute L-DOPA dose from 10 mg/kg to 
1 mg/kg reduced AIMs magnitude without completely abolishing the dyskinetic 
response to L-DOPA; suggesting a modest yet still measurable motor effect of the 
lower dose.  
However, while it has previously been shown that acute L-DOPA doses higher 
than that used here improve 6-OHDA lesion rats‟ performance on the adjusting step 
test (8 mg/kg; Olsson et al, 1995) the current data did not show improved forelimb 
function following administration of 1 mg/kg L-DOPA. Neither did it show an effect 
of acute L-DOPA on spontaneous activity as measured by the number of beam breaks 
recorded in activity chambers. The latter could be caused by limitations to the 
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apparatus used as the activity cages used were designed for mice and not rats (width 
at bottom of cage=20 cm; length at bottom of cage=36 cm). There was, however, 
improvement on the vibrissae test which, together with the low but measurable 
dyskinetic response to 1 mg/kg L-DOPA, suggested that the dose was sufficient to 
induce a motor response with minimal observable AIMs. Based on the data, the lower 
dose of 1 mg/kg L-DOPA dose was subsequently used in the simple discrimination 
task. Whilst it was not possible to conduct dyskinesia scoring during operant testing, 
rats were closely monitored before and after the operant task and, when possible, on 
video screens whilst in the operant boxes. Such observations did not reveal any 
instances of AIMs preventing rats‟ from performing the task.  
In line with the hypothesis and previous findings by e.g. Robbins and 
colleagues (1990), data from the simple discrimination task showed impaired 
performance in lesion relative to intact rats, albeit subtle. However, contrary to the 
hypothesis, the current data only showed a marginal effect of acute L-DOPA on 
operant performance. This may either suggest that the task was not sensitive to the 
psychopharmacological effects of the drug, or that the ability for all lesion rats in the 
current experiment to acquire the simple discrimination rule caused a ceiling effect 
which limited the possibility of observing a beneficial effect of L-DOPA. It is 
possible that more complex operant tasks are needed in order to observe a robust 
effect of lesion and acute L-DOPA in rats with unilateral 6-OHDA, MFB lesions. 
Following operant testing, rats underwent two versions of a sucrose 
consumption test, using a 0 s and a 5 s ITI respectively. The 5 s ITI version was 
considered less sensitive to motor impairments, as the longer ITI enabled both intact 
and lesion rats to complete consumption of an acquired sucrose pellet before they 
were able to panel press for another pellet. Therefore, motor deficits were considered 
less likely to affect the total number of sucrose obtained by rats in the 5 s ITI than in 
the 0 s ITI version of the task. The data showed that neither the lesion nor acute        
L-DOPA affected the total number of sucrose pellets consumed by the rats. This was 
true for both the 0 s and 5 s ITI version of the task. Thus, there was no evidence for an 
effect of lesion, acute L-DOPA, or strain on lesion rats‟ willingness to consume 
sucrose pellets in the current experiment.  
To conclude, the aim of the experiment was to determine whether Lister 
Hooded rats could be used in experiments combining the study of operant behaviour 
and dyskinesia, despite dyskinesia being more commonly studied in Sprague Dawley 
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rats (e.g. Monville et al, 2005; Breger et al, 2013). The experiment also aimed to 
determine whether a low dose of acute L-DOPA could produce a motor response in 
lesion rats that had been chronically treated with L-DOPA without simultaneously 
causing disabling AIMs. Based on the described data, it was decided to (i) use Lister 
Hooded rats in subsequent experiments incorporating both dyskinesia and operant 
testing (Chapters 7-8), and (ii) use the 1 mg/kg L-DOPA dose when acute L-DOPA 
was administered pre-operant testing to lesion rats that had previously received 
chronic L-DOPA treatment in Chapter 7.   
3.3. Experiment 2: Using non-pharmacological tests to determine 
lesion success in the unilateral 6-OHDA MFB model 
3.3.1. Introduction 
As described in the chapter introduction, the standard apomorphine and amphetamine 
induced rotations were deemed inappropriate methods for screening lesion success in 
later thesis experiments. To find reliable methods of assessing lesion extent that do 
not rely on pharmacological stimulation of the dopaminergic system, the ability of 
amphetamine-induced rotations and three non-invasive behavioural tests to accurately 
predict lesion success in male rats with unilateral 6-OHDA lesions to the MFB was 
compared.  
The rats from which the histological and motor data were obtained had been 
part of an operant pilot not reported in this thesis. For the purpose of the pilot 
experiment the same lesion protocol had been used for all rats, rather than attempting 
to produce lesions of varying size as would have been done had the original purpose 
been to identify correlations between dopamine loss and motor behaviour. The aim of 
the reported analysis was to use the histological and motor data already obtained from 
these rats to identify motor tests that could be used to screen for rats with a SNc 
dopamine loss of ≥90%, which was the cut-off criterion applied in the thesis project 
when deciding whether to include or exclude rats in final data analyses.  
 Based on the results from the analysis, two of the non-invasive behavioural 
tests (spontaneous rotations and the cylinder test) were used when screening for 
lesions in later thesis experiments. At the completion of these experiments, a 
retrospective analysis including spontaneous rotations, cylinder test performance, and 
TH+ counts from later experiments was conducted to validate the initial findings. 
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When available, AIMs scores from later experiments were also included in the 
analysis to test whether these correlated with performance on either behavioural test. 
3.3.1.1.  Aims 
The aim of the first analysis was to compare the ability of amphetamine-induced 
rotations, spontaneous rotations, the elevated body swing, and the cylinder test to 
identify rats with SNc dopamine denervation ≥90%. The experiment used male Lister 
Hooded rats with unilateral    6-OHDA lesion to the MFB.  
A second analysis was thereafter conducted in which behavioural and 
histological data from female Lister Hooded rats used in Chapters 6-8 were included. 
The aim of this was both to replicate the initial findings and to test whether 
spontaneous rotations or the cylinder test correlated with, or could predict, the 
magnitude of later AIMs. 
3.3.2. Methods 
3.3.2.1. Experimental Design 
Analysis of male Lister Hooded rats. Rats were given unilateral lesions to the MFB. 
Following 14 days recovery, their performance on the cylinder test, the elevated body 
swing and the net bias of their spontaneous rotations were measured. Following brief 
operant testing as part of an operant pilot experiment (data not included in this thesis) 
that utilised the simple discrimination task (2.7.1.2), the rats‟ amphetamine-induced 
rotations were recorded. The rats were then perfused and the brain tissue taken for 
histological analysis (Figure 3.7).  
It should be noted that (i) male rats were chosen instead of female rats used because 
the cohort was originally ordered to replicate data obtained using male rats, and (ii) 
because the original intended use of the rats had not been a lesion 
screening/correlation experiment all lesions were conducted using the same lesion 
protocol. Had the original intention been to conduct a correlation/lesion screening 
experiment, the experiment would have been designed to produce lesions of varying 
size.  
Analysis of female Lister Hooded rats. Rats included in the second analysis had 
undergone varied testing and pharmacological treatments prior to culling, as outlined 
in Chapters 6-8. In all instances, rats had been given unilateral 6-OHDA MFB lesions, 
screened using the cylinder test and spontaneous rotations, and been tested on the 
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staircase and LCRT tasks. In some instances rats had undergone chronic L-DOPA 
treatment after testing on the cylinder and spontaneous rotations tests. 
 
 
Figure 3.7. A graphical representation of the experimental design used in the 
lesion screening experiment including male Lister Hooded rats. The figure 
specifies both the duration of the individual testing phases, and the overall 
number of days in the experiment. Light grey boxes indicate testing not reported 
in this thesis. Amphet.=Amphetamine, FR=Food restriction, MFB=Medial 
forebrain bundle, Spont. rotations = Spontaneous rotations.  
 
3.3.3.2. Procedure 
 Analysis of male Lister Hooded rats. Twenty-one male Lister Hooded rats were 
given unilateral 6-OHDA lesions to the MFB (section 2.2.2). Following 14 days 
recovery their motor impairment was measured using the elevated body swing 
(section 2.4.5), spontaneous rotations (section 2.4.6.3) and the cylinder test (section 
2.4.4). After 25 days of participation in a pilot study (not reported), the rats were 
tested for amphetamine-induced rotations as described in section 2.4.6.2. The 
amphetamine-induced rotations were conducted at the end of testing to avoid the 
possibility of amphetamine exposure affecting performance on the other tests.  
 The non-invasive motor tests all measured the presence of a directional motor 
bias following a unilateral lesion. The elevated body swing measures the direction 
which rats turn their bodies when lifted by the base of their tail (Borlongan & 
Sanberg, 1995), the spontaneous rotation test measures the ipsilateral locomotor 
behaviour lesion rats exhibit when placed in a circular environment, and the cylinder 
test measures rats‟ preference for using their ipsilateral over their contralateral 
forelimb during explorative behaviour in a Plexiglas cylinder (Schallert et al, 2000). 
Previous publications have demonstrated that unilateral lesions induce a spontaneous 
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ipsilateral bias on the elevated body swing (Borlogan & Sanberg, 1995), an ipsilateral 
bias in non-drug induced locomotive behaviour (Ungerstedt, 1968; Fornaguera et al, 
1994), and a preference for using the ipsilateral over the contralateral paw in the 
cylinder task (Schallert et al, 2000). Amphetamine-induced rotations, which are more 
commonly used, measure the rotational bias observed following acute administration 
of amphetamine. Previous publications have reported an enhancement of the 
spontaneous ipsilateral bias exhibited by rats with unilateral 6-OHDA lesions 
following acute amphetamine administration (Ungerstedt & Arbuthnott, 1970; Torres 
et al, 2010).  
In the operant pilot study (not reported), rats were food restricted and 
underwent testing on the simple discrimination task described in sections 2.7.1.2 and 
Experiment 1. No drugs were administered as part of the pilot experiment and the rats 
were not tested on other motor behavioural tests than those reported in the results 
section. Once all operant and behavioural testing was completed, rats were euthanized 
by an overdose of Euthatal, perfused (section 2.8) and their brain tissue was taken for 
TH immunohistological staining (section 2.11). 
Analysis of female Lister Hooded rats. Rats included in the retrospective analysis 
had undergone varied behavioural testing prior to culling as further detailed in 
Chapters 6-8. A total of 169 lesion female Lister Hooded rats were included. All rats 
had undergone unilateral 6-OHDA MFB lesion (section 2.2.2) and, following 14 days 
recovery from surgery, been screened for lesions using the spontaneous rotation 
(section 2.4.6.3) and cylinder (section 2.4.4) tests. The correlation between the rats‟ 
SNc dopamine loss, VTA dopamine loss, ipsilateral bias on the cylinder test, and net 
ipsilateral bias on the spontaneous rotations were was calculated to validate the 
findings from the male cohort.  
In addition to validating the findings obtained from the male cohort, the data 
from the female rats were also used to test whether the cylinder or spontaneous 
rotation tests could predict later AIMs scores. Following lesion screening, 53 of the 
169 rats had received chronic L-DOPA treatment consisting of daily injections of 10 
mg/kg L-DOPA until their cohort exhibited stable AIMs. Note that rats that had been 
co-treated with a TAT2A peptide in an attempt to prevent LID onset in Experiment 10 
were not included in this analysis. A second correlation analysis only including the 53 
lesion, L-DOPA treated rats was conducted. The analysis contained the same 
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variables as above, as well as the cumulative AIMs score obtained from the rats‟ final 
AIMs scoring session. 
3.3.3.3. Statistical analysis 
For all analyses, cell counts of dopaminergic cell loss in the SNc and VTA were 
expressed as a percentage of the counts on the intact side of the brain. In the male 
cohort, the loss of dopaminergic cell bodies in the ipsilateral SNc and VTA, the 
ipsilateral bias on the cylinder and elevated body swing tests were not normally 
distributed. As parametric tests are more robust than their non-parametric 
counterparts, the data from the surviving SNc and VTA neurons was transformed 
using the Lg10 values, which resulted in them showing of a normal distribution. As 
the data from the cylinder and elevated body swing could not be transformed 
successfully the original values from these tests were used in the analysis. Dopamine 
loss was correlated with the parametric rotational bias using a Person correlation. All 
other correlations were conducted using a Spearman rho correlation. Finally, a partial 
correlation analysis was conducted. In addition to the correlations, one-way ANOVAs 
(for normally distributed data) or Mann-Whitney U tests (for non-normally distributed 
data) tests were conducted to determine whether there was a significant difference in 
motor performance between rats with ≥90% and <90% TH loss in the lesion SNc.  
In the analysis including female Lister Hooded rats, only the spontaneous 
rotation data showed a normal distribution. As the remaining data could not be 
transformed into a normal distribution all correlation data was correlated using a 
Spearman rho correlation. Between group differences were analysed using a Kruskal 
Wallis (in the case of spontaneous rotations) or a one-way ANOVA (in the case of the 
cylinder test).  
3.3.3. Results 
3.3.3.1. Analysis of Male Lister Hooded rats 
Dopamine depletion. The percentage of remaining dopaminergic cells ranged from 
2% to 72% in the lesion SNc, and from 9% to 86% in the lesion VTA (Figure 3.8A). 
The median percentage of surviving TH+ cells was 8% (1
st
 and 3
rd
 quartile: 4% and 
19%) in the SNc and 22% (1
st
 and 3
rd
 quartile: 15% and 40%) in the VTA. Nine of the 
21 rats showed less than 90% SNc depletion, which was the cut-off line used in other 
experiments to distinguish between lesion and non-lesion rats. The spread in the 
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dopamine denervation, which was greater than in later thesis experiments, made it 
appropriate to analyze the data using both correlations and cut-off thresholds.    
 
 
Figure 3.8. The median number of surviving TH+ cell bodies in the ipsilateral SNc 
and VTA, expressed as a percentage of the intact side (A), together with a photo 
of the SNc and the VTA (B) of a lesion rat included in the experiment. The boxplot 
shows the median, and the interquartile ranges, with the circles representing 
outliers. SNc=Substantia nigra pars compacta, TH=Tyrosine hydroxylase, 
VTA=Ventral Tegmental Area. 
 
Relationship between motor behaviour and SNc dopamine loss. The rats exhibited 
an ipsilateral bias on all four behavioural tests (Figure 3.9). The relationship between 
dopamine loss and ipsilateral bias was explored both using correlations and by 
exploring what, if any, thresholds that could be applied to the motor data to 
distinguish between rats with ≥90% and <90% SNc dopamine loss.  
SNc denervation correlated significantly with the ipsilateral bias exhibited in 
the cylinder test (Figure 3.10A; r=0.70, n=21, p<0.01), the spontaneous rotations 
(Figure 3.10B; r=0.64, n=21, p<0.01), and the amphetamine-induced rotations (Figure 
3.10C; r=0.52, n=21, p<0.05), but not with the net ipsilateral bias on the elevated 
body swing test (Figure 3.10D; r=0.32, n=21, n.s.). A further analysis was conducted 
to determine whether there was a statistically significant difference in the 
performance of rats with ≥90% or <90% TH loss in the SNc. A significant difference 
between the groups was observed in the spontaneous rotation (F1,20=5.85, p<0.05) and 
cylinder tests (U=9, n=21, p<0.05). Conversely, the bias exhibited in the 
amphetamine-induced (F1,20=1.28, n.s.) rotations and the elevated body swing  
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Figure 3.9. Boxplots (A, C, D) and barchart (B) illustrating the median (A, C, D) 
and mean (B) ipsilateral bias on the cylinder test (A), spontaneous rotations (B), 
amphetamine-induced rotations (C), and elevated body swing (D) tests in male 
Lister Hooded rats with unilateral 6-OHDA lesions to the MFB. The boxplots (A, C, 
D) show the median and interquartile ranges, with circles representing outliers. 
The error bars in the bar chart (B) show the standard error of the mean.  
 
(U=40.50, n=21, n.s.) did not differ between rats with a dopamine denervation of 
<90% and ≥90%.  
Data from the cylinder and spontaneous rotations tests, where a significant 
difference between rats with ≥90% and <90% SNc dopamine loss was observed, were 
further studied to determine appropriate cut-off thresholds for identifying rats with 
≥90% SNc denervation. By using a 100% ipsilateral bias on the cylinder test as a cut-
off line, 83.3% of rats with a SNc denervation of ≥90% were identified and only 
11.1%, i.e. a single rat, of the group with <90% SNc dopamine loss was falsely 
identified. The falsely identified rat had a SNc dopamine loss of 83%. For the 
spontaneous rotations, using an ipsilateral net bias of ≥10.0 also identified 83.3% of 
all rats with a SNc dopamine denervation ≥90%, but falsely identified 33.3% of the 
rats with lesser lesions. The average SNc denervation of the falsely identified rats was 
82% (sem ± 10%).   
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Figure 3.10. Scatter plots showing the relationship between percentage 
dopaminergic cell loss in the ipsilateral SNc and performance on the cylinder test 
(A), spontaneous rotations (B), amphetamine-induced rotations (C) and the 
elevated body swing (D) in 21 male rats with unilateral lesions to the MFB. For 
each scatterplot, it is specified whether there was a significant difference in the 
performance of rats with <90% and ≥90% SNc dopamine loss, and whether there 
was a significant correlation between dopamine loss and performance.  The 
dotted line in graphs A and B show the artificial cut-off line that was most 
appropriate for determining lesion success. n.s.=not significant; SNc=Substantia 
nigra pars compacta; TH=Tyrosine hydroxylase. *p<0.05, **p<0.01. 
 
Correlation between motor behaviour and VTA dopamine loss. The purpose of 
the experiment was to identify behavioural tests that could identify rats with ≥90% 
TH loss in the SNc. Because experiments reported in this thesis did not excluded rats 
based on VTA denervation, it was not appropriate to determine cut-off thresholds to 
identify rats with large dopamine loss in the VTA. However, because the data showed 
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a significant correlation between loss of SNc and loss of VTA dopaminergic neurons 
(r=0.61, n=21, p<0.01), non-parametric Spearman correlations were calculated to test 
whether there was a relationship between dopaminergic depletion in the VTA and 
performance on the behavioural tests (Figure 3.11). The analysis showed a significant 
correlation between net spontaneous rotations and VTA denervation (r=0.62, n=21, 
p<0.01) whilst net amphetamine-induced rotations (r=0.40, n=21, n.s.), the cylinder 
test (r=0.36, n=21, n.s.) and the elevated body swing (r=0.13, n=21, n.s.) tests did not 
correlate with dopamine loss in the VTA.  
Partial correlations. The data showed a significant correlation between SNc and 
VTA loss (r=0.61, n=21, p<0.01). To determine the impact of denervation in each 
region on the ipsilateral bias exhibited on the behavioural tests a partial correlation 
analysis was conducted. When controlling for SNc loss, VTA denervation no longer 
correlated significantly with any of the behavioural tests. Conversely, when 
controlling for VTA depletion, dopaminergic loss in the SNc still correlated 
significantly with ipsilateral bias on the cylinder test, albeit with a lower correlation 
coefficient (r=0.56, n=21, p<0.05) whilst the correlation with the other behavioural 
tests lost significance. This suggests that only performance on the cylinder test was 
dependent on SNc, but not VTA, denervation. 
Correlations with amphetamine-induced rotations. Amphetamine-induced 
rotations are commonly used to screen lesion success in the unilateral 6-OHDA rat 
model. Therefore, a correlation between the net bias on this test and performance on 
the other behavioural tests was also conducted. Although the correlation coefficients 
were not high, amphetamine-induced rotations correlated significantly with ipsilateral 
bias on the cylinder test (Table 3.1; r=0.55, n=21, p<0.01), net spontaneous rotations 
(r=0.53, n=21, p<0.05), and the elevated body swing (r=0.43, n=21, p<0.01). 
3.3.3.2. Analysis including Female Lister Hooded rats 
Based on the data obtained from the male Lister Hooded rats, described above, the 
cylinder and spontaneous rotations tests were used to balance experimental groups 
following lesion in Chapters 6-8. At the end of these experiments, the histological and 
motor data obtained in these experiments were used to retrospectively validate the 
earlier findings. 
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Figure 3.11. Scatter plots showing the relationship between the percentage 
dopaminergic cell loss in the VTA and performance on the cylinder test (A), 
spontaneous rotations (B), amphetamine-induced rotations (C) and the elevated 
body swing (D) in 21 male rats with unilateral lesions to the MFB. For each 
scatterplot, it is specified whether there was a significant correlation between 
VTA dopamine loss and performance. n.s.=not significant; TH=Tyrosine 
hydorxylase; VTA=Ventral tegmental area. **p<0.01. 
 
Table 3.1. The correlations between the ipsilateral bias exhibited by 21 male Lister 
Hooded rats‟ amphetamine-induced rotations (Amphet. Rot.), spontaneous 
rotations (Spont.rot.), the cylinder test and the elevated body swing. n.s.=not 
significant. *p<0.05, **p<0.01 
 Spont. Rot. Cylinder Test Body Swing 
Amphet. Rot. 0.53* 0.55** 0.43* 
Spont. Rot.  0.43* n.s. 
Cylinder Test   0.64** 
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Dopamine depletion. In the initial analysis, including all 169 female rats, the average 
loss of dopaminergic cell bodies in the SNc and VTA was 94% (Figure 3.12A; sem 
±17%) and 84% (sem ±22%) respectively. Out of the 169 rats, only 19 rats showed a 
SNc dopamine loss <90%. All rats showed an ipsilateral bias on the cylinder test 
(Figure 3.12B) and in their spontaneous rotations (Figure 3.12C). 
 
Figure 3.12. Loss of TH+ cell bodies in the ipsilateral SNc and VTA, expressed as a 
percentage of the intact side (A), of the 169 female Lister Hooded rats included in 
the second lesion screening analysis, together with their ipsilateral bias on the 
cylinder test (B) and spontaneous rotations test (C). The bars charts (A and C) 
show the mean and the standard error of the mean. The boxplot (B) shows the 
median and interquartile ranges, with circles representing outliers. 
SNc=Substantia nigra pars compacta; TH=tyrosine hydroxylase; VTA=Ventral 
tegmental area. 
 
In the second analysis, which only included the 53 rats that had received chronic      
L-DOPA treatment post lesion and post lesion screening, the average loss of 
dopaminergic cell bodies in the SNc and VTA was 95% (sem ±2%) and 85% (sem 
±3%) respectively. Out of these 53 rats, only 3 rats showed a SNc dopamine loss 
<90%. 
 
Relationship between motor behaviour and SNc dopamine loss. An analysis 
including all female rats (n=169) was conducted to test the ability of the spontaneous 
rotations and cylinder tests to predict lesion extent or distinguish between rats with 
 97 
 
≥90% or <90% dopamine loss in the SNc. An ipsilateral bias was observed in both the 
motor tests (Figure 3.12 B-C).  
In the cylinder test, rats with a SNc dopamine denervation ≥90% showed a 
median ipsilateral bias of 80% (1
st
 quartile=70%, 3
rd
 quartile=90%) whereas rats with 
a SNc dopamine denervation of <90% showed a median ipsilateral bias of 70% (1
st
 
quartile=60%, 3
rd
 quartile=80%) - a difference which was statistically significant 
(Figure 3.13A; H(1)=5.72, p<0.05). In addition there was a significant, albeit very 
low, correlation (r=0.16, p<0.05) between SNc dopamine loss and ipsilateral bias on 
the cylinder test. The data were also used to test appropriate thresholds for 
determination of lesion success. Applying the cut-off criterion of 100% ipsilateral bias 
on the cylinder test (which had been determined most appropriate in the analysis of 
the male Lister Hooded rats) only identified 6.7% of the rats with SNc dopamine loss 
≥90% and falsely identified 5.2% of rats showing <90% SNc dopamine loss. None of 
the cut off lines that were applied to the data set during analysis could reliably 
identify the majority of rats with a SNc dopamine loss ≥90% without simultaneously 
falsely identifying a large proportion of rats with SNc dopamine loss <90%. The most 
reasonable threshold was an ipsilateral bias of 80%. However, this threshold only 
identified 54.4% of rats with SNc dopamine depletion ≥90% while falsely identifying 
31.6% of rats with SNc dopamine loss <90%. 
In the spontaneous rotations test, rats with a dopamine denervation ≥90% had 
an average net ipsilateral bias of 38.6 (sem ± 1.2) whereas rats with <90% dopamine 
denervation had an average ipsilateral bias of 29.6 (sem ± 3.9) – a difference which 
was statistically significant (Figure 3.13B; F1,168=5.90, p<0.05). A correlation analysis 
between SNc depletion and spontaneous rotations was conducted but no significant 
correlation was found (r=0.01, n.s.). In addition, the data were used to test appropriate 
thresholds for determining extent of lesion. Applying the cut-off criterion that had 
been determined most appropriate in the analysis of  male Lister Hooded rats (net 
ipsilateral bias of 10.0), identified 96.7% of rats with SNc dopamine loss ≥90% but 
also falsely identified 94.7% of rats with a SNc dopamine loss <90%. While no clear 
cut off line could be obtained, the most discriminative cut off was a net ipsilateral bias 
of 35.0. This threshold identified 64.7% of the rats with SNc dopamine loss ≥90% but 
falsely identified 42.1% of rats with a dopamine loss <90%. The average SNc 
dopamine loss of the falsely identified rats was 58% (sem 7%).  
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Figure 3.13. Scatter plots showing the relationship between dopaminergic cell loss 
in the SNc (A-B) and VTA (C-D) and ipsilateral bias on the cylinder (A, C) and the 
spontaneous rotations test (B, D) in 169 female rats with unilateral lesions to the 
MFB. The scatterplots specify whether there was a significant difference in the 
performance of rats with <90% and ≥90% SNc dopamine loss on the behavioural 
tests (A-B), and whether there was a significant correlation between SNc/VTA 
dopamine loss and behavioural test performance. ns=not significant;  
SNc=Substantia nigra pars compacta; VTA=Ventral tegmental area. *p<0.05. 
 
Dopamine loss in the VTA did not correlate with any of the other factors included in 
the analysis, i.e. SNc denervation, net bias of spontaneous rotations, and ipsilateral 
bias on the cylinder test (Figure 3.13C-D). Because there was no correlation between 
VTA denervation and ipsilateral bias in the motor tests, a partial correlation was not 
conducted.  
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Correlation between motor behaviour and AIMs scores. Of the 169 female Lister 
Hooded rats, a subset of 53 rats had received chronic L-DOPA after lesion and testing 
on the cylinder and spontaneous rotations tests. An analysis only including these 53 
rats was conducted in order to determine whether there was a correlation between 
their ipsilateral bias on the behavioural tests and subsequent AIMs scores. The median 
cumulative AIMs recorded from the rats over a 2 h scoring session was 35, and AIMs 
scores ranged from 0 to 154. There was a small but significant correlation between 
dopamine loss in the SNc and ipsilateral bias on the cylinder test (Table 3.2; r=0.34; 
p<0.05). The analysis also showed a significant, but very low, correlation between 
AIMs scores and the net bias of spontaneous rotations (Figure 3.14C; Table 3.2; 
r=0.29, p<0.05). AIMs did not correlate significantly with any of the other factors, i.e. 
dopamine loss in the SNc, VTA, or ipsilateral bias on the cylinder test. 
 
 
Table 3.2. Correlations between loss of dopaminergic bodies in the SNc, VTA, the 
net ipsilateral bias of spontaneous rotations, and ipsilateral bias on the cylinder 
test and AIMs using collated data from 53 female Lister Hooded rats that were 
chronically treated with L-DOPA post lesion. AIM=Abnormal involuntary 
movements, ns=not significant, SNc= Substantia nigra pars compacta, 
VTA=Ventral tegmental area. *p<0.05, **p<0.01. 
 VTA  Rotations Cylinder  AIMs  
SNc  0.59** n.s. 0.34* n.s. 
VTA   n.s. n.s. n.s. 
Rotations   n.s. 0.29* 
Cylinder    n.s. 
 
3.3.4. Discussion 
Correlations from the male cohort 
The data in Experiment 2 were used to determine whether non-pharmacological tests 
could be used instead of amphetamine-induced rotations to reliably balance 
experimental groups post-lesion, and what cut-off thresholds that could be applied to 
identify rats with SNc dopamine depletion ≥90%.  
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Figure 3.14. Scatterplots showing the relationship between AIMs scores and 
percentage loss of dopaminergic cell bodies in the ipsilateral SNc (A) and VTA (B), 
the net bias of spontaneous rotations (C), and ipsilateral bias on the cylinder test 
(D). The coefficients and the p-values of the correlations are shown in the 
scatterplots. AIMS=Abnormal involuntary movements; SNc=Substantia nigra pars 
compacta; VTA=Ventral tegmental area. *p<0.05. 
 
An initial analysis including male Lister Hooded rats showed a significant 
correlation between dopamine loss in the SNc and ipsilateral bias on the cylinder test, 
spontaneous rotations, and amphetamine-induced rotations. In addition, there was a 
significant difference 
between the ipsilateral bias exhibited by rats with or without a unilateral SNc 
dopamine depletion of ≥90% on the spontaneous rotations and the cylinder tests. 
Inspection of the data suggested that a cut-off threshold of a net ipsilateral bias of 10.0 
over a 10 min period on the spontaneous rotations tests, and a 100% ipsilateral bias on 
the cylinder test was able to identify the vast majority of rats with SNc dopamine 
depletion ≥90% whilst only falsely identifying a minority of rats showing a SNc 
dopamine depletion <90%. 
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The observed correlation between SNc dopamine loss and the ipsilateral bias 
on amphetamine-induced rotations (r=0.52) was similar to previous publications 
where a correlation coefficient of e.g. 0.51 (p<0.05) has been reported (Hudson et al, 
1993). Interestingly, in the current experiment the correlations between SNc 
dopamine loss and ipsilateral bias on the cylinder (r=0.70) and spontaneous rotations 
(r=0.64) tests were higher than the correlation with amphetamine-induced rotations 
(r=0.52). This suggested that the cylinder and spontaneous rotation tests may be able 
to replace amphetamine-induced rotations as a means for balancing experimental 
groups post-lesion. This hypothesis was supported by the finding that there was a 
statistically significant difference in the performance on these tests by rats with a SNc 
dopamine loss of ≥90% and <90%. 
The high correlation between non-pharmacological tests and lesion extent is 
consistent with previously published data. For example, a correlation coefficient of 
0.91 (p<0.001) has previously been reported between ipsilateral bias in the cylinder 
test and dopamine loss (Schallert et al, 2000). Similarly, since spontaneous rotations 
in unilateral 6-OHDA lesion rats were first described by Ungerstedt (1968) later 
studies have demonstrated that a net quarter ipsilateral turns of ≥50, recorded over a 
15 min period in a square environment, indicate a striatal dopamine loss ≥85% 
(Fornaguera et al, 1994), and that there is a greater rotational ipsilateral bias in          
6-OHDA lesion rats with high versus low (97.8% ± 0.6% versus 59.6% ± 5.8%) 
striatal dopamine loss when recording their behaviour over night (Matsuda et al, 
1995). Based on previous literature, it was therefore expected that the net bias of 
spontaneous rotations would correlate with dopamine depletion in the current 
experiment. However, using a partial correlation it was found that the correlation 
between the spontaneous net bias and SNc dopamine loss lost significance when 
controlling for VTA denervation, suggesting that the bias was not purely SNc driven. 
An involvement of the VTA in spontaneous rotations is in line with data showing that 
VTA denervation contributes to amphetamine- and L-DOPA-induced rotations in the 
nigral 6-OHDA rat lesion model, thus supporting the notion that rotational bias may 
not be purely SNc driven (Thomas et al, 1994). Despite not demonstrated to be a pure 
measurement of SNc dopamine loss, the spontaneous rotations test is likely to still be 
of value as a test used to balance experimental groups in operant studies. The VTA 
plays a role in non-motor functions, such as reward seeking behaviour (e.g. Fields et 
al, 2007), and being able to balance experimental groups on both SNc and VTA 
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denervation before commencing operant testing may therefore be highly 
advantageous.  
The data obtained from the male Lister Hooded cohort thus suggested that (i) 
applying cut-off thresholds to the ipsilateral bias recorded form the spontaneous 
rotations and cylinder tests could identify the majority of rats with a SNc dopamine 
depletion ≥90%, and (ii) that ipsilateral bias on the spontaneous rotation test reflected 
both SNc and VTA dopamine loss. Based on these data, the cylinder and spontaneous 
rotation tests were used to balance experimental groups in Chapters 6-8. However, 
lesion rats were only excluded from the final analysis based on histological data. 
Thus, motor and histological data was also available from rats that did not meet the 
proposed cut off threshold. The data from all the rats included and excluded from the 
final analysis in Chapters 6-8 were therefore used to validate the findings from the 
male Lister Hooded cohort.    
Correlations from the female cohort 
A key difference between the histological data from the male and female cohort was 
the variation in the dopamine loss, with a lower proportion of the female rats showing 
a SNc dopamine loss <90%. The difference in lesion success is likely due to the 
lesion protocol used, which was developed using rats weighing 175-250 g (Torres et 
al, 2010). As such, the lesion coordinates used in this thesis project were likely better 
suited for adult female Lister Hooded rats that weigh approximately 225-310 g than 
for adult male Lister Hooded rats that weigh approximately 350-500 g (Charles River, 
2013).  
When analysing the data from the female Lister Hooded rats, only ipsilateral 
bias on the cylinder test correlated significantly with SNc dopamine loss. 
Furthermore, the cut-off thresholds that had been suggested based on data from the 
male cohort could no longer identify the majority of rats with SNc dopamine 
depletion ≥90% without also falsely identifying a large number of rats with <90% 
SNc dopamine loss. This is likely due to the more consistent lesion extent in the 
female rats, which is believed to have created a ceiling effect. The use of female rats 
may also have affected the degree of ipsilateral bias exhibited on the spontaneous 
rotations test as previous publications have demonstrated significantly higher 
amphetamine induced locomotion (Stöhr et al, 1998; Schindler et al, 2002), as well as 
a trend towards higher spontaneous locomotion (p=0.06; Stöhr et al, 1998), in female 
relative to male rats. 
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Data obtained from a subsample of the female rats that had received chronic 
L-DOPA post lesion were used to test whether the ipsilateral bias on behavioural tests 
correlated with, or could predict, the magnitude of future AIMs. The absence of a 
behavioural test that can predict susceptibility to, or future severity of, LID presents a 
problem to preclinical dyskinesia research. Availability of such a test would allow 
better balancing of experimental groups and therefore be highly valuable in e.g. 
research on anti-dyskinetic compounds. Therefore, an analysis exploring the 
correlation between the ipsilateral bias shown on the cylinder and spontaneous 
rotation tests and later AIMs magnitude was conducted. No significant correlation 
was found with between AIMs and ipsilateral bias on the cylinder test, even though 
such a correlation has previously been reported by Lundblad and colleagues (2002). 
Whereas the reason for the disparity in results has not been explicitly tested, it could 
potentially reflect a Type I error in the study by Lundblad and colleagues (2002) as a 
significant correlations between ipsilateral bias on the cylinder test and AIMs scores 
has, to my knowledge, not been reported by other groups.  
The current data did, however, show a small but significant correlation 
between AIMs scores and the net bias of spontaneous rotations (r=0.29, p<0.05). 
While the small magnitude of the correlation suggests the test is not a good predictor 
of future AIMs it may still be informative for our understanding of AIMs. The partial 
correlation analysis in the male correlation study suggested that the net bias of 
spontaneous rotations was reflective of both SNc and VTA denervation. This is in line 
with Kelly & Moore‟s (1976) findings that apomorphine induced rotations are more 
pronounced in rats with lesions to both the striatum and NAcc, which is innervated by 
the VTA, than in rats with only intra-striatal lesions. In addition to innervating the 
NAcc, the VTA also projects to the striatum (Ferreira et al, 2008) and antagonizing 
NMDA receptors in the VTA has been shown to decrease striatal dopamine release 
(Karreman et al, 1996). AIMs, in turn, are known to increase in response to elevated 
extracellular striatal dopamine (Carta et al, 2006). An indirect effect of VTA 
denervation on striatal dopamine levels may thus explain why performance on a 
behavioural test sensitive to VTA denervation also showed a low correlation with 
AIMs magnitude. The small magnitude of the correlation does, however, suggest that 
it is an indirect relationship. 
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3.3.4.1.  Chapter conclusions 
Experiment 1 did not demonstrate any gross strain differences in the motor and 
operant response to L-DOPA treatment. Furthermore, although the AIMs exhibited by 
Lister Hooded rats were of higher magnitude than those exhibited by Sprague Dawley 
rats, lesion rats in both strains developed LID following chronic L-DOPA treatment. 
Because later experiments were interested in exploring the effect of the onset of LID 
on non-motor behaviour, rather than studying the magnitude or development of AIMs 
scores, it was considered valid to use Lister Hooded rats in later experiments. 
Importantly, the data also demonstrated that it was possible to test lesion rats that had 
developed LID in operant chambers following administration of 1 mg/kg acute L-
DOPA without the presence of interfering AIMs. The finding informed 
methodological decisions in later studies where rats were administered acute L-DOPA 
before testing in nine-hole operant boxes (Chapters 7). 
Initial findings from Experiment 2 demonstrated that non-pharmacological 
tests could be used in place of the conventional amphetamine-induced rotations to 
assess lesion success. These non-pharmacological behavioural tests hold the 
advantage over amphetamine-induced rotations of not potentially confounding later 
operant data, and were therefore used to balance experimental groups in later 
experiments utilizing female Lister Hooded rats. Based on retrospective data from 
these later experiments, a second analysis was conducted to validate the initial 
findings. While the analysis showed that the previously identified cut-off thresholds 
could not be used to successfully predict lesion success in the data from the female 
Lister Hooded cohort, this was potentially due to the low variation in the female 
cohort‟s dopamine denervation.  
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4. The Effect of Food Restriction & Chronic     
L-DOPA on the Motor Response to Acute        
L-DOPA Administration 
Background: L-DOPA competes with dietary amino acids for transport across the 
blood-brain barrier (BBB). Therefore it was hypothesised that food restriction would 
increase the amount of L-DOPA that crossed the BBB and ultimately also increase the 
motor response to acute L-DOPA. Furthermore, chronic L-DOPA treatment sensitises 
striatal dopamine receptors. Therefore, chronic L-DOPA treatment was hypothesised 
to increase lesion rats‟ motor response to acute L-DOPA. To guide methodological 
decisions for later thesis experiments, these hypotheses were tested in two separate 
experiments.  
 
Aim: Two experiments tested the hypotheses that food restriction and chronic          
L-DOPA treatment increase the motor response to acute L-DOPA in lesion rats. 
 
Methods: The hypotheses were tested in both the intra-striatal and MFB 6-OHDA 
lesion models. Two dose response curves, conducted before and after chronic           
L-DOPA treatment, tested the motor response to acute L-DOPA in ad libitum and 
food restricted lesion rats using rotometers, the adjusting step test, and the vibrissae 
test.  
 
Results: Food restriction was found to increase the motor response to acute L-DOPA 
in rats with intra-striatal but not MFB lesions. Conversely, chronic L-DOPA treatment 
increased the motor response to acute L-DOPA in the MFB but not the intra-striatal 
lesion model. Interestingly, data from the intra-striatal, but not MFB model, suggested 
that previous history of food restriction may increase the magnitude of subsequent 
AIMs. The differences between the two models are discussed in light of the 
differences in the extent of dopamine loss they induce and the neural regions they 
affect.  
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4.1. Introduction 
L-DOPA alleviates motor symptoms arising from decreased dopaminergic innervation 
of the striatum. Being hydrophilic, L-DOPA can only cross the BBB by active 
transport across cell membranes via the L-type amino acid transporter LAT1 (del 
Amo et al, 2008; Kageyama et al, 2000). However, LAT1 is also implicated in the 
transport of dietary amino acids and the presence of the essential amino acids 
isoleucine, leucine, methionine, phenylaline, tryptophan, as well as non-essential 
amino acids including tyrosine, significantly decreases the amount of L-DOPA 
accessing LAT1 transport (Kageyama et al, 2000).  
The L-DOPA that successfully crosses the BBB is taken up by primarily 
striatal dopaminergic, but also some serotonergic, terminals that also contain the 
enzyme DOPA decarboxylase which facilitates the conversion of L-DOPA into 
dopamine (Flatmark et al, 2000). The newly synthesised dopamine is then released by 
dopaminergic and serotonergic terminals into extracellular space (Tanaka et al, 1999; 
Cenci & Lundblad, 2006; Lindgren et al, 2010). The subsequent effect of L-DOPA on 
motor function is dependent on both the amount of dopamine available and the 
sensitivity of the postsynaptic dopamine receptors.  
When evaluating motor and non-motor function in rat models of PD certain 
behavioural tasks, such as the LCRT paradigm used in Chapters 7 and 8 (section 
2.7.2.2), require that food intake is restricted during operant training and testing. 
Considering the competition between L-DOPA and dietary amino acids for LAT1 
transport, restricted food intake is likely to decrease L-DOPA‟s competition for 
transport across the BBB. This, in turn, may increase the overall amount of L-DOPA 
that enters the brain and, ultimately, the amount of dopamine that can synthesised. It 
was therefore hypothesised that food restricted lesion rats would show an increased 
motor response to acute L-DOPA relative to ad libitum controls. If true, dose response 
curves based on data from ad libitum rats may not be appropriate when selecting a 
therapeutic dose of L-DOPA to be administered to food restricted rats.  
Following extensive depletion of nigrostriatal dopamine, as induced in the rat 
6-OHDA model, there is a change in receptor populations, resulting in decreased 
binding to D1 type receptors and increased binding to D2 type receptors (Xu et al. 
2005). However, chronic administration of L-DOPA to lesion rats sensitises D1 type 
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receptors and also increases the rotational response to acute L-DOPA administration 
in rats that develop LID (Konradi et al, 2004; Henry et al, 1998).  
Long-term L-DOPA treatment also causes sensitization of D1 receptors and an 
increased contralateral rotational bias in response to later administration of acute      
L-DOPA (Henry et al, 1998; Cenci et al 2006; Konradi et al, 2004; Aubert et al, 
2005). Hence, rats that are L-DOPA naive or have been chronically treated with       
L-DOPA differ both in terms of the sensitivity of their dopamine receptors and their 
behavioural response to L-DOPA. Based on this, it was hypothesised that a lower     
L-DOPA dose would be required to produce a motor response in rats that had been 
chronically treated with L-DOPA relative to rats with little or no previous L-DOPA 
exposure. Therefore, both experiments described in this chapter included two dose 
response curves; generated before and after chronic L-DOPA treatment respectively. 
Chronic L-DOPA treatment was defined as the duration of treatment required for the 
groups to show stable AIMs scores. 
It should be noted that Experiment 3 commenced prior to Experiments 1 and 2 
(Chapter 3) and was therefore designed in the absence of data showing whether Lister 
Hooded rats were suitable for L-DOPA studies; or whether non-pharmacological 
lesion screening tests could reliably be used instead of amphetamine-induced 
rotations. To ensure consistency with previous in-house L-DOPA experiments that 
had been conducted using the same apparatus (e.g. Monville et al, 2005), the 
experiments in this chapter therefore used Sprague Dawley rats and lesion success 
was screened using amphetamine-induced rotations.  
Furthermore, the chapter reports both data from rats with intra-striatal 
(Experiment 3) and MFB (Experiment 4) lesions. Both models have been successfully 
utilised in the LCRT task that was planned to be used in later thesis chapters (e.g. 
Dowd & Dunnett, 2004, 2005a,b) and were therefore candidate lesion models for later 
thesis project experiments. The site of 6-OHDA infusion affects both the degree of 
dopamine denervation that is observed and the extent to which adjacent regions are 
affected. The intra-striatal 6-OHDA model causes focal loss of dopamine around the 
part of the striatum into which the infusion is administered. Conversely, infusing      
6-OHDA into the MFB induces almost complete unilateral denervation of ipsilateral 
nigral and striatal dopamine as well as reduced dopamine levels in the VTA and 
associated projection areas in the ventral striatum (Yuan et al, 2005; Deumens, 2002). 
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The conversion of L-DOPA to dopamine predominantly occurs in striatal 
dopaminergic terminals. It was therefore hypothesised that the near-complete striatal 
dopamine loss induced by MFB lesions would result in a ceiling effect, in which the 
limited number of remaining dopaminergic terminals in the lesion striatum would 
reduce the amount of L-DOPA that was able to be converted into dopamine. 
Ultimately, regardless of whether or not food restricted rats had a greater L-DOPA 
influx than ad libitum controls, this may be hypothesised to reduce the chance of 
observing a difference in food restricted and ad libitum MFB lesion rats‟ motor 
response to acute L-DOPA. Conversely, the relative sparing of striatal dopaminergic 
terminals in the intra-striatal, relative to the MFB, model was expected to decrease the 
risk of a ceiling effect. Hence, it was believed that the greater preservation of 
dopaminergic terminals observed in the intra-striatal model would allow greater 
uptake and conversion of striatal L-DOPA to dopamine, and therefore increase the 
likelihood of observing a difference between the food restricted and ad libitum cohort. 
Testing the hypothesis in both lesion models thus provided a more thorough testing of 
the hypothesis that food restriction increases L-DOPA influx in the rat. 
4.2 Experiment 3: The effect of food restriction and chronic L-DOPA 
on the motor response to acute L-DOPA in rats with intra-striatal       
6-OHDA lesions 
4.2.1. Introduction 
An initial dose-response curve was conducted in rats with intra-striatal lesions. In line 
with the chapter hypotheses, two dose response curves were conducted to compare the 
motor response of ad libitum and food restricted lesion rats, before and after chronic 
L-DOPA treatment. It was hypothesised that both food restriction and chronic          
L-DOPA would increase the motor response to the drug. 
4.2.2. Aims 
Two dose response curves were generated to measure the motor response to acute    
L-DOPA following (i) food restriction, and (ii) chronic L-DOPA treatment.  
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4.2.2. Methods 
4.2.2.1. Experimental Design 
Rats were given unilateral 6-OHDA infusions into the striatum. Lesion extent was 
assessed using amphetamine-induced rotations. Based on the net rotational bias, the 
cohort was divided into an ad libitum (n=7) and a food restricted (n=7) group and 
their motor response to saline and seven L-DOPA doses was assessed using 
automated rotometers, the adjusting step test and the vibrissae test. Following an 
initial dose response curve, rats were chronically treated with L-DOPA while allowed 
ad libitum access to food, and their AIMs were recorded. Following chronic L-DOPA 
treatment, the previously food restricted (n=7) group was once again food restricted 
and they and the ad libitum (n=7) group were used to generate a second dose response 
(Figure 4.1). 
 
Figure 4.1. A graphical representation of the experimental design of Experiment 3. 
The figure specifies both the duration of the individual testing phases and the 
overall number of days in the experiment. The „food status‟ boxes indicate when in 
the experiment the respective groups were given restricted (grey boxes) or ad 
libitum (white boxes) access to food. Ad lib=ad libitum; AIMs=Abnormal 
involuntary movements; Amphet.=amphetamine; FR=food restriction; 
s.c.=subcutaneous. 
 
4.2.2.2. Procedure 
Female Sprague Dawley rats (n=14) were given unilateral lesions to the striatum 
(section 2.2.3). Following a two week recovery period, amphetamine-induced 
rotations (section 2.4.6.2) were conducted to assess lesion extent and the results used 
to balance the groups. As previously stated, amphetamine-induced rotations were used 
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because this experiment was conducted prior to Experiment 2 where it was 
demonstrated that ipsilateral bias on the cylinder test and spontaneous rotations 
showed a stronger correlation with dopamine loss in a unilateral 6-OHDA model than 
amphetamine-induced rotations did.  
Two dose response curves were generated, using saline and seven L-DOPA 
doses (0.5, 1.0, 2.5, 5.0, 6.25, 7.5 and 10.0 mg/kg) administered in a counter-balanced 
order. The first dose response curve was generated using L-DOPA naïve rats. The 
second dose response curve was generated using the same rats after these had 
received chronic L-DOPA treatment. During the chronic L-DOPA period, rats 
received daily s.c. injections of 10 mg/kg L-DOPA for a period of 10 days. This was 
followed by 10 days of daily s.c. injections with 20 mg/kg L-DOPA, to ensure that 
rats exhibited the maximum possible AIMs scores. Throughout the chronic treatment 
period, rats were scored for AIMs as described in section 2.5.  
Motor behaviour data were generated using automated rotometers (section 
2.4.6.1), the adjusting step test (section 2.4.3), and the vibrissae test (section 2.4.8). At 
the start of testing, rats were placed in automated rotometers that were pre-set to 
record rotational behaviour for 90 min and turned on immediately following a s.c. 
injection of saline or L-DOPA. Twenty min post-injection, rats were temporarily 
removed from the rotometers and tested on the adjusting step test and the vibrissae 
test in an adjacent room. Immediately after hand testing, rats were returned to the 
rotometers until all rotational data had been collected. The adjusting step and 
vibrissae tests were selected because they have previously been shown sensitive to the 
therapeutic effect of dopaminergic drugs on motor behaviour (Winkler et al, 2002; 
Pinna et al, 2010). Furthermore, because of the non-spontaneous nature of the 
adjusting step and vibrissae tests, utilization of these tests made it possible to obtain a 
motor response from all rats in a minimum period of time, thereby increasing the time 
available to record L-DOPA induced rotations in the rotometers, something that could 
not have been guaranteed had e.g. the cylinder test been used. A wash-out period of a 
minimum of two days was allowed between each testing day.  
Following completion of behavioural testing, rats were given an overdose of 
Euthatal, perfused (section 2.8), and the brain tissue taken for TH immunohistological 
staining (section 2.10). The lesion extent was determined by counting TH positive 
cells in the SNc, as described in section 2.11, and by measuring TH optical density of 
the ipsilateral and contralateral striatum using Image J (section 2.12).  
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4.2.2.3. Statistical analysis 
Striatal optical density was analysed using two separate tests. First, the raw optical 
density measures from the ipsilateral versus contralateral striatum were compared 
using a t-test to confirm that the lesion had reduced TH+ staining in the lesion striata. 
Second, a one-way ANOVA with Group as between-subject factor was used to test 
whether the experimental groups differed in the percentage loss of ipsilateral striatal 
TH+ immunoreactivity induced by the lesion.  
The effect of the lesion on the number of TH+ cell bodies in the SNc and VTA 
was also analysed using two separate types of analyses. First, the presence of a lesion 
in the SNc or VTA was confirmed by comparing the raw cell counts in the ipsilateral 
and contralateral hemisphere using a t-test. For this analysis, the SNc and VTA were 
analysed separately. Once the presence of a lesion had been confirmed, an ANOVA 
was used to test whether there was a difference in (i) the relative extent of the 
experimental groups' dopamine denervation, and (ii) the loss of dopaminergic cell 
bodies observed in the SNc versus the VTA. The ANOVA was based on the 
percentage loss of TH+ cell bodies observed in the lesion SNc and VTA and included 
Region as a within-subject variable, and Group as a between-subject variable.  
To analyse the effect of Food restriction, motor data from the dose response 
curves were analysed using a repeated measures ANOVA. Data from the dose 
response curves generated before and after chronic L-DOPA treatment were analysed 
separately. For the adjusting step and vibrissae tests, data from the ipsilateral and 
contralateral performance were included in the same analysis. Significant between-
subject effects were analysed using a Tukey post-hoc test and significant interactions 
were analysed using a test of simple effects.  
To analyse the effect of chronic L-DOPA treatment on the motor response to 
subsequent acute L-DOPA administration, the motor data collected before and after 
chronic L-DOPA treatment were compared using a repeated measures ANOVA. 
When analysing the rotational bias data, Chronic L-DOPA and Dose were used as 
within-subject factors. When analysing the adjusting step and vibrissae test data, Side, 
Chronic L-DOPA, and Dose were used as within-subject factors.  
AIMs scores were analysed using a repeated measures ANOVA with Group as 
a between-subject factor and Dose as a within-subject factor. 
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4.2.3. Results 
4.2.3.1. Dopamine depletion 
The success of the intra-striatal lesion was demonstrated by a decrease in the optical 
density in the lesion, relative to the intact, striatum (Figure 4.2A) as well as a loss in 
dopaminergic cell bodies in the SNc and VTA (Figure 4.2B). The median optical 
density in the lesion striatum was 53% (sem: 9%) of that measured in the intact 
striatum and the number of dopaminergic cell bodies remaining in the lesion SNc and 
VTA were 24% (sem: 4%) and 61% (sem: 7%) of that in the intact side.  
Comparison between the optical density measured in the intact and lesion 
striatum confirmed that the 6-OHDA lesion had induced a significant loss of striatal 
immuno-reactivity in the ipsilateral hemisphere (t13=5.14, p<0.001). A further 
analysis was conducted to test whether there was a difference in the percentage 
reduction in striatal immunoreactivity observed in the ad libitum and food restricted 
groups. These data confirmed that the percentage reduction in ipsilateral striatal 
immune-reactivity was similar between the two groups (F1,12=0.09, n.s.). 
Subsequent analyses tested the effect of the lesion on loss of dopaminergic cell 
bodies in the SNc and VTA. Analysis of the raw cell counts demonstrated that both 
groups had significantly fewer dopaminergic cell bodies in the lesion than the intact 
SNc (t13=9.55, p<0.001) and VTA (t13=4.01, p<0.01). A further analysis was 
conducted to test whether there was a difference in the percentage loss of 
dopaminergic cell bodies observed in the lesion SN and VTA, and whether the 
groups‟ differed in their dopamine denervation in these structures. The data confirmed 
that the lesion induced a significantly greater percentage loss of dopaminergic cell 
bodies in the SNc than the VTA (Region: F1,12=16.74, p<0.001), and that the 
percentage loss of dopaminergic cell bodies was similar in the ad libitum and food 
restricted groups (Region x Group: F1,12=0.91, n.s.; Group: F1,12=0.10, n.s.). Based on 
the data in this and the preceding paragraph, the lesion was considered to have been 
successful and the groups to be appropriately matched. 
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Figure 4.2. Striatal optical density (A) and dopaminergic cell bodies in the SNc and 
VTA (B), both expressed as a percentage of the intact side, of the ad libitum (n=7) 
and food restricted (n=7) group, together with photos showing a striatum (C) and 
SNc and VTA (D) from a lesion rat included in the experiment. The bars show the 
mean, and the error bars the standard error of the mean. SNc=Substantia nigra 
pars compacta, TH=Tyrosine hydroxylase, VTA=Ventral tegmental area. **p<0.01 
 
4.2.3.2. First dose response curve 
Net rotations. An initial response curve was conducted to show the motor response to 
acute L-DOPA in rats with little or no L-DOPA exposure. Despite a trend towards an 
overall greater contralateral rotational bias in food restricted than ad libitum rats 
(Figure 4.3A; Group: F1,12=4.22, p=0.062), the difference only reached statistical 
significance following administration of specific L-DOPA doses. Specifically, the 
food restricted rats showed a greater contralateral net bias than the ad libitum controls 
following administration of 6.25 mg/kg L-DOPA (Dose: F7,84=4.71, p<0.001; Dose x 
Group: F7,84=3.83, p<0.01; Simple Effect of Group on Dose: F1,12=5.63, p<0.005). In 
addition, there was a trend towards a difference in the net rotational bias of the food 
restricted relative to the ad libitum control group following acute administration of 
saline and 1.0 mg/kg L-DOPA. At these doses the ad libitum rats showed a net 
ipsilateral rotational bias, whereas the food restricted rats did not demonstrate any 
rotational bias (Simple Effect of Group on Dose: min.F1,12= 4.31, p=0.06 and 0.054 
respectively). There was also a trend towards a greater contralateral bias in the food 
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restricted relative to the ad libitum control group following acute administration of 7.5 
mg/kg L-DOPA (Simple Effect of Group on Dose: F1,12=4.54 p=0.055).  
Adjusting step test. Both groups exhibited a contralateral deficit in the 
adjusting step test (Figure 4.3C,E; Side: F1,12= 107.07, p<0.01). While there was a 
significant overall effect of L-DOPA on adjusting step test performance, visual 
inspection of the data suggested this was due to random fluctuations in the data which 
did not relate to the experimental hypothesis (Figure 4.3E; Dose: F7,84=2.73, p<0.05; 
Group: F1,12=1.88, n.s.; Side x Group: F1,12=3.38, n.s.; Dose x Group: F7,84=0.73, n.s.). 
Vibrissae test. Both groups showed an impaired contralateral vibrissae reflex 
(Figure 4.3G, I; Side: F1,12=19.16, p<0.01; Side x Group: F1,12=2.86, n.s.). Acute      
L-DOPA improved both groups‟ contralateral performance, without affecting 
ipsilateral responses (Side x Dose: F7,84=2.73, p<0.05; Simple effect of Dose on Side: 
F7,6=7.68, p<0.05; Dose x Group: F7,84=1.17, n.s.). While there was a trend towards a 
higher performance in the food restricted relative to the ad libitum control group it did 
not meet statistical significance (Group: F1,12=4.33, p=0.06; Side x Group: F1,12=2.86, 
n.s.). 
4.2.3.2. Second dose response curve 
Net Rotations. A second dose response curve was conducted at the end of the 
chronic L-DOPA treatment. The food restricted group showed an overall greater 
rotational response to acute L-DOPA than the ad libitum control group, in which no 
rotational bias was observed (Figure 4.3B; Group: F1,12=6.90, p<0.05). The effect of 
food restriction was significant following administration of L-DOPA doses 7.5 and 
10.0 mg/kg (Dose: F7,84=5.59, p<0.001; Dose x Group: F7,84=5.22, p<0.001; Simple 
Effect of Group on Dose: min.F1,12= 7.22, p<0.05). 
Adjusting step test. The rats continued showing a significant, albeit modest, 
contralateral deficit in the adjusting step test during the second dose response curve 
(Figure 4.3D,F; Side: F1,12=23.44, p<0.001; Dose: F7,84=0.77, n.s.; Dose x Group: 
F7,84=1.47, n.s.; Side x Dose: F7,84=1.77, n.s.). The ad libitum group showed a subtle, 
but significantly higher performance than the food restricted group when tested on 
their ipsilateral, but not their contralateral, side (Group: F1,12=4.94, p<0.05; Side x 
Group: F1,12=10.27, p<0.01; Simple effect Group on Ipsilateral side: F1,12=8.13, 
p<0.05).  
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Figure 4.3. The motor effect of acute L-DOPA on net rotational bias (A-B), the 
adjusting step test (C-F), and the vibrissae (G-J) test in rats with intra-striatal 
lesions that had ad libitum (n=7) or restricted (n=7) access to food. The dose 
response curves were generated before (left panel) and after (right panel) chronic             
L-DOPA treatment.  The line charts show the mean and the error bars show the 
standard error of the mean. *Effect of Food restriction, ⱡEffect of Lesion, *p<0.05, 
ⱡ p<0.05, ⱡ ⱡ p<0.01 
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Vibrissae test. Following chronic L-DOPA treatment, the previously observed 
contralateral deficit in the vibrissae test disappeared (Figure 4.3H,J; Side: F1,12=4.25, 
n.s.; Side x Group: F1,12=4.25, n.s.). Whilst there was a trend towards a overall higher 
performance in the ad libitum relative to the food restricted group, this did not meet 
statistical significance (Group: F1,12=4.41, p=0.058) and because visual inspection of 
the data suggested that the trend did not reflect dose dependent change in 
performance, it was not considered relevant for the hypothesis being tested. Acute    
L-DOPA administration did not affect performance (Dose: F7,84=0.73, n.s.; Dose x 
Group: F7,84=0.73, n.s.; Side x Dose: F7,84=0.94, n.s.). This was likely due to a ceiling 
effect, as neither group exhibited a contralateral deficit after chronic L-DOPA 
treatment.  
4.2.3.3. Abnormal involuntary movements  
Between the first and second dose response curve, all rats were chronically treated 
with 10 mg/kg L-DOPA until showing stable AIMs. Interestingly, despite all rats 
being given ad libitum access to food during chronic L-DOPA treatment, the 
previously food restricted group exhibited higher AIMs scores than the ad libitum 
control group (Figure 4.4A). To test whether both groups were exhibiting their 
maximum achievable AIMs, or if the group difference would disappear if AIMs could 
be increased, the daily dose of L-DOPA injection was increased to 20 mg/kg            
L-DOPA. After 10 days of daily administration of 20 mg/kg L-DOPA, a final AIMs 
scoring session was conducted. Rats showed AIMs of similar magnitude as when they 
had been administered 10 mg/kg, suggesting that these were indeed the maximum 
AIMs that could be induced in them and that previously food restricted rats did indeed 
have higher AIMs than ad libitum controls (Group: F1,12=12.38, p<0.01; Dose: 
F1,12=0.02, n.s.; Dose x Group: F1,12=1.10, n.s.). 
To ensure that the data was not due to experimenter bias the AIMs were also 
scored by a second, blinded, scorer. The AIMs scores obtained by the blinded scorer 
confirmed that the previously food restricted rats showed higher AIMs than the ad 
libitum controls, and that these AIMs were similar when administered 10 mg/kg and 
20 mg/kg L-DOPA (Figure 4.4B; Group: F1,12=11.40, p<0.01; Dose: F1,12=4.13, n.s.; 
Dose x Group: F1,12=4.68, n.s.).  
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Figure 4.4. The cumulative AIMs scores of the ad libitum control group (n=7) and 
the previously food restricted group (n=7) when scored by the thesis author (A) 
and a blinded (B) scorer following administration of 10 mg/kg and 20 mg/kg L-
DOPA. The bars show the mean and the error bars the standard error of the mean. 
AIMs=Abnormal involuntary movements. *p<0.05 
 
4.2.3.4. The effect of chronic L-DOPA treatment on motor function 
To test whether acute L-DOPA induced a greater motor response in rats that had little 
L-DOPA exposure or that had a history of chronic L-DOPA treatment, a second dose 
response curve was conducted at the end of the chronic L-DOPA treatment. The 
following section presents a comparison of the motor response observed before, and 
after, chronic L-DOPA when data from all rats were analysed together.  
Net Rotations. Rats‟ net rotational response to acute L-DOPA was of similar 
magnitude both before and after chronic L-DOPA treatment (Figure 4.5A; Chronic   
L-DOPA: F1,12=0.05, n.s.; Chronic L-DOPA x Dose: F7, 91=0.95, n.s.). 
Adjusting Step Test. Chronic L-DOPA treatment did not affect the overall 
number of steps made on the adjusting step test (Figure 4.5B-C; Chronic L-DOPA: 
F1,13=4.35, n.s.; Chronic L-DOPA x Dose: F7,91=1.68, n.s.). While there was a 
decrease specifically in the number of ipsilateral steps made after, relative to before, 
chronic L-DOPA treatment,  
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Figure 4.5. The net rotational bias (A), and performance on the adjusting step (B-
C) and the vibrissae tests (D-E) before and after chronic L-DOPA treatment in rats 
with intra-striatal lesions (n=14). The line charts show the mean, and the error 
bars show the standard error of the mean. **p<0.01, ***p<0.001. 
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the actual difference was small and unlikely to be of relevance for the experiment 
hypothesis; which predicted a greater contralateral response after than prior to chronic 
L-DOPA (Chronic L-DOPA x Side: F1,13=19.70, p<0.01; Simple Effect of Chronic    
L-DOPA on Side: F1,13=7.51, p<0.05).  
Vibrissae test. Chronic L-DOPA treatment caused an overall improvement, 
exclusively in contralateral performance (Figure 4.5D,E; Chronic L-DOPA: 
F1,13=28.71, p<0.001; Chronic L-DOPA x Side: F1,13=24.22, p<0.001; Simple Effect 
of Chronic L-DOPA on Side: F1,13=16.76, p<0.01). Visual inspection of the data 
suggested that the statistically significant effect of chronic L-DOPA was due to the 
disappearance of the contralateral deficit in the second dose response curve (Side: 
F1,13=12.52, p<0.01; Chronic L-DOPA x Dose: F7,91=1.80, n.s).  
4.3. Experiment 4: The effect of food restriction and chronic  L-DOPA 
on the motor response to acute L-DOPA in rats with MFB 6-OHDA 
lesions 
4.3.1. Introduction 
It had been hypothesized that food restriction would increase the transport of            
L-DOPA across the BBB, and that this would in turn increase the motor response to 
acute L-DOPA. Unexpectedly, Experiment 3 also suggested an effect of a history of 
food restriction on the magnitude of subsequent AIMs. However, based on data from 
the previous experiment, it was not clear whether the effect of food restriction on later 
AIMs was due to a long-lasting effect of food restriction itself or if it was caused by 
an interaction between food restriction and L-DOPA exposure. In addition to testing 
the chapter hypotheses, the current experiment therefore also further explored the 
previously observed effect of food restriction on subsequent AIMs magnitude by 
comparing AIMs scores between rats that had (i) never been food restricted, (ii) been 
food restricted during previous L-DOPA exposure, or (iii) only been food restricted in 
the absence of L-DOPA.  
4.3.2. Aims 
The experiment tested (i) the effect of food restriction on the motor response to acute 
L-DOPA, (ii) the effect of chronic L-DOPA on the motor response to subsequent 
acute L-DOPA, and (iii) whether previous food restriction impacted on the magnitude 
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of AIMs observed when later administered chronic L-DOPA while allowed ad libitum 
access to food. 
4.3.2. Methods 
4.3.2.1. Experimental design 
Twenty-four rats were given unilateral 6-OHDA lesions to the MFB. Following 
recovery the lesion extent was assessed using amphetamine-induced rotations. Based 
on their net rotations, rats were divided into five subgroups and two dose response 
curves were generated. Between the two dose response curves was one drug free 
interval period followed by chronic L-DOPA treatment. All groups were given ad 
libitum access to food during chronic L-DOPA treatment. However, the groups 
differed from each other in the duration and timing of their food restriction during the 
other testing phases, as illustrated in Figure 4.6. The ‘ad libitum control‟ group (n=9) 
was never food restricted. The „FR control‟ group (n=4) was food restricted during 
the first and second dose response curve, but not during the drug free interval. The 
„FR 1‟ group (n=5) was food restricted during the first dose response curve but given 
ad libitum access to food through the remaining testing phases. The „FR interval‟ 
group (n=3) was food restricted during the drug-free interval but given ad libitum 
access during the two dose response tests. The „FR interval + 2‟ group (n=3) was food 
restricted during the drug-free interval and second dose response curve, but given ad 
libitum access to food during the first dose response curve. In the first dose response 
curve there were thus 15 ad libitum rats and 9 food restricted rats whereas the second 
dose response curve included 17 ad libitum rats and 7 food restricted rats. As 
previously stated, all rats were allowed ad libitum access to food during the chronic 
L-DOPA phase. The purpose of the design was to test whether there was an effect of 
food restriction on later AIMs as suggested in Experiment 3 while also testing 
whether there was a difference between the AIMs observed in rats food restriction in 
the absence or presence of L-DOPA. 
Hence, the first dose response curve compared the motor response of rats 
receiving ad libitum (total n=15) or restricted (total n=9) food access to saline and six 
L-DOPA doses using automated rotometers, the adjusting step test and the vibrissae 
test. A second dose response curve was then conducted, comparing the motor 
response of rats with ad libitum (total n=17) or restricted (total n=7) food access to 
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saline and the same six L-DOPA doses using the same motor tests as the initial dose 
response curve. 
 
Figure 4.6. A graphical representation of the experimental design of Experiment 4. 
The „food status‟ boxes indicate when in the experiment the respective groups 
were given restricted (grey boxes) or ad libitum (white boxes) access to food. Ad 
lib=ad libitum; AIMs=Abnormal involuntary movements; Amphet.=amphetamine, 
FR=food restriction; s.c.=subcutaneous. 
 
4.3.2.2. Procedure 
Female Sprague Dawley rats (n=24) were given unilateral lesions to the MFB (section 
2.2.2). Following a two week recovery period, amphetamine-induced rotations 
(section 2.4.6.2) were conducted to assess lesion extent and the results used to balance 
the groups. 
Two dose response curves including saline and six L-DOPA doses (0.5, 1.0, 
2.5, 5.0, 7.5 and 10.0 mg/kg) were conducted using the same procedure as in 
Experiment 3 (section 4.2.3.2). The 6.5 mg/kg dose that had been included in the 
intra-striatal Experiment 3 was not included in the current dose response curves. The 
decision to exclude the dose was based on the fact that there was little difference 
between the L-DOPA concentration in this and adjacent doses. Excluding it thus 
increased animal welfare by reducing unnecessary drug exposure without 
compromising the experiment.  
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4.3.2.3. Statistical analysis 
Striatal optical density was analysed using two separate, non-parametric tests. First, 
the raw optical density measures from the ipsilateral versus contralateral striatum 
were compared using a Wilcoxon test to confirm that the lesion had reduced TH+ 
staining in the lesion striata. Second, a Mann-Whitney U-test was used to test whether 
the experimental groups differed in the percentage loss of ipsilateral striatal TH+ 
immunoreactivity induced by the lesion.  
The effect of the lesion on the number of TH+ cell bodies in the SNc and VTA 
was also analysed using two separate types of analyses. First, the presence of a lesion 
in the SNc or VTA was confirmed by comparing the raw cell counts in the ipsilateral 
and contralateral hemisphere using a t-test. For this analysis, the SNc and VTA were 
analysed separately. Once the presence of a lesion had been confirmed, an ANOVA 
was used to test whether there was a difference in (i) the relative extent of the 
experimental groups' dopamine denervation, and (ii) the loss of dopaminergic cell 
bodies observed in the SNc versus the VTA. The ANOVA the percentage loss of TH+ 
cell bodies observed in the lesion SNc and VTA and included Region as a within-
subject variable, and Group as a between-subject variable. 
To analyse the effect of Food restriction, motor data from the dose response 
curves were analysed using a repeated measures ANOVA. Data from the dose 
response curves generated before and after chronic L-DOPA treatment were analysed 
separately. For the adjusting step and vibrissae tests, data from the ipsilateral and 
contralateral performance were included in the same analysis. Significant interactions 
were analysed using a test of simple effects. Because of a significant difference 
between the ad libitum and food restricted groups‟ VTA depletion during the first 
dose response curve, VTA depletion was included as a covariate when analysing 
behavioural data from the first dose response curve. 
The final AIMs scores data were analysed using a one-way ANOVA, whereas 
the development of AIMs was analysed using a repeated measures ANOVA with 
Group as a between-subject variable and Day as a within-subject factor.   
To analyse the effect of chronic L-DOPA treatment on the motor response to 
subsequent acute L-DOPA, the motor data from before and after chronic L-DOPA 
treatment were compared using a repeated measures ANOVA. When analysing the 
rotational bias data, Chronic L-DOPA and Dose were used within-subject factors. 
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When analysing the adjusting step and vibrissae test data, Side, Chronic L-DOPA, 
and Dose were used as within-subject factors.  
4.3.3. Results 
4.3.3.1. Dopamine depletion  
As further described in the subsequent results section, the motor and AIMs data from 
all rats that had ad libitum or restricted access to food in the test phase being analysed 
(i.e. the first dose response curve, the chronic L-DOPA phase, and the second dose 
response curve) were pooled in the statistical analysis. However, as illustrated in 
Figure 4.6, the time of food restriction differed between the experimental groups and, 
as a result, the total number ad libitum or food restricted rats was different in the three 
testing phases. Therefore, once statistical analysis had confirmed that the lesion 
reduced optical density and dopaminergic cell bodies int the lesion hemisphere, three 
further analyses were conducted to test whether there was a difference between the 
dopamine denervation in food restricted and ad libitum rats. Each analysis was 
restricted to one phase of experiment. For simplicity, the difference ad libitum and 
food restricted rats‟ striatal immunoreactivity and SNc and VTA denervation is 
discussed in separate paragraphs. 
Overall lesion success. The lesion successfully reduced the number of dopaminergic 
cell bodies observed in the lesion relative to the intact SNc (t23=14.38, p<0.001) and 
VTA (t23=17.28, p<0.001), as well as the optical density measured in the ipsilateral 
relative to the contralateral striatum (Figure 4.7H; Z=-4.29, p<0.001)  
Histological data from the first dose response curve. Overall, there was a 
greater percentage loss of cell bodies in the lesion SNc than in the lesion VTA (Figure 
4.7A; Region: F1,22=46.53, p<0.001). This VTA denervation was significantly more 
pronounced in the ad libitum than in the food restricted group (Group: F1,22=5.93, 
p<0.05; Group x Region: F1,22=4.84, p<0.05; Simple Effect of Group on VTA: 
F1,22=5.63, p<0.05). The groups were, however, matched on the other measures of 
dopamine denervation, i.e. percentage loss of cell bodies in the lesion SNc (Simple 
Effect of Group on VTA: F1,22=1.62, n.s.) and percentage reduction in the optical 
density of the lesion striata (Figure 4.7E; U=41.00, n.s). 
Histological data from the drug free interval & chronic L-DOPA 
treatment phase. The percentage loss of dopaminergic cell bodies in the SNc and 
VTA was similar for ad libitum and food restricted rats (Figure 4.7B; Group: 
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F1,22=1.10, n.s.; Group x Region: F1,22=0.60, n.s.), with both groups showing a greater 
percentage loss of cell bodies in the SNc than in the VTA (F1,22=19.13, p<0.001). Ad 
libitum and food restricted rats also showed a similar percentage reduction in the 
optical density of the lesion striata (Figure 4.7F; U=41.50, n.s). 
Histological data from the second dose response curve. As before, the 
percentage reduction in ipsilateral cell bodies was greater in the SNc than in the VTA 
(Figure 4.7C; Region: F1,22=30.94, p<0.001). The percentage loss of SNc and VTA 
cell bodies was similar for ad libitum and food restricted rats (Region x Group: 
F1,22=0.67, n.s.; Group: F1,22=0.43, n.s.), who were also matched in terms of the 
percentage reduction of optical density in their lesion striata (Figure 4.7G; U=49.50, 
n.s). 
4.3.3.2. First dose response curve 
Because the five original groups (Figure 4.6) did not differ from each other in terms 
of their rotational bias (Group: F4,19=0.69, n.s.), or in their performance on the 
adjusting step test (Group: F4,19=0.66, n.s.), and the vibrissae test (Group: F4,19=0.37, 
n.s.), data from all rats that had ad libitum or restricted food intake during the first 
dose response curve were pooled to create one ad libitum (n=15) and one food 
restricted (n=9) group and a second analysis conducted.  
 
 
Figure 4.7. The surviving TH+ cell bodies in the SNc and VTA (top row) and the 
striatal optical density (bottom row), both expressed as a percentage of the intact 
side, in rats with ad libitum (n= 15/19/17) and restricted (n=9/5/7) food access 
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during the first dose response curve (left column), the chronic L-DOPA treatment 
phase (middle column), and in the second dose response curve (right column). 
The figure also includes an illustrative example of the dopamine denervation 
observed in the SNc, VTA (D), and striatum (H). The bar charts show the mean, 
and the error bars show the standard error of the mean. The box plots show the 
median and interquartile ranges. Circles represent outliers. SNc=Substantia nigra 
pars compacta; VTA=Ventral tegmental area; TH=Tyrosine hydroxylase. 
***p<0.001.  
 
Net rotations. Acute L-DOPA increased the contralateral bias of rats‟ rotations, with 
a similar rotational bias observed in the ad libitum and food restricted groups (Figure 
4.8A; Dose: F6,126=4.27, p<0.01; Group: F1,21=0.30, n.s.; Dose x Group: F6,126=1.52, 
n.s.). While the groups‟ differed in the extent of their VTA denervation, this did not 
affect the net rotational bias to L-DOPA (Dose x VTA depletion: F6,126=0.41, n.s.).  
Adjusting step test. The food restricted group made more adjusting steps than 
the ad libitum group both when using their ipsilateral and contralateral forelimb 
(Figure 4.8C,E; Group: F1,21=11.01, p<0.01). However, despite food restricted rats 
making overall more adjusting steps, there was no significant difference in the relative 
contralateral deficit observed in the two groups, with all rats making relatively fewer 
adjusting steps with their contralateral than ipsilateral forelimb (Side: F1,21=52.41, 
p<0.001; Side x Group: F1,21=0.05, n.s.). Acute administration of L-DOPA improved 
contralateral performance in both ad libitum and food restricted rats (Dose: 
F6,126=4.58, p<0.05; Dose x Side: F1,126=3.09, p<0.01; Simple Effect: F6,16=17.14, 
p<0.001; Dose x Group: F1,126=0.34, n.s.). VTA denervation did not affect the 
contralateral deficit, nor did it affect the response to acute L-DOPA (Side x VTA: 
F1,21=0.14, n.s.; Dose x VTA: F6,126= 2.17, n.s.) 
Vibrissae test. Both the ad libitum and food restricted group exhibited a 
contralateral impairment in the vibrissae test (Figure 4.8G,I; Side: F1,21=88.01, 
p<0.001) that showed a modest improvement following acute L-DOPA administration 
(Dose: F6,126=2.77, p<0.05 Dose x Side: F1,126=2.25; Simple Effect: min.F1,21=55.62, 
p<0.001). Neither food restriction nor VTA denervation affected the motor response 
to acute L-DOPA (Group: F1,21=0.32, n.s; Dose x Group: F6,126=1.23, n.s.; VTA x 
Side: F1,21=0.10, n.s.; VTA x Dose: F6,126=1.54, n.s.).  
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4.3.3.3. Second dose response curve 
Because the five original groups (Figure 4.6) did not differ from each other in terms 
of rotational bias (Group: F4,19=0.13, n.s.), the adjusting step test (Group: F4,19=0.79, 
n.s.), and the vibrissae test (Group: F4,19=1.54, n.s.), data from all rats that had ad 
libitum or restricted food intake during the second dose response curve were pooled to 
create one ad libitum (n=19) and one food restricted (n=5) group. Because there was 
no difference in the food restricted and ad libitum groups‟ VTA depletion during the 
second dose response curve this was not used as a covariate in the analysis below.  
Net rotations. The groups continued showing an increase in the contralateral 
bias of their net rotations following acute L-DOPA administration. The net rotational 
bias was not affected by food restriction (Figure 4.8B; Group: F1,22=0.02, n.s.; Dose: 
F6,132=22.21, p<0.001; Group x Dose: F6,132=0.50, n.s.).   
Adjusting step test. The contralateral deficit in the adjusting step test was still 
evident following chronic L-DOPA treatment (Figure 4.8D,F; Side: F1,22=71.95, 
p<0.001), but was alleviated by acute L-DOPA administration (Dose: F6,132=7.56, 
p<0.001; Side x Dose: F6,132=34.14, p<0.001; Effect of Dose on Side: F6,17=37.03, 
p<0.001). There was no effect of food restriction on rats‟ motor response to acute L-
DOPA (Group: F1,22=3.67, n.s.; Group x Dose: F6,132=0.65, n.s.).  
Vibrissae test. The contralateral deficit in the vibrissae test persisted after 
chronic L-DOPA treatment (Figure 4.8H,J; Side: F1,22=81.59, p<0.001). Both the ad 
libitum and food restricted rats showed improvement of their contralateral vibrissae 
reflex following acute L-DOPA administration (Dose: F6,132=4.21, p<0.01; Side x 
Dose: F6,132=5.84, p<0.001; Simple Effect of Dose on Side: F6,17=4.36, p<0.05). The 
motor response to acute L-DOPA was not affected by food restriction (Group: 
F1,22=0.74, n.s.). 
4.3.3.4. The effect of food restriction on abnormal involuntary movements 
The experiment was designed to allow a comparison between the AIMs of rats that 
had (i) never been food restricted, (ii) been previously food restricted in the absence 
of L-DOPA, or (iii) previously been food restricted while administered L-DOPA. As 
illustrated in Figure 4.6, there was no difference in the treatment received by the „FR 
control‟ and the „FR 1‟ groups at the point of chronic L-DOPA treatment. Similarly, 
at the same time point, there was no difference between the treatment received by the 
„FR interval‟ and the „FR interval +2‟ group. Because the experience of the „FR 
control‟ and the „FR 1‟ groups were identical the time of chronic L-DOPA treatment  
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Figure 4.8. The motor effect of acute L-DOPA on net rotational bias (A-B), the 
adjusting step test (C-F), and the vibrissae (G-J) test on rats with MFB lesions that 
had ad libitum (n=15) or restricted (n=9) access to food. The dose response 
curves were generated before (left panel) and after (right panel) chronic L-DOPA 
treatment. The line charts show the mean, and the error bars show the standard 
error of the mean. MFB=Medial forebrain bundle. ⱡEffect of Lesion, *Effect of       
L-DOPA; ⱡp<0.05, *p<0.05, ⱡ ⱡ p<0.01, **p<0.01,  ⱡ ⱡ ⱡ p<0.001, ***p<0.001 
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and their AIMs scores did not differ (Group: F4,23=2.80, n.s.), their data were pooled 
when analysing AIMs scores. The same was true for the „FR interval‟ and the „FR 
interval +2‟ groups.  
Analysis following pooling showed that there was no difference in AIMs of 
rats that had never been food restricted („ad libitum controls‟), that had been food 
restricted during the first dose response curve (the „FR control‟ and „FR1‟ groups), or 
that been food restricted in the absence of L-DOPA (the „FR interval‟ and the „FR 
interval +2‟ groups; Figure 4.9A; Group: F2,21=0.74, n.s.). Nor was there a difference 
between the groups when comparing the change in their AIMs magnitude in the 
chronic L-DOPA phase (Figure 4.9B; Group: F1,21=0.37, n.s., Day x Group: 
F12,126=0.63, n.s.). 
4.3.3.5. The effect of chronic L-DOPA treatment on the motor response to 
acute L-DOPA 
To test whether chronic L-DOPA treatment increased lesion rats‟ motor response to 
subsequent acute L-DOPA, the motor data from the first and second dose response 
curve were compared. In the following section data from all rats were analysed 
together. 
 
 
Figure 4.9. The final AIMs scores (A) and the development of the AIMs (B) in the 
ad libitum control group (n=9), and rats that were food restricted during the first 
dose response curve (n=9; FR control & FR+1), and rats that were restricted 
between the two dose response curves (n=6; FR interval & FR+2). The bar charts 
and line charts show the mean, and the error bars show the standard error of the 
mean. Ad lib=Ad libitum; AIMs=Abnormal involuntary movements, FR=Food 
restriction. 
 
Net rotations. After chronic L-DOPA treatment, rats showed a greater net 
contralateral rotational bias following acute administration of L-DOPA doses 1.0, 2.5, 
 129 
 
5.0, 7.5 and 10.0 mg/kg (Figure 4.10A; Chronic L-DOPA: F1,22=22.49, p<0.001, 
Chronic L-DOPA x Dose: F6,132=4.72, p<0.001; Simple Effect: min.F1,22= 4.71, 
p<0.05). 
Adjusting step test. After chronic L-DOPA treatment, there was a significant 
increase in the number of contralateral steps made following acute administration of 
1.0, 2.5, 7.5, and 10.0 mg/kg L-DOPA, as well as a small but significant decrease in 
the number of ipsilateral steps made following acute administration of  0.5 and 10.0 
mg/kg L-DOPA (Figure 4.10B,C; Chronic L-DOPA: F1,23=0.13, n.s.; Chronic           
L-DOPA x Dose x Side: F6,138=10.24, p<0.001; Simple Effect: min.F1,23= 6.76, 
p<0.01).  
Vibrissae test. Chronic L-DOPA treatment significantly increased the number of 
contralateral responses made in response to vibrissae stimulation following acute 
administration of 0.5, 1.0, 2.5, and 5.0 mg/kg L-DOPA (Figure 4.10D,E; Chronic     
L-DOPA: F1,23=10.08, p<0.01; Chronic L-DOPA x Side x Dose: F6,138=2.20, p<0.05; 
Simple Effect: min.F1,23= 6.55, p<0.05).  
4.4. Discussion 
L-DOPA competes with dietary amino acids for LAT1 mediated transport across the 
BBB (del Amo et al, 2008; Kageyama et al. 2000) and the presence of dietary amino 
acids has been shown to significantly decrease the amount of L-DOPA accessing 
LAT1 transport (Kageyama et al, 2000). It was therefore hypothesised that food 
restriction would increase the amount of L-DOPA crossing the BBB in food restricted 
relative to ad libitum rats, and that this would result in a greater motor response to 
acute L-DOPA in food restricted rats. If true, this would have implications for the 
dose of L-DOPA that was chosen for acute administration in later experiments where 
the experimental paradigm necessitated that rats were food restricted during testing.  
Later thesis project experiments also planned to test the behavioural effect of 
acute L-DOPA in rats that had previously received chronic L-DOPA treatment. The 
behavioural response to acute L-DOPA depends not only on the amount of L-DOPA 
that crosses the BBB, but also on the sensitivity of striatal dopamine receptors. 
Following LID onset these receptors become sensitized (Konradi et al, 2004) and the 
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Figure 4.10. The effect of chronic L-DOPA treatment on the MFB lesion groups‟ 
(n=24) net rotational bias (A), adjusting step test (B-C), and vibrissae test (E-F) 
performance. The line graphs show the acute motor response to the six L-DOPA 
doses before and after chronic L-DOPA treatment. The line graph shows the mean, 
and the error bars the standard error of the mean.* p<0.05. 
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rotational response to L–DOPA increase (Henry et al 1998). Therefore, it was 
hypothesised that rats that had been chronically treated with L-DOPA would show a 
greater motor response to acute L-DOPA than rats with little or no previous L-DOPA 
exposure. The hypotheses were tested both in rats with unilateral intra-striatal and 
MFB lesions.  
4.4.1. The effect of food restriction 
There was an increased motor response to acute L-DOPA following food restriction in 
the intra-striatal lesion model. The effect was most evident when comparing the ad 
libitum and food restricted groups‟ net rotational bias. However, it is worth noting that 
this significant group difference was driven by a contralateral net bias in the food 
restricted group and a near absence of rotations in the ad libitum group. It is also 
worth noting that the contralateral rotational bias in the food restricted group was not 
greater at 10.0 mg/kg than at 5 mg/kg L-DOPA as would have been expected. The 
latter could be related to the occurrence of AIMs; AIMs magnitude increase following 
administration of higher L-DOPA doses (Winkler et al, 2002) and personal 
observations suggest that rats rotate less when exhibiting high forelimb and axial 
AIMs. No robust effect of food restriction was observed in the intra-striatal cohort 
when analysing data from the adjusting step and vibrissae tests. It is possible that the 
modest contralateral deficit observed in these tests caused a ceiling effect, thus 
making these tests less sensitive to detecting L-DOPA mediated improvements of 
motor function in the intra-striatal lesion model.  
Unexpectedly, there was no effect of food restriction on the motor response to 
L-DOPA in the MFB model. In the intra-striatal model, the effect of acute L-DOPA 
on motor function had been most evident when measuring the rats‟ rotational bias. 
When discussing the absence of an effect of food restriction in the MFB model it is 
therefore worth noting that, unlike the intra-striatal lesion rats, both the ad libitum and 
food restricted MFB lesion rats showed a contralateral rotational bias following acute 
L-DOPA administration (Figures 4.3 and 4.8). A rotational response to L-DOPA 
requires denervation of not only the SNc but also the VTA (Thomas et al, 1994). The 
MFB model, which causes greater denervation in both of these structures than intra-
striatal lesions (e.g. Deumens, 2002; Yuan et al, 2005) may therefore be more 
sensitive to L-DOPA-induced rotations. I therefore hypothesised that the greater 
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striatal and VTA dopamine denervation in the MFB lesion model contributed to a 
ceiling effect which masked the effect of food restriction in this model.  
In all, the data from the intra-striatal experiment supported the hypothesis that 
food restriction increases transport of L-DOPA across the BBB, and that this results in 
an increased motor response to acute L-DOPA. While data from the MFB model did 
not support the hypothesis it is possible that an effect of food restriction on motor 
behaviour was masked by a ceiling effect, caused by the extensive dopamine 
denervation that occurs following MFB lesions. On a practical level, the findings 
suggest that the dose of acute L-DOPA administered to rats in order to achieve a 
therapeutic effect without overdosing them needs to be adjusted following food 
restriction in the intra-striatal but not in the MFB lesion model.  
4.4.2. Abnormal Involuntary Movements 
Unexpectedly, the data from the intra-striatal lesion model showed higher AIMs 
scores in rats that had been food restricted during the first L-DOPA dose response 
curve. This was in spite of the fact that all rats were allowed ad libitum access to food 
during chronic L-DOPA treatment. The development of LID is believed to depend on 
stimulation of D1 type receptors (e.g. Pearce et al, 1998). Imaging experiments have 
shown that, in the rat 6-OHDA MFB model, as few as seven injections of a D1 
agonist lead to an increased striatal blood-oxygen-level dependent (BOLD) signal 
following subsequent D1 agonist exposure and that this signal correlates with at least 
forelimb AIMs (Delfino et al, 2007). These data suggest that D1 stimulation underlies 
not only the development of LID, but also the acute expression of AIMs. It can 
therefore be hypothesised that the greater AIMs observed in the intra-striatal lesion 
group that was food restricted during initial L-DOPA exposure was driven by greater 
D1 sensitization in this, relative to the ad libitum control, group. 
 In addition to higher AIMs, the food restricted intra-striatal lesion group also 
showed greater contralateral turning in response to acute L-DOPA than the ad libitum 
group. Contralateral turning in at least MFB lesion rats is driven by synergestic 
stimulation of D1 and D2 receptors (Paul et al, 1992). Similar to the effect of D1 
agonist stimulation on AIMs (Delfino et al, 2007), repeated D1 agonism increases the 
rotational response to dopamine agonist administration in lesion rats (Delfino et al, 
2004). While the greater contralateral net bias observed in the intra-striatal food 
restricted relative to the ad libitum group was originally hypothesised to be driven by 
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greater L-DOPA influx, it could therefore also be hypothesised that it was linked to 
increased D1 sensitization in the food restricted relative to the ad libitum group. 
Supporting the hypothesis are previously published findings showing that food 
restricting rats to 80% of their baseline weight increases the motor activity induced by 
acute D1 agonist administration (Carr et al, 2003). To further test this hypothesis, 
future experiments may wish to measure D1 receptor sensitivity following food 
restriction. Such assays were, however, beyond the scope of the current experiment 
and therefore not conducted as part of the experiments presented in this chapter.  
 One limitation of the intra-striatal lesion experiment was that it was unclear 
whether an effect of food restriction on behaviour was due to food restriction alone, or 
due to an interaction between food restriction and L-DOPA treatment. While the 
primary aim of the MFB experiment was to test the effect of food restriction and 
chronic L-DOPA on the motor response to acute L-DOPA administration, the 
experiment also included additional experimental groups to allow exploration of 
unanswered questions from the intra-striatal experiment. To this end, the MFB lesion 
experiment compared the AIMs scores exhibited by rats that had (i) never been food 
restricted, (ii) been food restricted in the absence of drugs, or (iii) been food restricted 
while initially exposed to L-DOPA. However, no effect of food restriction on 
subsequent AIMs was found in the MFB model.  
As previously stated, MFB lesions cause a more extensive dopamine loss than 
intra-striatal lesions. Previously published studies have demonstrated that greater 
dopamine loss increases both the magnitude of AIMs scores, and the proportion of 
rats that develop dyskinesia following chronic L-DOPA treatment (Winkler et al, 
2002). Furthermore, dopamine activated striatal adenylyl cyclase activity, which is 
linked to stimulation of D1 receptor which in turn are implicated in LID, is higher in 
tissue from rats with complete rather than partial (57% loss) dopamine denervation 
(Pifl et al, 1992), which would mimic the MFB over the intra-striatal model. It is thus 
possible that a potential effect of food restriction on AIMs magnitude, if linked to D1 
receptor sensitisation, may have been masked by a ceiling effect in the MFB lesion 
model which is characterised by a more extensive dopamine loss, as well as greater 
AIMs (Winkler et al, 2002). 
When discussing the potential effect of food restriction on AIMs it should be 
noted that there are currently no tests available to accurately predict the susceptibility 
to LID and magnitude of subsequent AIMs. Therefore, before firm conclusions can be 
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drawn from the intra-striatal experiment, the data should be replicated to ensure the 
validity of the findings. Ideally, such experiment would use the design of the MFB 
lesion experiment to allow dissociation between the effect of food restriction in the 
absence of L-DOPA versus the effect of food restriction in conjunction with L-DOPA 
on later AIMs.  
4.4.3. The Effects of Chronic L-DOPA 
Chronic L-DOPA has previously been shown to sensitize D1 receptors in lesion rats 
(Konradi et al, 2004), increase the rotational response to L-DOPA (Henry et al, 
1998), and improve performance on simple motor tests (Winkler et al, 2002). 
Experiments 3 and 4 therefore tested the effect of chronic L-DOPA treatment on the 
motor response to acute L-DOPA, as measured by rotometers, the adjusting step test, 
and the vibrissae test. 
In the intra-striatal experiment an increased contralateral motor response to 
acute L-DOPA following chronic treatment was only observed in the vibrissae test. 
The small magnitude of this effect and the absence of an altered contralateral response 
on the other motor tests suggest that the effect of chronic L-DOPA on the motor 
response to subsequent L-DOPA is minimal in this model. 
In the MFB model, chronic L-DOPA treatment increased the motor response 
to acute L-DOPA administration on all three tests of motor function. The data 
therefore confirmed previous reports of an effect of chronic L-DOPA on the adjusting 
step test (Winkler et al, 2002) and net rotational bias (Henry et al, 1998) whilst 
extending previous findings by also showing an effect on the vibrissae test.  
The different effects of chronic L-DOPA in the two models are hypothesised 
to relate to the extent of dopamine loss the two lesions induce. MFB lesions cause 
more extensive denervation in both the SNc and VTA than intra-striatal lesions. As 
previously stated, VTA denervation increases the rotational response to L-DOPA 
(Thomas et al, 1994). Hence, the difference in the two models‟ rotational response to 
L-DOPA is hypothesised to be caused by the greater extra-striatal dopamine loss in 
the MFB relative to the intra-striatal lesion model. Furthermore, the difference in the 
observed effect of chronic L-DOPA on the adjusting step is hypothesised to relate to 
the greater baseline deficit observed on this test in the MFB, relative to the intra-
striatal, lesion model.  
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4.4.4. Conclusions 
The data provided partial support for the hypotheses that restricted food intake and 
chronic L-DOPA exposure both increase the motor response to acute L-DOPA, whilst 
also highlighting vital differences between two commonly used preclinical models of 
PD. The less severe intra-striatal lesion model exhibited a modest motor response to 
acute L-DOPA that was increased in the food restricted group. Conversely, the MFB 
model showed greater baseline motor deficits and heightened motor response to acute 
L-DOPA following chronic treatment but not food restriction.  
 The differences between the two lesion models have methodological 
implications for preclinical experiments involving acute L-DOPA administration to 
lesion rats following food restriction or chronic L-DOPA treatment. When 
administering acute L-DOPA to rats with MFB lesions the dose needs to be decreased 
if the therapeutic effect is to be similar in rats that have received long-term L-DOPA 
treatment and rats that are drug naïve. When acute L-DOPA is administered to rats 
with intra-striatal lesions, the dose needs to be decreased if a similar therapeutic effect 
is to be observed in rats on food restriction relative to rats with ad libitum access to 
food. 
While the data provided partial support for the experimental hypothesis that 
food restriction increases L-DOPA influx, it is noted that the current chapter only 
measured the behavioural output of L-DOPA administration and food restriction. As 
such, the mechanism underlying the observed effect of food restriction on the motor 
response to L-DOPA in the intra-striatal model was not directly tested. To test the 
hypothesis that food restriction increased the rotational response to acute L-DOPA in 
the intra-striatal model by increasing the influx of L-DOPA, Chapter 5 used 
microdialysis to measure the striatal extracellular DOPA levels before and after acute 
L-DOPA administration in rats with free or restricted food intake.  
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5. Investigating the Effect of Food restriction 
on Striatal L-DOPA Influx 
Background: The experiments reported in Chapter 4 revealed evidence of an 
increased rotational response to acute L-DOPA following food restriction in the intra-
striatal 6-OHDA lesion model of PD. This was hypothesized to be caused by 
increased L-DOPA influx via the BBB in food restricted versus ad libitum rats.   
 
Chapter aim: The aim of Experiment 5 was to test whether food restriction increases 
influx of L-DOPA in rats with 6-OHDA lesions to the striatum or MFB. 
 
Methods: The hypothesis was tested in both the intra-striatal and MFB 6-OHDA 
model. Bilateral microdialysis was used to measure striatal DOPA levels in freely 
moving rats with restricted or ad libitum access to food before, and after, acute         
L-DOPA administration.  
 
Results: Food restriction did not affect the striatal DOPA levels observed following 
acute L-DOPA administration in the intra-striatal or MFB lesion model. Therefore, 
the hypothesis was not supported. Food restriction did, however, decrease baseline 
dopamine levels. In addition, food restriction increased 5HIAA levels in the intra-
striatal, but not the MFB model. 
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5.1 Introduction 
Chapter 4 described an increased rotational response to acute L-DOPA following food 
restriction of rats with intra-striatal 6-OHDA lesions. L-DOPA in known to compete 
with dietary amino acids for transport across the BBB (reviewed in del Amo et al, 
2008). It was therefore hypothesized that food restriction, by decreasing competition 
for LAT1-mediated transport, indirectly increased the amount of L-DOPA that 
crossed the BBB. Ultimately, this was hypothesized to have caused higher dopamine 
levels in the striata of food restricted rats relative to ad libitum rats, leading to a 
greater motor response to acute administration of L-DOPA. This is in line with the 
recognition that food intake affects L-DOPA response in the PD patients. In the clinic, 
this recognition has led to recommendations that patients experiencing LID or “off 
periods” should redistribute protein intake so as to consume less protein during 
breakfast and lunch (Olanow et al, 2001; Cereda et al, 2010). The rationale behind the 
suggestion is that in advanced PD, when there is reduced striatal dopamine storage 
capacity, striatal dopamine levels are highly sensitive to small changes in the            
L-DOPA transport into the brain (Olanow et al, 2001). Hence, by decreasing protein 
intake, and thus increasing the amount of L-DOPA that accesses transport across the 
BBB, it is believed that the motor response to L-DOPA can be enhanced (Olanow et 
al, 2001).  
Based on current literature, it was hypothesised that the increased rotational 
response to L-DOPA observed following food restriction in the intra-striatal model 
(Experiment 3) was due to greater influx of L-DOPA. However, food restriction may 
also affect the motor response to L-DOPA through other routes. For example, food 
restriction increases the motor response to D1 agonists (Carr et al, 2003) and one year 
exposure to a low protein diet reduces dopamine clearance in 6-OHDA lesion rats 
(Sevak et al, 2008). To further determine the mechanism underlying the phenomenon 
observed in Chapter 4, the hypothesis that the increased motor response to L-DOPA 
observed in food restricted intra-striatal lesion rats was mediated by an increase in the 
L-DOPA that was transported over the BBB was tested in the current chapter using 
microdialysis in freely moving lesion rats with ad libitum or restricted access to food. 
Using a microdialysis paradigm, extracellular levels of DOPA, DOPAC, HVA, 
dopamine, and 5HIAA in dorsolateral striatum were measured before and after acute 
s.c. administration of L-DOPA were measured. DOPA levels were of most interest as 
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they allowed direct testing of the hypothesis that food restriction increases the amount 
of L-DOPA that crosses the blood brain barrier. Dopamine, DOPAC, HVA levels 
were measured to as these are indicative of the impact L-DOPA has on dopamine and 
therefore also the motor response to the drug. In addition, the DOPAC/dopamine ratio 
was calculated as an estimate of dopamine utilization (e.g. Cartmell et al, 2000; 
Jentsch et al, 1998). 5HIAA was used as a control substrate to demonstrate that a 
potential increase in the neurotransmitter concentrations measured post L-DOPA 
injection was specific to DOPA, dopamine and its metabolites rather than reflective of 
a non-specific effect on both dopaminergic and non-dopaminergic systems. It was 
thus hypothesised that 5HIAA levels would remain constant after acute L-DOPA 
injection while levels of DOPA, dopamine, DOPAC, and HVA would increase. To 
ensure consistency with Chapter 4, the hypothesis was tested in rats with sham or 6-
OHDA lesions to the striatum or MFB.  
5.1.2. Aims 
The aim of the experiment was to test the hypothesis that reduced food intake 
increases the influx of L-DOPA to the striatum. The hypothesis was tested by 
measuring extracellular levels of DOPA in the dorsolateral striatum before and after 
acute L-DOPA administration using microdialysis in freely moving rats with sham or 
6-OHDA lesions to the MFB or striatum. Half of the rats in each experimental group 
were food restricted while the remaining half was kept as ad libitum controls.  
5.2. Methods 
5.2.1. Experimental Design 
Rats were given 6-OHDA or sham lesions to the striatum or MFB. Rats with             
6-OHDA lesions were allocated to an ad libitum or food restricted group based on 
their amphetamine induced rotations. After one week of restricted or free access to 
chow, rats underwent microdialysis probe surgery. Following a 48 h recovery period, 
extracellular striatal levels of L-DOPA, dopamine, DOPAC, HVA, and 5HIAA were 
measured before and after acute administration of 5 mg/kg L-DOPA. Figure 5.1 
contains a graphical representation of the procedures each rat underwent. Please note 
that, for practical reasons, a limited number of rats could be tested at one time. 
Therefore, animal orders, lesions, probe implants, and dialysis were staggered and the 
experiment conducted over a 4 month period    
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Figure 5.1. A graphical representation of the procedures each rat in Experiment 5 
underwent. Please note that the experiment included eight batches of rats, which 
underwent their lesions, implants, and dialysis at the same time. For practical 
reasons, the testing or each group was staggered causing the total experiment to 
span over 11 weeks. Amphet=amphetamine, FR=Food restriction, MFB=Medial 
forebrain bundle. 
5.2.2. Procedure 
Female Sprague Dawley rats were randomly allocated to one of four surgery groups 
and given unilateral sham MFB, 6-OHDA MFB, sham intra-striatal, or 6-OHDA 
intra-striatal lesions. MFB and intra-striatal lesions were induced using the previously 
described lesion protocol (sections 2.2.2 and 2.2.3). Sham controls received an 
infusion of PBS at the same rate and in the same coordinates as their 6-OHDA 
counterparts. The net ipsilateral bias of 6-OHDA lesion rats‟ amphetamine induced 
rotations (section 2.4.6.2) was used to allocate them to food restricted and ad libitum 
groups. Amphetamine-induced rotations were used over other motor tests to ensure 
consistency with Chapter 4, which the current experiment was based on. For the same 
reason, Sprague Dawley rats were used instead of the Lister Hooded strain utilised in 
the experiments presented in Chapters 6 to 8.  
Eight experimental groups were included in the experiment: sham MFB ad 
libitum (n=6); sham MFB food restricted (n=7); 6-OHDA MFB ad libitum (6); 6-
OHDA MFB food restricted (n=8); sham intra-striatal ad libitum (n=7); sham intra-
striatal food restricted (n=6); 6-OHDA intra-striatal ad libitum (n=5); 6-OHDA intra-
striatal food restricted (n=6). 
Following lesion recovery and amphetamine-induced rotation testing, rats 
were allowed one week of free or restricted access to food. They thereafter underwent 
probe implantation surgery (2.6.1) and, following a 48 h recovery session, a 
micordialysis session was conducted. The dialysis session spanned over 5 h and 35 
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min, as further described in section 2.6.2. Microdialysis samples were taken every 15 
min, and immediately stored at -20˚C before being moved to -80˚C at the end of 
testing. Two hours and 15 min after the first dialysis sample was taken, the rats were 
given one s.c. injection of L-DOPA at a concentration of 5 mg/kg and a volume of 1 
ml/kg. Sampling thereafter continued until the end of the microdialysis session, when 
rats were euthanized using CO
2
. While other experiments reported in this thesis used 
Euthatal for euthanizing rats, CO
2
 was used in the current experiment as it was 
conducted in another facility (Eli Lilly & Co Ltd, Windlesham, Surrey) and therefore 
also under another project licence. In instances where one probe became blocked or 
damaged prior to microdialysis testing, unilateral sampling was conducted. The 
number of rats in each group from whom ipsilateral and contralateral samples were 
collected is specified in Table 5.1.  
The L-DOPA dose used (5 mg/kg) had previously been shown to produce a 
motor response to L-DOPA in the MFB and intra-striatal lesion models (Chapter 4) 
and was as such considered a valid choice. Furthermore, in a pilot study including two 
lesion rats (data not shown), the AIMs and L-DOPA induced rotations observed in 
MFB lesion rats following acute administration of 10 mg/kg L-DOPA interfered with 
the microdialysis set-up and increased the risk of harm to the rats. Specifically, when 
exhibiting AIMs of high magnitude, rats risked becoming entangled in the tubing 
which posed a risk of injury. In addition, entangling and twisting of the tubes 
disrupted the flow of aCSF. Decreasing the dose of acute L-DOPA administered to 
lesion rats is known to reduce the magnitude of their AIMs (e.g. Winkler et al, 2002). 
Using a L-DOPA dose of 5 mg/kg, rather than the 10 mg/kg used during chronic      
L-DOPA treatment in the other experiments reported in this thesis, was therefore 
preferable for animal welfare reason (reduced risk of rats becoming entangled in 
tubing) as well as for scientific reasons (reduced risk for disruption to the aCSF flow 
and lost microdialysis samples).        
HPLC analysis of dialysis samples was conducted by Jane Cooper (Eli Lilly & 
Company, Windlesham, Surrey, UK) as described in 2.6.3. In instances where the 
HPLC was unable to detect the substance being measured or provided a read-out 
value less than 0.1, a value of 0.1 ng/ml was inserted in its place. This corresponds to 
the lowest level the HPLC could reliably measure and the approach is in accordance 
with the standard practise in the lab conducting the HPLC analysis.  
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Table 5.1. The table shows the number of rats in each experimental group from 
which microdialysis samples from the intact and lesion striata could be collected. 
Ad Lib = ad libitum. FR = food restricted, MFB=Medial forebrain bundle 
 
5.2.3. Statistical analysis 
The MFB and intra-striatal lesion rats were analysed separately to ensure consistency 
with the analysis of the dose-response curves in Chapter 4.   
Amphetamine induced rotations were analysed using a one-way ANOVA. 
Baseline microdialysis levels were measured by inserting the mean concentration 
(ng/ml) from the five baseline samples into a repeated measures ANOVA where Side 
was used as a within subject variable, and Lesion and Food restriction were used as 
between-subject variables.  
The effect of acute L-DOPA was measured in two ways. First, all 18 samples 
were analysed in a repeated measures ANOVA where Time and Side were used as 
within-subject variables, and Food restriction and Lesion used as between-subject 
variables. This analysis (i) provided information on the time course of neurochemical 
changes that occurred following L-DOPA injection, and (ii) took into consideration 
the difference in the groups‟ baseline levels. In the second analysis, the average post-
injection levels was expressed as a percentage of baseline and analysed using a 
repeated measures ANOVA where Side was used as a within-subject variable, and 
Lesion and Food restriction were used as between-subject variables. This analysis 
tested whether the groups differed in the relative change of neurochemical levels 
following L-DOPA injection. The analysis supplemented the previous analysis by not 
taking baseline differences between the groups into consideration and instead 
comparing the groups in terms of their relative change in DOPA, dopamine, DOPAC, 
HVA, and 5HIAA levels. In both analyses, significant between-group differences 
were analysed using a post-hoc Scheffe test and significant interactions analysed 
using a test of simple effects.  
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5.3. Results 
5.3.1. Amphetamine induced rotations 
Two weeks post-lesion, all rats were given an acute amphetamine administration and 
the lesion rats‟ rotations were recorded using automated rotometers. The results were 
used to allocate 6-OHDA lesion rats to a food restricted or ad libitum group. All 
lesion rats showed a strong ipsilateral bias in their rotations (Figure 5.2). There was 
no difference in the net bias of rats that were later food restricted or kept as ad libitum 
controls in either the 6-OHDA MFB (F1,14=0.23, n.s.) or the 6-OHDA intra-striatal 
(F1,12=0.00, n.s.) cohort.  
 
Figure 5.2. The net ipsilateral bias of the amphetamine induced rotations 
measured in rats with MFB or intra-striatal 6-OHDA lesions. All rotations were 
conducted prior to food restriction. “Ad Lib” and “FR” indicate later group 
allocation and not the food status at the time of amphetamine rotations. The bars 
show the mean bias and the error bars the standard error of the mean. Ad 
Lib=(subsequently) ad libitum, FR= (subsequently) food restricted, MFB=Medial 
forebrain bundle 
5.3.2 Baseline measurements 
5.3.2.1. DOPA 
MFB model. There was a slight but significant asymmetry in the DOPA levels in the 
sham ad libitum group, with marginally higher DOPA levels observed in the intact 
than lesion striata. There was no difference between the amount of DOPA measured 
in the intact and lesion striata of the other groups (Figure 5.3A; Side x Lesion x Food 
restriction: F1,24=5.19; Simple Effect of Side: F1,24=7.56, p<0.01). 
Intra-striatal model. The intra-striatal cohort showed an equal amount of DOPA in 
both the lesion and intact striata (Figure 5.3B; Side: F1,20=0.74, n.s.; Side x Lesion: 
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F1,20=0.45, n.s.). Neither the 6-OHDA lesion nor food restriction affected baseline 
DOPA levels (Lesion: F1,20=0.97,n.s.; Food restriction: F1,20=2.40, n.s.). 
5.3.2.2. Dopamine 
MFB model. The 6-OHDA lesion caused a marked asymmetry in baseline dopamine 
levels, with lower dopamine levels in the lesion striata (Figure 5.3C; Side x Lesion: 
F1,24=7.25, p<0.05; Simple Effect of Side on 6-OHDA group: F1,24=17.20, p<0.001). 
Food restriction did not affect baseline dopamine levels (Food restriction: F1,24=0.85, 
n.s.). 
Intra-striatal model. The 6-OHDA lesion decreased dopamine levels in the lesion 
striata (Figure 5.3D; Side x Lesion: F1,20=12.66, p<0.001; Simple Effect of Lesion: 
F1,20=10.64, p<0.01). In addition, there was a strong trend towards a reduction in 
baseline dopamine levels following food restriction (Food: F1,20=4.05, p=0.058). 
5.3.2.3. DOPAC 
MFB model.  6-OHDA lesions significantly decreased DOPAC levels in the lesion 
striata (Figure 5.3E; Side x Lesion: F1,24=6.87, p<0.05; Simple Effect of Lesion: 
F1,24=27.20, p<0.001). Food restriction did not affect baseline DOPAC levels (Food 
restriction: F1,24=0.00, n.s.).  
Intra-striatal model. In the intra-striatal model, DOPAC levels decreased in both the 
sham and 6-OHDA groups‟ lesion striata (Figure 5.3F; Side: F1,20=22.94, p<0.001), 
although a marginally greater decrease was observed in the 6-OHDA lesion group 
(Side x Lesion: F1,20=4.61, p<0.05; Simple Effect of Side: F1,20=22.18, p<0.05). Food 
restriction did not affect DOPAC levels (Food: F1,20=0.42,n.s.). 
5.3.2.4. HVA 
MFB model. 6-OHDA lesions decreased HVA levels in the lesion striata (Figure 
5.3G; Side x Lesion: F1,24=15.71, p<0.001; Effect of Side on Group: F1,24=33.68, 
p<0.001). Food restriction did not affect baseline HVA levels (Food restriction: 
F1,24=0.07, n.s.). 
Intra-striatal model. Reduced HVA levels in the lesion striata of 6-OHDA rats were 
also observed in the intra-striatal model (Figure 5.3H; Side x Lesion: F1,20=11.71, 
p<0.01; Effect of Lesion on Side: F1,21=37.62, p<0.001). Whilst not reaching 
statistical significance, there was a trend towards a further reduction in HVA levels 
following food restriction (Food restriction: F1,21=3.65, p=0.07). 
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5.3.2.5. DOPAC / DA 
MFB model. 6-OHDA lesions decreased dopamine utilization in the lesion as well as 
the intact striatum (Figure 5.3I; Lesion: F1,24=7.23 p<0.05; Side: F1,24=1.70, n.s.; Side 
x Lesion: F1,24=0.00, n.s.). Food restriction did not affect baseline dopamine 
utilization (Food restriction: F1,24=0.02, n.s.; Side x Food restriction: F1,24=0.28, n.s.) 
Intra-striatal model. Overall, both the sham and 6-OHDA lesion group‟s dopamine 
utilization was lower in the lesion than intact striata (Side: F1,20=9.15, p<0.01).          
6-OHDA lesions were associated with a further decrease in dopamine utilization 
(Figure 5.3J; Lesion: F1,20=17.18, p<0.001). While visual inspection of the data 
suggested the decreased utilization in the 6-OHDA group‟s was greater in the lesion 
than intact striata this did not meet statistical significance (Side x Lesion: F1,20=2.77, 
n.s.) due to high variability in the data. Food restriction was associated with 
marginally higher overall dopamine utilization, although the variation in the data 
suggest that this statistically significant difference should be interpreted with caution 
(Food restriction: F1,20=5.06, p<0.05; Side x Food restriction: F1,20=0.24, n.s.). 
5.3.2.6. 5HIAA 
MFB model. The 6-OHDA lesion group had significantly lower 5HIAA levels in the 
lesion striata than sham controls (Figure 5.3K; Side x Lesion: F1,24=13.05, p<0.01;  
Effect of Side on 6-OHDA groups: F1,24=32.19, p<0.001). There was also an effect of 
food restriction, which increased extracellular 5HIAA levels (Food restriction: 
F1,24=6.83, p<0.05).  
Intra-striatal model. In the intra-striatal cohort, the food restricted sham and the ad 
libitum 6-OHDA animals had lower 5HIAA levels in their ipsilateral relative to their 
intact striata (Figure 5.3L; Side x Lesion x Food restriction: F1,20=4.60, p<0.05; Effect 
of Food restriction: min.F1,20=5.31, p<0.05).  
5.3.3. Effect of acute L-DOPA on DOPA levels 
MFB model. All MFB groups showed a peak in their extracellular DOPA levels 
following L-DOPA injection (Figure 5.4A-B, D-E; Time: F17,408=55.71, p<0.001). 
This was reflected in the higher than baseline DOPA levels observed in all MFB 
groups after L-DOPA injection (Figure 5.4C,F).  
 
 145 
 
 
Figure 5.3. The average baseline levels of DOPA (A-B), dopamine, (C-D), DOPAC 
(E-F), HVA, (G-H), and 5HIAA (I-J) measured in rats with sham or 6-OHDA lesions 
to the MFB (left column) or striatum (right column). The error bars show the 
standard error of the mean. Ad lib=Ad libitum, FR=Food restriction. *Significant 
difference between sham and 6-OHDA lesion rats, #Significant difference 
between ad libitum and food restricted rats, ⱡSignificant difference intact and 
lesion, *p<0.05, #p<0.05, **p<0.01, ⱡⱡp<0.01, ***p<0.001  
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There was no significant difference between the extracellular DOPA levels measured 
in the sham and 6-OHDA lesion group when analysing all time points together 
(Lesion: F1,24=0.62, n.s.; Side: F1,24=0.31, n.s.; Side x Lesion: F1,24=3.19,  n.s), nor 
when measuring the post-injection levels expressed as a percentage of baseline 
(Lesion: F1,24=0.54, n.s.; Side x Lesion: F1,24=3.13, n.s.).  
Neither did food restriction affect extracellular DOPA levels. This was true 
both when analysing all time points together (Food restriction: F1,24=0.99, n.s.), and 
when comparing the groups‟ post-injection levels expressed as a percentage of 
baseline (Food restriction: F1,24=0.01, n.s.; Side x Food restriction: F1,24=0.09, n.s.).  
Intra-striatal model. All intra-striatal groups showed a peak in their extracellular 
DOPA levels after L-DOPA injection (Figure 5.4G-H,J-K; Time: F17,340=19.46, 
p<0.001). This was reflected in the higher than baseline DOPA levels observed in all 
groups post-injection (Figure 5.4I,L).   
There was no significant difference between the DOPA levels observed in the 
sham and 6-OHDA lesion groups when including all time points in the analysis 
(Lesion: F1,20=0.18, n.s.), nor when comparing the average post-injection DOPA 
levels expressed as a percentage of baseline (Lesion: F1,20=0.14, n.s.).  
While visual inspection of the data suggested higher absolute DOPA levels in 
the food restricted 6-OHDA lesion group, this was associated with a greater variation 
in their data and did meet statistical significance when including all time point in the 
analysis (Food restriction: F1,20=1.60, n.s.; Time x Food: F17,340=0.65, n.s.), nor when 
only comparing average pre- and post-injection DOPA levels (Food restriction: 
F1,20=0.00, n.s.; Side x Food restriction: F1,20=0.00, n.s.). 
5.3.4. Effect of acute L-DOPA on dopamine levels 
MFB model. There was no notable increase or peak in extracellular dopamine levels 
following L-DOPA injection in the sham lesion group (Figure 5.5A-B). This was 
confirmed by data showing that their post-injection dopamine levels were averaging 
at approximately 100% of baseline levels (Figure 5.5C). The ad libitum 6-OHDA 
lesion group exhibited significant fluctuations in their extracellular dopamine levels 
over the course of testing (Figure 5.5D-E), a phenomenon which was not observed in 
the 6-OHDA lesion food restricted group (Time x Lesion x Food: F17,408=1.92, 
p<0.05; Effect of Time on 6-OHDA ad libitum group: F8,17=4.10, p<0.05).
 147 
 
 
Figure 5.4. The DOPA levels in the intact and lesion striata of rats with sham or 6-
OHDA lesions to the MFB (A-F) or the striatum (G-L) that experienced free or 
restricted access to food. The arrow represents the time point at which rats were 
administered 5 mg/kg L-DOPA. The column furthest to the right shows the mean 
post-injection DOPA levels relative to baseline, with 100% corresponding to 
baseline levels. The error bars show the standard error of the mean.  MFB=Medial 
forebrain bundle. 
 
However, visual inspection of the data and the finding that the lesion groups did not 
differ when comparing their average post-injection dopamine levels expressed as a 
percentage of baseline (Figure 5.5F; Lesion: F1,24=1.78, n.s.; Side x Lesion: 
F1,24=2.49, n.s.) suggested that the changes were driven by fluctuations in the data 
rather than an actual increase in dopamine levels.  
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Reflecting the success of the lesion, 6-OHDA lesion rats showed significantly 
decreased extracellular dopamine levels in the lesion, relative to the intact, striatum 
when including all time points in the analysis (Figure 5.5F; Side x Lesion; F1,24=7.92, 
p<0.05; Effect of Side on 6-OHDA groups: F1,24=17.21, p<0.001). However, when 
comparing the groups‟ post-injection levels expressed as a percentage of baseline the 
sham or 6-OHDA groups did not differ (Figure 5.5F; Lesion: F1,24=1.79, n.s.; Side x 
Lesion: F1,24=2.49, n.s.). Hence, while the 6-OHDA group had lower dopamine 
baseline levels than sham controls, there was no difference between the percentage 
change in dopamine levels observed in the sham and 6-OHDA groups following L-
DOPA injection.  
Food restriction did not affect dopamine levels when including all time points 
in the analysis (Figure 5.5A-B, D-E; Side x Food restriction: F1,24=1.79, n.s.; Food 
restriction: F1,24=1.62, n.s.). Neither was there a difference between the food restricted 
and ad libitum groups when measuring the average post-injection dopamine levels 
expressed as a percentage of baseline (Figure 5.5C,F; Food restriction: F1,24=0.30, 
n.s.; Side x Food restriction: F1,24=0.03, n.s.)  
Intra-striatal lesion. The intra-striatal groups exhibited fluctuations in their 
extracellular dopamine levels over the course of testing (Figure 5.5G-H, J-K; Time: 
F17,340=2.32, p<0.01). However, there was no peak or clear time-dependent increase in 
dopamine levels post L-DOPA injection and the post-injection dopamine levels 
averaged around 100% of baseline levels (Figure 5.5I,L). 
As expected, the dopamine asymmetry in the 6-OHDA groups that had been 
observed at baseline persisted throughout testing, with lower dopamine levels 
observed in the lesion relative to intact striata (Figure 5.5J-K; Side x Lesion; 
F1,20=10.57, p<0.01; Simple Effect of Side: min.F1,20=24.63, p<0.001). Analysis of the 
average post-injection dopamine levels, expressed as a percentage of baseline, showed 
increased dopamine levels exclusively in the lesion striatum of the 6-OHDA group 
(Figure 5.5L; Side x Lesion: F1,20=4.61, p<0.05; Simple Effect of Lesion: F1,20=4.77, 
p<0.05). This suggests that while the intra-striatal 6-OHDA lesion decreased 
ipsilateral dopamine levels, the lesion striatum was also the only one in which 
dopamine levels increased post-injection. 
Inspection of the data when including all time points in the analysis showed a  
trend towards reduced dopamine levels in the food restricted groups (Figure 5.5G-H, 
J-K; Food restriction: F1,20=3.81, p=0.065). However, there was no effect of food 
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restriction on the percentage change in dopamine levels post-injection (Food 
restriction: F1,20=0.22, n.s.; Side x Food restriction: F1,20=0.00; n.s.). This suggests 
that while there was a trend towards lower baseline dopamine levels in the food 
restricted groups, food restriction did not affect the percentage increase in dopamine 
occurring following acute L-DOPA injection. 
 
Figure 5.5. The dopamine levels in the intact and lesion striata of rats with sham 
or 6-OHDA lesions to the MFB (A-F) or the striatum (G-L) that experienced free or 
restricted access to food. The arrow represents the time point at which rats were 
administered 5 mg/kg L-DOPA. The column furthest to the right shows the mean 
post-injection dopamine levels relative to baseline, with 100% corresponding to 
baseline levels. The error bars show the standard error of the mean. 
DA=dopamine, MFB=medial forebrain bundle. *Significant difference between 
sham and 6-OHDA lesion rats. *p<0.05 
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5.3.5. Effect of acute L-DOPA on DOPAC levels 
MFB model. Overall, DOPAC levels were lower in the 6-OHDA than in the sham 
lesion rats (Figure 5.6A-B, D-E; Lesion: F1,24=5.62, p<0.05). While there were 
fluctuations in all MFB groups‟ DOPAC levels there was no observable DOPAC peak 
following L-DOPA injection (Time: F17,408=18.33, p<0.001; Time x Lesion: 
F17,408=1.16, n.s.). 
Analysis of average post-injection DOPAC levels, expressed as a percentage 
of baseline showed a higher increase in DOPAC levels in the lesion striatum of         
6-OHDA than sham lesion rats (Figure 5.6C,F; Side x Lesion: F1,24=6.86, p<0.05; 
Simple Effect of Lesion on Ipsilateral side: F1,24=6.87, p<0.05). Hence, while            
6-OHDA lesions decreased DOPAC levels, acute L-DOPA administration induced a 
proportionally larger increase in the DOPAC levels in the lesion striata of 6-OHDA 
lesion than of the sham lesion group. 
There was no difference in the DOPAC levels of food restricted and ad libitum 
rats when including all time points in the analysis (Figure 5.6A-B; D-E; Food 
restriction: F1,24=0.00, n.s.; Time x Food restriction: F17,408=1.10, n.s.). Neither did 
food restriction increase the average percentage increase in extracellular DOPA 
observed following L-DOPA injection (Food restriction: F1,24=1.39, n.s.; Side x Food 
restriction: F1,24=1.57, n.s.).   
Intra-striatal model. The 6-OHDA lesion rats had overall lower DOPAC levels than 
sham controls (Figure 5.6G-H, J-K; Lesion: F1,20=6.43, p<0.05). While all intra-
striatal groups showed fluctuations in their DOPAC levels (Time: F17,340=12.25, 
p<0.001; Time x Lesion: F17,340=0.75, n.s.) there was no clear peak in DOPAC levels 
post L-DOPA injection.  
Analysis of the average DOPAC levels post-injection, expressed as a 
percentage of baseline, showed an absolute increase in all intra-striatal lesion groups 
(Figure 5.6I,L). This increase was higher in the lesion striata of the 6-OHDA group 
than in other groups (Side x Lesion: F1,20=16.15, p<0.01; Simple Effect of Lesion: 
F1,20=16.66, p<0.01).   
 Food restriction did not affect DOPAC levels when including all time points 
in the analysis (Figure 5.6G-H, J-K; Food restriction: F1,20=0.09, n.s.; Time x Food 
restriction: F17,340=1.23, n.s.). Neither did it impact on the percentage change in 
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DOPAC levels following L-DOPA injection (Figure 5.6I, L; Food restriction: 
F1,20=1.71, n.s.; Side x Food restriction: F1,20=1.41, n.s.).  
 
 
Figure 5.6. The DOPAC levels in the intact and lesion striata of rats with sham or 
6-OHDA lesions to the MFB (A-F) or the striatum (G-L) that experienced free or 
restricted access to food. The arrow represents the time point at which rats were 
administered 5 mg/kg L-DOPA. The column furthest to the right shows the mean 
post-injection DOPAC levels relative to baseline, with 100% corresponding to 
baseline levels. The error bars show the standard error of the mean. MFB=Medial 
forebrain bundle. *Significant difference between sham and 6-OHDA lesion rats. 
*p<0.05, **p<0.01  
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5.3.6. Effect of acute L-DOPA on HVA levels 
MFB model. While there was no peak in HVA levels post L-DOPA injection, there 
was a slight increase in the extracellular HVA levels in the 6-OHDA group‟s intact 
striata (Figure 5.7A-B, D-E; Side x Time x Lesion: F17,408=2.63, p<0.001; Simple 
Effect of Time: F8,17=3.74, p<0.05). Average post-injection HVA levels, expressed as 
a percentage of baseline, confirmed a greater increase in the HVA levels of the          
6-OHDA lesion groups‟ lesion striatum relative to their intact striatum and the sham 
lesion group (Figure 5.7C,F; Side x Lesion: F1,24=6.71, p<0.05; Simple Effect of Side: 
F1,24=16.45, p<0.001). This suggests that while 6-OHDA MFB lesions decrease HVA 
levels, which are indicative of dopamine turnover, acute L-DOPA administration 
preferentially increase dopamine turnover in the lesion striata.   
Intra-striatal model. Whilst there was no clear HVA peak post-injection, there was a 
gradual increase in extracellular HVA following acute L-DOPA administration 
(Figure 5.7G-H, J-K; Time: F17,340=18.42, p<0.001). The change in HVA levels was 
similar between food restricted and ad libitum rats (Time x Food restriction: 
F17,340=065, n.s). While both 6-OHDA and sham lesion rats showed a slight increase 
in their HVA levels over the course of testing, the 6-OHDA lesion rats consistently 
had lower absolute HVA levels in their lesion striata than sham controls (Side x Time 
x Lesion: F17,340=1.81, p<0.05; Simple Effect of Lesion: min.F1,20=6.39, p<0.05). 
Nonetheless, measuring the average HVA levels expressed as a percentage of baseline 
showed that the relative increase in HVA levels was greater in the 6-OHDA than in 
the sham lesion groups (Figure 5.7I,L; Lesion: F1,20=8.34, p<0.05). Visual inspection 
of the data suggested this was driven by greater percentage increase specifically in the 
lesion striata of 6-OHDA rats, and the statistical analysis showed a strong tend 
towards supporting this (Side x Lesion: F1,20=4.10, p=0.056). 
Food restriction decreased HVA levels in the 6-OHDA rats but not in intact 
controls (Figure 5.7G-H, J-K; Food restriction x Lesion: F1,20=4.51, p<0.05; Simple 
Effect of Food restriction: F1,20=5.77, p<0.05). However, despite differences in the 
baseline samples, food restricted and ad libitum groups did not differ in terms of 
overall percentage HVA increase observed following L–DOPA administration (Figure 
5.7I,L; Food restriction: F1,20=1.48, n.s.; Side x Food restriction: F1,20=0.34, n.s.) 
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Figure 5.7. The HVA levels in the intact and lesion striata of rats with sham or 6-
OHDA lesions to the MFB (A-F) or the striatum (G-L) that experienced free or 
restricted access to food. The arrow represents the time point at which rats were 
administered 5 mg/kg L-DOPA. The column furthest to the right shows the mean 
post-injection HVA levels relative to baseline, with 100% corresponding to 
baseline levels. The error bars show the standard error of the mean. ◊Significant 
difference between the 6-OHDA lesion group‟s ipsilateral striatum, relative to 
their contralateral striatum and either of the sham lesion group‟s striata, 
*Significant difference between sham and 6-OHDA lesion rats. #p<0.05, *p<0.05, 
MFB=Medial forebrain bundle. 
 
5.3.7. Effect of acute L-DOPA on DOPAC / DA ratio 
MFB model. Dopamine utilization was marginally higher in the sham than the lesion 
group when including all time points in the analysis (Figure 5.8A-B, D-E; Lesion: 
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F1,24=5.27, p<0.05; Side x Lesion: F1,24=0.02, n.s.). In addition, the sham lesion 
group‟s dopamine utilization fluctuated more over the course of testing, causing the 
sham group to have significantly higher ratio than the lesion group both before (60-90 
min into testing) and after (105, 135, 150, 180, and 210 min into testing) acute          
L-DOPA administration (Time x Lesion: F17,408=2.18, p<0.01; Simple Effect: 
min.F1,24=4.42, p<0.05). There was no effect of food restriction on DOPAC/DA ratio 
(Food restriction: F1,25=0.04, n.s.; Side x Food: F1,25=1.88, n.s.). 
The percentage change in dopamine utilization after acute L-DOPA 
administration did not differ between the 6-OHDA and sham lesion groups (Figure 
5.8C,F; Lesion: F1,24=1.14, n.s.), between the lesion and intact striata (Side: 
F1,24=1.75, n.s.; Side x Lesion: F1,24=0.01, n.s.) or between ad libitum and food 
restricted rats (Food restriction: F1.24=0.18, n.s.; Side x Food restriction: F1,24=0.04, 
n.s.). 
Intra-striatal model. Overall, dopamine utilization was slightly higher in the sham 
than in the 6-OHDA lesion rats (Figure 5.8G-H, J-K; Lesion: F1,20=24.52, p<0.001), 
and in food restricted versus ad libitum  rats (Food restriction: F1,20=10.01, p<0.01). 
There was also a trend towards higher dopamine utilization in the intact than lesion 
striata (Side: F1,20=3.74, p=0.067; Side x Lesion: F1,20=1.60, n.s.; Side x Food 
restriction: F1,21=0.84, n.s.).  
There were significant fluctuations in the dopamine utilization measured in the 
sham but not 6-OHDA lesion group (Time: F17,340=7.10, p<0.001; Time x Lesion: 
F17,340=1.86,p<0.05; Simple Effect: F4,17=10.40, p<0.05) which inspection of the data 
suggested was due to outliers in the sham lesion group skewing the data. Interestingly, 
the analysis also showed a significant difference between the change in dopamine 
utilization of the ad libitum and food restricted rats, with the latter showing increased 
dopamine utilization over the course of testing (Time x Food restriction: F17,340=1.72, 
p<0.05; Simple Effect: F4,17=8.56, p<0.05).  
 Analysis of the percentage change in dopamine utilization after acute L-DOPA 
injection showed that, overall, the 6-OHDA lesion rats‟ dopamine utilization 
increased less than that of sham controls (Figure 5.8I,L; Lesion: F1,20=12.08, p<0.01; 
Side x Lesion: F1,20=2.93, n.s.). Interestingly, there was also an effect of food 
restriction, which was associated with an overall greater increase in dopamine 
utilization relative to ad libitum controls (Food restriction: F1,20=10.00, p<0.01). 
While this difference was numerically higher in the 6-OHDA lesion group‟s lesion 
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than intact striata, the side specific increase did not meet statistical significance (Side 
x Food restriction: F1,20=0.09, n.s; Side x Lesion x Food restriction: F1,20=0.85, n.s.). 
 
 
Figure 5.8. The DOPAC/DA ratio in the intact and lesion striata of rats with sham 
or 6-OHDA lesions to the MFB (A-F) or the striatum (D-L) that experienced free or 
restricted access to food. The arrow represents the time point at which rats were 
administered 5 mg/kg L-DOPA. The column furthest to the right shows the mean 
post-injection 5HIAA levels relative to baseline, with 100% corresponding to 
baseline levels. The error bars show the standard error of the mean. MFB=Medial 
forebrain bundle. #Significant difference between ad libitum and food restricted 
rats, *Significant difference between sham and 6-OHDA lesion rats. ##p<0.01, 
**p<0.01. 
5.3.8. Effect of acute L-DOPA on 5HIAA levels 
MFB model. While extracellular 5HIAA levels fluctuated throughout the testing 
session there was no peak, or clear time-dependent increase, following L-DOPA 
injection (Figure 5.9A-B, D-E; Time: F17,408=1.97, p<0.05; Time x Lesion: 
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F17,408=1.11, n.s.). Measuring the post-injection 5HIAA levels as a percentage of 
baseline confirmed that there was little change in extracellular 5HIAA levels after 
acute L-DOPA, with the exception of the 6-OHDA lesion ad libitum group, where one 
outlier increased the variation in the data (Figure 5.9C,F; Side x Lesion: F1,24=2.87, 
p<0.05; Effect of Side in 6-OHDA lesion group: F1,24=5.62, p<0.05)  
 In the sham lesion groups, food restriction was associated with higher 5HIAA 
levels relative to ad libitum controls. In the 6-OHDA lesion group, the reverse trend 
was observed in the intact striata (Side x Lesion x Food restriction: F1,24=7.28, 
p<0.05; Simple Effect of Food restriction: min.F1,24=5.03, p<0.05). However, 
analysing post-injection 5HIAA levels expressed as a percentage of baseline did not 
show a difference between ad libitum and food restricted rats (Food restriction: 
F1,24=2.23, n.s.; Side x Food restriction: F1,24=2.69, n.s.). This suggests that while 
there were baseline differences between the ad libitum and food restricted groups they 
did not differ in the relative change of their 5HIAA levels post L-DOPA injection.  
Intra-striatal model. While the intra-striatal cohort showed fluctuations in their 
extracellular 5HIAA levels, which were especially pronounced in the lesion striatum 
(Figure 5.9G-H, J-K; Side x Time: F17,340=1.66, p<0.05; Effect of Time on lesion side: 
F4,17=8.51, p<0.05), there was no peak in 5HIAA levels post L-DOPA injection. 
While there was a significant difference in the percentage increase in 5HIAA levels 
observed following acute L-DOPA in the 6-OHDA and sham lesion groups, 
inspection of the raw data suggested this was due to an outlier in the 6-OHDA food 
restricted group (Figure 5.8I,L; Lesion: F1,20=9.57, p<0.05; Side x Lesion: F1,20=0.03, 
n.s.). 
  There was no overall effect of food restriction on 5HIAA levels when 
including all time points in the analysis (Figure 5.9G-H, J-K; Food restriction: 
F1,20=2.24, n.s.). However, visual inspection of the data suggested lower 5HIAA 
levels specifically in the intact striatum of the 6-OHDA lesion group and there was a 
strong trend supporting this (Side x Lesion x Food restriction: F1,20=4.32, p=0.05). 
There was no significant difference in the percentage increase in 5HIAA levels 
following acute L-DOPA injection (Figure 5.8I, L; Food restriction: F1,20=1.79, n.s.; 
Side x Food restriction: F1,20=0.94, n.s.) 
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Figure 5.9. The 5HIAA levels in the intact and lesion striata of rats with sham or 6-
OHDA lesions to the MFB (A-F) or the striatum (D-L) that experienced free or 
restricted access to food. The arrow represents the time point at which rats were 
administered 5 mg/kg L-DOPA. The column furthest to the right shows the mean 
post-injection 5HIAA levels relative to baseline, with 100% corresponding to 
baseline levels. The error bars show the standard error of the mean. MFB=Medial 
forebrain bundle. *Significant difference between sham and 6-OHDA lesion rats, 
#Significant difference between ad libitum and food restricted rats *p<0.05, 
#p<0.05 
5.4. Discussion 
Lesion rats with free or restricted access to food were included in a microdialysis study to test 
the hypothesis that food restriction increased the amount of L-DOPA that crosses the BBB. 
The hypothesis was tested by comparing extracellular DOPA levels following acute L-DOPA 
administration in rats with free or restricted access to food.  
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DOPA is the precursor to dopamine and converted into the latter by the enzyme 
DOPA decarboxylase (Flatmark et al (2000). To provide information on lesion success and 
the ability for the administered dose of acute L-DOPA to increase dopamine levels and 
dopamine utilization, which are indicative of the therapeutic effect L-DOPA exerts, the 
experiment also measured dopamine, its metabolites DOPAC and HVA, and the 
DOPAC/dopamine ratio. In line with previous experiments (e.g. Lindgren et al, 2010), the 
success of the unilateral 6-OHDA lesions was demonstrated by a pronounced asymmetry in 
the dopamine levels of lesion rats‟ intact and lesion striata.  Interestingly, the lesion did not 
only decrease ipsilateral dopamine levels but also increased extracellular dopamine in the 
intact striata. Previous studies have demonstrated increased TH proteins levels in the intact 
striatum following unilateral 6-OHDA lesions to the striatum (Kozlowski et al, 2004). In 
addition, unilateral nigral 6-OHDA lesions have been shown to increase both dopamine 
levels in contralateral striatal tissue and levels of extracellular dopamine in the contralateral 
striatum (Zhang et al, 1988). These data are consistent with the current findings and have 
previously been hypothesised to represent a compensatory mechanism (Kozlowski et al, 
2004), which has been suggested to be mediated by increased dopamine release per terminal 
or an increase in the number of dopamine terminals in the contralateral hemisphere (Zhang et 
al, 1988).  
5.4.1. Effect of food restriction on L-DOPA influx 
The aim of the current experiment was to directly test the hypothesis that food restriction 
increases L-DOPA influx via the BBB. The hypothesis was tested in the intra-striatal and 
MFB 6-OHDA models of PD by measuring striatal extracellular levels of DOPA, dopamine, 
and dopamine metabolites in freely moving rats before and after acute L-DOPA 
administration. The data did not show a difference in the extracellular DOPA levels of food 
restricted and ad libitum rats, and as such did not support the hypothesis.  
Previous studies have reported a peak in MFB lesion rats‟ extracellular DOPA and 
dopamine levels approximately 40 min after acute administration of 6 mg/kg L-DOPA (Carta 
et al, 2006; Lindgren et al, 2010). A similar DOPA peak was observed in the current 
experiment following 5 mg/kg L-DOPA (Figure 5.4). However, there was no peak in the 
extracellular dopamine levels observed after L-DOPA injection. Whilst the absence of a 
dopamine peak was unexpected, other studies have failed to find a noticeable peak in 
extracellular dopamine levels of intact  L-DOPA naïve rats unless using a L-DOPA dose ≥25 
mg/kg, although it should be noted that the authors did not report the accompanying 
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benserazide dose (Abercrombie et al, 1990). Other microdialysis studies, including one 
utilizing drug naïve MFB lesion rats report a dopamine peak 1 h after acute administration 
when 15 mg/kg L-DOPA + 10 mg/kg benserazide were administered (Jonkers et al, 2000). 
Hence, previously published literature show differences not only between the doses required 
to measure a peak in extracellular dopamine in intact versus lesion rats, but also in the time 
post-injection when the peak is observed. It is possible that a higher L-DOPA dose, such as 
the 15 mg/kg used by Jonkers and colleagues (2000), would have been required for an 
extracellular dopamine peak to be observed in the current experiment. A higher dose was not 
used because a pilot study (data not reported) in which 10 mg/kg L-DOPA was administered 
to MFB lesion rats during microdialysis testing demonstrated AIMs of sufficient magnitude 
for rats to risk entangling themselves in the tubing as well as L-DOPA induced rotations of 
sufficient magnitude to twist the tubing and thereby interrupting aCSF flow. Therefore, for 
animal welfare reasons as well as to minimise the number of samples that may have been lost 
due to disrupted aCSF flow, the lower dose of 5 mg/kg L-DOPA was used. The choice of 
dose was justified based on (i) previous dose response curves (Chapter 4) demonstrating an 
effect of 5 mg/kg L-DOPA on motor function in lesion rats, and (ii) the observation that the 
AIMs and L-DOPA induced rotations observed in L-DOPA naïve MFB lesion rats at this 
dose did not disrupt microdialysis testing.  
The food restricted groups did not show significantly higher DOPA levels than ad 
libitum controls and the current data therefore suggest that, contrary to the hypothesis, food 
restriction does not increase L–DOPA influx in the rat striatum. There are, however, caveats 
associated with the use of microdialysis which may have influenced the measured DOPA 
levels. For example, it is possible that the probe implantation 48 h prior to surgery disrupted 
the blood brain barrier, thereby decreasing the likelihood of observing a difference between 
the ad libitum and food restricted groups. Previously published studies measuring BBB 
permeability have shown that microdialysis probe implantation causes an acute increase in 
the permeability of the BBB of male Sprague Dawley rats 1-2 h after insertion, with the 
maximum effect on permeability being observed 1-2 days after microdialysis implantation 
(Groothuis et al, 1998). To comply with the project license under which the current 
experiment was conducted, the microdialysis session was conducted 48 h after microdialysis 
implantation. Previous in-house studies (not published) using the same interval between 
probe implantation and microdialysis have successfully measured increases in DOPA levels 
after acute L-DOPA injection using the same set-up and it was therefore not expected that 
increased BBB permeability would interfere with the experiment. However, considering the 
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findings by Groothuis and colleagues (1998), the possibility that an increased permeability in 
the BBB at the time of testing led to an overall increase in L-DOPA influx, thereby reducing 
the likelihood of observing a difference between the food restricted and ad libitum rats cannot 
be excluded.  
5.4.2. Effect of food restriction on dopamine levels and utilization 
While the aim of the experiment was to test the effect of food restriction on L-DOPA influx it 
also reported levels of dopamine and its metabolites as well as the DOPAC/dopamine ratio, 
which has previously been used to estimate dopamine utilization (e.g. Cartmell et al, 2000; 
Jentsch et al, 1998). Including these measurements in the analysis supplemented data on 
DOPA influx by providing insight into not only extracellular dopamine levels but also the 
control and experimental groups‟ utilization of the available dopamine.  
Restricting rats‟ food intake in the current experiment produced a strong trend 
towards reduced baseline dopamine levels in the intra-striatal model (Figure 5.3D; p=0.058) 
accompanied by increased dopamine utilization (Figure 5.3J, 5.8J). Previous publications 
have demonstrated that acute food restriction decrease dopamine clearance rates in intact rats 
(Sevak et al, 2008), and that feeding young (20-25 g) rats a low-protein diet for 1 year 
reduces striatal dopamine levels (Mathangi & Namasivayam, 2001). In addition, 72 hours 
food restriction has been shown to increase striatal DOPAC/dopamine ratio in rats (Tsuji et 
al, 1988). The current findings of decreased dopamine levels and increased dopamine 
utilization in food restricted rats with intra-striatal lesions thus align with existing literature 
on the effect of food restriction on intact rats. While the reason for these changes was not 
directly tested it is noted that L-tyrosine (the precursor for DOPA) is derived from food and 
that L-phenylalanine (the precursor for L-tyrosine) is either derived from food or synthesised 
from L-tyrosine (Figure 1.5; Flatmark et al, 2000). Changes in diet or quantity of food intake 
may thus be hypothesised to indirectly affect dopamine levels by affecting transmitters 
further down its synthesis pathway. This would be in line with previous data demonstrating 
an effect of diet on brain tyrosine levels (Wurtman et al, 1980). The increased dopamine 
utilization observed following food restriction in the intra-striatal lesions may in turn 
represent a compensatory mechanism. It has previously been demonstrated that the 
dopaminergic system is able to compensate for dopamine loss by increasing the dopamine 
utilization in 6-OHDA lesion rats (Hefti et al, 1985) and MPTP lesion monkeys (Pifl et al, 
2006), a phenomenon which has been hypothesised to reflect a compensatory mechanism 
(Hornykiewicz, 1998). It is thus plausible that decreased dopamine levels caused by dietary 
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changes may induce a similar compensatory response, which could explain the increased 
DOPAC/dopamine ratio observed in the food restricted rats with intra-striatal lesions.     
The rotational bias exhibited by rats with unilateral 6-OHDA lesions is believed to 
reflect the dopamine asymmetry between the lesion and intact striata in rats with unilateral 
lesions (Ungerstedt, 1968, 1970). If food restriction decreases dopamine levels in the intact 
but not lesion striatum, it follows that food restriction would indirectly decrease the dopamine 
asymmetry between the two hemispheres. It may be therefore be hypothesised that, because 
of this decreased asymmetry, less L-DOPA was required to restore the dopamine balance 
between the intact striata and lesion striata in food restricted relative to ad libitum lesion rats. 
If true, it would also follow that less L-DOPA would be required to shift the dopamine 
balance from the intact to the lesion striata in food restricted relative to ad libitum rats and to 
produce a contralateral rotational bias. While an untested hypothesis, it may explain why the 
dose response curves in Chapter 4 showed greater rotational bias in food restricted than ad 
libitum intra-striatal lesion rats despite the current chapter not demonstrating a greater          
L-DOPA influx in food restricted rats.  
5.4.3. Effect of food restriction on the serotoninergic system 
In addition to DOPA, dopamine, and dopamine metabolites the current experiment also 
measured levels of the serotonin metabolite 5HIAA. Serotonin is formed from L-tryptophan 
which is supplied to the central nervous system via the blood, and levels of which are 
affected by diet (Fernstrom, 1981). Following MAO initiated catabolism of serotonin, the 
neurotransmitter is broken down to 5HIAA (Ferstrom, 1981) which was included as a control 
measurement in the current microdialysis experiment. Following acute L-DOPA injection, 
there was a clear peak in extracellular DOPA but not 5HIAA levels which suggested that the 
injection induced changes observed in the microdialysis data were specific to DOPA and the 
dopaminergic system.    
In addition to decreased dopamine levels, 6-OHDA lesions to the MFB or striatum 
also decreased baseline 5HIAA levels. This effect of dopamine depletion on 5HIAA levels is 
in accordance with previously published data showing reduced striatal 5HIAA levels as well 
as decreased firing in dorsal raphé serotonergic neurons following dopamine depletion 
(Karstaedt et al, 1994; Guiard et al, 2008).  
Furthermore, the data demonstrated altered 5HIAA levels following food restriction. 
Both the MFB and intra-striatal 6-OHDA models showed decreased 5HIAA levels in their 
intact striata following food restriction. These findings are in line with previous publications 
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showing decreased serotonin and 5HIAA levels after food restriction of intact rats (Schweiger 
et al, 1989; Mathangi & Namasivayam, 2001). Interestingly, food restriction had different 
effects on the 5HIAA levels in the lesion striatum of rats with MFB or intra-striatal 6-OHDA 
lesions. While rats with MFB lesions showed increased ipsilateral 5HIAA levels following 
food restriction, no effect was observed in the intra-striatal cohort. The two lesion models 
differ in the extent of the nigral dopamine loss they produce, with more pronounced loss 
being observed following MFB than intra-striatal lesions (e.g. Yuan et al, 2005). Previous 
studies have demonstrated increased striatal levels of serotonin and 5HIAA following >90% 
loss of nigral dopamine in 6-OHDA lesion rats (Zhou et al, 1991) which is similar to the 
nigral loss induced by MFB lesions. It is therefore possible that the observed differences 
between ipsilateral 5HIAA levels in the MFB and intra-striatal model were linked to 
differences in the striatal serotonergic sprouting they produce, as serotonergic sprouting only 
occurs following near complete dopamine depletion (Zhou et al, 1991).   
5.4.4. Conclusions 
The aim of the experiment was to test the hypothesis that food restriction increases L-DOPA 
influx in the rat. 6-0HDA lesions to the MFB and striatum decreased dopamine levels and 
dopamine utilization (as measured by DOPAC/DA levels and HVA) in the lesion striatum. 
Injection of acute L-DOPA produced a measurable peak in extracellular DOPA levels but 
there was no effect of food restriction, with similar extracellular DOPA levels observed in 
both food restricted and ad libitum rats. Hence, the data did not support the hypothesis that 
food restriction increases L-DOPA influx to the striatum. Based on the current data it cannot, 
as previously hypothesised, be concluded that the increased rotational bias in food restricted 
relative to ad libitum intra-striatal lesion rats observed in Chapter 4 was due to higher L-
DOPA influx. 
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6. Effect of Dopaminergic Treatment on the 
Acquisition and Maintenance of Motor Skills 
Background: Current literature suggests that synaptic plasticity may enhance or mediate 
learning of new motor skills, while not being essential for the maintenance of already 
acquired skills. The onset of LID has been shown to disrupt synaptic plasticity in the rat MFB 
model of PD. Based on previously published literature, it was therefore hypothesised that 
LID onset would impair acquisition of a novel motor skill, but not performance of a skill that 
had been acquired prior to lesion and chronic L-DOPA treatment.  
 
Aim: The aim of the chapter was to test whether chronic L-DOPA administration, which 
induces LID in the vast majority of MFB lesion rats would (i) impair the rate with which 
MFB lesion rats learn a motor task de novo, and (ii) affect performance on the same task in 
lesion rats that had learned the task prior to lesion and L-DOPA treatment. 
 
Methods: The hypothesis was tested by measuring performance on the staircase task. 
Experiment 6 compared post-lesion performance of intact, lesion saline treated, and lesion    
L-DOPA treated rats that had learned the task prior to lesion and drug treatment. Experiment 
7 compared the performance of intact, lesion saline treated, and lesion L-DOPA treated rats 
when having to learn the task de novo after lesions. Experiment 8 was designed to replicate 
the findings from Experiment 7 while also including an intact and lesion group treated with 
the D2 agonist bromocriptine. 
 
Results: As hypothesised, chronic L-DOPA did not affect performance of rats that had 
learned the staircase task prior to lesion and L-DOPA treatment. An L-DOPA induced 
impairment in the acquisition of the task was found in Experiment 7 but not in Experiment 8. 
The presented data were therefore insufficient to determine whether or not LID onset impairs 
acquisition of the staircase task. 
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6.1. Introduction 
It has long been known that dopamine is involved in the execution of motor actions. 
However, another crucial aspect of motor function is the ability to learn novel motor actions 
and to refine pre-existing motor skills. Motor skill learning is a complex procedure, which is 
believed to be mediated by the cortico-cerebellar and cortico-striatal pathways. Whilst the 
cortico-cerebellar pathway is believed to play a role in the spatial awareness that is required 
for the execution of motor actions, the cortico-striatal pathway is believed to hold 
representations of the individual motor actions that form part of a motor sequence (Hikosaka 
et al, 2002). Measuring neural activation in healthy participants as they either perform a 
previously learned motor sequence, or learn a novel motor sequence, has demonstrated that 
only the latter is associated with significant activation in the prefrontal cortex (Jenkins et al, 
1994). In addition, there was greater activation in the cerebellum, lateral premotor cortex, and 
parietal cortex during de novo learning. Conversely, the putamen was activated in both de 
novo learning and during performance on a previously learned sequence, suggesting that the 
basal ganglia are implicated in both acquisition and maintenance of motor skills (Jenkin et al, 
1994). As predicted from imaging studies of healthy controls, both PD patients and patients 
with lesions to the cerebellum are impaired relative to healthy in their ability to learn a novel 
motor sequence (Doyon et al, 1994), and PD patients are also been shown to be impaired in 
their ability to adapt a motor repertoire to changes in the environment (Krebs et al, 2011).  
In line with clinical data, preclinical findings also implicate the basal ganglia in the 
acquisition of novel motor skills. Some of these preclinical findings have been accomplished 
using the skilled reach task, which measures the success with which rats grasp and retrieve 
food pellets placed on a pedestal located 1.5 cm away from them. Using this paradigm, Luft 
et al (2004) demonstrated impaired acquisition of the paw-reaching skill following infusion 
of the protein synthesis inhibitor anisomycin, which inhibits HFS induced LTP (Okulski et al, 
2002),  to the motor cortex. Conversely, if anisomycin was infused after the task had already 
been acquired it did not affect performance (Luft et al, 2004). The effect of infusing 
anisomycin into the dorsal striatum, which is connected to the motor cortex, on motor 
learning, was studied in a separate experiment (Wächter et al, 2010). This study utilised a 
similar apparatus, in which rats could open an automatic door in their test cage by nose 
poking. Once open, rats could reach for a food pellet located 1.5 cm away using their 
preferred paw. In line with Luft et al‟s (2004) data, Wächter and colleagues (2010) found that 
infusing anisomysin into the dorsal striatum prior to motor task training decreased the 
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number of successful reaches the rats made. Conversely, if the infusion was made once a 
plateau in the rats‟ motor performance had been reached the animyosin did not affect 
behaviour. In neither condition did anisomysin affect the time taken for rats to initiate new 
trials, which was taken to suggest that the impaired motor learning was not mediated by 
decreased motivation (Wächter et al, 2010). The role of synaptic plasticity in motor skill 
learning was further investigated by Yin et al (2009). Using in-vivo and ex-vivo recordings 
from mice that received rotarod training, Yin and colleagues (2009) showed an increase in 
neuronal activity and synaptic strength in the dorsomedial striatum during early motor 
training that was transferred to the dorsolateral striatum once the skill had been fully learned. 
The data by Yin et al (2009) thus demonstrated striatal synaptic plasticity in the dorsomedial 
striatum during the acquisition of novel motor skills, and in the dorsolateral striatum during 
the maintenance of recently learned motor skills. While the precise role of synaptic plasticity 
in motor learning has been debated (e.g. Conner et al, 2003l Kilgard, 2012), the studies 
described above suggest (i) that the cortico-striatal pathway plays a role in the acquisition of 
motor skills, and (ii) that not only dopamine but also synaptic reorganization is involved in 
motor skill acquisition. 
As previously discussed in section 1.6, the onset of LID is associated with disrupted 
synaptic plasticity in the dopaminergic system (Picconi et al, 2003; Prescott et al, 2009; 
Huang et al, 2011). In the rat MFB model, the onset of LID is associated with restored ability 
for LTP formation but lost ability for depotentiation in the cortico-striatal pathway (Picconi et 
al, 2003). Based on previously published data showing an involvement of striatal synaptic 
plasticity in motor skill acquisition, it was hypothesised that LID onset in the MFB model 
would render rats less able to refine their motor repertoire during motor skill learning, and 
that LID onset would therefore interfere with the acquisition, but not maintenance, of motor 
skills. Three experiments were conducted to test the hypothesis. Experiment 6 tested the 
effect of MFB lesions and chronic L-DOPA treatment, which induces LID in the majority of 
MFB lesion rats (Winkler et al, 2002), on pre-trained rats‟ ability to maintain successful 
reaching in the staircase boxes. Experiment 7 tested the effect of lesions and chronic            
L-DOPA treatment on rats‟ ability to learn to retrieve sucrose pellets from staircase boxes de 
novo. Experiment 8 was conducted to replicate the findings from Experiment 7 whilst also 
including a lesion and intact group chronically treated with the D2 agonist bromocriptine. 
Bromocriptine is used to treat motor symptoms of PD in the clinic but, unlike L-DOPA, does 
not induce LID (Pearce et al, 1998). It was therefore used as a dopaminergic control drug to 
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L-DOPA in the current chapter. Further description of bromocriptine‟s affinity for dopamine 
receptors is provided in section 6.4 
 All experiments used rats with MFB lesions as this is the lesion model in which 
previous studies have demonstrated disrupted synaptic plasticity following LID onset 
(Picconi et al, 2003). Furthermore, Lister Hooded rats were used over Sprague Dawley rats as 
the cohorts used in this chapter were also utilised in operant experiments where Lister 
Hooded rats were more appropriate. 
6.2. Experiment 6 (part I): The effect of dopamine denervation and chronic 
L-DOPA treatment on maintenance of a previously acquired motor skill 
6.2.1. Introduction  
Whilst plasticity in the dopaminergic system has been suggested to play a role in motor skill 
acquisition (Luft et al, 2004; Yin et al, 2009; Wächter et al, 2010), synaptic reorganization 
does not appear to be crucial for the maintenance of motor skills (Wächter et al, 2010). 
Chronic L-DOPA, which induces LID in the majority of MFB lesion rats (Winkler et al, 
2002), was therefore hypothesised to not affect rats‟ ability to maintain a previously learned 
motor skill. To test this hypothesis, rats that had been pre-trained on the staircase task and 
later given unilateral MFB lesions and chronic saline or L-DOPA treatment were compared 
in their performance on the staircase task. In line with previous publications (Wishaw et al, 
1997) it was hypothesised that dopamine loss would impair performance on the staircase task 
when rats used their contralateral paw. However, chronic L-DOPA was not expected to 
further affect performance. 
6.2.1.2. Aims 
The aim of the experiment was to test whether dopamine denervation and chronic L-DOPA 
treatment affected pre-trained rats‟ ability to maintain their ability to retrieve sucrose pellets 
from staircase boxes  
6.2.2. Methods 
6.2.2.1. Experimental design 
Female Lister hooded rats that were also used in the LCRT experiment described in section 
7.3 were utilised in the experiment. All rats were pre-trained on the LCRT task and in 
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staircase boxes before a subgroup of the rats was given unilateral 6-OHDA lesions to the MFB. Rats were then chronically treated with saline or 
L-DOPA. Following one week food restriction, rats were tested in staircase boxes that were bilaterally baited with three sucrose pellets per step 
(Figure 6.1). 
 
Figure 6.1. The experimental design used in Experiment 6. Grey boxes indicate testing reported further in section 7.3. The figure specifies 
both the duration of the individual testing phases, and the overall number of days in the experiment. AIMs=Abnormal involuntary 
movements, FR=Food restriction, LCRT=Lateralised choice reaction time task, MFB=Medial forebrain bundle. 
6.2.2.2 Procedure 
Forty-eight female Lister Hooded rats were pre-trained on the LCRT task for one month (section 2.7.2.2) and in the staircase boxes (section 
2.4.7) for 10 days before 38 rats were given unilateral 6-OHDA lesions to the MFB (section 2.2.2). Following two weeks recovery, rats‟ lesion 
extent was assessed using the cylinder test and spontaneous rotations (sections 2.4.4 and 2.4.6.3). All intact and 26 of the lesion rats were then 
chronically treated with 1 ml/kg saline, and the remaining 12 lesion rats with 10 mg/kg L-DOPA for two weeks. AIMs were scored in  
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accordance with the previously described protocol (section 2.5). Only lesion rats treated with 
L-DOPA were scored for AIMs. This decision was based on the fact that LID is induced by 
chronic L-DOPA or D1 agonists, and is therefore not observed following only saline 
treatment. This was also confirmed in Experiment 10 where AIMs scoring of both saline and 
L-DOPA treated rats was conducted by a blinded scorer. Following induction of stable AIMs, 
rats were food restricted for before being tested in staircase boxes bilaterally baited with three 
pellets per step for five days.  
During staircase testing rats were placed in the same staircase boxes they had been 
trained in and were allowed 15 min to reach for sucrose pellets, after which they were 
returned to their home cages. At the end of each session, the number of pellets remaining on 
each step was recorded to provide a measurement of the number of pellets the rats had 
successfully retrieved. In addition, the number of displaced pellets was counted as an 
indicator of attempted but failed retrievals, and the furthest away step the rats was been able 
to access was used as an indicator of reaching ability. A displaced pellet was defined as a 
pellet that was pushed from a higher step to a lower step. For example, if a step had been 
baited with three pellets, but five pellets were located on it at the end of staircase testing, two 
of these pellets must have been pushed there from an above step and were therefore defined 
as displaced. 
At the end of testing, rats were used in an operant experiment (section 7.3) and 
thereafter perfused (section 2.8). Immunohistochemical staining was conducted as outlined in 
2.10 and TH+ cell bodies were counted in the SNc and VTA (section 2.11) to confirm a 
lesion induced dopamine denervation.    
6.2.2.3. Statistical analysis 
The effect of the lesion on the number of TH+ cell bodies in the SNc and VTA was analysed 
using two separate types of analyses. First, the presence of a lesion in the SNc or VTA was 
confirmed by comparing the raw cell counts in the ipsilateral and contralateral hemisphere 
using a t-test. For this analysis, the SNc and VTA were analysed separately. Once the 
presence of a lesion had been confirmed, an ANOVA was used to test whether there was a 
difference in (i) the relative extent of the experimental groups' dopamine denervation, and (ii) 
the loss of dopaminergic cell bodies observed in the SNc versus the VTA. The ANOVA used 
the percentage loss of TH+ cell bodies observed in the lesion SNc and VTA as input data and 
included Region as a within-subject variable, and Group as a between-subject variable. 
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Baseline staircase data was analysed in a repeated measures ANOVA with Side as 
within-subject factor and Group as between-subject factor. Staircase data was analysed using 
a repeated measures ANOVA with Side and Day as within-subject factors and Group as 
between-subject factors. Significant between-factor differences were analysed using a 
Scheffe post-hoc test, whereas significant interactions were analysed using a test of simple 
effects. 
6.2.3. Results 
6.2.3.1. Lesion & Drug Effects 
The success of the lesion was demonstrated by a significant reduction in the number of 
dopaminergic cell bodies observed in the ipsilateral compared to the contralateral SNc 
(t37=23.73, p<0.001) and VTA (t37=6.99, p<0.001). An analysis of the rats‟ percentage loss in 
their lesion relative to their intact hemisphere demonstrated that the lesion induced greater 
dopamine denervation in the SNc than in the VTA (Region: F1,36=37.33, p<0.001), but that 
the two groups‟ did not differ in the extent of their dopamine loss (Group: F1,36=1.56, n.s.; 
Group x Region: F1,36=0.59, n.s.).   
The unilateral dopamine loss was reflected in a pronounced ipsilateral bias in rats‟ 
spontaneous rotations (Figure 6.2C) and in their performance on the cylinder task (Figure 
6.2D). There was no difference between the ipsilateral bias exhibited by the lesion groups on 
either of these motor tests (Spontaneous rotations: F1,35=0.13, n.s.; Cylinder test: U=131.5, 
n.s.), suggesting that the lesion had a similar effect on motor function on all lesion groups.  
Following chronic L-DOPA treatment, the lesion L-DOPA group exhibited high and 
stable AIMs scores in response to acute L-DOPA administration (Figure 6.2E).  
6.2.3.2. Staircase data 
Pre-lesion performance. To demonstrate that there was no difference in the groups‟ baseline 
performance three analyses were conducted; analysing the number of retrieved pellets, 
furthest step reached, and the number of displaced pellets respectively. There was no 
difference between the overall number of pellets the number of pellets the groups retrieved, 
the furthest step they could reach, or the overall number of pellets they displaced at baseline 
(Group: max.F2,45=1.17, n.s.). Neither was there a difference in their ipsilateral bias on the 
above-mentioned measurements (Side: max.F1,45=0.70, n.s.; Side x Group: max.F2,45=0.46, 
n.s.). 
Post-lesion performance: Pellets Retrieved. The two lesion groups retrieved 
significantly fewer pellets than intact controls when using their contralateral forelimb but 
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there was no effect of L-DOPA treatment on the lesion rats‟ performance (Figure 6.3A-B; 
Side: F1,45=57.64, p<0.001; Side x Group: F2,45=21.56, p<0.001; Simple Effect: min.F1,45= 
64.53, p<0.001). While most rats‟ performance was stable over the course of testing (Day: 
F4,180=1.13, n.s.), the saline treated lesion group showed a small but significant increase in the 
number of pellets they could retrieve using their ipsilateral paw (Side x Day x Group: 
F8,180=2.37, p<0.05; Simple Effect: F4,42=4.16, p<0.05), as well as a small but significant 
 
Figure 6.2. Surviving dopaminergic cell bodies in the SNc and VTA of rats that were         
L-DOPA naive or L-DOPA treated, expressed as a percentage of the intact side (A), 
together with the a photo showing the loss of TH+ cell bodies in the SNc and VTA in one 
lesion rat included in the experiment (B), the ipsilateral bias exhibited by lesion rats that 
were later L-DOPA naive or L-DOPA treated in the spontaneous rotations (C) an cylinder 
(D) tests, and the cumulative AIMs s scores for the lesion L-DOPA treated rats following 
chronic L-DOPA treatment (E). It is noted that all rats were L-DOPA naive at the time of 
lesion and the motor behavioural tests The bars charts (A, C) show the mean and 
standard error of the mean. The box plot (D) shows the median and the interquartile 
ranges. SNc=Substantia nigra pars compacta; TH=Tyrosine hydroxylase; VTA=Ventral 
tegmental area. ***p<0.001 
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decrease in the number of pellets they could retrieve using their contralateral paw (Simple 
Effect: F4,42=4.75, p<0.01). 
 
Figure 6.3. The number of pellets retrieved from staircase boxes (A-B), the furthest step 
pellets were retrieved from (C-D), and the number of pellets displaced (E-F) by drug 
naïve intact (n=10), lesion drug naïve (n=26), and lesion L-DOPA treated rats (n=12) 
rats. *p<0.05, ***p<0.001 
 
Post-lesion performance: Furthest Step Reached. Both lesion groups could reach 
further when using their ipsilateral than when using their contralateral forelimb (Figure 6.3C-
D; Side x Group: F2,45=23.36, p<0.001; Simple Effect: min.F1,45=62.32, p<0.001). There was  
an overall change in ipsilateral reaching ability over the course of testing which was driven 
by a slight improvement in the performance of the intact, but not lesion, rats (Side x Day: 
F4,180=3.04, p<0.05; Simple Effect: F4,42=4.20, p<0.01). Overall, the intact and the lesion     
L-DOPA treated groups could both reach steps located further away than the lesion saline 
treated group could (Group: F2,45=4.54, p<0.05).  
Post-lesion performance: Displaced Pellets. There was no difference between the 
number of pellets that were displaced by the three groups, regardless of whether the 
ipsilateral or contralateral forelimb was used (Figure 6.3E-F; Side: F1,45=0.07, n.s.; Side x 
Group: F2,45=0.71, n.s.). While the overall number of displaced pellets fluctuated over the 
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course of testing, visual inspection of the graphs suggested this was merely due to noise in 
the data (Day: F4,180=2.66, p<0.05; Side x Day: F4,180=1.26, n.s.; Day x Group: F8,180=0.81, 
n.s.; Side x Group x Day: F8,180=1.29, n.s.; Group: F2,45=0.12, n.s.).  
 
6.3. Experiment 7: The effect of dopamine denervation and chronic  L-DOPA 
treatment on the ability for de novo motor learning 
6.3.1. Introduction  
Based on data demonstrating synaptic reorganization in the motor cortex and dorsal striatum 
following learning of a novel motor skill (Luft et al, 2004; Yin et al, 2009; Wächter et al, 
2010), it was hypothesized that the aberrant plasticity occurring in the dopaminergic system 
following LID onset (Picconi et al, 2003) would impair acquisition of a novel motor skill. To 
test this hypothesis, the rate with which MFB lesion chronically treated with saline or L-
DOPA learned to retrieve sucrose pellets from staircase boxes when no pre-training had 
been given was compared. In line with previous publications (Whishaw et al, 2007) it was 
hypothesised that unilateral MFB lesion cause lesion rats to retrieve fewer pellets than intact 
controls when using their contralateral paw. Furthermore, it was hypothesised that lesion rats 
treated with L-DOPA, which causes LID onset in the vast majority of MFB lesion rats 
(Winkler et al, 2002) would show a slower rate of learning on the staircase task than lesion 
rats treated with saline.  
6.3.2. Aims 
The aim of the experiment was to study the effect of chronic L-DOPA treatment and LID 
onset on MFB lesion rats‟ ability to learn to retrieve sucrose pellets in staircase boxes.  
6.3.2. Methods 
6.3.2.1. Experimental design 
While written up as the second staircase experiment, the current section describes the first 
staircase experiment conducted in this thesis project. The rat cohort described was used both 
in the staircase testing described in this section, and in an operant pilot study (not reported). 
As part of the operant pilot study, all rats were given 3-4 days of magazine and lever press 
training before a subgroup received unilateral MFB lesions. After recovery, the lesion group 
was chronically treated with saline or L-DOPA and thereafter tested on an operant task. 
Following operant testing, a second AIMs scoring session took place to ensure the L-DOPA 
treated rats still exhibited AIMs. All rats were thereafter tested for 20 days in unilaterally 
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baited staircase boxes (Figure 6.4). Thus, it is noted that the current experiment and 
Experiment 6 did not only differ in terms of whether or not rats were pre-trained on the 
staircase task but also in the type and length of operant training which they underwent. 
6.3.2.2. Procedure 
Thirty-five female Lister hooded rats were given 3-4 days magazine training in two-lever 
operant boxes before a subgroup (n=20) was given unilateral lesion lesions of the MFB 
(section 2.2.2). Following two weeks recovery, lesion extent was assessed using the cylinder 
test and spontaneous rotations (sections 2.4.4 and 2.4.6.3). A subgroup of the lesion rats 
(n=9) was chronically treated with 10 mg/kg L-DOPA, daily, for two weeks whilst the 
remaining rats received saline injections. AIMs were scored in accordance with the 
previously described protocol (section 2.5). Only lesion rats treated with L-DOPA were 
scored for AIMs. This decision was based on the fact that LID is by definition not induced by 
saline, something which was also confirmed in Experiment 10 where AIMs scoring of both 
saline and L-DOPA treated rats was conducted.  
Following induction of stable AIMs, rats were tested on a simple discrimination task 
(section 2.7.1.2) before being tested in staircase boxes. The L-DOPA group was given a 
further injection/AIMs scoring session between operant and staircase testing to ensure they 
still exhibited a dyskinetic response to 10 mg/kg L-DOPA, which all rats did.  
Staircase testing was conducted using the same protocol as described in section 6.2 
but using unilaterally baited rather than bilaterally baited staircase boxes. The side of baiting 
alternated each day. Unilateral rather than bilateral baiting was used to force lesion rats to use 
their contralateral paw, thereby ensuring that the data reflected de novo learning rather than a 
decrease in the willingness to exert effort for a reward following 6-OHDA lesions as has 
previously been observed (Cousins & Salamone, 1994). The side which rats first began 
testing on (i.e. ipsilateral or contralateral to the lesion) was counterbalanced. 
Following staircase testing, rats were tested on the 100 pellets test. Described in 
further detail in section 2.4.1, the test assessed the amount of time taken for rats to eat 100 
freely available sucrose pellets and was used as an indicator of the rats‟ motivation to 
consume the sucrose pellets. 
At the end of testing, all rats were culled (2.8). The tissue was used for immunohistochemical 
staining as outlined in section 2.10 and TH+ cell bodies were counted in the SNc and VTA 
(2.11) to confirm the success of the lesion. Striatal tissue was intended to be used for 
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molecular studies but as it was not within the timeframe of the thesis project to optimise the 
necessary protocols such data are not reported.  
6.3.2.3. Statistical analysis 
The effect of the lesion on the number of TH+ cell bodies in the SNc and VTA was analysed 
using two separate types of analyses. First, the presence of a lesion in the SNc or VTA was 
confirmed by comparing the raw cell counts in the ipsilateral and contralateral hemisphere 
using a t-test. For this analysis, the SNc and VTA were analysed separately. Once the 
presence of a lesion had been confirmed, an ANOVA was used to test whether there was a 
difference in (i) the relative extent of the experimental groups' dopamine denervation, and (ii) 
the loss of dopaminergic cell bodies observed in the SNc versus the VTA. The ANOVA used 
the percentage loss of TH+ cell bodies observed in the lesion SNc and VTA as input data and 
included Region as a within-subject variable, and Group as a between-subject variable. 
Baseline staircase performance was measured by analysing performance on the final 
testing day with Side as a within-subject factor and Group as a between-subject factor. Post-
lesion staircase performance was analysed in a repeated measures ANOVA with Side and 
Day as within-subject factors and Group as between-subject factors. Data from the 100 
Pellets Test were analysed using a one-way ANOVA with Time as a within-subject factor 
and Group as a between-subject factor Significant between-subject differences were analysed 
using a Scheffe post-hoc test whereas significant interactions were analysed using a test of 
simple effects. 
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Figure 6.4. A graphical representation of the experimental design of Experiment 7. The figure specifies both the duration of the individual 
testing phases, and the overall number of days in the experiment. Grey boxes indicate testing undertaken for a pilot experiment not 
reported in the thesis. AIMs=Abnormal involuntary movements, FR=Food restricted, MFB=Medial forebrain bundle, s.c.=subcutaneous 
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6.3.3. Results 
6.3.3.1. Lesion & Drug Effects 
The lesion induced a profound loss of dopaminergic cell bodies in the ipsilateral SNc (Figure 
6.5A; t24=14.93, p<0.001) and the VTA (t24=12.35, p<0.001). A further analysis 
demonstrated that the percentage TH loss was greater in the SNc than in the VTA (Region: 
F1,23=54.71, p<0.001) and that the denervation was similar between the groups (Group: 
F1.23=1.18, n.s.; Region x Group: F1,23=0.25, n.s.).   
The success of the lesion was also reflected in an ipsilateral bias in the rats‟ 
spontaneous rotations (Figure 6.5C) and in the cylinder test (Figure 6.5D). There was no 
difference between the groups‟ ipsilateral bias on either of these motor tests (Spontaneous 
rotations: F1,24=0.03, n.s.; Cylinder test: U=72.00, n.s.). Chronic   L-DOPA treatment induced 
LID, characterised by stable AIMs in all L-DOPA treated rats (Figure 6.5E). 
6.3.3.2. Staircase data 
Pellets retrieved. Lesion rats retrieved significantly fewer pellets than intact controls but 
there was no difference between the overall number of pellets retrieved by lesion rats treated 
with saline and L-DOPA (Figure 6.6A-B; Group: F2,32=8.84, p<0.01). While lesion rats 
retrieved fewer pellets than intact controls using their ipsilateral paw on days 5, 6, and 9 of 
testing, the lesion induced deficit was most pronounced when rats had to use their 
contralateral forelimb to retrieve pellets. When using their contralateral forelimb, lesion rats 
were impaired from the second until the last day of testing (Side x Day x Group: F18,288=2.11, 
p<0.05; Simple Effect: min.F2,32= 3.48, p<0.05).  
Furthest Step Reached. Overall, intact rats could reach steps located further away 
than lesion rats treated with L-DOPA while there was no overall difference between intact 
rats and lesion rats treated with saline (Figure 6.6C-D; Group: F2,32=7.31, p<0.01). However, 
a general lesion deficit did present itself when rats used their contralateral forelimb, with both 
lesion groups but not the intact rats exhibiting a significant ipsilateral bias throughout the 
course of testing (Side x Day x Group: F18,288=2.01; Simple Effect of Side: min.F1,32=2.63, 
p<0.05). There was also a difference in the degree of their improvement over the course of 
testing. When using the ipsilateral forelimb, lesion L-DOPA treated rats could initially not 
reach as far as the other two groups but due to a rapid learning curve their ipsilateral 
performance aligned with that of the intact and saline treated lesion rats at the end of testing. 
When using their contralateral forelimb, both intact and saline treated lesion rats showed a 
significant improvement over the course of testing (Simple Effect: min F9,24=2.63, p<0.05). 
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While there was a trend towards a similar improvement in the lesion L-DOPA treated group 
this did not reach statistical significance (p=0.057).  
 
 
Figure 6.5. Surviving dopaminergic cell bodies in the SNc and VTA (A), expressed as a 
percentage of the intact side, together with the ipsilateral bias on the spontaneous 
rotations (C) and cylinder (D) tests of lesion rats that were later chronically treated with 
saline (n=11) or L-DOPA (n=9). The graph also shows the average cumulative AIM scores 
from the lesion L-DOPA groups‟ last two dyskinesia scoring sessions (E). It is noted that 
all rats were L-DOPA naive at the time of lesion and the motor behavioural tests. 
AIMs=Abnormal involuntary movements, SNc=Substantia nigra pars compacta, 
TH=Tyrosine hydroxylase, VTA=Ventral tegmental area. ***p<0.001 
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Displaced Pellets. The number of displaced pellets was similar for all three groups, 
when measuring ipsilateral as well as contralateral performance (Figure 6.6E-F; Group: 
F2,32=1.51, n.s.; Side: F1,32=0.06, n.s.; Side x Group: F2,32=1.00, n.s.; Side x Day x Group: F18, 
288=1.57, n.s.). While there were some fluctuations in the number of pellets that were 
displaced when rats used their contralateral paws, this was not specific to any experimental 
group and visual inspection of the data suggested that it was due to noise in the data (Side x 
Day: F18,288=3.13, p<0.01; Simple Effect: F9,24=2.62, p<0.05; Day: F9,288=1.80, n.s.; Day x 
Group: F18, 288=0.59, n.s). 
 
 
Figure 6.6. The number of pellets obtained from staircase boxes (A-B), the furthest step 
pellets were retrieved from (C-D), and the number of pellets displaced (E-F) by intact 
(n=15), lesion drug naïve (n=11), and lesion rats chronically treated with L-DOPA (n=9) 
rats. *Significant difference between intact rats and lesion rats treated with saline and   
L-DOPA. #Significant difference between intact and lesion rats treated with L-DOPA, 
ⱡSignificant difference between lesion saline treated and lesion L-DOPA treated rats‟ 
contralateral and ipsilateral performance.  *p<0.05, ##p<0.01, ⱡp<0.01 
 
6.3.3.3. 100 Pellets Test 
When given the opportunity to consume 100 freely available sucrose pellets, the two lesion 
groups took significantly longer time than the intact controls to consume all pellets (Figure 
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6.7). There was no further effect of L-DOPA treatment on lesion rats‟ performance (Group: 
F2,33=5.28, p<0.05).  
 
Figure 6.7. The time (min) taken for intact rats (n=15), and lesion rats chronically 
treated with saline (n=11) or L-DOPA (n=9) to consume 100 freely available sucrose 
pellets. Lesion rats took significantly longer time than intact controls to consume the 
available pellets, but there was no effect of L-DOPA treatment. **p<0.01 
 
6.4. Experiment 8 (part I): The effect of dopamine denervation and chronic 
L-DOPA or bromocriptine treatment on the ability for de novo motor 
learning 
6.4.1. Introduction 
Data from Experiment 7 suggested impaired acquisition of a novel motor skill following 
chronic L-DOPA treatment to lesion rats. More precisely, chronic L-DOPA treatment was 
associated with impaired ability to retrieve sucrose pellets from steps located further away, 
i.e. pellets located on steps that were more difficult for rats to reach. While significant, the 
impairment was subtle. In addition to attempting to replicate the phenomenon, the current 
experiment therefore also increased the number of sucrose pellets located on each staircase 
step from three to four pellets in an attempt to make the test more sensitive and thereby 
increase the likelihood of observing a difference between lesion rats treated with saline or    
L-DOPA. 
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Chronic L-DOPA induces LID in the majority of MFB lesion rats (Winkler et al, 
2002), a condition that has been associated with disrupted synaptic plasticity in the cortico-
striatal pathway (Picconi et al, 2003). Given the relationship between striatal synaptic 
plasticity and learning new motor skills (e.g. Luft et al, 2004) it was hypothesized that the 
impaired ability to reach sucrose pellets on steps located further away following L-DOPA 
treatment in Experiment 7 had been associated with LID onset. Ideally, this hypothesis would 
be tested by comparing the performance of lesion rats that did or did not developed LID 
following chronic L-DOPA treatment. However, previous publications have demonstrated 
that only a small proportion of MFB lesion rats do not develop LID in response to chronic L-
DOPA (Winkler et al, 2002) and none of the lesion     L-DOPA treated rats in Experiment 7 
remained non-dyskinetic following L-DOPA treatment. Conversely, LID is not induced 
chronic treatment with the dopamine agonist bromocriptine (Pearce et al, 1998; Lieberman & 
Goldstein, 1985; Pearce et al, 1998; Kvernmo et al 2006; Stern, 2008) which primarily binds 
to D2 receptors (Table 6.1; Kvernmo et al, 2006). To further test the hypothesis that the 
previously observed difference between lesion rats treated with saline or L-DOPA was due to 
LID onset rather than mere exposure to dopaminergic treatment, bromocriptine was used as a 
control drug in the current experiment.  
 
Table 6.1. Bromocriptine‟s binding affinities (Ki in nmol/L) for dopaminergic and 
serotonergic receptors. Adapted from Kvernmo et al (2006). 
D1type D2type D2 D3 D4 D5 5-HT1B 5-HT1B 5-HT1D 5-HT2A 5-HT2B 5-HT2C 
1659 12.2 2.5 12.2 59.7 1691 12.9 354.8 10.7 107.2 56.2 741.3 
 
In addition to comparing the performance of lesion rats treated with L-DOPA and 
bromocriptine, the experiment also expanded on the previous findings by testing whether 
chronic L-DOPA also affected intact rats‟ performance. As L-DOPA does not induce LID in 
intact rats, it was hypothesized that any effect of L-DOPA would be restricted to the lesion 
group. Similarly, because bromocriptine does not induce LID when administered to lesion 
rats as a monotherapy (Pearce et al, 1998) it was further hypothesised that no effect would be 
observed by bromocriptine treatment. 
6.4.2. Aims 
The aim of the experiment was to (i) replicate the findings in Experiment 7, which suggested 
that chronic L-DOPA impaired lesion rats‟ learning on the staircase task, and (ii) test whether 
chronic bromocriptine also affected staircase task learning in lesion rats.  
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6.4.2. Methods 
6.4.2.1. Experimental design 
The cohort reported here was also used in an operant experiment described in section 7.4. All 
rats underwent LCRT task training before a subgroup was given unilateral 6-OHDA lesions 
to the MFB. Intact and lesion rats were then chronically treated with saline, bromocriptine, or 
L-DOPA. Following one week of food restriction, rats were tested in unilaterally baited 
staircase boxes for 20 days (Figure 6.8). Further details on the operant testing the rats 
underwent are provided in section 7.4. It is caveated that because rats were used in more than 
one experiment, in order to reduce the overall number of licensed procedures that were 
conducted and the number of rats that were sacrificed as part of the thesis project, there are 
some differences in the operant testing that the rats in this and Experiment 7 underwent. 
6.4.2.2. Procedure 
Eighty-five female Lister hooded rats were pre-trained on the LCRT task for 1 month (section 
2.7.2.2) before a subset of rats (n=55) was given unilateral lesion lesions to the MFB (section 
2.2.2). Following two weeks recovery, the lesion extent was assessed using the cylinder test 
and spontaneous rotations (sections 2.4.4 and 2.4.6.3) and rats were then chronically treated  
with their respective drug: 1 mg/kg saline (intact, n=19; lesion, n=15), 2.5 mg/kg 
bromocriptine (intact, n=10; lesion, n=15) or 10 mg/kg           L-DOPA (intact, n=10; lesion, 
n=25) once daily for 3 weeks. AIMs were scored in accordance with the previously described 
protocol (section 2.5). Only lesion rats treated with L-DOPA or bromocriptine were scored 
for AIMs. This decision was based on the fact that LID by definition does not occur in lesion 
saline treated rats. This was also demonstrated in Experiment 10 where AIMs scoring of 
lesion rats treated with saline or L-DOPA was conducted by a scorer blinded to the drug 
treatments the rats received. In addition to AIMs scoring, the effect of chronic bromocriptine 
treatment was assessed every third day of treatment by measuring the rats‟ net rotational bias 
in automated rotometers (section2.4.6.1) for 90 min post-injection. The effect of L-DOPA 
was not assessed using rotometers as previous authors have demonstrated that L-DOPA 
induced rotations are not a good indicator for LID (Lundblad et al, 2002) and because of 
limited availability of rotometers.  
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Figure 6.8. A graphical representation of the experimental design of Experiment 8. Grey boxes represent testing reported in section 7.4. 
The figure specifies both the duration of the individual testing phases, and the overall number of days in the experiment. AIMs=Abnormal 
involuntary movements, BRC=Bromocriptine, FR=Food restriction, LCRT task=Lateralised choice reaction time task, MFB=Medial 
forebrain bundle. 
 
It is brought to the reader‟s attention that, unlike Experiment 7, a subset (n=4) of lesion rats in the current experiment remained non-dyskinetic 
following L-DOPA treatment. In this thesis, a rat was defined as dyskinetic if she exhibited severity AIMs >1 on the orolingual, axial, or 
forelimb AIMs subtypes during any of the 1 min AIMs scoring time points. This classification is in line with criteria used in previous rat 
dyskinesia studies (Lindgren et al, 2010) and has been shown to distinguish between rats with high and low striatal levels of dyskinesia markers 
such as phosphorylated ERK1/2 (Westin et al, 2007), FosB, and PDyn mRNA (Andersson et al, 1999). In addition, following acute L-DOPA 
administration, rats classified as non-dyskinetic using this cut-off have been shown to have lower levels of extracellular DOPA in the SNc and 
striatum than dyskinetic controls (Lindgren et al, 2010), and, unlike dyskinetic rats, do not show an angiogenic response to L-DOPA treatment 
(Westin et al, 2006) 
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At the end of drug treatments, rats were food restricted for one week. They were 
thereafter tested in unilaterally baited staircase boxes for 20 days in the same manner as 
described in 7.2 but with four, instead of three, sucrose pellets per step. Because the 
difference observed between lesion drug naïve and lesion L-DOPA rats in Experiment 7 had 
been subtle, the number of pellets per step was increased to increase the sensitivity of the test 
and therefore also the likelihood of observing a significant difference between the groups. As 
in section Experiment 7, the side of baiting alternated daily and the side rat began testing on 
(i.e. ipsilateral or contralateral to the lesion) was counterbalanced.  
At the end of testing, the rats were culled using an overdose of Euthatal and 
decapitated. Rats‟ striata were dissected out and their hindbrains postfixed overnight in 4% 
PFA before being transferred to a 25% sucrose solution (2.9). Immunohistochemical staining 
was conducted as outlined in section 2.10 and nigral TH+ cell bodies counted in each 
hemisphere (section 2.11) to confirm a lesion induced dopamine denervation. While the 
striatal tissue was originally intended for Western blotting it was not possible to refine the 
appropriate Western blotting protocols and conduct molecular work within the time frame of 
the thesis project.    
6.4.2.3. Statistical analysis 
The effect of the lesion on the number of TH+ cell bodies in the SNc and VTA was analysed 
using two separate types of analyses. First, the presence of a lesion in the SNc or VTA was 
confirmed by comparing the raw cell counts in the ipsilateral and contralateral hemisphere 
using a t-test. For this analysis, the SNc and VTA were analysed separately. Once the 
presence of a lesion had been confirmed, an ANOVA was used to test whether there was a 
difference in (i) the relative extent of the experimental groups' dopamine denervation, and (ii) 
the loss of dopaminergic cell bodies observed in the SNc versus the VTA. The ANOVA used 
the percentage loss of TH+ cell bodies observed in the lesion SNc and VTA as input data and 
included Region as a within-subject variable, and Group as a between-subject variable. 
When analysing staircase data, Side and Day were used as within-subject factors, and 
Group as a between-subject factor. The change in bromocriptine induced rotations following 
chronic treatment was analysed using a one-way ANOVA. Rats that had begun testing on the 
ipsilateral and contralateral side respectively were pooled according to lesion and drug 
treatment and the following groups were generated: intact + saline (n=10), intact + L-DOPA 
(n=10), intact + bromocriptine (n=10), lesion + saline (n=15), lesion + L-DOPA (n=25), 
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lesion + bromocriptine (n=15). Four of the lesion L-DOPA treated rats did not develop LID 
following L-DOPA treatment. Data from Experiment 7 had not provided insight into whether 
the observed L-DOPA effect had been due to chronic L-DOPA or LID onset. Therefore, two 
analyses were conducted in the current section; one grouping all lesion L-DOPA treated rats 
together during statistical analysis and a second separating this group into a dyskinetic and 
non-dyskinetic group. 
6.4.3. Results 
6.4.3.1. Lesion & Drug effects 
The lesion induced a significant loss of dopaminergic cell bodies in the ipsilateral SN (Figure 
6.9A; t54=30.98, p<0.001) and VTA (t54=31.02, p<0.001). A further analysis demonstrated 
that there was a greater percentage loss of dopaminergic cell bodies in the ipsilateral SNc 
than in the ipsilateral VTA (Region: F1,51=26.43, p<0.001) and that the dopamine denervation 
was similar between the groups (Group: F3,51=0.66, n.s.; Region x Group: F3,51=0.39, n.s.). 
The lesion induced an ipsilateral bias on the spontaneous rotations and cylinder tests 
(Figure 6.9C-D) that did not differ between the three groups (Spontaneous rotations: 
F2,52=1.55, n.s.; Cylinder test: H(2)=0.74, n.s.). The lesion group treated with L-DOPA 
exhibited high AIMs scores following chronic treatment (Figure 6.9E), something which was 
not observed in the lesion group treated with bromocriptine (Group: F1,39=16.97, p<0.001). 
Chronic bromocriptine did, however, produce an increase in the net bias of rats‟ drug-induced 
rotations (Figure 7.16F; F1,15=12.39, p<0.01). 
Using a previously published cut-off for AIMs (Lindgren et al, 2010) all but four of 
the lesion L-DOPA rats were classified as dyskinetic. Conversely, AIMs induced by chronic 
bromocriptine treatment fell below the previously published cut-off line for dyskinetic rats 
and these rats were therefore considered non-dyskinetic. Bromocriptine treatment did, 
however, increase the net bias of bromocriptine-induced rotations as shown when comparing 
the first and last rotometer session (Figure 6.9C; t15=-3.9, p<0.01). 
6.4.3.2. Staircase data: L-DOPA treated rats treated as one group 
While lesion rats were impaired relative to intact controls in the number of pellets they could 
retrieve using their contralateral paw (Group x Side: F5,79=13.92, p<0.001; Simple Effect of 
Side: min.F1,79=40.64, p<0.001) and the furthest step they could reach on their contralateral 
side (Group x Side: F5,79=10.09, p<0.001; Simple Effect of Side min.F1,79=34.29, p<0.001) 
there was no difference between the three intact groups on these measures. Similarly, while 
lesion rats treated with bromocriptine displaced overall more pellets than the remaining 
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Figure 6.9. The figure shows the surviving dopaminergic cell bodies in the SNc and VTA, 
expressed as a percentage of the intact side (A), a photo showing the SNc and VTA 
denervation of a lesion rat included in the experiment (B), the ipsilateral bias exhibited 
on the spontaneous rotations (C) and cylinder tests (D), the AIMs scores (E) of lesion rats 
chronically treated with L-DOPA (n=25), and bromocriptine (n= 15), as well as net 
rotational bias of rotations following acute bromocriptine administration (C). 
AIMs=Abnormal involuntary movements, SNc=Substantia nigra pars compacts, 
TH=Tyrosine hydroxylase, VTA=Ventral tegmental area. **p<0.01, ***p<0.001 
 
groups (Group x Side: F5,79=0.58, n.s.; Group: F5,79=2.89, p<0.05) there was no difference 
between the number of pellets displaced by the intact groups. Therefore, the data from the 
intact groups were pooled in the analyses presented below. 
Pellets retrieved. The number of successfully retrieved pellets increased in all groups 
over the course of testing (Figure 6.10A-B; Day: F9,729=54.63, p<0.001; Day x Group: 
F27,729=1.03, n.s.). However, a significant contralateral deficit was observed in all lesion 
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groups. Relative to their ipsilateral performance, lesion rats treated with saline or L-DOPA 
were impaired throughout testing when using their contralateral forelimb side. A similar 
impairment was observed from the second until the last day testing in the lesion group that 
had been treated with bromocriptine (Side x Day x Group: F27,729=2.07, p<0.01; Simple 
Effect: min.F1,81=5.65, p<0.05).  
Furthest Step Reached. The lesion groups could not reach as far as the intact 
controls when using their contralateral paw. This contralateral deficit was statistically 
significant from the second until the last day of testing in all lesion groups (Figure 6.10C-D; 
Side x Day x Group: F27,729=1.76, p<0.05;  Effect of Side: min.F1,81=8.99, p<0.01). 
Displaced Pellets. Overall, intact controls displaced fewer pellets than the lesion rats 
(Figure 6.10E-F; Group: F3,81=4.86, p<0.05). While the number of pellets displaced by the 
rats fluctuated over the ten testing days (Day: F9,729=22.05, p<0.001), visual inspection of the 
data suggested this was due to noise in the data rather than reflective of an improvement or 
worsening of performance. 
6.4.3.2. Staircase data: lesion L-DOPA treated group divided into dyskinetic and 
non-dyskinetic rats 
A second analysis was conducted in which the L-DOPA treated group was split into two 
cohorts depending on whether or not they were classified as non-dyskinetic using a 
previously published cut-off (Lindgren et al, 2007). 
Pellets retrieved. Intact rats retrieved more pellets than lesion rats, but there was no 
overall difference between the four lesion groups (Figure 6.11A-B; Group: F4,80=8.90, 
p<0.001). Lesion rats were impaired when using their contralateral paw (Side x Day x Group: 
F36,729=19.40, p<0.05; Simple Effect of Side: min.F1,80=4.38, p<0.05). Intact rats showed day-
to-day improvement in their ipsilateral as well as contralateral performance. Conversely, 
lesion rats treated with saline, bromocriptine, or rats that developed LID following L-DOPA 
treatment only showed a significant day-to-day improvement in their ipsilateral performance. 
Lesion rats that remained non-dyskinetic following L-DOPA treatment showed significant 
fluctuations in their contralateral performance. However, visual inspection of the data 
suggested this change in performance was due to random fluctuations and not a day-to-day 
improvement in their performance (Simple Effect of Day: min.F9,72=2.30, p<0.05).  
Furthest step reached. Rats performance improved over the course of testing, as 
evidenced by a greater ability to reach steps located far away at the end versus the beginning 
of the testing period (Figure 6.11C-D; Day: F9,720=50.84, p<0.001). While intact rats‟  
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Figure 6.10. The number of pellets obtained from staircase boxes (A-B), the furthest step 
pellets were retrieved from (C-D), and the number of pellets displaced (E-F) by intact 
(n=30), lesion drug naïve (n=15), lesion rats chronically treated with L-DOPA (n=25), 
and lesion rats chronically treated with bromocriptine (n=15) rats. Data from intact rats 
chronically treated with saline, L-DOPA, or bromocriptine was pooled for clarity.*Intact 
versus all lesion groups. ǂIntact versus lesion + bromocriptine. ǂ p<0.05, *p<0.05, 
**p<0.01. 
 
performance improved over the course of testing regardless of what paw they used, all lesion 
groups demonstrated a contralateral deficit (Side x Day x Group: F36,720=1.70, p<0.01). This 
contralateral impairment was evident from the second day of testing in all lesion rats, apart 
from those that remained non-dyskinetic following chronic L-DOPA, in whom the deficit 
manifested itself after the fourth day of testing (Simple Effect of Side: min.F1,80=4.74, 
p<0.05). However, there was no overall difference in the performance of the four lesion 
groups who were all impaired relative to intact contros (Group: F4,80=4.00, p<0.01). 
 
 188 
 
Figure 6.11. The number of pellets obtained from staircase boxes (A-B), the furthest step 
pellets were retrieved from (C-D), and the number of pellets displaced (E-F) by intact 
(n=30), lesion drug naïve (n=15), lesion rats that developed LID following chronic L-
DOPA (n=21), lesion rat that did not developed LID following chronic L-DOPA (n=4), and 
lesion rats chronically treated with bromocriptine (n=15) rats. Data from intact rats 
chronically treated with saline, L-DOPA, or bromocriptine were pooled for clarity. 
*Contralateral deficits in all lesion rats, #Contralateral deficit in lesion rats treated with 
saline, bromocriptine, or rats treated with L-DOPA that developed LID. ◊Contralateral 
deficit in lesion rats that remained non-dyskinetic following L-DOPA treatment. *p<0.05, 
◊p<0.05, ##p<0.01.  
 
Displaced pellets. Overall, marginally more pellets were displaced by the lesion rats 
treated with bromocriptine than intact rats (Figure 6.11E-F; Group: F4,80=3.64, p<0.01). 
However, there was no difference between the number of pellets that were displaced when 
intact or lesion rats used their contralateral versus their ipsilateral paw, suggesting that the 
slight increase in the number of pellets displaced by the lesion bromocriptine treated rats was 
not due to a contralateral impairment (Side: F1,80=2.75, n.s.; Side x Group: F4,80=0.88, n.s.). 
While there were some fluctuations in the number of pellets displaced over the course of 
testing (Day: F9,720=3.74, p<0.001), these were similar for intact and lesion rats (Day x  
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Group: F36,720=0.89, n.s.; Side x Day: F9,720=1.04, n.s.; Side x Group x Day: F36, 720=1.36, 
n.s.).  
6.5. Discussion 
The experiments described in this chapter were conducted to test the hypothesis that the 
disrupted synaptic plasticity associated with LID onset would impair learning of novel motor 
skills. The hypothesis was based on previously published data suggesting an involvement of 
the cortico-striatal pathway and synaptic plasticity in the learning of novel motor skills (Luft 
et al, 2004; Yin et al, 2009; Wächter et al, 2010). Prior to discussing the data, it is, however, 
noted that the precise role of plasticity in learning has been debated. In addition to direct 
recordings of e.g. LTP, plasticity may also be assessed by measuring cortical map expansion, 
i.e. the post-training increase in the size of the cortical areas responding to the trained motor 
skill. While previous publications have demonstrated that lesions to the nucleus basalis 
magnocellularis, which disrupt post-lesion cortical map expansion, impair learning of a novel 
motor skill they do not prevent learning from occurring (Conner et al, 2003). This may be 
taken to suggest that while plasticity enhances learning it is not essential for it to occur, i.e. 
there is not a direct causal relationship between the two. The potential causal role of plasticity 
in learning has also been disputed by authors noting that if learning is associated with large 
scale changes to map plasticity, the learning of a new task should undo previous learning, 
which is not the case (Kilgard, 2012). Yet other authors have shown that while artificially 
inducing cortical plasticity in rats outside of a behavioural training context improved 
subsequent auditory discrimination learning, renormalization of cortical map plasticity 30 
days after training did not impact on rats‟ performance (Rees et al, 2011). Hence, while 
cortical plasticity enhanced learning, renormalization of plasticity did not impact on the 
learned behaviour (Rees et al, 2011).  
The sometimes conflicting data on plasticity and learning have led some authors to 
suggest that the role of cortical map expansion is to increase the pool of neurons, and 
therefore indirectly the number of neural circuitries, that become activated during 
performance of a novel task. During learning, it has been suggested that the neural circuitry 
that is most essential for successful completion of a task is chosen and that, at the end of 
learning, only this circuitry becomes activated during task performance (Kilgard, 2012). This 
model may explain why, following cortical map expansion, there is renormalization of the 
cortical map following completed training (Rees et al, 2011) as well as why plasticity is 
crucial for learning but not maintenance of new skills (e.g. Luft et al, 2004).  
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While the precise role of synaptic plasticity in learning remains a topic of debate, its 
involvement in the acquisition of novel skills nonetheless led to the hypothesis that chronic       
L-DOPA treatment to MFB lesion rats, which causes LID in the vast majority of instances 
(e.g. Winkler et al, 2002), would impair learning of a novel motor sequence but not 
maintenance of a previously acquired motor skill. The hypothesis was tested by measuring 
rats‟ performance in staircase boxes. In line with previous experiments (Montoya et al, 1995; 
Wishaw et al, 1997) unilateral lesions decreased the number of pellets that rats were able to 
retrieve using their contralateral paw. In accordance with the hypothesis, Experiment 6 
demonstrated that L-DOPA treatment did not affect performance of lesion rats that were pre-
trained on the task before lesion and drug treatment.  
Experiments 7 and 8 tested the second part of the hypothesis, i.e. the effect of 
dopamine denervation and exposure to chronic L-DOPA on rats‟ ability to learn how to 
successfully retrieve sucrose pellets from staircase boxes de novo. Data from Experiment 7 
suggested that chronic L-DOPA treatment may induce a mild impairment in the rate with 
which rats that had not received staircase training prior to lesion learned to perform the task. 
This interpretation was based on the diminished ability of lesion L-DOPA treated rats to 
collect pellets located on the steps located further away, i.e. the pellets that were more 
difficult for rats to retrieve, during initial testing days. Interestingly there was also a trend 
towards a decrease in the number of ipsilateral pellets they retrieved (Figure 6.6A-C). The 
bilateral nature of the deficit was unexpected but may be explained by data suggesting that, 
despite being designed as a lateralized motor test, successful performance on the staircase test 
requires coordination of both ipsilateral and contralateral muscles (Wishaw et al, 1997). It is 
also recognised that some authors have demonstrated bilateral changes in monoamine 
neurochemistry following unilateral lesion lesions (Berger et al, 1991; Pierucci et al, 2009), 
and that this may have impacted on ipsilateral performance. Therefore, while the lesion may 
have created a flooring effect when measuring performance on the more impaired 
contralateral side, an effect of chronic L-DOPA on lesion rats‟ learning may have been more 
readily observed on the ipsilateral side where rats were less impaired and where there was 
therefore no flooring effect (Wishaw et al, 1997). Nonetheless, when discussing the data from 
Experiment 7 it is caveated that the observed difference between lesion rats treated with 
saline and L-DOPA was mild and only apparent in the beginning of the ten day testing 
period. It was therefore considered necessary to replicate the effect before any conclusions on 
the effect of chronic L-DOPA on staircase learning could be drawn.  
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In addition it was noted that a difference in performance of lesion rats treated with 
saline or chronic L-DOPA may have related to non-motor factors such as motivation rather 
than ability for motor skill learning. Therefore, the time taken for the groups to consume 100 
freely available pellets was compared at the end of staircase testing in Experiment 7 to 
provide a gross estimate of motivation to consume sucrose pellets. Whilst there is a motor 
component to the sucrose consumption task, which likely explains differences between the 
intact and lesion groups, there were no significant differences in the two lesion groups‟ 
performance. This suggests that the two lesion groups did not differ in their motivation to 
consume freely available sucrose pellets, and that the effect of chronic L-DOPA on learning 
in staircase boxes was unlikely related to crude motivational factors.  
Having identified a potential effect of chronic L-DOPA on lesion rats‟ learning on the 
staircase task, a further experiment was conducted to replicate the findings. As it had been 
hypothesised that an effect of chronic L-DOPA on learning would be linked to the disrupted 
synaptic plasticity that is associated with the onset of LID, this later experiment also included 
a lesion group that was chronically treated with the D2 agonist bromocriptine following 
lesion. Unlike L-DOPA, bromocriptine does not induce LID in lesion rats (Pearce et al, 1998) 
and was therefore hypothesised to not affect learning. As the difference between the lesion 
saline and lesion L-DOPA group in Experiment 7 had been minimal, an attempt was also 
made to increase the sensitivity of the test, and therefore the likelihood of observing a 
difference between the experimental groups, by increasing the number of pellets available on 
each step from three to four. As hypothesised; lesion rats chronically treated with 
bromocriptine did not differ from lesion saline treated controls in their acquisition of the 
staircase task. This suggests that treatment with the clinically available D2 agonist 
bromocriptine does not impair acquisition of a novel motor skill in 6-OHDA lesion rats as 
measured using the staircase task.  
However, contrary to previous findings, no deficit following L-DOPA treatment of 
lesion rats was found in section 6.3. It is noted that the effect of chronic L-DOPA on lesion 
rats‟ synaptic plasticity differs depending on whether or not rats develop LID. While all 
lesion rats in Experiment 7 developed LID in response to chronic L-DOPA, a subgroup of L-
DOPA treated lesion rats in Experiment 8 remained non-dyskinetic. To exclude the 
possibility that the different results was due to the proportion of lesion L-DOPA treated rats 
that developed LID, a further analysis of the data in Experiment 8 was conducted wherein the 
lesion L-DOPA treated group was split into a dyskinetic and non-dyskinetic cohort. This 
second analysis confirmed that the effect observed in dyskinetic rats in Experiment 7 could 
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not be replicated in Experiment 8. While there were some behavioural differences between L-
DOPA treated rats that did or did not develop LID in Experiment 8, these were not very 
pronounced (Figure 6.11). Furthermore, considering the different effects of LID onset in 
Experiments 7 and 8, any statistical difference between dyskinetic and non-dyskinetic rats 
should be treated with caution as the behaviour in the dyskinetic control group is not 
replicable. 
The inability to replicate the findings may have been due to differences in the 
methodology of the Experiments 7 and 8. Experiment 7 included a more extended food 
restriction prior to staircase testing than Experiment 8 (total of 70 vs. 44 days). Food 
restriction is known to increase the sensitivity of D1 and D2 receptors, both of which are 
implied in striatal plasticity, (Carr et al, 2003) as well as to affect motor cortex plasticity by 
enhancing LTD induction (Cohen & Castro-Alamancos, 2005). The possibility that the 
extended food restriction, which was a prerequisite for the operant training in Experiment 8, 
may have impacted on dopamine receptors and synaptic plasticity in those rats cannot be 
excluded.  
Considering the different findings in Experiments 7 and 8, and the possibility that 
food restriction may be hypothesised to affect staircase learning by impacting on synaptic 
plasticity (Carr et al, 2003; Cohen & Castro-Alamancos, 2005), future studies may wish to 
further test the effect of chronic L-DOPA treatment utilizing behavioural tasks that do not 
require food restriction. One such task is the rotarod task. Learning on the rotatrod task has 
previously been linked to changes in synaptic plasticity, characterised by higher synaptic 
strength in the dorsomedial striatum during early training phases but higher synaptic strength 
in the dorsolateral striatum after extended training (Yin et al, 2009). As such, the rotarod task 
may be a suitable paradigm for testing the hypothesis that LID onset impairs motor learning. 
Unfortunately, due to limited availability to rat rotarods this paradigm was not used in this 
project. 
In all, the data presented in this chapter support the hypothesis that L-DOPA 
treatment does not affect lesion rats‟ ability to perform motor skills learned prior to lesion 
and L-DOPA treatment. However, they did not provide replicable support for the hypothesis 
that chronic L–DOPA treatment impairs lesion rats‟ ability to learn de novo motor skills as 
measured using the staircase task. Future experiments may wish to test whether an effect can 
be found if using motor learning paradigms that do not require food restriction.   
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7. Dopaminergic Treatments & the Lateralised 
Choice Reaction Time Task 
Background: The LCRT task can measure attention (reaction time), motor (reaction time 
and movement time) and non-motor (accuracy of responding) function in the unilateral rat   
6-OHDA model of PD. Previous authors have demonstrated that rats‟ performance on the 
LCRT task is mediated by the striatal dopaminergic system and that both motor and non-
motor performance on the task is disrupted by unilateral 6-OHDA lesions.  
 
Aims: The aim of the experiments presented in this chapter was to test the effect of acute and 
chronic dopaminergic treatments on lesion rats‟ motor and non-motor performance on the 
LCRT task in MFB lesion rats.  
 
Methods: The effects of acute and chronic bromocriptine and L-DOPA in intact rats and 
MFB lesion rats were explored in three separate experiments, all using the LCRT task. The 
first experiment tested the effects of acute bromocriptine administration on lesion rats‟ LCRT 
task performance. The second experiment was designed to (i) replicate findings of a long-
lasting effect of acute bromocriptine on the accuracy of contralateral responding, and (ii) test 
the effect of chronic L-DOPA administration on later LCRT task performance in lesion rats. 
The third experiment was designed to replicate previous findings of an effect of chronic       
L-DOPA treatment on LCRT task performance, and compare it with the effects of chronic 
bromocriptine administration. In addition, the experiment tested the effect of acute L-DOPA 
and bromocriptine on LCRT task performance.   
 
Results: 6-OHDA lesions impaired both motor and non-motor performance on the LCRT 
task. Acute bromocriptine improved lesion rats‟ accuracy of responding but had limited effect 
on motor function. The reverse trend was observed following acute L-DOPA administration, 
which improved motor function but did not affect accuracy of responding. Chronic L-DOPA, 
but not chronic bromocriptine, caused a further impairment of lesion rats‟ non-motor 
function.  
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 7.1. Introduction 
The previous chapter described experiments designed to the effect of chronic L-DOPA 
treatment on lesion rats‟ acquisition of a novel motor skill. However, in addition to motor 
learning (e.g. Wächter et al, 2010), dopamine input to the striatum is also implicated in non-
motor functions such as reward signalling, and goal directed and habitual behaviour (Schultz 
2010; Yin et al, 2005; Faure et al, 2005). Chronic L-DOPA induces changes to the striatal 
system in the form of sensitised dopamine receptors (e.g. Aubert et al, 2005; Konradi et al, 
2004) and altered plasticity (e.g. Picconi et al, 2003). In addition to causing LID, it is 
therefore likely that chronic L-DOPA could affect performance on operant paradigms 
measuring goal directed and/or habitual behaviour reliant on striatal function. 
LID can be induced in lesion rats by administering them chronic L-DOPA. While LID 
may be induced in both rats with intra-striatal and MFB lesions, it is more consistently 
induced in the latter model (Winkler et al, 2002). It is also in the unilateral MFB lesion model 
that previous authors have demonstrated an effect of LID onset of cortico-striatal plasticity 
(Picconi et al, 2002). For these reason, the unilateral 6-OHDA, MFB model was utilised in 
the experiments presented in this chapter.  
This choice of lesion model required an operant paradigm that did not only tap into 
striatally mediated behaviour, but that was also designed for use in rats with unilateral lesions 
and that could measured both motor and non-motor behaviour. The current chapter therefore 
used the LCRT task, which is described in detail in sections 1.7.6.1 and 2.7.2. Briefly, the 
task takes place in nine-hole boxes where rats are required to respond to the onset of a central 
light cue by nose poking into the hole the light was presented in. After a variable delay, a 
lateralised light cue is presented for 50 ms to either the contralateral or ipsilateral side of the 
lesion, and rats are rewarded with a sucrose pellet if discontinuing the central hold and nose 
poking into the recently illuminated hole. The LCRT task provides measurements of the 
number of trials rats initiate, their reaction time, movement time, and the accuracy with 
which they respond to lateralised cues. Of these parameters, the movement time has the 
strongest motor element to it. While reaction time is influenced by motor function, it also has 
an attention aspect to it as an effect of lesion on reaction but not movement times would 
indicate an attention rather than motor deficit. Conversely, while accurate responding 
requires a motor response, continued accurate responding also requires maintenance of 
stimulus-response association and unlike the previous measurements this parameter therefore 
also measures non-motor function.  
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In addition to impairing reaction and movement times, unilateral 6-OHDA lesions 
have been shown to induce a gradual decline in the accuracy of rats‟ contralateral responding 
(Dowd & Dunnett, 2004, 2005a,b). While the nature of this deficit has not been conclusively 
determined, it has been hypothesised that 6-OHDA lesions cause loss of the dopaminergic 
reward signal which otherwise occurs following presentation of a CS (Dowd & Dunnett, 
2004; Schultz, 2010). This, in turn has been hypothesised to lead to extinction of contralateral 
responding, reflected in the gradual decrease in lesion rats‟ contralateral accuracy (Dowd & 
Dunnett, 2004, 2007). 
Three experiments, described in sections 7.2, 7.3, and 7.4, were conducted. In section 
7.2, the effect of acute administration of a D2 agonist on LCRT task performance was tested; 
section 7.3 describes an experiment designed to replicate the first experiment while also 
assessing the effect of chronic L-DOPA on LCRT task performance; and section 7.4 
describes an experiment testing the effect of chronic and acute L-DOPA and bromocriptine 
treatment on LCRT task performance.  
7.2. Experiment 9: The effect of D2 agonism on LCRT task performance 
7.2.1. Introduction 
While previous publications have demonstrated that accurate performance on the LCRT task 
relies on striatal dopamine (Carli et al, 1989; Dowd & Dunnett, 2004), no studies 
investigating the underlying pharmacology have been reported. In addition to replicating the 
previously reported gradual decline in lesion rats‟ contralateral accuracy on the LCRT task 
(Dowd & Dunnett, 2004, 2005a,b), this experiment therefore also sought to test the effect of 
acute agonism of D2 receptors on lesion rats‟ LCRT task performance.  
This was accomplished using bromocriptine, which primarily binds to D2 receptors 
but also has affinity for D3 receptors as well as minimal binding to other dopaminergic and 
serotonergic receptors (Table 7.1). Bromocriptine alleviates motor deficits associated with 
PD, and has been used in the clinic since the 1970‟s (Lieberman & Goldstein, 1985). In 
addition to motor symptoms, previous publications also suggest a role of D2 receptors in non-
motor behaviour. For example, the effect of D2 antagonism on a reaction time paradigm has 
previously been tested by Smith and colleagues (2000). Their paradigm took place in two-
lever operant boxes where rats were required to sustain a lever press for a variable length of 
time until the onset of a visual light cue (CS). Releasing the lever within 700 ms of CS 
presentation resulted in the delivery of a food pellet. Smith and colleagues (2000) 
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demonstrated that antagonism of D2, but not D1 or D3, receptors decreased the number of 
trials in which rats successfully released the lever press within the 700 ms period. Because 
the number of trials the rats completed was similar regardless of the time (300, 500, 700, or 
900 ms) which rats had to sustain the lever press for before presentation of a CS, it was 
argued that the decrease in responding was not reflective of rats merely always pressing the 
lever for the same length of time; and the possibility that the decreased responding could 
reflect a decrease of reward efficacy of the sucrose pellet was presented (Smith et al, 2000). 
Other authors have shown that agonism of D2 receptors by acute bromocriptine increase the 
frequency with which rats press a reinforced, relative to a non-reinforced, lever in order to 
obtain a conditioned reward (Beninger & Ranaldi, 1992; Ranaldi & Beninger, 1995; Sutton et 
al, 2001). Based on the previously published hypothesis that 6-OHDA lesions decrease 
accuracy in the LCRT task because of a lesion-induced loss of the dopamine reward signal 
rather than loss of motor function (Dowd & Dunnett, 2004, 2007), and the ability of 
bromocriptine to not only mimic the effect of the dopamine that is lost following 6-OHDA 
lesions, but also enhance responding for a reward (Beninger & Ranaldi, 1992; Ranaldi & 
Beninger, 1995; Sutton et al, 2001), it was hypothesized that acute bromocriptine 
administration would increase lesion rats‟ accuracy on the day of administration. This 
hypothesis was tested over a 10 day testing cycle in which bromocriptine was administered to 
lesion rats on the second day of testing. 
In a final testing cycle, the same rats were administered acute raclopride prior to 
operant testing. Raclopride is a dopamine antagonist with high affinity for D2 receptors, as 
detailed in Table 7.2. Because raclopride primarily inhibits D2 receptors (Köhler et al, 1985) 
it was hypothesised that acute administration of the antagonist would have the opposite effect 
to acute bromocriptine on LCRT task performance. Hence, raclopride was used to control 
whether an effect of bromocriptine on accuracy was caused by the acute agonism of, 
primarily, D2 receptors. Furthermore, based on previous publications showing that raclopride 
worsens reaction and movement times in intact Sprague Dawley rats performing a reaction 
time task (MacDonald et al, 2006), it was hypothesized that acute raclopride would induce a 
transient reaction and movement time deficit in intact rats, as well as further impairing the 
reaction and movement time deficit observed in lesion rats.  
 
 
 197 
Table 7.1. Bromocriptine‟s binding affinities (Ki in nmol/L) for dopaminergic and 
serotonergic receptors. Adapted from Kvernmo et al (2006). 
D1type D2type D2 D3 D4 D5 5-HT1B 5-HT1B 5-HT1D 5-HT2A 5-HT2B 5-HT2C 
1659 12.2 2.5 12.2 59.7 1691 12.9 354.8 10.7 107.2 56.2 741.3 
 
Table 7.2. Raclopride‟s inhibitory potency (IC50, µM) on receptors in the rat striatum. 
Adapted from Köhler et al (1985).  
D1 D2 D3 α1-
adrenergic 
α2-
adrenergic 
β-
adrenergic 
5HT1 5HT2 Histamine 
H1 
Muscarinic 
>100 0.026 0.90 32 38 >100 49 13 8.4 >100 
 
7.2.1.1. Aims  
The aim of the experiment was to (i) replicate previous findings of a gradual decline in 
contralateral accuracy following 6-OHDA lesions, and (ii) probe the neurobiological 
mechanisms underlying the contralateral accuracy deficit on the LCRT task by testing the 
effect of acute administration of the D2 receptor agonist, bromocriptine, on LCRT task 
performance.  
7.2.2. Methods 
7.2.2.1. Experimental design 
All rats were pre-trained on the LCRT task before a subgroup was given unilateral 6-OHDA 
lesions to the MFB. Following recovery, rats were tested on the LCRT task at 3 and 8 weeks 
post-lesion. At the end of the second testing cycle, all lesion rats were administered acute 
bromocriptine prior to operant testing (Figure 7.1).  
The original experimental design planned for the lesion group to be tested on the 
LCRT task following acute administration of three doses of bromocriptine, with a wash out 
period in between each. The intention was then to select the most effective dose and compare 
the performance of lesion rats tested on and off bromocriptine at this dose. Due to unforeseen 
effects of bromocriptine administration, the design was altered and rats were tested on the 
LCRT task off-medication for 9 days following one initial bromocriptine administration. 
Performance on the LCRT task, the vibrissae test, and the adjusting step test was thereafter 
assessed following acute administration of the D2 antagonist raclopride. 
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Figure 7.1. A graphical representation of the experimental design of Experiment 9. The figure specifies both the duration of the individual 
testing phases, and the overall number of days in the experiment. FR=Food restriction; BRC=bromocriptine; LCRT task=Lateralised choice 
reaction time task; MFB=Medial forebrain bundle. 
 
7.2.2.2. Procedure  
The gradual decrease in lesion rats‟ contralateral accuracy on the LCRT task reported by Dowd & Dunnett (2004, 2005a,b) had been observed 
using male rats. To replicate the original findings as closely as possible, the first experiment in the chapter therefore included male rats.  
Twenty-two male Lister Hooded rats received 32 days of training on the LCRT task (section 2.7.2.2) after which a cohort of 12 rats were 
given unilateral 6-OHDA lesions to the MFB (section 2.2.2). Two weeks post-lesion, lesion extent was assessed using spontaneous rotations 
(section 2.4.6.3). The intact (n=10) and lesion (n=12) groups‟ performance on the operant task was then tested for five consecutive days, at 3 and 
at 8 weeks post-lesion. Immediately following the second post-lesion testing cycle, rats were retested on the LCRT task and the lesion group 
received 1.25 mg/kg bromocriptine, prepared and administered as described in section 2.3.1, two hours prior to operant testing. Both groups 
were thereafter tested in the absence of any drug for a further nine consecutive days. Finally, the effect of raclopride 
 199 
on LCRT task and motor performance was assessed in a three day testing cycle where 0.2 
mg/kg raclopride (dose chosen based on in-house data), prepared as described in section 
2.3.5, was administered 30 min prior to testing on the second day. Motor performance was 
measured the day before, of, and after raclopride administration using the adjusting step 
(section 2.4.3) and vibrissae (section 2.4.8) tests. Motor tests were always conducted 
immediately following operant testing. These tests were chosen because of their non-
spontaneous nature which, unlike e.g. the cylinder test, guaranteed that a motor response 
could be recorded within a limited amount of time. In addition, two more days of testing were 
conducted to determine the effect of 0.4 mg/kg raclopride on motor function and LCRT task 
performance. However, at this dose the antagonist suppressed motor function to the extent 
that no LCRT task data could be gathered and this data is as such not reported. 
At the end of the experiment, rats were administered an overdose of Euthatal and 
perfused (section 2.8). The tissue was used for TH immunohistological staining (section 
2.10). Dopaminergic cell loss in the SNc and VTA was assessed by counting TH+ cell bodies 
(section 2.11) whereas dopamine denervation in the striatum was assessed by measuring 
optical density (section 2.12). 
7.2.2.3. Statistical analysis 
Dopamine denervation was assessed using a paired samples t-test. LCRT task performance 3 
and 8 weeks post-lesion was analysed using a repeated measures ANOVA with Group as 
between-subject factor and Cycle, Side, and Day as within-subject factors. The effect of acute 
bromocriptine was measured using a repeated measures ANOVA with Group as between-
subject factor and Day as within-subject factor. Days included the day before (baseline), the 
day of drug administration, and the nine days after post-bromocriptine exposure. The effect 
of raclopride on the vibrissae and adjusting step tests and was analysed using a repeated 
measures ANOVA with Group as a between-subject factor and Day and Side as within-
subject factors. Significant between-subject effects were analysed using a post-hoc Scheffe 
test and significant interactions analysed using a test of simple effects.  
7.2.3. Results 
7.2.3.1. Lesion effect 
The lesion caused a profound loss of dopaminergic cell bodies that was more pronounced in 
the SNc than in the VTA (Figure 7.2; t11=3.48, p<0.01). In addition, there was a significant 
reduction of striatal terminals as assessed by comparing optical density in the ipsilateral and 
contralateral striatum (percentage of intact side: 31% ± 3%; t11=13.82, p<0.01). 
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Figure 7.2. The bar charts show the mean surviving dopaminergic cell bodies in the lesion 
SNc and VTA (A), and the optical density (B) in their lesion striatum of the lesion group 
(n=12).  Both are shown as a percentage of the intact side. The photos depict the loss of 
dopaminergic cell bodies in the striatum (C), SNc, and the VTA (D). The error bars 
represent the standard error of the mean. SNc=Substantia nigra pars compacta; 
TH=Tyrosine hydroxylase; VTA=Ventral tegmental area. **p<0.01 
 
7.2.3.2. Effect of DA depletion on LCRT task performance 
Usable trials. Lesion rats made fewer usable trials than intact controls (Figure 7.3A; Group: 
F1,20=43.38, p<0.001). The lesion group showed a small but significant decrease in their 
number of usable trials over the course of testing (Day x Group: F4,80=13.32, p<0.001; Simple 
Effect: min.F4,17=3.75, p<0.05; Day: F4,80=032, n.s.; Cycle x Day: F4,80=1.43, n.s.; Cycle x 
Day x Group: F4,80=0.30, n.s.). The number of usable trials made by the rats was similar when 
tested three and eight weeks post-lesion (Cycle: F1,20=0.99, n.s.; Cycle x Group: F1,20=4.15, 
n.s.).  
Reaction time. Overall, the lesion group had significantly longer reaction times than 
intact controls (Figure 7.3B-C; Group: F1,20=167.83, p<0.001). While, at three weeks post-
lesion, the lesion group showed longer reaction times than controls following both 
presentation of ipsilateral and contralateral cues, only the contralateral deficit remained 
significant at eight weeks post-lesion (Cycle x Side x Group: F1,20=5.93, p<0.05; Simple 
Effect: min.F1,20=4.37, p<0.05). The lesion rats‟ contralateral reaction time deficit gradually 
worsened over the five-day testing cycle (Side x Day x Group: F4,80=13.18, p<0.001; Simple 
Effect: min.F4,17=3.8, p<0.05). As a result of the gradual nature of the deficit, the lesion rats‟ 
contralateral reaction time was similar to that of controls on the first day of each testing cycle 
but significantly longer the remaining four days of each cycle (min.F1,20=30.29, p<0.001). 
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Movement Time. Lesion rats‟ movement times were longer than those of intact 
controls. The deficit manifested itself when rats made contralateral responses, and gradually 
worsened over the course of each five-day testing cycle (Figure 7.3D-E; Group: F1,20=54.88, 
p<0.001; Side x Day x Group: F4,80=2.64, p<0.05; Simple Effect: F4,17=5.10, p<0.01). 
Overall, the contralateral deficit was greater eight than three weeks post lesion (Cycle x Side 
x Group: F1,20=7.51, p<0.05; Simple Effect: F1,20=28.65, p<0.001).  
Accuracy. The lesion rats were significantly less accurate in their responding than 
intact controls (Figure 7.3F-G; Group: F1,20=52.92, p<0.001) both three and eight weeks post-
lesion (Cycle: F1,20=0.44, n.s.; Cycle x Group: F1,20=0.50, n.s.). In line with previous 
publications, there was a gradual decline in the accuracy with which lesion rats responded to 
contralateral cues (Side x Day x Group: F4,80=3.91, p<0.01; Simple Effect: F4,17=17.03, 
p<0.001). 
7.2.3.3. Effect of acute bromocriptine on LCRT task performance 
The effect of acute bromocriptine on LCRT task performance was measured in an 11 day 
cycle, where bromocriptine was administered to lesion rats on the second day of testing.  
Usable trials. The lesion group continued making fewer usable trials than intact 
controls during the bromocriptine testing cycle (Figure 7.4A; Group: F1,20=41.29, p<0.001). 
There were some fluctuations in the number of usable trials made by the lesion but not intact 
rats (Day x Group: F10,200=6.75, p<0.001; Simple Effect: F9,12=3.00, p<0.05) but thse were 
not specific to the day of bromocriptine administration. 
Reaction time. The lesion group continued showing longer reaction times than intact 
controls when responding to cues presented on their contralateral side (Figure 7.4B-C; 
Group: F1,20=8.08, p<0.05; Group x Side: F1,20=50.18, p<0.001; Simple Effect: F1,20=114.80, 
p<0.001). Reaction time did not decrease on the day of acute bromocriptine administration 
(Day: F10,200=1.14, n.s.; Day x Group: F10,200=1.07, n.s.; Side x Day: F10,200=1.23, n.s.; Side x 
Day x Group: F10,200=1.48, n.s.).  
Movement time. The lesion group continued showing longer movement time than 
intact controls when responding to contralateral cues throughout the testing cycle (Figure 
7.3D-E; Group x Side: F10,200=3.52, p<0.001; Simple Effect: min.F1,20=10.44, p<0.01).  
Accuracy. Lesion rats continued being less accurate than intact controls when 
required to respond to contralateral cues (Figure 7.3F-G; Group: F1,20=16.86, p<0.01; Side x 
Group: F1,20=7.30, p<0.05; Simple Effect: F1,20=16.92, p<0.01). As hypothesised, acute 
bromocriptine administration increased the lesion group‟s accuracy on the day of  
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Figure 7.3. The intact (n=10) and lesion (n=12) groups‟ usable trials (A), together with 
their ipsilateral and contralateral correct reaction time (B-C), correct movement time (D-
E), and accuracy (F-G) when tested 3 and 8 weeks post-lesion. The error bars represent 
the standard error of the mean. *p<0.05, **p<0.01, ***p<0.001 
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administration. Interestingly, while this increase in accuracy was expected to be transient, the 
contralateral accuracy of the lesion group did not return to baseline the day after 
bromocriptine administration. Therefore, testing continued for nine days post bromocriptine 
injection. Lesion rats continued being significantly less accurate than controls the day of, and 
four days after acute bromocriptine administration. However, because of a gradual increase in 
contralateral responding, beginning on the day of acute bromcoriptine administration, lesion 
rats‟ performance was similar to that of intact controls five days after acute bromocriptine 
after which it stabilised (Day x Group: F10,200=2.11, p<0.05; Simple Effect: min. F1,20=6.97, 
p<0.05) . 
7.2.3.4. Effect of acute raclopride on simple motor and LCRT task performance 
The effect of 0.2 mg/kg acute raclopride on behaviour was assessed in a three day cycle using 
the vibrissae test, the adjusting step test, and the LCRT task. Unlike the long-lasting effect of 
bromocriptine, the effect of raclopride was transient and only observed on the day of 
administration.  
Adjusting Step Test. As expected, the lesion group made overall fewer adjusting 
steps than intact controls (Figure 7.5A-B; Group: F1,20=39.75, p<0.001). Acute raclopride 
administration decreased the number of ipsilateral and contralateral adjusting steps made by 
both groups (Side x Day x Group: F2,40=22.93, p<0.001; Simple Effect: min.F2,19=18.15, 
p<0.001). 
Vibrissae test. The lesion group made fewer paw placements in response to vibrissae 
stimulation than intact controls (Figure 7.5C-D; Group: F1,20=71.29, p<0.001). Acute 
raclopride administration decreased both ipsilateral and contralateral motor performance in 
the intact group whereas, due to their pre-existing contralateral impairment, it only further 
decreased the number of ipsilateral responses made in the lesion group (Side x Day x Group: 
F2,40=28.06, p<0.001; Simple Effect: F2,19=41.58, p<0.001).  
Usable trials. While the lesion group continued making overall fewer usable trials 
than intact controls (Figure 7.6A; Group: F1,20=13.58, p<0.01) the intact group‟s usable trials 
decreased to the same level as the lesion group on the day of acute raclopride adminstration 
(Day x Group: F2,40=8.04, p<0.01; Simple Effect on days 1 and 3: min.F1,20=30.59, p<0.001). 
Reaction time. The lesion group continued showing longer reaction times than intact 
controls (Figure 7.6B-C; Group: F1,20=6.19, p<0.05; Side x Group: F1,20=19.71, p<0.001; 
Simple Effect: F1,20=49.47, p<0.001). Neither lesion nor intact rats‟ reaction time increased  
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Figure 7.4. The usable trials (A) and ipsilateral and contralateral reaction time (B-C), 
movement time (D-E), and accuracy (F-G) of intact (n=10) and lesion (n=12) rats before 
and after administration of acute bromocriptine. The arrows represent the day of 
bromocriptine administration. The line chart show the mean performance and the error 
bars represent the standard error of the mean. Base=baseline, BRC=bromocriptine. 
*p<0.05, **p<0.01, ***p<0.001 
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Figure 7.5. The ipsilateral and contralateral performance of intact (n=10) and lesion 
(n=12) rats on the adjusting step (A-B) and vibrissae tests (C-D) the day before, on, and 
after acute raclopride administration. The arrows represent the day of raclopride 
administration. The bars show the mean and the error bars represent the standard error 
of the mean. ***p<0.001 
 
significantly as a result of acute raclopride administration (Day x Group: F2,40=3.17, n.s.; Side 
x Day x Group: F2,40=0.52, n.s). 
Movement time. The lesion group continued taking longer time to respond to 
contralateral cues than intact controls (Figure 7.6D-E; Group: F1,20=25.95, p<0.001; Side x 
Group: F1,20=19.83, p<0.001; Simple Effect of Side: F1,20=21.13, p<0.001). Neither group‟s 
movement time increased as a result of acute raclopride administration (Day x Group: 
F2,40=1.86, n.s.; Side x Day: F2,40=0.80, n.s.; Side x Day x Group: F2,40=0.79, n.s.) 
Accuracy. At the time of the raclopride testing cycle, the difference in accuracy 
originally observed between the intact and lesion groups‟ had disappeared as a result of the 
increased accuracy in the lesion group‟s contralateral responding (Figure 7.6F-G; Group:  
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Figure 7.6. The effect of 0.2 mg/kg acute raclopride on intact (n=10) and lesion (n=12) 
rats‟ usable trials (A) and ipsilateral and contralateral reaction time (B-C), movement 
time (D-E), and accuracy (F-G) of intact (n=10) and lesion (n=12) rats following 
administration of acute bromocriptine. The arrows represent time of raclopride 
administration. The bars show the mean and the error bars represent the standard error 
of the mean. ***p<0.001 
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F1,20=0.02, n.s.; Side: F1,20=0.08, n.s.; Side x Group F1,20=4.36, n.s.). Neither group‟s 
accuracy levels were affected by acute raclopride administration (Day: F2,40=.046, n.s.; Day x 
Group: F2,40=1.57, n.s.; Side x Day: F2,40=0.75, n.s.; Side x Day x Group: F2,40=0.31, n.s.). 
7.2.4. Discussion 
The primary aim the experiment was to replicate the previously reported gradual decline in 
contralateral accuracy following unilateral 6-OHDA lesions (Dowd & Dunnett 2004, 
2005a,b) and to investigate the neural substrates underpinning the LCRT task deficit by 
testing the effect of acute bromocriptine on performance. The previous findings of a gradual 
decline in contralateral accuracy (Dowd & Dunnett, 2004, 2005a,b) was successfully 
replicated both three and eight weeks post-lesion. The nature of this deficit is discussed in 
greater detail in the chapter discussion.  
In contrast to previous data on the effects of bromocriptine on motor behaviour 
(Lundblad et al, 2002; Lindgren et al, 2007), acute administration of 1.25 mg/kg 
bromocriptine did not improve lesion rats‟ reaction or movement times on the day of drug 
administration. This difference may be due to the different paradigms used; whereas the 
current experiment measured reaction and movement time in the LCRT task on a trial per 
trial basis, earlier authors demonstrated an effect of bromocriptine on rotational bias over a 
180 min (Lindgren et al, 2007) or 300 min (Lundblad et al, 2002) period. There were thus 
differences both in regard to the motor behaviour being measured and the time span over 
which it was measured.  
Acute bromocriptine significantly improved the lesion group‟s contralateral accuracy, 
which suggests that accurate responding on the LCRT task is primarily D2 driven. 
Unexpectedly, the drug‟s beneficial effect on accuracy outlasted its known half-life. Whilst 
originally aiming to counterbalance drug administration once a therapeutic dose of 
bromocriptine had been established, thereby allowing a direct comparison between lesion rats 
tested on and off bromocriptine, the drug‟s unforeseen long-lasting effect made this 
impossible. Instead, the effect of bromocriptine was analysed by comparing performance 
before and after bromocriptine administration. This analysis reavealed a significant and long-
lasting improvement in the accuracy with which lesion rats responded to contralateral cues 
post bromocriptine administration. Interestingly, the long-term effects are not likely to have 
been driven by a continuous stimulation of dopamine receptors as bromocriptine has a half-
life of approximately 3h (Lieberman & Goldstein, 1985).  
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To fully exclude the possibility that the long-term effect was not mediated by 
stimulation of D2/3 receptors, rats were administered raclopride prior to operant testing. 
Raclopride is a dopamine antagonist with a high affinity for D2, but also D3, receptors (Table 
7.2; Kebabian et al, 1997). The antagonist successfully reduced motor function, as evidenced 
by data from the adjusting step and vibrissae tests. However, it did not affect accuracy on the 
LCRT task. Two conclusions may be drawn from the findings. First, the long-term effect of 
bromocriptine was unlikely caused by a long-term stimulation of D2 relative to D1 type 
receptors. Second, because raclopride significantly suppressed motor function without 
affecting LCRT task accuracy, the data suggest that there is a dissociation between the 
neurological mechanisms driving motor function and accurate LCRT task responding.   
A possible explanation for the long-lasting effect of bromocriptine on accuracy is that 
acute bromocriptine administration induced downstream changes in the striatal dopaminergic 
system. However, due to the unexpected effects of bromocriptine, the experimental design 
did not allow for a lesion bromocriptine naive control group which would have been needed 
to test this hypothesis. Instead, the hypothesis was tested in a subsequent experiment which 
included a lesion bromocriptine paired (administered bromocriptine 2 h prior to LCRT task 
texting), a lesion bromocriptine unpaired (administered bromocriptine 2 h after LCRT task 
testing), and a lesion bromocriptine naive group. If the effect of bromocriptine described 
above was due to downstream changes, both the paired and the unpaired group should show 
improved accuracy after bromocriptine administration, whereas no change should be 
observed in the contralateral accuracy of the lesion bromocriptine naive group.  
A possible second explanation for the phenomenon is that bromocriptine conditioned 
accurate LCRT task responding. It has previously been shown that rats which have repeatedly 
been administered bromocriptine in a paired environment exhibit increased activity levels 
when placed in the paired environment in the absence of bromocriptine (Hoffman & Wise, 
1992). This suggests that bromocriptine is able to condition behaviour associated with 
contextual cues. It could thus be hypothesised that the conditioning effects of bromocriptine 
extend to also affecting accurate responding on the LCRT task. More specifically, acute 
administration of bromocriptine may have enhanced accurate contralateral responding on the 
day of administration by alleviating the effort associated with performing contralateral 
responses while simultaneously conditioning the drug-induced accurate responding, thereby 
ultimately causing a long-lasting improvement in the observed contralateral accuracy. This 
hypothesis may be tested by comparing the contralateral accuracy of lesion rats that are 
administered bromocriptine prior to (i.e. paired) or after (i.e. unpaired) LCRT task testing. 
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Due to the unexpected long-lasting effect of bromocriptine the current experimental design 
did not allow such a test to be conducted. Instead, this hypothesis was tested in the 
experiment described in the following section.  
7.3. Experiment 6 (part II): The effect of acute bromocriptine and chronic   
L-DOPA on LCRT task performance 
7.3.1. Introduction 
The primary aim of the current experiment was to replicate the findings of a long-lasting 
effect of acute bromocriptine on accurate LCRT task responding reported in Experiment 9 
whilst including appropriate control groups. To this end, the experiment included both lesion 
bromocriptine naive rats, lesion rats administered acute bromocriptine 2 h prior to LCRT task 
testing (paired group), and lesion rats administered acute bromocriptine 2 h post LCRT task 
testing (unpaired group). 
In addition, the experiment also tested the effect of chronic L-DOPA administration 
on LCRT task performance. Chronic L-DOPA administration causes LID onset in the 
majority of MFB lesion rats (Winkler et al, 2002). LID is associated with increased binding 
to striatal D1 receptors (Konradi et al, 2004; Aubert et al, 2005), upregulation of striatal 
mGlu5 receptors (Sanchez-Pernaute et al, 2008; Ouattara et al, 2011), and abnormal synaptic 
plasticity in the cortico-striatal pathway (Picconi et al, 2003). As discussed in further detail in 
the chapter discussion, reduced contralateral accuracy in the LCRT task has previously been 
hypothesised to be caused by either a decrease in general motivation or extinction of 
contralateral responding following loss of the dopaminergic reward signal (see Lelos et al, 
2012). It was hypothesised that if the task was mediated extinction, the regained ability for 
LTP formation observed in tissue from lesion rats chronically treated with L-DOPA, but not 
L-DOPA naive rats (Picconi et al, 2003) would aid extinction learning (Farinelli et al, 2006) 
and as such induce a further decrease in contralateral accuracy. 
7.3.1.2. Aims 
The primary aim of the experiment was to replicate the previous findings of a bromocriptine 
induced improvement in lesion rats‟ contralateral responding on the LCRT task (Experiment 
9) whilst including appropriate lesion control groups. A second aim was to test the effect of 
chronic L-DOPA treatment on lesion rats‟ LCRT task performance. Depending on the 
psychological nature of the task, it was hypothesised that chronic L-DOPA would either not 
affect behaviour, or further reduce contralateral accuracy. 
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7.3.2. Methods 
7.3.2.1. Experimental design 
Rats were trained on the LCRT task before undergoing unilateral 6-OHDA lesions. 
Following recovery and lesion assessment using the spontaneous rotation and cylinder tests, a 
subgroup of the lesion rats was chronically treated with L-DOPA until showing stable AIMs. 
Lesion rats were then tested in staircase boxes and, thereafter, on the LCRT task. Following a 
second post-lesion LCRT testing cycle, a subgroup from each experimental group was 
administered acute bromocriptine prior to operant testing (paired group). Remaining rats were 
given the same bromocriptine dose after LCRT task testing (unpaired group) or kept 
bromocriptine naive. Following one day of paired or unpaired LCRT task testing, all rats 
were tested for three more days in the absence of any further drug administrations. The 
procedure was replicated in two 5 day testing cycles (Figures 7.7 and 7.8). 
7.3.2.2. Procedure 
The previous experiment used male rats to ensure consistency with the LCRT task 
publications that I aimed to replicate (Dowd & Dunnett 2004, 2005a,b). Having replicated 
earlier findings, the subsequent chapters used female rats. This decision was made both on 
the basis of the practical advantages of using female rats and for scientific reasons. First, 
female rats are smaller and less aggressive than males, and more rats can therefore be housed 
in one cage if using females, which decreases the overall holding space required. Second, the 
rat AIMs scoring system used in this project (Winkler et al, 2002) and findings of abnormal 
plasticity in the cortico-striatal pathway of dyskinetic rats (Picconi et al, 2003) were all based 
on experiments using female rats. Finally, the lesion coordinates used in this thesis project 
had been shown to produce more stable lesions in smaller rats (Torres et al, 2011).  
Forty-seven female Lister Hooded rats were pre-trained on the LCRT task for 1 
month (section 2.7.2.2) before a subgroup of 37 rats was given unilateral 6-OHDA lesions to 
the MFB (section 2.2.2). Following a two week recovery period, lesion extent was assessed 
using the cylinder test and spontaneous rotations (sections 2.2.4 and 2.4.6.3). Twelve of the 
lesion rats were then administered daily injections of 10 mg/kg L-DOPA (section 2.3.3) for 
two weeks before being tested on the staircase task for three weeks (section 2.4.4) and,  
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Figure 7.7. A graphical representation of the experimental design in experiment 6. The figure specifies both the duration of the individual 
testing phases, and the overall number of days in the experiment. Light grey boxes represent testing phases that are described in further 
detail in section 6.2.  BRC=bromocriptine; FR=Food restriction; LCRT task=Lateralised choice reaction time task; MFB=Medial forebrain 
bundle 
 
finally, on the LCRT task (section 2.7.2.2)for two five-day cycles. The data from the staircase testing are described in section 6.2. 
Following an initial five-days post-lesion testing cycle in the absence of any drugs, two further five-day test cycles were conducted in 
which acute bromocriptine was administered on the second day of each test cycles. In these testing cycles, the L-DOPA naïve lesion rats were 
split into a drug naïve control group (n=10), a paired group which received bromocriptine 2h before LCRT task testing (n=7), and an unpaired 
group which received bromocriptine 2h after LCRT task testing (n=8). Hence, only the paired group was tested on the LCRT task while under 
the influence of bromocriptine. Including lesion BRC naive, paired, and unpaired rats in the experimental design allowed distinction to be made
 212 
between the potential behavioural effects following bromocriptine administration in a specific 
environment (i.e. conditioning) and potential effects arising from mere bromocriptine 
exposure (i.e. mediated by downstream changes). Due to limited numbers of rats, the intact 
rats were only split into a paired (n=5) and drug naïve (n=5) group, as were the L-DOPA 
treated lesion rats (paired n=6, drug naïve n=6). Figure 7.8 shows the number of rats in each 
experimental group that were administered acute bromocriptine before or after LCRT task 
testing. At the end of operant testing, the rats were culled, their striata dissected out, and their 
hindbrains fixed in 4% PFA. Striatal tissue was gathered to enable later molecular 
comparison between lesion rats that were bromociprtine naïve, bromocriptine paired, or 
bromocriptine unpaired. However, as it was not possible to optimise a Western blotting 
protocol within the time frame of the thesis project such data are not presented. 
 
Figure 7.8. The number of rats in the intact (n=10), lesion L-DOPA naive (n=25), and 
lesion L-DOPA treated (n=12) groups that remained bromocriptine naive, or that were 
administered acute bromocriptine 2h before (paired) or 2h after (unpaired) LCRT task 
testing. BRC=bromocriptine 
 
7.3.2.3. Statistical analysis 
The effect of the lesion on the number of TH+ cell bodies in the SNc and VTA was analysed 
using two separate types of analyses. First, the presence of a lesion in the SNc or VTA was 
confirmed by comparing the raw cell counts in the ipsilateral and contralateral hemisphere 
using a t-test. For this analysis, the SNc and VTA were analysed separately. Once the 
presence of a lesion had been confirmed, an ANOVA was used to test whether there was a 
difference in (i) the relative extent of the experimental groups' dopamine denervation, and (ii) 
the loss of dopaminergic cell bodies observed in the SNc versus the VTA. The ANOVA used 
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the percentage loss of TH+ cell bodies observed in the lesion SNc and VTA as input data and 
included Region as a within-subject variable, and Group as a between-subject variable. 
AIMs were not normally distributed and analysed using a Mann-Whitney test. All 
LCRT task data were analysed using a repeated measures ANOVA with Group as between-
subject factor, and Side, Cycle, and Day as within-subject factors. Significant between-
subject effects were analysed using a Scheffe post-hoc test and significant interactions 
analysed using a test of simple effects.  
7.3.3. Results 
7.3.3.1. Effect of lesion & drug treatments 
The lesion induced a profound loss of TH+ cell bodies that was greater in the SNc (Figure 
7.9A-B; t36=24.07, p<0.001) than the VTA (t36=6.84, p<0.001). A further analysis of the data 
demonstrated that there was a more pronounced loss of dopaminergic cell bodies in the SNc 
than in the VTA (Region: F1,33=34.45, p<0.001), and that the dopamine denervation was 
similar between the experimental groups (Group: F3,33=0.49, n.s.; Region x Group: 
F3,33=0.30, n.s.).  
The unilateral dopamine loss was reflected in a pronounced ipsilateral bias in rats‟ 
spontaneous rotations (Figure 7.9C) and in their performance on the cylinder task (Figure 
7.9D). There was no difference between the ipsilateral bias exhibited by the lesion groups on 
either of these motor tests (Spontaneous rotations: F3,33=0.45, n.s.; Cylinder test: H=1.19, 
df=3, n.s.), suggesting that the lesion had a similar effect on motor function on all lesion 
groups.  
Following chronic L-DOPA treatment, the lesion L-DOPA group exhibited high and 
stable AIMs scores in response to acute L-DOPA administration (Figure 7.9E). There was no 
difference in the magnitude of AIMs observed in lesion, L-DOPA treated rats that would later 
be allocated to the paired and unpaired bromocriptine groups (U=16.00, n.s.). 
7.3.3.2. Post-lesion LCRT task performance 
Usable trials. While the lesion rats made fewer usable trials than intact controls (Group: 
F6,40=12.19, p<0.05), there was no difference between the lesion rats  that were later assigned 
to the bromocriptine naive, bromocriptine paired, or bromocriptine unpaired groups. As 
neither their usable trials nor their treatment at this point of testing differed, their data were 
pooled and the analysis repeated only including an intact, a lesion L-DOPA naive, and a 
lesion L-DOPA treated group in the analysis.  
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Figure 7.9. Surviving dopaminergic cell bodies in the SNc and VTA, expressed as a 
percentage of the intact side (A), together with the a photo showing the loss of TH+ cell 
bodies in the SNc and VTA in one lesion rat included in the experiment (B), the ipsilateral 
bias exhibited by lesion rats in the spontaneous rotations (C) an cylinder (D) tests during 
lesion screening, and the cumulative AIMs s scores for the lesion L-DOPA treated rats 
that remained BRC naive throughout testing or that were later administered acute 
bromocriptine prior to LCRT testing (E). The bars charts (A, C) show the mean and 
standard error of the mean. The box plots (D, E) shows the median and the interquartile 
ranges. BRC=Bromocriptine; SNc=Substantia nigra pars compacta; VTA=Ventra 
tegmental area; TH=Tyrosine hydroxylase. ***p<0.001 
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The second analysis demonstrated that Lesion rats conducted overall fewer usable 
trials than intact controls, but there was no significant difference between the number of 
usable trials made by the lesion L-DOPA naive and the lesion L-DOPA treated rats (Figure 
7.10A; Group: F2,44=28.77, p<0.01). The number of usable trials made by intact and lesion L-
DOPA treated rats fluctuated in the first five-day testing cycle but remained stable in the 
second post-lesion testing cycle (Cycle x Day x Group: F8,176=5.06, p<0.001: Simple Effect 
of Day: min. F4,41= 3.33, p<0.05).  
Reaction Time. There was no difference in the reaction time of the lesion groups that 
would later be bromocriptine naive, bromocriptine paired, or bromocriptine unpaired (Group: 
F6,40=0.31, n.s.). As neither their reaction time nor their treatment at this point of testing  
differed their data were pooled and the analysis repeated only including an intact, a lesion    
L-DOPA naive, and a lesion L-DOPA treated group in the analysis.  
Both the lesion groups had longer reaction times than intact controls when cues were 
presented on their contralateral side. Lesion rats‟ contralateral reaction time increased over 
the course of each five-day testing cycle (Figure 7.10B-C; Group: F2,44=0.87, n.s; Side x Day 
x Group: F8,176=3.32, p<0.01; Simple Effect of Day: F4,41=min.6.56, p<0.001). Reactions 
times fluctuated more in the second than first testing cycle (Cycle: F1,44=9.68, p<0.01; Cycle 
x Group: F2,44=0.90, n.s.) 
Movement Time. There was no difference in the movement time of the lesion groups 
that would later be bromocriptine naive, bromocriptine paired, or bromocriptine unpaired 
(Group: F6,40=1.77, n.s.). As neither their movement time nor their treatment at this point of 
testing differed their data were pooled and the analysis repeated only including an intact, a 
lesion L-DOPA naive, and a lesion L-DOPA treated groups in the analysis.  
The second analysis demonstrated that both lesion groups showed longer overall 
movement time than intact controls (Figure 7.9D-E; Group: F2,44=15.32, p<0.05). The 
movement times increased gradually over the five-day testing block (Cycle x Day x Side: 
F4,176=3.70, p<0.05; Simple Effect: min.F4,41=2.84, p<0.05). Movement times were somewhat 
longer in the second than first than the second post-lesion testing cycle (Cycle: F1,44=5.27, 
p<0.05).   
Accuracy. There was no difference in the accuracy of the lesion groups that would 
later be bromocriptine naive, bromocriptine paired, or bromocriptine unpaired (Group: 
F6,40=15.40, p<0.001). As neither their accuracy nor their treatment at this point of testing 
differed their data were pooled and the analysis repeated only including an intact, a lesion    
L-DOPA naive, and a lesion L-DOPA treated groups in the analysis.  
 216 
Lesion rats were significantly less accurate in their responding than intact rats, but 
there was no overall difference between lesion rats that were L-DOPA naive or that had 
received chronic L-DOPA treatment (Figure 7.10F-G; Group: F2,44=39.48, p<0.001). The 
lesion groups‟ deficit manifested itself when rats were required to make contralateral 
responses, and gradually worsened over each five-day testing cycle (Side x Day x Group: 
F8,176=2.86, p<0.01; Simple Effect of Day: min.F4,41=6.06, p<0.01). The gradual nature of the 
deficit was most readily observed in the first five-day testing cycle. In the second cycle, 
lesion rats‟ contralateral responding did not align with that of intact controls on the first day 
of testing thus making the gradual nature of the deficit less pronounced (Cycle x Side x Day: 
F4,176=5.46, p<0.05; Simple Effect of Cycle: min.F1,44= 5.05, p<0.05).  
Because the deficit primarily manifested itself on the contralateral side a further analysis, 
restricted to the contralateral side, was conducted. As in the previous analysis, the lesion 
groups were less accurate than intact controls and their performance gradually decreased over 
the five days of testing (Day x Group: F8,176=6.32, p<0.001; Simple Effect of Day: min.F4,41= 
6.06, p<0.01) both when tested three and eight weeks post-lesion (Day x Group x Cycle: 
min.F1,41= 9.82, p<0.001). In addition, and in contrast to the analysis including both sides, 
there was a significant difference between lesion L-DOPA naive and   L-DOPA treated rats 
with chronic L-DOPA treatment further impairing the accuracy with which lesion rats 
responded to contralateral cues (Group: F2,44=60.00, p<0.001).  
7.3.3.3. Effect of acute BRC on LCRT task performance  
At the end of the second post-lesion testing cycle a subset of each experimental group 
(„paired‟ groups) was administered 1.25 mg/kg bromocriptine 2 h prior to LCRT testing. The 
following section describes the effect of paired bromocriptine administration on LCRT task 
performance. While the statistical analysis included all groups, the data from the L-DOPA 
naive and L-DOPA treated lesion rats are shown in separate graphs to increase the ease with 
which the graphs can be read. Similarly, while the statistical analysis did not pool data from 
intact rats that were bromcoriptine naïve or paired, data from these rats are shown as one 
group in the graphs to increase the ease with which the graphs can be read. 
Usable trials. Lesion rats conducted fewer usable trials than intact controls in both 
five-day testing cycles (Figure 7.11; Cycle: F1,6=0.43, n.s.; Cycle x Group: F6,40=1.07, n.s.; 
Group: F6,40=10.08, p<0.001). In neither cycle did acute bromocriptine significantly increase 
the number of usable trials conducted at the day of administration (Day: F4,160=1.19, n.s.; Day 
x Group: F24,160=1.13, n.s.).  
 217 
 
 
Figure 7.10. The post-lesion usable trials (A) together with ipsilateral and contralateral 
correct reaction time (B-C), movement time (D-E), and accuracy (F-G) of intact (n=10), 
lesion drug naïve rats (n=25), and lesion rats that had been chronically treated with L-
DOPA (n=12). The lines show the mean and the error bars represent the standard error 
of the mean. 
 
 218 
Reaction Time. There was no overall difference in intact and lesion groups‟ reaction 
times (Figure 7.12; Group: F6,40=1.56, n.s.). While there was a trend towards longer reaction 
times on the contralateral than ipsilateral side this did not meet statistical significance (Side: 
F1,40=3.73, p=0.06; Side x Group: F6,40=1.85, n.s.). Reaction times were of similar length in 
the first and second five day testing cycle (Cycle: F1,40=1.45, n.s.; Cycle x Group: F6,40=0.61, 
n.s.). Together, these data indicate that acute bromocriptine administration did not 
significantly affect intact or lesion rats‟ reaction times.  
 
 
Figure 7.11. The percentage of usable trials conducted by intact rats, lesion L-DOPA naive 
(top row), and lesion rats that had been chronically treated with L-DOPA (bottom row). A 
subset of rats were administered acute bromocriptine 2 h prior to testing (paired group) 
or 2 h after testing (unpaired group) on the second day of each five-day testing cycle. 
The arrows indicate the day of acute bromocriptine administration. The lines show the 
mean and the error bars show the standard error of the mean. Base=baseline, 
BRC=bromocriptine 
 
Movement Time. The lesion groups took longer time than intact controls to respond 
to cues presented on their contralateral side (Figure 7.13; Side x Group: F6,40=4.61, p<0.01; 
Simple Effect of Side: min.F1,40=8.94, p<0.01). While the lesion, bromocriptine paired group‟ 
movement time fluctuated over the course of testing, these fluctuations were not specific to 
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the days of bromocriptine administration (Group x Day: F24,160=1.65, p<0.05; Simple Effect 
of Day: F4,37=5.41, p<0.01), suggesting that bromocriptine did not significantly affect 
movement times. The movement times were similar in the first and second five-day testing 
cycles (Cycle: F1,40=0.53, n.s.; Cycle x Group: F6,40=0.26, n.s.). 
 
 
Figure 7.12. The ipsilateral (top row) and contralateral (bottom row) reaction times 
exhibited by intact rats, lesion L-DOPA naive rats (left column), and lesion rats that had 
been chronically treated with L-DOPA (right column). A subset of rats were administered 
acute bromocriptine 2 h prior to testing (paired group) or 2 h after testing (unpaired 
group) on the second day of each five-day testing cycle. The arrows indicate the day of 
acute bromocriptine administration. The lines show the mean and the error bars show 
the standard error of the mean. Base=baseline, BRC=bromocriptine 
 
Accuracy. The lesion groups were, overall, less accurate in their responding than 
intact controls (Figure 7.14; Group: F6,40=6.30, p<0.001). This lesion deficit manifested itself 
when rats responded to contralateral cues (Side x Group: F6,40=6.77, p<0.001; Simple Effect: 
F6,40=8.71, p<0.0001). The accuracy with which rats responded to cues presented on their 
contralateral side changed over the course of testing exclusively in the two lesion groups that 
received acute bromocriptine two hours prior to LCRT task (Side x Day x Group: 
F24,160=2.18, p<0.01; Effect of Day on paired lesion groups: min.F4,37=4.99, p<0.01). 
However, while acute bromocriptine increased accuracy on the day of administration, there 
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was no long-lasting effect of the drug on accuracy as had been observed in Experiment 9. 
Overall accuracy was significantly higher in the second (average: 64.12%) than first 
(average: 59.33%) five-day testing block (Cycle: F1,40=4.83, p<0.05; Cycle x Group: F6,40= 
0.84, n.s.).  
 
Figure 7.13. The ipsilateral (top row) and contralateral (bottom row) movement time 
exhibited by intact rats, lesion L-DOPA naive rats (left column), and lesion rats that had 
been chronically treated with L-DOPA (right column). A subset of rats were administered 
acute bromocriptine 2h prior to testing (paired group) or 2h after testing (unpaired 
group) on the second day of each 5 day testing cycle. The arrows indicate the day of 
acute bromocriptine administration. The lines show the mean and the error bars show 
the standard error of the mean. Base=baseline, BRC=bromocriptine 
 
7.3.4. Discussion 
The primary aim of the experiment was to determine whether acute bromocriptine 
administration had long-lasting effects on contralateral accuracy, as indicated in Experiment 
9 (section 7.2). Whilst the drug produced a transient increase in contralateral accuracy, the 
current data failed to replicate the long-lasting effect on accuracy that was observed in the 
previous section. The difference may be by due to a type I error in Experiment 9, or 
methodological differences in the experiments.  
Whilst Experiment 9 used male rats in an attempt to follow the original LCRT task 
protocol (Dowd & Dunnett, 2004) as closely as possible, the current experiment used female 
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Figure 7.14. The ipsilateral (top row) and contralateral (bottom row) accuracy exhibited 
by intact rats, lesion L-DOPA naive (left column), and lesion rats that had been 
chronically treated with L-DOPA (right column). A subset of rats were administered acute 
bromocriptine 2 h prior to testing (paired group) or 2 h after testing (unpaired group) on 
the second day of each 5 day testing cycle. The arrows indicate the day of acute 
bromocriptine administration. The lines show the mean and the error bars show the 
standard error of the mean. Base=baseline, BRC=bromocriptine 
 
 
rats for practical reasons and for consistency with other experiments reported in this thesis. 
There are demonstrated gender differences in the human dopaminergic system in terms of D2 
binding and the adverse effects of dopmine agonists (Kaasinen, 2001; Munro et al, 2006; 
Joutsa et al, 2012). The possibility that gender differences in the psychopharmacological 
effects of bromocriptine translate to the rat cannot be excluded and may explain the different 
results obtained in this and in the previous section.  
It should also be noted that the rats in this experiment showed greater loss of 
dopaminergic cell bodies than the rats in Experiment 9. This was likely an indirect effect of 
the gender difference, as the lesion coordinates used in the experiments have been optimised 
for female rats that are smaller than the male rats used in Experiment 9 (Torres et al, 2011). It 
was previously hypothesised that the long-lasting effect of acute bromocriptine 
administration on lesion rats‟ contralateral responding was due to conditioning. It is possible 
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that, in order for a conditioning effect to occur, there must be more surviving dopaminergic 
fibres than what was present in the current experiment. 
The data were, however, valuable insofar as providing further insight into the 
mechanism underlying the contralateral accuracy deficit. In line with what had been expected 
in Experiment 9, bromocriptine administration induced a transient increase in the 
contralateral accuracy of both drug naïve and L-DOPA treated lesion rats. Interestingly, the 
chosen bromocriptine dose was able to improve lesion rats‟ accuracy whilst no effect was 
observed on reaction or movement times. Thus, the data supports earlier findings that 
accurate responding in the LCRT task is D2 reliant and that it is dissociated from motor 
aspects of the LCRT task.  
A main finding was the further decrease in contralateral accuracy observed in the 
lesion L-DOPA treated group. Whilst long-term L-DOPA treatment is known to induce 
adverse side effects in the form of AIMs in lesion rats and patients these are of a motor nature 
and are only present when on medication. In the current experiment, chronic L-DOPA 
treatment was shown to decrease contralateral accuracy in lesion rats tested in the absence of 
acute L-DOPA. The data thus suggests that chronic L-DOPA medication might have long-
term effects on non-motor function, something which is further discussed in the chapter 
discussion. The findings of an effect of chronic L-DOPA treatment on LCRT task 
performance were followed up in two subsequent experiments described in sections 7.4 and 
8.2. 
7.4. Experiment 8 (part II): The Effect of Chronic L-DOPA and Chronic 
Bromocriptine Treatment on LCRT Task Performance 
7.4.1. Introduction 
Previous findings (section 7.3) suggested that chronic L-DOPA treatment further impaired 
lesion rats‟ accuracy on the LCRT task. In addition to L-DOPA, D2 agonists are also used to 
treat motor symptoms of PD and unlike L-DOPA, these do not induce LID if administered as 
a first-line monotherapy (Perace et al, 1998). As further elaborated on in the chapter 
discussion, it was hypothesized that the previously observed L-DOPA induced deficit was 
linked to changes in synaptic plasticity which occurs in lesion rats following chronic            
L-DOPA (Picconi et al, 2003). To test the hypothesis, while also allowing a comparison 
between the effects of common dopaminergic PD treatments on motor and non-motor 
function, the current experiment tested whether chronic treatment with the D2 type agonist 
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bromocriptine would induce a similar impairment as chronic L-DOPA. Bromocriptine was 
chosen as the D2 agonist to be tested both because previous finding (sections 7.2 to 7.3) had 
shown a beneficial effect of acute bromocriptine on lesion rats‟ non-motor performance in the 
LCRT task, and because it does not induce LID in drug naive lesion rats (Pearce et al, 1998). 
Including bromocriptine in the current experiment thus allowed a comparison to be made 
between (i) acute (as demonstrated in sections 7.2 and 7.3) and chronic effects of 
bromocriptine on LCRT task performance, and (ii) the chronic effect of LID inducing (L-
DOPA) and non-LID inducing (bromocriptine) drugs on LCRT task performance.  While 
testing the acute effects of  bromocriptine and L-DOPA was not a primary aim of the 
experiment, the opportunity was seized to also test the ability of acute L-DOPA and 
bromocriptine to alleviate lesion induced deficits on the LCRT task at the end of testing.  
7.4.1.2. Aims 
The aims of the experiment were to (i) test the effect of chronic L-DOPA and bromocriptine 
treatment on intact and lesion rats‟ LCRT task performance, and (ii) test the ability of acute 
L-DOPA and bromocriptine to improve LCRT task performance in lesion rats with a 
previous history of L-DOPA or bromocriptine treatment. 
7.4.2. Methods 
7.4.2.1. Experimental design 
Rats were trained on the LCRT task before a subgroup was given unilateral 6-OHDA MFB 
lesions. Following recovery, lesion extent was assessed using the cylinder test and 
spontaneous rotations. Intact and lesion rats were then divided into three groups and 
chronically treated with saline, L-DOPA, or bromocriptine respectively. After treatment, rats 
were tested in staircase boxes (reported in section 6.4) and on the LCRT task in the absence 
of any drugs.  Following LCRT testing off-medication, rats were also tested in the LCRT task 
following acute administration of the drug with which they had previously been treated 
(Figure 7.15). Striatal tissue had originally been intended to be used for molecular analysis, it 
was not therefore not appropriate to administer rats more than one type of injection (i.e. 
saline, L-DOPA, or bromocriptine). Therefore, the effect of acute bromocoriptine was only 
tested in rats that had previously received chronic bromocriptine, and the effect of acute L-
DOPA was only tested in rats that had received chronic L-DOPA. 
7.4.2.2. Procedure 
Eighty-five female Lister Hooded rats were trained on the LCRT task (section 2.7.2.2) for six 
weeks before 58 rats were given unilateral 6-OHDA lesions to the MFB (section 2.2.2). Two 
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weeks post-lesion, the lesion extent was assessed using the cylinder test (section 2.4.4.) and 
by measuring rats‟ spontaneous rotations (section 2.4.6.3). Intact and lesion rats were then 
chronically treated with 1 ml/kg saline (intact n=10, lesion n=15), 10 mg/kg L-DOPA (intact 
n=10, lesion n=25), or 1.25 mg/kg bromocriptine (intact n=10, lesion n=15). Chronic 
treatment lasted for three weeks, during which period rats received daily injections of their 
respective drug. The lesion L-DOPA and bromocriptine treated groups were scored for AIMs 
throughout the treatment period (section 2.5). The behavioural effect of bromocriptine was 
also assessed twice weekly by measuring lesion rats‟ rotational bias in automated rotometers 
(section 2.4.6) for 90 min post-injection. Saline treated rats were not scored for AIMs.  
At the end of the chronic drug treatment, rats were tested in staircase boxes for three 
weeks (section 6.4), during which period weekly maintenance injections of the groups‟ 
respective drugs were provided at the same dose as before. To demonstrate that the dyskinetic 
effect of L-DOPA was not lost during this period, the effects of acute L-DOPA and 
bromocriptine were measured again at the end of staircase testing, using the same protocol as 
during chronic drug treatment.  
Rats were thereafter tested on the LCRT task, in the absence of any drugs for 5 days 
before a second testing cycle measuring the effect of acute drug administration commenced. 
In the acute testing cycle, intact and lesion rats were given acute administrations of the same 
drug they had been chronically treated with, either before (paired group) or after (unpaired 
group) LCRT task testing. Bromocriptine (section 2.3.1) was administered i.p. at a 
concentration of 1.25 mg/kg and a volume of 2 ml/kg 2 h before/after testing, whereas 1 
mg/kg saline and 1 mg/kg L-DOPA (2.3.2) was administered s.c. at a volume of 1 ml/kg 
either 20 min before or 2h after testing.  
The intention was to use striatal tissue from rats treated with saline, L-DOPA, or 
bromocriptine to determine if there were differences in the molecular effects the drugs 
produced. To not confound later molecular analysis, it was necessary to only expose rats to 
one single drug treatment. For this reason, the acute effects of saline, L-DOPA and 
bromocriptine were only tested in rats that had previously been treated with the same drug. 
Unfortunately, it was not however possible to optimise the relevant protocol and run such 
analyses within the time frame of this thesis project and molecular data are therefore not 
reported in this section. 
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Figure 7.15. A graphical representation of the experimental design. The figure specifies both the duration of the individual testing phases, 
and the overall number of days in the experiment. Light grey boxes indicate testing that was conducted as part of another experiment and 
which is further described in section 6.4. BRC=bromocriptine; FR=Food restricted; LCRT task=Lateralised choice reaction time task; 
MFB=Medial forebrain bundle 
 
One intact rat treated with L-DOPA was excluded from acute administration testing cycle due to health reasons. Hence, the following 
groups were included in the acute challenge testing cycle: intact paired/unpaired saline (n=5/4), lesion paired/unpaired saline (n=7/8), intact 
paired/unpaired L-DOPA (n=5/5), lesion paired/unpaired L-DOPA (n=13/12), intact paired/unpaired bromocriptine (n=5/5), lesion 
paired/unpaired bromocriptine (n=7/8).  
At the end of the acute testing cycle, rats were euthanized by an overdose of Euthatal, their hindbrains were post-fixed in 4% PFA, and 
their striata dissected out (section 2.9) placed on dry ice and thereafter moved to -80°C. Immunohistolgical staining for TH and counting of cell 
bodies in the ipsilateral and contralateral SNc and VTA was used to determine lesion extent as described in sections 2.10 and 2.11.
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While the striatal tissue was originally kept for later Western blotting tests, it was not 
possible to optimise the Western blot protocol during the time of the thesis project and data 
from striatal tissue is therefore not reported. 
7.4.2.2. Statistical analysis 
The effect of the lesion on the number of TH+ cell bodies in the SNc and VTA was analysed 
using two separate types of analyses. First, the presence of a lesion in the SNc or VTA was 
confirmed by comparing the raw cell counts in the ipsilateral and contralateral hemisphere 
using a t-test. For this analysis, the SNc and VTA were analysed separately. Once the 
presence of a lesion had been confirmed, an ANOVA was used to test whether there was a 
difference in (i) the relative extent of the experimental groups' dopamine denervation, and (ii) 
the loss of dopaminergic cell bodies observed in the SNc versus the VTA. The ANOVA used 
the percentage loss of TH+ cell bodies observed in the lesion SNc and VTA as input data and 
included Region as a within-subject variable, and Group as a between-subject variable. 
Data from the spontaneous rotations and cylinder tests were analysed using a one-way 
ANOVA and a Kruskal-Wallis test, respectively. Changes in the net bias of bromocriptine-
induced rotations were analysed using a repeated measures ANOVA, where the net rotational 
bias from the first and last rotometer session in the chronic treatment phase were used as 
within-subject factors. AIMs scores were analysed using a one-way ANOVA. 
LCRT operant data were analysed using a repeated measures ANOVA. Significant 
between-subject differences were analysed using the Scheffe post-hoc test, and significant 
interactions analysed using a test of simple effects.   
7.4.3. Results 
7.4.3.1. Effect of lesion and drug treatments 
The lesion induced a significant loss of dopaminergic cell bodies in the ipsilateral SN (Figure 
7.16A-B; t54=30.98, p<0.001) and VTA (t54=31.02, p<0.001). A further analysis 
demonstrated that there was a greater percentage loss of dopaminergic cell bodies in the 
ipsilateral SNc than in the ipsilateral VTA (Region: F1,51=26.43, p<0.001) and that the 
dopamine denervation was similar between the groups (Group: F3,51=0.66, n.s.; Region x 
Group: F3,51=0.39, n.s.). 
Reflective of their lesion, all groups showed an ipsilateral bias on the spontaneous 
rotations and cylinder tests (Figure 7.16C-D) that did not differ between the three groups 
(Spontaneous rotations: F2,52=1.55, n.s.; Cylinder test: H(2)=0.74, n.s.). The lesion group 
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treated with L-DOPA exhibited high AIMs scores following chronic treatment (Figure 
7.16E), something which was not observed in the lesion group treated with bromocriptine 
(Group: F1,39=16.97, p<0.001). Chronic bromocriptine did, however, produce an increase in 
the net bias of rats‟ drug-induced rotations (Figure 7.16F; F1,15=12.39, p<0.01). 
 
 
Figure 7.16. The top row shows the percentage of surviving TH+ cell bodies in the SNc 
and VTA, relative to the intact side, (A) and a photograph of the dopamine depletion in 
the same neural regions of one lesion rat included in the experiment (B). The middle row 
shows the net ipsilateral bias of rats‟ spontaneous rotations (C), and the ipsilateral bias 
on the cylinder test (D) post lesion but prior to drug treatment. The bottom row shows 
the cumulative AIMs scores from the final scoring session (E), together with the net 
ipsilateral bias of bromocriptine induced rotations observed in the lesion = bromocriptine 
treated group (F). The dotted line in graph F represents the rotational bias exhibited on 
the first test session. The bars charts (A,C, F) show the mean and the error bars the 
standard error of the mean. The box plots (D,E) show the median and the interquartile 
ranges, with circles representing outliers. AIMs=Abnormal involuntary movements; 
SNc=Substantia nigra pars compact; TH=Tyrosine hydroxylase; VTA=Ventral tegmental 
area. **p<0.01 
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7.4.3.2. Post-lesion performance on the LCRT task 
There was no significant effect of drug treatment on intact rats‟ performance, and data from 
these groups were therefore pooled in subsequent analyses. Four groups were thus included in 
the analysis; intact controls, lesion + saline; lesion + L-DOPA; and lesion + bromocriptine. 
For transparency, the LCT task data from the intact groups is shown in Table 7.3 to Table 7.6 
and the results from the statistical analysis including all intact subgroups are shown in 
Appendix I. 
Usable Trials. Lesion rats produced fewer usable trials than intact controls but there 
was no effect of drug treatment (Figure 7.17A; Group: F3,81=29.42, p<0.001). The number of 
usable trials made increased over the course of testing (Day: F4,324=105.05, p<0.001).  
 
 
Table 7.3. The mean percentage of usable trials performed by the intact groups 
chronically treated with saline, L-DOPA, or bromocriptine during the first five days of 
post-lesion testing. The standard error of the mean is shown after each value. 
BRC=bromocriptine 
Usable trials (%) Day 1 Day 2 Day 3 Day 4 Day 5 
Intact + saline 21.0 ± 2.5 35.9 ± 4.0 46.5 ± 4.6 44.2 ± 3.9 54.7 ± 3.1 
Intact + L-DOPA 23.2 ± 2.2 33.5 ± 4.4 46.8 ± 4.7 50.7 ± 4.7 51.7 ± 4.7 
Intact + BRC 18.7 ± 3.7 34.5 ± 3.5 42.3 ± 4.8 47.4 ± 3.3 48.8 ± 2.6 
 
 
Table 7.4. The mean reaction time (s) exhibited by the intact groups chronically treated 
with saline, L-DOPA, or bromocriptine during the first five days of post-lesion testing. The 
standard error of the mean is shown after each value. BRC=bromocriptine  
Reaction 
time (s) 
Ipsilateral Contralateral 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 1 Day 2 Day 3 Day 4 Day 5 
Intact + 
saline 
0.28  
± 0.01 
0.28  
± 0.01 
0.29  
± 0.01 
0.30  
± 0.02 
0.30  
± 0.01 
0.26  
± 0.01 
0.28  
± 0.01 
0.29  
± 0.01 
0.28 
± 0.01 
0.31  
± 0.01 
Intact +  
L-DOPA 
0.26  
± 0.02 
0.31  
± 0.01 
0.32  
± 0.01 
0.30  
± 0.03 
0.34  
± 0.03 
0.28  
± 0.02 
0.30  
± 0.02 
0.32  
± 0.02 
0.30  
± 0.01 
0.32 
± 0.02 
Intact + 
BRC 
0.35  
± 0.04 
0.32  
± 0.05 
0.32  
± 0.03 
0.33  
± 0.03 
0.33  
± 0.03 
0.30  
± 0.02 
0.32  
± 0.05 
0.31  
± 0.03 
0.31  
± 0.02 
0.31  
± 0.02 
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Table 7.5. The mean movement time (s) exhibited by the intact groups chronically 
treated with saline, L-DOPA, or bromocriptine during the first five days of post-lesion 
testing. The standard error of the mean is shown after each value. BRC=bromocriptine 
Movement 
time (s) 
Ipsilateral Contralateral 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 1 Day 2 Day 3 Day 4 Day 5 
Intact + 
saline 
0.81  
± 0.17 
0.50  
± 0.05 
0.49  
± 0.07 
0.45  
± 0.05 
0.43  
± 0.06 
0.65  
± 0.07 
0.55  
± 0.21 
0.45  
± 0.03 
0.38  
± 0.02 
0.38 
 ±0.02 
Intact +  
L-DOPA 
0.69  
± 0.08 
0.55  
± 0.10 
0.47  
± 0.05 
0.38  
± 0.02 
0.46  
± 0.06 
0.64  
± 0.08 
0.46  
± 0.02 
0.49  
± 0.04 
0.40  
± 0.02 
0.37  
± 0.02 
Intact + 
BRC 
1.37  
± 0.51 
0.58  
± 0.05 
0.59  
± 0.09 
0.44  
± 0.03 
0.42  
± 0.03 
0.88  
± 1.20 
0.53  
± 0.06 
0.55  
± 0.08 
0.44  
± 0.03 
0.42  
± 0.03 
 
 
Table 7.6. The mean percent accurate trials conducted by the intact groups chronically 
treated with saline, L-DOPA, or bromocriptine during the first five days of post-lesion 
testing. The standard error of the mean is shown after each value. BRC=bromocriptine 
Accuracy  
(%) 
Ipsilateral Contralateral 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 1 Day 2 Day 3 Day 4 Day 5 
Intact + 
saline 
69.1 
± 5.3 
81.0 
±2.3 
82.4  
± 6.4 
87.1  
± 4.1 
87.3 
± 3.3 
74.1  
± 3.7 
82.1  
± 5.0 
84.1  
± 3.0 
86.0 
± 3.9 
90.0. 
± 2.2 
Intact +   
L-DOPA 
59.2  
±  7.5 
78.2  
± 3.8 
72.4  
± 5.7 
82.3  
± 3.1 
86.4 
± 4.1 
69.6  
± 4.1 
80.6  
± 3.5 
86.9  
± 4.9 
82.5  
± 2.1 
86.1 
± 2.0 
Intact + 
BRC 
50.2  
± 10.2 
69.0  
± 9.0 
81.1  
± 6.7 
81.9  
± 6.1 
80.8 
± 5.6 
62.6  
± 5.8 
80.1 
 ± 4.3 
80.1 
 ± 5.2 
86.7  
± 2.7 
88.6  
± 3.2 
 
Reaction time. While there was no overall difference in the groups‟ reaction times 
(Figure 7.17B-C; Group: F3,81=0.93, n.s.) the lesion groups exhibited marginally longer 
reaction times than intact controls when the cues were presented on their contralateral side 
(Side x Group: F3,81=7.03, p<0.001; Simple Effect: F3,81=3.40, p<0.05). The reaction times 
fluctuated over the course of testing (Day: F4,324=5.67, p<0.001). However, these fluctuations 
were not specific to any group (Group x Day: F12,324=1.13, n.s.) or side (Side x Day: 
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F4,324=1.67, n.s.; Side x Day x Group: F12,324=1.17, n.s.)  which suggested that they were due 
to random fluctuations in the data rather than reflective or a lesion or drug induced deficit.  
Movement time. The intact controls had significantly shorter overall movement time 
than lesion rats. In addition, lesion rats chronically treated with L-DOPA exhibited overall 
longer movement times than lesion rats treated with saline (Figure 7.17D-E; Group: 
F3,81=21.85, p<0.0001). This deficit was most evident when rats were required to respond to 
visual cues presented on their contralateral side (Side x Group: F3,81=7.84, p<0.001; Simple 
Effect of Side on L-DOPA group: F3,81=35.98, p<0.001). A second analysis, restricted to the 
contralateral side, was therefore conducted. This analysis demonstrated that the lesion groups 
treated with L-DOPA and bromocriptine had longer movement times than intact controls 
(Group: F3,81=3.51, p<0.05) and that the lesion L-DOPA rats showed a gradual increase in the 
time required to perform contralateral responses over the course of the five testing days (Day 
x Group: F12,324=2.41, p<0.05; Simple Effect: F4,78=5.46, p<0.01).  
Accuracy. Intact rats were overall more accurate than lesion rats, but there was no 
overall difference between the lesion groups treated with saline, L-DOPA, or bromocriptine 
(Figure 7.17F-G; Group: F3,81=31.17, p<0.001). The lesion induced deficit manifested itself 
when rats were required to make contralateral responses (Side x Group: F3,81=59.97, p<0.001; 
Simple Effect: F3,81=69.06, p<0.001). Restricting the analysis to the contralateral side showed 
a further exacerbation of the deficit in lesion rats treated with L-DOPA, but not 
bromocriptine (Group: F3,81=68.60, p<0.001).  
7.4.3.3. Effect of acute saline on LCRT task performance 
At the end of the initial post-lesion testing, the effect of acute saline, L-DOPA, and 
bromocriptine on LCRT task performance was tested. The following section describes the 
effect of acute saline administration on the number of usable trials, reaction time, movement 
time, and accuracy in drug naive intact and lesion rats. 
Usable trials. Lesion rats continued performing fewer usable trials than controls 
(Figure 7.18A; Group: F3,21=8.20, p<0.01) but there was no difference between the usable 
trials made by paired and unpaired groups. While there was some variation in the usable trials 
made by the intact unpaired group, their number of usable trials made on the day of saline 
administration did not differ from other days (Day x Group: F12,84=3.44, p<0.001; Effect of 
Day in unpaired intact group: F4,18=5.94, p<0.01), suggesting that saline did not impact on the 
number of usable trials rats made on the LCRT task. The number of usable trials made 
remained similar in both five day testing cycles (Cycle: F1,21=1.13, n.s.)  
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Figure 7.17. The percentage of usable trials (A), ipsilateral and contralateral reaction 
time (B-C), movement time (D-E), and accuracy (F-G) of the intact (n=30), lesion + 
saline (n=15), lesion + L-DOPA (n=25), and lesion + bromocriptine (n=15) groups. The 
intact groups treated with saline, L-DOPA, and bromocriptine have been pooled for 
clarity. The lines show the mean, and the error bars represent the standard error of the 
mean. BRC = bromocriptine.  
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Figure 7.18. The usable trials (A), reaction time (B-C), movement time (D-E), and 
accuracy (F-G) of intact (paired n=5, unpaired n=5) and lesion (paired n=7, unpaired 
n=8) rats given acute saline prior to testing or not. The arrows indicate the day of saline 
administration. The lines show the mean and the error bars represent the standard error 
of the mean. 
 
Reaction time. The lesion groups continued requiring longer time to respond to cues than 
intact controls (Figure 7.18B-C; Group: F3,21=4.12, p<0.05). As expected, administering 
saline prior to LCRT task testing did not affect reaction times (Day x Group: F12,84=0.89, n.s.; 
Day x Side x Group: F4,84=0.51, n.s.). There was a slight difference between the ipsilateral 
reaction time recorded in the two five-day testing cycles. This was due to noise in the data on 
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the fourth day of testing and as such not related to the saline administration (Cycle x Side: 
F1,21=11.72, p<0.01; Simple Effect of Cycle: F1,21=9.10, p<0.01). 
Movement time. Lesion rats continued showing longer movement times than intact 
controls, but as expected there was no significant difference between the paired and unpaired 
groups (Figure 7.18D-E; Group: F3,21=5.10, p<0.05). Movement times were similar across 
both five-day testing cycles (Cycle: F1,21=0.30, n.s.; Cycle x Group: F3,21=0.71, n.s.; Cycle x 
Side: F1,21=3.13, n.s.). 
Accuracy. Lesion rats continued being less accurate than intact controls when 
responding to contralateral cues but there was no difference in the accuracy of the paired and 
the unpaired groups (Figure 7.18F-G; Day x Side x Group: F12,84=2.88, p<0.01; Simple 
Effect: min.F1,21=16.18, p<0.001). There were slight differences between performance in the 
two five-day testing cycles (Cycle x Side x Day: F4,84=107.10, p<0.001; Simple Effect of 
Cycle: F1,21=min.6.35, p<0.05). However, this was due to both lesion groups being more 
accurate in their contralateral responding during the second five day testing cycle rather than 
being an effect of acute saline administration.  
7.4.3.4. Effect of acute L-DOPA on LCRT task performance 
Usable trials. The lesion rats continued producing fewer usable trials than controls, but there 
was no difference between the L-DOPA paired and unpaired groups (Figure 7.19A; Group: 
F3,30=8.93, p<0.001; Day x Group: F12,120=1.39, n.s.). There was a slight but significant 
difference between the usable trials made by the intact paired rats in the first and second five 
day testing cycle (Cycle x Group: F1,27=3.90, p<0.05; Simple Effect of Cycle: F1,27=4.24, 
p<0.05). This was due to marginally fewer usable trials made by the intact paired group 
during the first five-day testing cycle.  
Reaction time. Lesion rats continued showing longer reaction times than intact 
controls (Figure 7.19B-C; Group: F3,30=6.04, p<0.01) but there was no difference between the 
reaction time of the paired and unpaired groups (Day x Side x Group: F12,120=1.22, n.s.; Day 
x Side: F4,120=1.80, n.s.). Lesion rats‟ had marginally higher reaction times in the second than 
first five-day testing cycle (Cycle x Group: F3,30=4.63, p<0.01; Simple Effect of Cycle on the 
lesion groups: F1,30=min.17.63, p<0.001). However, this was not specific to a difference  
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Figure 7.19. The usable trials (A), reaction time (B-C), movement time (D-E), and 
accuracy (F-G) of intact (paired n=5, unpaired n=4) and lesion  (paired n=13, unpaired 
n=12) rats administered an acute L-DOPA prior to testing or not. The arrows indicate the 
day of L-DOPA administration. The line chart shows the mean performance of the groups 
and the error bars represent the standard error of the mean. 
 
between paired and unpaired rat and as such not indicative of an effect of acute L-DOPA on 
reaction times.  
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Movement time. Lesion rats continued showing longer movement times than intact 
controls (Figure 7.19D-E; Group: F3,30=7.70, p<0.001). Acute L-DOPA abolished the 
contralateral impairment in the paired lesion group on the day of administration (Day x Side 
x Group: F4,12=2.93, p<0.01; Simple Effect: min.F3,30=4.61, p<0.01), although it is noted that 
the effect was marginal in the first five-day testing cycle. The recorded movement time was 
similar across the two five-day testing cycles (Cycle: F1,30=0.19, n.s.; Cycle x Group: 
F3,30=0.86, n.s.). 
Accuracy. Lesion rats continued being less accurate than intact controls but there was 
no difference between paired and unpaired rats (Figure 7.19F-G; Group: F3,30=5.41, p<0.01; 
Day x Side x Group: F12, 120=0.87, n.s.) as would have been expected if L-DOPA alleviated 
the accuracy deficit. Whereas there was a difference in the accuracy of responding in the first 
and second five- day testing cycle, this was driven by variation in the ipsilateral accuracy data 
(Cycle x Side x Day: F4,120=60.52, p<0.001; Simple Effect of Cycle: F4,27=105.84, p<0.001) 
and not related to differences in the performance of paired and unpaired rats.  
7.4.3.5. Effect of acute bromocriptine on LCRT task performance 
Usable trials. The lesion groups continued producing fewer usable trials than controls 
(Figure 7.20A; Group: F3,21=10.57, p<0.001). Acute bromocriptine administration caused a 
transient decrease in the number of usable trials made by the paired lesion group on the day 
of administration (Day x Group: F12,84=3.07, p<0.01; Simple Effect of Day: F4,18=4.06, 
p<0.05). There was a significant difference between the performance across the two five-day 
testing cycles (Cycle x Day x Group: F12,64=3.24, p<0.01) driven by more usable trials being 
made by the paired lesion and paired intact groups on the day of bromocriptine administration 
in the second testing cycle (Simple Effect of Cycle: min.F1,16= 6.35, p<0.05). 
Reaction time. Whilst the lesion continued impairing reaction times (Figure 7.20B-C; 
Group: F3,21=12.00, p<0.001), the difference between the intact and the paired lesion group 
disappeared on the day of bromocriptine administration when the paired lesion group 
exhibited a temporary improvement in their reaction times (Day x Group: F12,84=2.04, 
p<0.05: Simple Effect: min.F3,21= 9.80, p<0.001). There was a significant difference between 
the reaction time recorded in the first and second five-day cycle (Cycle x Side x Day: 
F4,84=11.93, p<0.001). This was driven by marginally longer reaction times on the day of 
bromocriptine administration in the second, relative to the first, cycle five-day testing cycle, 
and a fluctuation in the ipsilateral reaction times recorded on day 4 of each cycle and  
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Figure 7.20. The usable trials (A), reaction time (B-C), movement time (D-E), and 
accuracy (F-G) of intact (paired n=5, unpaired n=5) and lesion (paired n=7, unpaired 
n=8) rats administered an acute L-DOPA prior to testing or not. The arrows indicate the 
day of bromocriptine administration. The line charts show the mean performance of the 
groups and the error bars represent the standard error of the mean. 
 
contralateral reaction times on the final day of each cycle (Simple Effect of Cycle: 
F1,21=min.7.30, p<0.05). 
Movement time. Lesion rats continued exhibiting longer movement times than 
controls (Figure 7.20D-E; Group: F3,21=15.87, p<0.001). Acute bromocriptine decreased the 
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time taken for the paired lesion group to make contralateral responses on the day of 
administration (Day x Side x Day: F12,84=4.04, p<0.001; min.F1,21=5.80, p<0.05). Overall, the 
variation in the groups‟ movement time was less pronounced in the second than in the first 
five-day testing cycle (Cycle: F1,21=4.97, p<0.05.; Cycle x Group: F3,21=2.35, n.s.). 
Accuracy. The lesion rats continued making fewer accurate responses than intact 
controls when responding to contralateral cues (Figure 7.20F-G; Group: F3,21=4.71, p<0.05; 
Side x Group: F3,21=4.63, p<0.05; Simple Effect: F3,21=5.69, p<0.01). Acute  bromocriptine 
administration caused a gradual improvement of paired lesion rats‟ contralateral accuracy 
starting on the day of administration. In addition, there was a gradual increase in accuracy 
with which the unpaired group responded to contralateral cues which began the day after 
acute bromocriptine administration. By the second five-day testing cycle, the lesion rats‟ 
performance had reached a plateau (Day x Side x Cycle: F4,84=2.47, p<0.05; Simple effect of 
Day: F1,18=13.32, p<0.001)   
7.4.4. Discussion 
The experiment was conducted to replicate previous findings of a further impairment in the 
accuracy with which lesion rats responded to contralateral cues on the LCRT task following 
chronic L-DOPA treatment while also investigating the effect of chronic bromocriptine, 
which unlike L-DOPA, does not induce LID, on LCRT task performance. It was 
hypothesised that chronic L-DOPA, but not bromocriptine, would further impair lesion rats‟ 
performance on the CRT task. At the end of testing, the opportunity was also seized to test 
effect of acute saline, L-DOPA, and bromocriptine on LCRT task performance. 
7.4.4.1. The effect of L-DOPA 
The results replicated previous findings (section 7.3) of a further impairment in LCRT task 
performance in lesion rats chronically treated with L-DOPA, as well as showing that chronic 
L-DOPA treatment only affected performance of dopamine denervated rats and not 
performance of intact rats.  
In accordance with what is already known about L-DOPA‟s beneficial effects on 
motor function (Birkmayer & Hornykiewicz, 1961), acute administration of the drug 
improved lesion rats‟ movement time. Interestingly, it did not affect accuracy which 
suggested it was unable to restore non-motor function measured in the LCRT task at the 
current dose. 
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7.4.4.2. The effect of bromocriptine 
Contrary to what was observed following chronic L-DOPA, there was no effect of chronic 
bromocriptine on lesion rats‟ LCRT task performance. As elaborated on in the chapter 
discussion, the dissociate effect of chronic L-DOPA and bromocriptine is hypothesised to 
relate to changes in synaptic plasticity following LID onset, which is only induced by          
L-DOPA. 
Whilst no difference was observed between the performance of paired and unpaired 
lesion rats prior to the acute bromocriptine challenges, both groups exhibited an increase in 
contralateral accuracy the days following acute bromocriptine administration. Interestingly, a 
closer inspection of the data (Figure 7.20G) showed that the paired lesion group‟s 
contralateral accuracy began increasing at the day of administration whilst the unpaired lesion 
group‟s contralateral accuracy only began to increase the following day. Whilst a definitive 
interpretation is not feasible without further investigation, the results may suggest that the 
bromocriptine administered to the unpaired group 2 hours after operant testing induced a 
behavioural change similar to that observed in the paired group that became apparent in the 
next testing session. 
Bromocriptine has a half-life of approximately 3 h (Lieberman & Goldstein, 1985), 
making it unlikely that the increase in the unpaired lesion group‟s accuracy the day after 
administration was driven by an acute effect of bromocriptine. It could be hypothesised that 
bromocriptine induce downstream changes that affect operant behaviour. This, however, 
appears unlikely in the light of the current findings as lesion rats chronically treated with 
bromocriptine did not differ from saline treated lesion controls prior to the paired and 
unpaired bromocriptine administrations. It is also noted that the lesion rats treated with saline 
also showed higher accuracy in the second relative to the first five-day testing cycle. Based 
on the current data alone, conclusions on the effect of acute bromocriptine on LCRT task 
accuracy can therefore not be drawn   
7.4.4.3. Conclusions 
The data demonstrated a replicable effect of L-DOPA treatment on lesion rats‟ performance, 
wherein chronic L-DOPA impairs later contralateral accuracy on the LCRT task. The deficit 
was specific to lesion rats, and did not occur following chronic treatment with the clinically 
available D2 agonist bromocriptine which unlike L-DOPA does not induce LID. A second 
aim of the experiment was to test the acute effects of L-DOPA and bromocriptine on the 
LCRT task. It was concluded that whilst both drugs improved performance they affected 
different parameters. Acute L-DOPA alleviated motor impairments but was unable to 
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improve contralateral accuracy. Conversely, acute bromocriptine improved accuracy on the 
day of administration while no effect was observed on motor function. Based on the findings 
from this, and the previous experiment, it was hypothesised that cellular changes associated 
with LID onset, which was induced in lesion rats following chronic L-DOPA treatment, 
underlie the decreased accuracy with which lesion rats responded to contralateral cues on the 
LCRT task. This is further discussed in section 7.5.3. 
7.5. Discussion 
7.5.1. The LCRT task deficit 
The LCRT task was initially developed by Carli and colleagues (1985) as a means of testing 
the effect of dopamine loss on sensorimotor function in rats with unilateral 6-OHDA lesions. 
The task allows recording of reaction and movement time, as well as the accuracy with which 
rats respond to visual cues presented on either the ipsilateral or contralateral side of the 
lesion. The lateralised nature of the task is thus suitable for rats with unilateral lesions, as it 
enables comparisons between responses made on the ipsilateral and contralateral sides to the 
lesion.  
Reaction time in the LCRT task measures the time elapsed between onset of a 
lateralised light cue and withdrawal from the central hole, i.e. initiation of a movement in 
response to the cue. In addition to the motor initiation aspect the measure includes a 
movement element, and could be argued to also contain a level of visual attention. For 
example, if lesion rats were impaired relative to controls in their reaction but not motor time, 
the deficit could be argued to represent an attentional impairment. However, previous 
publications have demonstrated that the LCRT reaction time deficit observed in rats with 
unilateral 6-OHDA lesions depends on the direction of the movement the cue indicates (i.e. 
ipsilateral or contralateral to the lesion), rather than the location of the visual cue itself (Carli 
et al, 1985). Therefore, the 6-OHDA induced reaction time deficit is unlikely to reflect 
impaired visual attention and is instead hypothesised to be driven by a motor deficit.  
In addition to reaction time, the LCRT task also records movement time, which is 
defined as the time elapsed between withdrawal from the central hole and completion of a 
correct lateralised nose poke. While the initial LCRT task publication did not report a 
movement time deficit in 6-OHDA lesion rats (Carli et al, 1987), a contralateral movement 
deficit was observed in later studies where the distance between the central hole and the 
lateralised response holes was increased (Dowd & Dunnett 2004a,b, 2005). Increased 
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movement times relative to healthy controls have also been observed in PD patients. For 
example, Sanes and colleagues (1985) demonstrated that PD patients took longer than healthy 
controls to move a stylus, held like a pen, between two targets. In line with preclinical data 
suggesting that lesion rats‟ LCRT movement time deficit is dependent on the distance to the 
response hole (Carli et al, 1984; Dowd & Dunnett, 2004, 2005a,b) Sanes and colleagues 
(1985) demonstrated a greater movement time deficit in PD patients when the distance 
between the targets increased. Hence, the movement time deficit is believed to reflect a lesion 
induced motor deficit also observed in PD. 
In addition to reaction and movement times, the LCRT task measures the accuracy 
with which rats perform contralateral and ipsilateral responses. Preclinical data have shown 
decreased contralateral accuracy following unilateral 6-OHDA lesions (Dowd & Dunnett, 
200, 2005a,b). However, the precise nature of the deficit has not been established. While 
determining the exact psychological mechanism underlying the contralateral accuracy deficit 
was beyond the scope of the current experiment, a discussion of potential explanations for the 
deficit will be provided. First, it may be hypothesized that lesion rats were unable to detect 
the contralateral cue because of lesion induced visual neglect. This hypothesis may, however, 
be rejected based on findings of Brown & Robbins (1989) who demonstrated that rats with 
unilateral lesions can detect and respond to contralateral cues when cues are only presented 
on the contralateral side and no ipsilateral option is available. 
Second, it could be argued that the lesion-induced motor impairment prevented lesion 
rats from performing contralateral motor actions. However, this explanation may be rejected 
based on previously published data showing that lesion rats will make contralateral motor 
responses when the task is modified so as to require them to respond to light cues presented 
on the ipsilateral side by making contralateral responses and vice versa (Carli et al, 1985).  
A third hypothesis is that whilst rats were able to detect contralateral light cues, they 
may be unable to direct motor actions in contralateral space. This is based on a hypothesis 
originally proposed by Brown & Robbins (1989). Brown & Robbins (1989) utilized a task 
where rats with intra-striatal 6-OHDA lesions, tested in nine-hole boxes, were trained to 
respond to light cues presented in one of two response holes. The response holes were always 
located on the same, i.e. ipsilateral or contralateral, side of the lesion. Brown & Robbins 
(1989) showed that lesion rats were not biased to either response hole when these were 
located ipsilateral to the lesion. However, when both response holes were located 
contralateral to the lesion, lesion rats were biased to responding to the nearer, more 
ipsilateral, response location. Interestingly, if blocking one of the contralateral response holes 
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so that there was only one contralateral response location available the lesion deficit 
disappeared. Based on this data, Brown & Robbins (1989) argued that unilateral 6-OHDA 
lesions induce a response related deficit where rats are unable to direct contralateral 
responses. Clinical studies have demonstrated impaired movement accuracy in PD patients 
which could be argued to bear resemblance to a deficit in directing movements. For example, 
Rand and colleagues (2000) measured movement accuracy by contrasting the time required 
by PD patients and healthy controls to move a stylus towards a visual target presented on a 
digitizer table. The task included two conditions: one emphasised the accuracy of the 
movement and the other did not. Rand and colleagues (2000) found that, relative to controls, 
PD patients‟ movement time increased proportionally more in the condition that emphasised 
accuracy. The increased movement time was especially pronounced in the final approach 
phase of the movement, which the authors suggested was indicative of a deficit in movement 
accuracy. However, while it could be hypothesised that 6-OHDA MFB lesions impair rats‟ 
ability to direct movements in contralateral space, and that this caused an overall decrease in 
lesion rat‟s contralateral responding in the LCRT task, such a hypothesis does not explain 
why the contralateral accuracy would manifest itself gradually. Rather, if impaired accuracy 
in the LCRT task was due to an inability to direct contralateral responding, the impairment 
would be expected to remain stable post-lesion. 
 A fourth hypothesis it that dopamine loss may have decreased the motor effort rats 
were willing to exert for a sucrose pellet reward. This is based on the finding that dopamine is 
implicated in cost-effort decisions. For example, Cousins & Salamone (1994) demonstrated 
that food restricted  rats with 6-OHDA lesions to the NAcc performed an equal number of 
lever presses in exchange for a sucrose pellet reward on a FR5 schedule as intact controls did. 
However, if food pellets were available on the floor of the operant chamber during testing the 
number of lever presses made by lesion rats decreased as they settled for the less palatable 
food pellets, while no such effect was observed in intact rats (Cousins & Salamone, 1994). It 
is ambiguous to what extent the findings presented by Cousins & Salamone (1994) translate 
to the clinic. While PD is known to increase apathy, which some authors link to motivation 
(Czernecki et al, 2002), it is unclear to what extent, if at any, the decreased willingness to 
exert effort for a reward described in preclinical experiments (Cousins & Salamone, 1994) 
translates to patients‟ symptoms. In terms of explaining the LCRT task accuracy deficit, it 
should also be noted that the previously published findings of a decreased willingness to exert 
effort for a sucrose reward were linked to dopamine loss in the NAcc (Cousins et al, 1993; 
Cousins & Salamone, 1994). Conversely, the LCRT task accuracy deficit has been linked to 
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striatal dopamine loss (Carli et al, 1989). While  MFB lesions induce dopamine loss in both 
the dorsal and ventral striatum, the LCRT accuracy deficit is not observed following loss of 
NAcc dopamine alone (Carli et al, 1989). Thus, while NAcc mediated motivation may have 
affected performance, it is unlikely to be the primary mechanism driving the contralateral 
accuracy deficit.  
A fifth hypothesis, first presented by Dowd & Dunnett (2004) is that dopamine 
denervation renders the system unable to produce a dopamine reward signal. Previous 
publications have demonstrated a phasic dopamine peak following unexpected rewards that is 
transferred to the CS presentation following repeated training (Schultz, 2010; Tobler et al, 
2003). Based on this data, it was hypothesised that 6-OHDA lesions caused a loss of the 
neural reward signal, and that this in turn caused extinction of contralateral responding 
(Dowd & Dunnett, 2004, 2007). The notion of an impaired prediction error signal following 
dopamine loss, although not directly measured in Dowd & Dunnett‟s (2004, 2005a,b) 
experiments, bears similarities to clinical data. For example, Schonberg and colleagues 
(2010) used fMRI to record PD patients‟ and healthy controls‟ neural activity while 
participants performed a reward based learning task. The task required participants to choose 
between one of two virtual slot machines. Both machines had a pseudorandomised 
probability of generating a win, and participants were asked to try to maximise their 
winnings. The positive prediction error signal observed in the dorsolateral striatum following 
a winning was greater in healthy controls than patients, while no difference was observed in 
their negative error signal following the absence of a win (Schonberg et al, 2010). This 
suggested that the dopaminergic system in PD is impaired at generating the phasic dopamine 
signal that is typically observed following delivery of an unexpected reward. The hypothesis 
presented by Dowd & Dunnett (2004) could explain not only the decrease in contralateral 
responding, but also the gradual decline in accuracy, which is similar to what is observed in 
rats undergoing extinction on the LCRT task following physical removal of sucrose pellets 
(Dowd & Dunnett, 2007). However, the hypothesis cannot explain why lesion rats continue 
responding to contralateral cues in paradigms where no ipsilateral option is available (e.g. 
Brown & Robbins, 1989).  
While several hypotheses regarding the precise nature of the contralateral accuracy 
task observed in the LCRT task may be proposed, no hypothesis explains both the gradual 
decline in lesion rats‟ contralateral accuracy and the ability of lesion rats‟ to respond to 
contralateral cues when no ipsilateral option is available. It was not within the scope of the 
thesis project to test the psychological nature of the LCRT task deficit. However, based on 
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available literature, it is likely that the phenomenon is mediated by both a decrease in 
motivation to exert effort for a reward, and an absence or reduction in the phasic dopamine 
signal that typically follows delivery of a reward.       
7.5.2. The effect of acute drug administration on LCRT task performance 
L-DOPA and bromocriptine are both clinically available to treat the motor symptoms of PD, 
with the former offering greater symptomatic relief of motor deficits. As part of this chapter, 
the effect of acute L-DOPA and bromocriptine administration on motor (reaction and 
movement time) and non-motor (accuracy) parameters of the LCRT task was tested. The 
results showed that while L-DOPA was able to restore motor function, only bromocriptine 
was able to improve the accuracy with which rats responded to contralateral cues. There thus 
appears to be a dissociation between the neurological functions the drugs affect. 
Bromocriptine‟s ability to reinstate responding for sucrose pellets suggests that accurate 
LCRT task responding relies primarily on striatal D2 function, although it cannot be ruled out 
based on the current experiments whether other receptors which bromocriptine show affinity 
to were also implicated. It is possible that acute bromocriptine increased accuracy by 
enhancing the reinforcing effects of the reward, in line with data suggesting that antagonizing 
D2/3/4 receptors reduces the reinforcing effects of cocaine, as measured by a progressive 
ratio task (Bari & Pierce, 2005), or that acute bromocriptine enhances responding to a 
reinforced lever (Beninger & Ranaldi, 1992; Ranaldi & Beninger, 1995; Sutton et al, 2001). 
This would tie in with the hypothesis that the contralateral accuracy deficit was mediated by a 
decreased willingness to exert effort for a reward. However, considering differences in the 
observed effects of acute bromocriptine administration on LCRT task responding in 
Experiments 9 and 6, further tests are required to determine the nature of the bromocriptine 
mediated improvement in responding.  
7.5.3. Effect of chronic drug administration on LCRT task performance 
A primary aim of this thesis project was to test whether chronic administration of 
dopaminergic drugs affects non-motor function in lesion rats. In the current chapter, this was 
tested by comparing LCRT task performance of lesion rats that were drug naïve, or 
chronically treated with saline, bromocriptine or L-DOPA prior to LCRT task testing. Whilst 
chronic saline and bromocriptine did not alter the behaviour of lesion rats, chronic L-DOPA 
caused a further impairment of both movement time and accuracy. A main difference 
between the effects of chronic L-DOPA and bromocriptine on lesion rats is that only the 
former induces LID. It may thus be hypothesised that the difference in LCRT task 
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performance between lesion rats chronically treated with L-DOPA or bromocriptine is due to 
differences in striatal function of lesion rats that have or have not develop LID. Among other 
changes, chronic L-DOPA has been associated with restored ability for cortico-striatal LTP 
and, following LID onset, loss of the ability for depotentiation (Picconi et al, 2003).  
Following the initial identification of a gradually emerging contralateral accuracy 
deficit in drug naïve lesion rats, Dowd & Dunnett (2004, 2007) hypothesised that the deficit 
represented extinction of contralateral responding following a lesion induced abolishment of 
the dopaminergic reward signal reinforcing such responses. It could thus be hypothesized that 
chronic L-DOPA further decreased lesion rats‟ accuracy by affecting either the generation, or 
utilization, of the dopamine reward signal. However, there was no difference in the dopamine 
denervation observed in lesion rats treated with saline and L-DOPA in Experiments 6 and 8 
(sections 7.3 and 7.4). While not directly tested, this suggests that there was no difference in 
their system‟s ability to generate a phasic dopamine reward signal. Chronic L-DOPA does 
not decrease binding to D2 receptors (Aubert et al, 2005) which data in Experiments 9 and 6 
(sections 7.2 and 7.3) suggest are involved in accurate LCRT task responding. Therefore, 
while the possibility cannot be firmly excluded based on current data, it is counterintuitive 
that lesion rats chronically treated with L-DOPA would be impaired relative to saline treated 
controls in their ability to detect a dopamine reward signal, and that the LCRT accuracy 
deficit was instead mediated by other factors.  
While chronic L-DOPA is unlikely to have affected the generation, or utilization of, a 
dopamine reward signal it may have had an impact on extinction. Extinction is believed to 
not represent unlearning of a previous rule, but instead the learning of a new CS-US 
association in which the CS is no longer predictive of a reward and, as a result, the original 
CR is inhibited (Myers & Davis, 2002). This learning is believed to rely on synaptic 
plasticity, and LTP induction has been shown to be essential for e.g. fear extinction in rats 
(Farinelli et al, 2006). Whilst the data by Farinelli and colleagues (2006) was obtained from 
the hippocampus, it may be hypothesised that cortico-striatal LTP is implicated in extinction 
of striatally mediated behaviour such as LCRT task performance. Chronic L-DOPA restores 
the ability for cortico-striatal LTP formation in lesion rats (Picconi et al, 2003). It may thus 
be argued that, in the absence of a perceived reinforcement following a correct contralateral 
response, rats that had received chronic L-DOPA treatment were able to more readily acquire 
a new CS-US association, in which the original CR was inhibited – thereby increasing the 
rate with which their contralateral responding decreased. Whilst providing a potential 
explanation for the data presented in this chapter, the hypothesis requires further testing. 
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Future experiments may wish to test whether e.g. experimental inhibition of LTP formation 
in lesion L-DOPA treated rats abolishes the effect of chronic L-DOPA on contralateral 
accuracy, as would be predicted from the above hypothesis.  
7.5.4. Conclusions 
The data extended on previous knowledge by suggesting that contralateral accuracy on the 
LCRT task is primarily D2 receptor driven. The data also showed a robust effect of chronic 
L-DOPA on the performance of lesion rats tested off-medication. Specifically, chronic           
L-DOPA was associated with a more rapid decline in lesion rats‟ contralateral accuracy. The 
replicable effect of chronic L-DOPA therefore suggests that long-term treatment does not 
only induce adverse motor symptoms, but also affect non-motor function. Interestingly, 
chronic bromocriptine did not affect LCRT performance. One difference between chronic     
L-DOPA and chronic bromocriptine treatment is that only the former is linked to the onset of 
LID. Therefore, Chapter 8 further explored whether the observed L-DOPA induced deficit 
was linked to LID onset by comparing the LCRT task performance of lesion rats that did or 
did not develop LID in response to chronic L-DOPA.  
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8. Dissociating Between the Effect of LID onset 
and Chronic L-DOPA on LCRT Task Performance 
Background: The results presented in Chapter 7 demonstrated exacerbation of the lesion 
induced accuracy deficit on the LCRT task following chronic L-DOPA treatment. Chronic   
L-DOPA treatment induces LID in the majority of MFB lesion rats while only a small 
minority remain non-dyskinetic. Based on the data in Chapter 7, it could therefore not be 
determined whether the LCRT task deficit observed in lesion rats chronically treated with     
L-DOPA was due to chronic L-DOPA exposure or LID onset.  
 
Aim: The aim of the current chapter was to dissociate between the effects of chronic            
L-DOPA treatment and LID onset on lesion rats‟ performance on the LCRT task.  
 
Methods: In Experiment 10, an inactive vehicle or a novel anti-dyskinetic compound was co-
administered with L-DOPA to create „lesion + L-DOPA-treated‟ groups that did, or did not, 
develop LID. Following training, lesion, and drug treatments, all rats were tested on the 
LCRT task. In Experiment 11, LCRT task data from experiments 9 and 10 which both 
included non-dyskinetic rats were pooled to allow a comparison between the performance of 
lesion L-DOPA treated rats that did or did not develop LID.  
 
Results: An exacerbation of the lesion induced LCRT task accuracy deficit was apparent in 
L-DOPA treated rats that developed LID, while lesion rats that remained non-dyskinetic 
following L-DOPA treatment did not differ from saline treated lesion controls. The data thus 
showed that LID onset, rather than chronic L-DOPA, further impairs lesion rats‟ responding 
on the LCRT task 
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8.1. Introduction 
The results in Chapter 7 revealed a replicable effect in which chronic L-DOPA administration 
caused a further decrease in the contralateral accuracy of lesion rats tested on the LCRT task. 
Lesion L-DOPA treated rats that develop LID differ from their non-dyskinetic counterparts in 
a range of parameters including increased levels or prodynorphin and FosB proteins, glutamic 
acid decarboxylase, upregulation of D1 receptors, and increased levels of extracellular striatal 
dopamine following L-DOPA administration (Cenci et al, 1998; Andersson et al, 1999; 
Konradi et al, 2004; Carta et al, 2006). In addition, LID has been linked to altered cortico-
striatal plasticity. While chronic L-DOPA restores the otherwise lost ability for LTP 
formation in cortico-striatal tissue from lesion rats, the ability for depotentiation, i.e. the 
ability to reverse a previously potentiated response to baseline levels, is lost in tissue from 
rats that develop LID (Picconi et al, 2003). 
Previous publications suggest that depotentiation affects extinction learning. For 
example, if depotentiation is pharmacologically induced after fear memory reactivation, it 
disrupts the long-term retention of the memory (Kim et al, 2010). Similarly, inducing 
depotentiation after a fear extinction trial using low-frequency stimulation decreases 
extinction learning, as indicated by higher levels of freezing in rats that received LFS than in 
controls when both groups are tested in later retention trials (Farinelli et al, 2006). While 
acknowledged that the study by Farinelli and colleagues (2006) examined the hippocampal-
prefrontal cortex pathway, a role of depotentiation in extinction may be of relevance to the 
results presented in Chapter 7.  
The majority of MFB lesion rats that are chronically treated with L-DOPA develop 
LID (Winkler et al, 2002). As previously stated, dyskinetic rats are believed to lose the ability 
for cortico-striatal depotentiation, whereas their non-dyskinetic counterparts retain this ability 
(Picconi et al, 2003). If the lesion induced LCRT task deficit reflects extinction as proposed 
by Dowd & Dunnett (2004), and extinction learning is disrupted by depotentiation induction, 
it could be hypothesised that lesion rats that develop LID will be less likely to experience 
depotentiation-related disruption of extinction learning as they are unable to exhibit this form 
of synaptic plasticity. This may result in greater extinction learning, and therefore a more 
pronounced decrease in contralateral accuracy in dyskinetic relative to non-dyskinetic rats. 
 In order to test the effect LID onset on lesion, L-DOPA treated rats‟ LCRT task 
performance, it was necessary to compare the performance of lesion rats that did and did not 
develop LID in response to chronic L-DOPA. Because few MFB lesion rats remain non-
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dyskinetic following long-term L-DOPA treatment (e.g. Winkler et al, 2002), an anti-
dyskinetic compound was used to attempt to pharmacologically produce such a group in 
Experiment 10. The hypothesis was also tested in Experiment 11 by pooling and comparing 
data from dyskinetic and non-dyskinetic lesion, L-DOPA treated rats from Experiments 9 and 
10. 
8.2. Experiment 10: The Effect of a Novel Anti-Dyskinetic Compound on 
Lesion L-DOPA Treated Rats’ LCRT Task Performance 
8.2.1. Introduction 
Despite roughly half of all PD patients experiencing dyskinesias within 5 years of L-DOPA 
treatment (Nutt, 2001), there is currently no treatment available that prevents the 
development of LID. The clinically available NMDA antagonist Amantadine has proven able 
to reduce the magnitude of AIMs in patients and preclinical PD models (Sawada et al, 2000; 
Breger et al, 2012). Preclinical and phase II/III data also suggest that AIMs magnitude can be 
reduced without compromising the beneficial effects of L-DOPA on motor function using 
other pharmacological agents such as mGlu5 antagonists (Verhagen Metman et al, 1998; 
Johnston et al, 2010; Morin et al, 2012; Rascol et al, 2011), 5HT1A/B antagonists (Bézdard 
et al, 2013), and partial 5HT1A agonists (Lundblad et al, 2005; Eskow et al, 2007; Bonifati et 
al, 1994).  
NMDA receptors‟ involvement in LID is demonstrated both by the anti-dyskinetic 
effects of the clinically available NMDA antagonist Amantadine (Sawada et al, 2010; Breger 
et al, 2012) and by findings of aberrant NMDA-dependent synaptic plasticity in tissue from 
lesion rats that developed LID (Picconi et al, 2003). Functional NMDA receptors contain 
NR2A and NR2B subunits, both of which are found in striatal neurons (Landwehrmyer et al, 
1995), and which express glycine and glutamate binding sites respectively (Prybylowski & 
Wenthol, 2004). Among the many proteins known to interact with NR2A and NR2B subunits 
are the membrane associated guanylate kinases (MAGUKs). Amongst their other functions, 
MAGUKs are believed to stabilise the delivery of NR2B subunits to synapses, and bring 
NMDA receptor modulators into close proximity with the channel (Prybylowski & Wenthold, 
2004). MAGUKs also interact with NR2A subunits, in particular the MAGUK protein PSD-
95, which is located in the postsynaptic membrane (Kim & Sheng, 2004).  
Preclinical data analysing NMDA subunit levels in the postsynaptic compartment of 
striatal rat tissue have demonstrated an increase in NR2A levels and a decrease in NR2B 
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levels in lesion rats and primates that develop LID (Gardoni et al, 2006; Hallet et al, 2006). 
This has led to the hypothesis that LID is caused by an increased NR2A/B ratio (Gardoni et 
al, 2012). This hypothesis is supported by preclinical data showing that administering a cell 
permeable TAT2B peptide to lesion, otherwise non-dyskinetic rats can decrease NR2B levels 
and induce acute AIMs (Gardoni et al, 2006). It is also supported by findings that 
administration of a cell permeable TAT2A peptide which is known to decouple the PSD-
95/NR2A complex (Gardoni et al, 2006; Paille et al, 2010) and reduce NR2A levels in the 
postsynaptic compartment (Vastagh et al, 2012), decreases the incidence of LID in lesion rats 
when co-administered with L-DOPA (Gardoni et al, 2012). The TAT2A peptide does not, 
however, reduce AIMs if administered to rats that have already developed LID (Gardoni et 
al, 2012). This suggests that decoupling the PSD-95/NR2A complex and reducing TAT2A 
levels in the postsynaptic compartment can prevent LID onset in rats treated with L-DOPA, 
but is unable to reverse pathological changes underlying LID once these have occurred.   
Unlike the clinically available anti-dyskinetic drug Amantadine, which suppresses the 
expression of dyskinesia, this TAT2A peptide has therefore been shown able to prevent LID 
onset by targeting molecular mechanisms associated with dyskinesia (Gardoni et al, 2012). 
To test the hypothesis that the contralateral accuracy deficit observed in lesion rats tested on 
the LCRT task following chronic L-DOPA treatment was caused by LID onset it was 
necessary to compare the performance of lesion L-DOPA treated rats that ere dyskinetic and 
non-dyskinetic. The current experiment therefore administered the TAT2A peptide that has 
previously been shown to hold anti-dyskinetic effects (Gardoni et al, 2012) to a subgroup of 
lesion L-DOPA rats in order to allow for a comparison between dyskinetic and non-
dyskinetic rats‟ LCRT task performance.  
8.2.1.2. Aims 
The primary aim was to compare the performance of lesion, L-DOPA treated rats that did or 
did not develop LID on the LCRT task.   
8.2.2. Methods 
8.2.2.1 Experimental design 
After training on the LCRT task a subgroup of rats underwent unilateral 6-OHDA, MFB 
lesions. After recovery, lesion extent was assessed using the cylinder test and spontaneous 
rotations. Based on the results, lesion rats were allocated to one of four groups and 
chronically treated with saline + TAT2A; saline + SDV; L-DOPA + TAT2A; or L-DOPA + 
SDV. Intact rats were divided into four groups, whose treatments matched those of lesion 
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rats. The experimenter was blinded to the rats‟ treatment regimen during AIMs scoring. 
Following drug treatment and dyskinesia scoring, rats were food restricted and tested on the 
LCRT task for 5 days. Whilst testing was conducted off-medication, rats received daily 
injections with their respective treatments at the end of each testing day, in line with the 
protocol described by Gardoni and colleagues (2012) when they first reported on the TAT2A 
peptide‟s anti-dyskinetic effects. 
8.2.2.2. Procedure 
Eighty-nine female Lister Hooded rats were trained on the LCRT task (section 2.7.2.2) for six 
weeks, after which 58 rats were given unilateral 6-OHDA lesions of the MFB (section 2.2.2). 
Two weeks post-lesion, lesion extent was assessed using the cylinder test (section 2.4.4) and 
by measuring rats‟ spontaneous rotations in automated rotometers (section 2.4.6.3). These 
behavioural tests were used to balance the lesion groups. Intact and lesion rats were then 
chronically treated with saline+TAT2A (intact n=9, lesion n=14), saline + SDV (intact n=9, 
lesion n=13), L-DOPA+TAT2A (intact, n=9, lesion n=13), or L-DOPA + SDV (intact n=9, 
lesion n=13) for 3 weeks. In accordance with the protocol described by Gardoni and 
colleagues (2012), TAT2A or the inactive control peptide (SDV), which lacked the relevant 
NR2A interaction domain (Gardoni et al, 2012), were injected i.p. 20 min prior to L-DOPA 
administration at a volume of 1 ml/kg and a concentration of 3 nmol/kg during the first week 
of treatment. The TAT2A and SDV dose was increased to 6 nmol/kg two weeks into 
treatment when it became apparent that there was no effect of the TAT2A peptide on AIM 
scores. L-DOPA was administered s.c. at a concentration of 10 mg/kg, with 15 mg/kg 
benserazide, at a volume of 1 ml/kg throughout the testing period. The dyskinetic effect of     
L-DOPA + TAT2A/SVD was assessed by scoring animals‟ AIMs three times weekly, with 
the first scoring taking place 20 min after L-DOPA administration, i.e. 40 min after 
TAT2A/SDV administration. The TAT2A and SDV were prepared by a second person who 
dispensed the drugs into vials that were numbered but did not contain the name of the drug on 
them, so as to ensure that the thesis author was blinded to the content of the prepared drug 
vials and group allocation during AIMs scoring.  
Following chronic treatment, rats were food restricted for 1 week, and thereafter 
tested on the LCRT task for five days. Although rats were tested off-medication, they 
received daily injections of their respective drugs at the end of the daily testing session to 
ensure consistency with the dosing regimen reported by Gardoni and colleagues (2012). At 
the end of LCRT task testing, rats were euthanized by an overdose of Euthatal, the striatum
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Figure 8.6. A graphical representation of the experimental design of Experiment 10. AIMs=Abnormal involuntary movements, FR=Food 
restriction, LCRT=Lateralised Choice Reaction Time task, MFB=Medial forebrain bundle, PFA=Paraformaldehyde  
 
dissected fresh and immediately placed on dry ice (2.9), and the hindbrain fixed in 4% PFA and used for TH staining of the nigra (2.11). Striatal 
samples were sent to Dr. Fabrizio Gardoni‟s (Department of Pharmacology, Milan University, Italy) lab where the tissue was homogenised and 
Western blots run to detect NR2A and NR2B levels as described in section 2.12. It should be noted that data that were returned from the 
collaborators showed the data from experimental groups expressed as a percentage of the intact group treated with saline and SDV, and that no 
raw data was available. Therefore, data from the intact group treated with saline and SDV was not included in the statistical analysis presented in 
the results section. Furthermore, the collaborators were sent striatal tissue from nine lesion, non-dyskinetic rats that had been co-treated with 
either the TAT2A or SDV peptide, and of which it was discovered after cell counting that not all met the criteria for having a full lesion 
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 (≥90% SNc dopamine loss). However, only data from four of these samples were provided, 
and due to missing lab notes in the collaborator‟s lab it was not possible to determine what 
tissue samples that had been used in the Western blot. Because it could not be determined 
whether the data that was labelled as coming from non-dyskinetic rats (i) came from rats with 
a similar SNc loss as the dyskinetic rats included in the analysis, or (ii) came from four non-
dyskinetic rats that had received the same TAT2A/SDV treatment, and (iii) because of the 
large variability within the non-dyskinetic sample, it was not appropriate to present this data 
as coming from one experimental group. Therefore, this group was omitted from the analysis 
presented in the results section.  
8.2.2.3. Statistical analysis 
Dopamine denervation data were analysed in two separate analyses. First, the raw optical 
density measures from the ipsilateral versus contralateral striatum were compared using a t-
test to confirm that the lesion had reduced TH+ staining in the lesion striata. Second, an 
ANOVA was used to test whether the experimental groups differed in the percentage loss of 
ipsilateral striatal TH+ immunoreactivity induced by the lesion. The ANOVA used included 
Region as a within-subject variable and Group as a between-subject variable. 
Spontaneous rotation data were analysed using a one-way ANOVA. The cylinder test 
data were not normally distributed and therefore analysed using a Kruskal-Wallis test. 
Western blot data was only normally distributed for the NR2B levels. Therefore, NR2B 
levels were analysed using a one-way ANOVA whereas the NR2A levels and the 
NR2A/NR2B ratio were analysed using a Kruskal-Wallis test.  
AIMs scores were analysed using a repeated measures ANOVA with cumulative 
scores from each of the six testing sessions included in the analysis. Two analyses were 
conducted: one analysis using the global AIMs scores as had been done in previous 
experiments presented in this thesis, and a second analysis only including the severity scores 
as presented in the article by Gardoni et al (2012).  
LCRT task performance was measured using a repeated measures ANOVA. 
Significant between-group differences were analysed using a Scheffe post-hoc test and 
significant interactions analysed using tests of simple effects.  
8.2.3. Results 
8.2.3.1. Effect of lesion and drug treatments 
The lesion induced a significant loss of dopaminergic cell bodies in the lesion SN (Figure 
8.2A; t57=21.81, p<0.001) as well as the lesion VTA (Figure 8.2B; t57=15.39, p<0.001). A 
 253 
further analysis demonstrated that the percentage loss of ipsilateral dopaminergic cell bodies 
was greater in the SN than in the VTA (Region: F1,54=12.79, p<0.01) but that the extent of 
dopamine denervation was similar between the experimental groups (Group: F3,54=2.09, n.s.; 
Region x Group: 0.50, n.s.).  
 Reflective of their lesions, all lesion groups showed an ipsilateral bias in their 
performance on the cylinder and spontaneous rotations tests (Figure 8.2C-D). The ipsilateral 
bias exhibited was similar between the four lesion groups (Cylinder test: H=1.86, df=3, n.s.; 
Spontaneous rotations: F3,54=1.62, n.s.) 
 
Figure 8.2. The top panel shows surviving dopaminergic cell bodies in the lesion SNc (A) 
and VTA (B), expressed as a percentage of the intact side, in lesion rats subsequently 
treated with L-DOPA (red bars) or saline (grey bars) together with the TAT2A peptide or 
the inactive SDV vehicle. The bottom panel shows the ipsilateral bias on the cylinder test 
(C) and the net ipsilateral bias on the spontaneous rotations test (D). The bar charts (A, 
B, D) show the mean and the error bars the standard error of the mean. The boxplot (C) 
shows the median and interquartile range, with circles representing outliers. 
SNc=Substantia nigra pars compacta, TH=Tyrosine hydorxylase, VTA=Ventral tegmental 
are 
 254 
Despite differences in the median scores, the groups‟ NR2A and PSD-95 
coimmunoprecipitation levels did not differ significantly from each other (Figure 8.3A; 
H=6.57, df=6, n.s.). NR2B and PSD-95 coimmunoprecipitation levels were higher in lesion 
rats treated with saline + SDV than in lesion rats treated with L-DOPA + SDV (Figure 8.3B; 
F6,21=3.81, p<0.05) suggesting that these levels were decreased by L-DOPA treatment. 
Conversely, there was no difference in the NR2B and PSD-95 coimmunoprecipitation levels 
of lesion rats treated with saline + TAT or L-DOPA + TAT, suggesting that the TAT2A 
peptide prevented the L-DOPA induced increase in NR2B levels. Despite differences in the 
median scores, the NR2A/NR2B ratio did not differ significantly between the groups 
(H=4.65, df=6, n.s.). Visual inspection of the raw NR2A data and NR2A/NR2B ratio scores 
suggested that the lack of a significant effect was due to the large variation in the scores 
coupled with a small sample size (n=4).  
 
Figure 8.3. Western blot data showing NR2A (A), and NR2B  levels (B), as well as the 
NR2A/NR2B ratio (C) in ipsilateral striatal tissue samples from intact (grey bars) and 
lesion (red bars) rats that were chronically treated with either saline or L-DOPA in 
conjunction with the TAT2A peptide or an inactive vehicle (SDV). All data are shown as 
percentage of the intact group treated with saline and SVD. The boxplots (A,C) show the 
median and interquartile ranges, while the barchart (B) shows the mean and the 
standard error of the mean. All n=4. *p<0.05 (versus lesion rats treated with saline + 
SDV) 
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Chronic L-DOPA induced stable AIMs in all lesion groups (Figure 8.4B), with no difference 
observed between rats that were co-treated with the inactive SDV vehicle or the TAT2A 
peptide. The absence of a significant effect of the TAT2A peptide was true both when 
analysing the global AIMs (Figure 8.4A-B; Group: F1,27=0.02, n.s.; Scoring session: 
F5,135=12.39, p<0.001; Scoring session x Group: F5,135=0.55, n.s.) and when only including 
AIMs severity scores (Figure 8.4C-D; Group: F1,27=0.02, n.s.; Scoring session: F5,135=12.64, 
n.s.; Scoring session x Group: F5,135=1.07, n.s.), which is how the AIMs scores were analysed 
in the original paper showing an anti-dyskinetic effect of the TAT2A peptide (Gardoni et al, 
2012).   
 
Figure 8.4. The global (top panel) and severity (bottom  panel) AIMs scores recorded 
during each scoring session (left panel) and at the final scoring session (right panel) in 
lesion rats that were administered a TAT2A peptide (dotted line) or an inactive vehicle 
(full line) together with L-DOPA. The bar and line charts show the mean, and the error 
bars show the standard error of the mean. AIMs=Abnormal involuntary movements.  
 
8.2.3.2. Post-lesion performance on the LCRT task 
The data did not reveal a significant effect of the TAT2A peptide on AIMs scores (8.2.4.1.), 
nor was there an effect of the peptide on any of the LCRT task parameters (Appendix II). 
Because there was no difference between the TAT and SDV treated groups‟ LCRT task 
performance, and because the aim of the experiment was to test the effect of LID onset rather 
than TAT2A treatment on lesion rats‟ LCRT task performance, the TAT2A and SDV groups 
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were pooled. This led to four groups being included in the final analysis: intact + saline; 
intact + L-DOPA; lesion + saline; and lesion + L-DOPA. 
Usable Trials. Lesion rats made fewer overall usable trials than intact rats, with a 
further decrease observed in lesion rats treated with L-DOPA (Figure 8.5A; Group: 
F3,85=3.85, p<0.001). The intact rats showed an increase in the number of usable trials they 
made over the course of testing, whereas a slight decrease was observed in lesion rats treated 
with L-DOPA (Day x Group: F12,340=12.75, p<0.001; Simple Effect: min.F3,82=2.61, p<0.05).  
Reaction Time. An initial analysis including both ipsilateral and contralateral 
performance was conducted. In this analysis, both of the lesion, but neither of the intact, 
groups showed longer reaction times when responding to contralateral than ipsilateral cues 
(Figure 8.5B-C; Side x Group: F3,85=9.97, p<0.01; Simple Effect of Group on Side: 
F3,85=6.10, p<0.001). However, while there was a trend toward an overall group difference 
this did not reach significance (Group: F3,85=2.64, n.s.). Restricting the analysis to the 
contralateral side, where the lesion deficit manifested itself, confirmed that lesion rats showed 
longer contralateral reaction times than controls but did not reveal a significant difference 
between lesion rats treated with saline or L-DOPA (Figure 8.5C; Group: F3,85=6.10, p<0.01). 
The lesion deficit manifested itself gradually, causing the lesion rats to only differ 
significantly from intact controls on days 3 to 5 of testing (Day: F4,340=18.57, p<0.001; Day x 
Group: F12,340=4.15, p<0.001; Simple Effect: min.F3,85=2.74, p<0.05)    
Movement Time. Both of the lesion, but neither of the intact, groups showed longer 
movement times when responding to contralateral than ipsilateral cues (Figure 8.5D-E; Side 
x Group: F3,85=2.88, p<0.05; Simple Effect of Side: F1,85=8.87, p<0.01). The difference in 
ipsilateral and contralateral movement times manifested itself gradually (Side x Day: 
F4,340=2.51, p<0.05; Simple Effect of Day: F4,82=5.76, p<0.001). In addition to the lesion 
deficit there was a further effect of L-DOPA treatment, with lesion rats treated with L-DOPA 
exhibiting longer movement time than lesion rats treated with saline (Group: F3,85=29.96, 
p<0.001).   
Accuracy. Lesion rats were less accurate than intact controls when responding to 
cues presented on their contralateral, but not ipsilateral, side (Figure 8.5G-H; Side x Group: 
F3,85=49.34, p<0.001; Simple Effect of ). The deficit manifested itself gradually, with lesion  
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Figure 8.5. The post-lesion percentage of usable trials (A), together with the ipsilateral 
and contralateral reaction time (B-C), movement time (D-E), and accuracy (F-G) of intact 
(n=36), lesion saline treated (n=27), and lesion L-DOPA treated (n=26) rats tested on 
the lateralised choice reaction time task. The line chart shows the mean response on 
each testing day and the error bars show the standard error of the mean.  
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but not intact, rats showing a gradual decline in their contralateral accuracy (Side x Day x 
Group: F12,340=6.51, p<0.001; Simple Effect of Day: min.F4,82=24.93, p<0.001). As described 
previously in this thesis, lesion rats that had received chronic L-DOPA treatment were less 
accurate than lesion rats treated with saline (Group: F3,85=64.56, p<0.001). 
8.2.4. Discussion 
The experiment used a novel anti-dyskinetic compound (TAT2A; Gardoni et al, 2012) to 
produce a lesion L-DOPA treated group that did not develop LID, with the aim of 
dissociating between the effects of chronic L-DOPA versus LID onset on LCRT task 
performance. Unlike the previous publication by Gardoni and colleagues (2012), the current 
data did not demonstrate an anti-dyskinetic effect of the TAT2A peptide. It did, however, 
demonstrate a decrease in striatal NR2B levels in lesion, dyskinetic rats relative to lesion, 
saline treated rats. This is in line with what has previously been reported (Gardoni et al, 
2006) and suggest that the peptide may have exerted a molecular effect in the current 
experiment. Unfortunately, to fully conclude whether or not the molecular changes observed 
in the dyskinetic rats aligned with previously published data it would have been necessary to 
compare this data with data from a lesion, L-DOPA treated non-dyskinetic cohort. Tissue 
sample from nine non-dyskinetic rats, two of which were not included in the behavioural 
analysis of the LCRT task data as their SNc denervation was less than the pre-determined 
90% cut off (88.7% and 74.4% SNc loss respectively), were sent to the collaborators who 
conducted the Western blot analysis. These non-dyskinetic rats had been treated with either 
L-DOPA + SDV or L-DOPA + TAT. However, the Western blot data received from the 
collaborator only included a subsample of these non-dyskinetic group (n=4) and, due to 
missing lab notes in the collaborator‟s lab, it was not possible to determine what individual 
tissue samples that Western Blot data returned from the collaborators corresponded to. 
Because of the lack of knowledge of the lesion extent and previous drug treatment of the non-
dyskinetic rats from which the Western blot data was obtained, and the considerable variation 
in the same Western blot data, it was not appropriate to pool these data and treat it as one 
homogenous non-dyskinetic group. Hence, a thorough analysis of the effect of LID and the 
TAT2A peptide on NR2A levels could not be achieved. Therefore, the presented data was not 
robust enough to either support or challenge the validity of the previously reported link 
between striatal postsynaptic NR2A levels and LID (Gardoni et al, 2012). The reason for the 
large variation in the Western blot data is difficult to determine as the tissue was 
homogenised, the Western blot run, and the optical density of the bands measured by 
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researchers in Dr. Fabrizio Gardoni‟s lab. It is possible that the variance in the data reflect 
natural variation between individual rats, and that a greater sample size would be required to 
test the hypothesis that NR2A levels are linked to LID.  
While the Western blot data were not sufficiently robust to determine whether or not 
there was a molecular effect of the TAT2A peptide, it was evident from the AIMs scores 
recorded by a scorer who was blinded to the rats‟ treatment that the peptide did not produce 
an anti-dyskinetic effect in the current experiment. A key difference between the experiments 
reported in this thesis project and the data previously published by Gardoni et al (2012) is the 
proportion of lesion rats that remained non-dyskinetic following chronic L-DOPA treatment. 
While Gardoni and colleagues (2012) reported that 40% of their lesion, L-DOPA treated rats 
that did not receive an anti-dyskinetic drug remained non-dyskinetic, only 10% of rats with 
complete MFB lesions in the current experiment remained non-dyskinetic. The latter 
percentage of non-dyskinetic rats is similar to other in-house dyskinesia studies. The 
difference in rats‟ LID susceptibility may relate to genetic differences, as the rats in this 
thesis project and Gardoni and colleagues (2012) experiment were obtained from different 
breeding centres, or one or several of the methodological differences between the 
experiments discussed below.  
One difference was the gender of the rats included in the studies; Gardoni et al (2012) 
used male rats, while the current experiment employed female rats. This decision was made 
to ensure consistency with previous experiments using the LCRT task (Chapter 7; Carli et al, 
1985; Dowd & Dunnett, 2004, 2005a,b). However, it should also be noted that while Gardoni 
and colleagues used male rats, the dyskinesia scoring protocol employed in this, as well as in 
Gardoni et al‟s (2012), experiment was developed using female rats (Winkler et al, 2002).  
A second difference between the studies is the rat strain used; whereas Gardoni et al 
(2012) used Wistar rats, the current experiment used Lister Hooded rats. Lister Hooded rats 
were preferred as their superior vision relative to albino strains (Prusky et al, 2002) made 
them more suitable for testing on the LCRT task which requires rats to respond to visual 
cues. While Experiment 1 showed similar development of LID in an albino strain and Lister 
Hooded rats, it is not known whether rat strains differ in their response to the TAT2A 
peptide. Previously published data have reported strain differences in the binding to striatal 
NMDA receptors (Martin et al, 2003). Therefore, the possibility that Lister Hooded and 
Sprague Dawley rats differ in their NR2A subunits levels, which the TAT2A peptide targeted 
(Gardoni et al, 2012), and that this could have affected their response to the peptide treatment 
cannot be excluded. To test whether there are strain differences in NR2 subunits, it would be 
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necessary to compare baseline NR2A and NR2B levels in striatal tissue from Lister Hooded 
and Sprague Dawley rats, something which was beyond the scope of this experiment. 
However, if rat strain differences did account for the different findings, it could be queried 
whether the anti-dyskinetic properties of the TAT2A peptide are sufficiently robust to 
translate to the clinic.  
A third difference between this and Gardoni et al‟s (2012) experiment is the long 
period of operant training prior to lesion and drug treatment the rats in the current experiment 
underwent. It was suggested by the author of the original TAT2A paper (Gardoni, verbal 
communication) that motor training may have affected baseline NR2A/B levels which could 
in turn have affected the later impact of the peptide. The view is partly supported by data 
showing that e.g. visual stimulation increases NR2A levels in the rat visual cortex (Quinlan et 
al, 1999), suggesting that environmental exposure may affect the expression of the NR2 
subunits.  
It is also worthwhile to note that the operant training/testing necessitated animals to 
be food restricted. Previously published data have suggested that in utero food restriction 
enhances later hippocampal LTD induction in intact Sprague Dawley rats (Titterness & 
Christie, 2008). Similarly, food restricting adult Sprague Dawley rats has been found to 
enhance LTD in the motor cortex (Cohen & Castro-Alamancos, 2005). An effect of food 
restriction on synaptic plasticity, which has previously been linked to LID (Picconi et al, 
2003) may therefore have impacted on LID development.   
There was also a difference in the dose of benserazide used. Benserazide inhibits 
DOPA decarboxylase, which converts L-DOPA to dopamine, and is co-administered with    
L-DOPA to prevent the latter from being decarboxylated in the periphery. By reducing the 
amount of L–DOPA that is decarboxylated in the periphery, benserazide reduces adverse side 
effects such as nausea and vomiting, but also crucially increases the amount of L-DOPA that 
enters the brain (Da Prada et al, 1984). Whilst Gardoni et al (2012) co-administered rats 6 
mg/kg benserazide, all experiments in this thesis project used a benserazide dose of 15 
mg/kg. Hence, the higher benserazide dose used here may have increased the amount of      
L-DOPA entering the brain. Higher L-DOPA doses induce greater AIMs than lower drug 
doses (Lindgren et al, 2007) and the risk of LID onset may be reduced if lowering the 
administered L-DOPA dose (Putterman et al, 2007). Thus, it could be hypothesised that the 
higher benserazide dose may have increased the risk of LID development in this, relative to 
Gardoni and colleagues‟ (2012), experiment. 
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Despite differences in experimental designs, it is worth noting that the current 
experiment held several advantages over the original publication. First, there was an overall 
higher success rate in MFB lesions (45% in Gardoni et al, 2012, compared to 85% in the 
current experiment). Whilst both the current experiment and that reported by Gardoni et al 
(2012) ultimately only included lesion rats with near complete dopamine denervation, the 
difference in success rates may suggest more consistent lesions in the current experiment. 
Furthermore, whilst Gardoni et al (2012) used apomorphine induced rotations to assess lesion 
success the current study used non-pharmacological behavioural tests, thereby avoiding the 
potentially confounding effect of exposing rats to dopaminergic drugs prior to L-DOPA and 
TAT2A treatment. During AIMs scoring, Gardoni et al (2012) only measured the severity of 
dyskinetic movements whilst the current experiment also included the duration of AIMs 
thereby making the overall AIMs score more sensitive. Unlike what was reported in Gardoni 
and colleagues‟ publication (2012), the design in this experiment also ensured that the 
experimenter was blinded to the rats‟ treatment during AIMs scoring, thereby minimising 
experimenter bias. 
It is worth noting that while the reasons for the diverging results are unclear, the 
primary aim of the current experiment was not to test the efficacy of the TAT2A peptide per 
se but to use it as a tool to create the non-dyskinetic lesion L-DOPA treated group needed to 
test the hypothesis that the previously observed exacerbation of the LCRT deficit observed in 
lesion rats treated with L-DOPA was related to LID onset. While the lack of an anti-
dyskinetic effect of the TAT2A peptide prevented testing of the hypothesis the experiment 
replicated the L-DOPA induced LCRT deficit in lesion rats, thus demonstrating the 
robustness of the effect. It also extended our understanding of the phenomenon by 
demonstrating that the L-DOPA induced deficit was present following overnight, as opposed 
to long-term, L-DOPA withdrawal. The latter was valuable in demonstrating that the            
L-DOPA effect was present in a situation more closely resembling the clinically defined 
“off” phase (12 h post last L-DOPA dose; e.g. Cools et al, 2010). Finally, while the TAT2A 
peptide was not shown to hold anti-dyskinetic properties in the current setting, the high 
number of lesion L-DOPA rats included in the experiment provided a small sample of non-
dyskinetic rats that could be used in the analysis described in Experiment 11. 
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8.3. Experiment 11: Analysis of Pooled Behavioural Data from Dyskinetic 
and Non-Dyskinetic Rats 
8.3.1. Introduction 
To test the hypothesis that the LCRT deficit was linked to LID onset, rather than chronic     
L-DOPA, the current analysis pooled behavioural data from dyskinetic and non-dyskinetic 
rats that had been used in Experiments 9 and 10. By pooling the data, it was possible to 
generate a lesion L-DOPA treated non-dyskinetic group with a sufficiently large n to conduct 
statistical analysis on. As previous experiments had found a selective effect of L-DOPA 
treatment on contralateral movement time and accuracy, the analysis was restricted to these 
parameters. 
Considering the large difference in the magnitude of AIMs observed in the dyskinetic 
and non-dyskinetic cohort, a demonstrated difference between the two groups‟ LCRT task 
performance could be hypothesised to be linked to differences in AIMs magnitude rather than 
LID onset. Therefore, a second analysis was conducted in which lesion L-DOPA treated rats‟ 
AIMs scores were divided into four quartiles, and the movement times and accuracy of these 
four lesion L-DOPA treated groups were compared.  
8.3.1.2. Aims 
The primary aim was to test the hypothesis that there was a dissociation between dyskinetic 
and non-dyskinetic rats‟ performance on the LCRT task. To exclude the possibility that a 
difference in the two cohorts‟ LCRT task performance was linked to difference in AIMs 
magnitude rather than LID onset, the current section also tested whether AIMs magnitude 
affected rats‟ performance.  
8.3.2. Methods 
Pooling of the data from Experiments 9 and 10 resulted in the following groups: intact 
controls (n=56), lesion + saline (n=42), lesion + L-DOPA with dyskinesia (n=42), and lesion 
+ L-DOPA without dyskinesia (n=9). A rat was defined as dyskinetic if she exhibited severity 
AIMs >1 on the orolingual, axial, or forelimb AIMs subtypes at any one scoring point. This 
classification is in line with criteria used in previous rat dyskinesia studies (Lindgren et al, 
2010) and has been shown to distinguish between rats with high and low striatal levels of 
dyskinesia markers such as phosphorylated ERK1/2 (Westin et al, 2007), FosB, and PDyn 
mRNA (Andersson et al, 1999). In addition, following acute L-DOPA administration, rats 
classified as non-dyskinetic using this cut-off have been shown to have lower levels of 
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extracellular DOPA in the SNc and striatum than dyskinetic controls (Lindgren et al, 2010), 
and, unlike dyskinetic rats, do not show an angiogenic response to L-DOPA treatment 
(Westin et al, 2006).  
 A second analysis was conducted to test whether LCRT task performance was 
affected by the magnitude of AIMs, as opposed to the onset of LID. In the absence of 
published criteria for how to reliably divide dyskinetic rats into separate subgroups based on 
AIMs magnitude, and without obvious groupings of the rats‟ AIMs scores, a mathematical 
approach was taken where rats were divided into four quartiles based on their AIMs scores.  
8.3.2.1. Statistical analysis 
Dopamine denervation was analysed using two separate analyses. First, to confirm the 
presence of a lesion, a t-test was used to to compare the raw number of cell bodies that were 
present in the lesion and intact SN or VTA. Second, the percentage of dopaminergic cell 
bodies in the lesion SN and VTA (relative to the intact side) were analysed in an ANOVA 
with Region as within-subject variable and Group as a between-factor variable. Spontaneous 
rotations were analysed using a one-way ANOVA. Ipsilateral bias on the cylinder test was 
analysed using a  Kruskal-Wallis test. LCRT task performance was analysed using a repeated 
measures ANOVA with Day and Side as within-subject variables and Group as within-
subject variables. Significant between-subject differences were analysed using a Scheffe 
post-hoc test and significant interactions analysed using a test of simple effects. 
8.3.3. Results 
8.3.3.1. Dyskinetic versus non-dyskinetic rats 
Lesion effects. The lesion induced a significant loss of dopaminergic cell bodies in the 
ipsilateral SNc (Figure 8.4A; t92=-29.74, p<0.001) and VTA (t92=-33.83, p<0.001). A further 
analysis was conducted to compare the percentage SNc and VTA denervation induced in the 
lesion groups. This analysis confirmed that there was a greater loss of dopaminergic cell 
bodies in the SNc than in the VTA (Region: F1,90=28.62, p<0.001) but that the extent of the 
dopamine loss was similar across the lesion groups (Group: F2,90=0.13, n.s.; Region x Group: 
F2,90=0.26, n.s.). 
The success of the lesions was also reflected in an ipsilateral bias in rats‟ spontaneous 
rotations. Interestingly, the spontaneous rotational bias was less pronounced in the L-DOPA 
treated non-dyskinetic group than in the other lesion groups (Figure 8.4B; F2,91=10.23, 
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p<0.01). In addition, all lesion rats showed a pronounced ipsilateral bias in the cylinder test 
which was equal for all groups (Figure 8.4C; H=2.56, df=2, n.s.). 
 
Figure 8.6. Surviving dopaminergic cell bodies in the lesion SNc and VTA, expressed as a 
percentage of the intact side (A), together with the net ipsilateral bias of rats‟ 
spontaneous rotations (B), and the ipsilateral bias on the cylinder test (C) of lesion rats 
treated with saline (n=42) as well as lesion, L-DOPA treated rats classified as dyskinetic 
or non-dyskinetic (n=42 and 9). The bar charts (A,B) show the mean, and the error bars 
the standard error of the mean. The boxplot (C) shows the median and interquartile 
ranges. SNc=Substantia nigra pars compacta; TH=Tyrosine hyrdoxylase, VTA=Ventral 
tegmental area. *p<0.05, **p<0.01 
 
LCRT task movement time. An initial analysis including both ipsilateral and contralateral 
performance was conducted. The intact groups required a similar amount of time when 
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responding to cues presented on the ipsilateral and contralateral side to the lesion. 
Conversely, all lesion groups took significantly longer to respond to contralateral cues 
(Figure 8.7A-B; Side x Group: F3,144=8.52, p<0.001; Simple Effect: min.F1,144=10.64, 
p<0.01). While intact rats‟ movement times were shorter than those of lesion rats, there was 
no overall difference between lesion rats that did or did not develop LID following L-DOPA 
treatment (Group F3,144=56.16, p<0.001).  
Because the lesion deficit manifested itself on the contralateral side, a further analysis 
restricted to contralateral performance was conducted. This analysis demonstrated that lesion 
dyskinetic rats were significantly slower than the other lesion groups, which did not differ 
significantly from each other (Group: F3,145=41.48, p<0.001). There was a gradual increase in 
the time taken to execute contralateral responses in all lesion rats, apart from the L-DOPA 
treated non-dyskinetic cohort (Figure 8.7B; Day: F4,580=4.83, p<0.01; Day x Group: 
F12,580=5.15, p<0.001; Simple Effects: min.F4,142=9.27, p<0.001).  
 
Figure 8.7. The ipsilateral and contralateral movement time (A-B) and accuracy (C-D) of 
intact (n=56), lesion saline treated (n=42), lesion, L-DOPA treated dyskinetic (n=42), 
and lesion, L-DOPA treated non-dyskinetic rats (n=9) tested on the LCRT task. The line 
chart shows the mean response on each testing day, and the error bars show the 
standard error of the mean. LCRT=Lateralised choice reaction time task. 
 
LCRT task accuracy. Intact rats‟ accuracy levels were similar when responding to ipsilateral 
and contralateral cues. Conversely, lesion rats were less accurate when responding to cues 
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presented contralateral than ipsilateral to the lesion (Figure 8.7C-D; Group x Side: 
F3,144=103.47, p<0.001; Side x Group x Day: F12,576=10.37, p<0.001; Simple Effect of Side: 
min.F1,144=9.63, p<0.01).Chronic L-DOPA treatment further impaired the lesion induced 
deficit in rats that developed LID in response to L-DOPA. Notably, the dyskinetic cohort 
showed a greater decrease in their contralateral accuracy than lesion L-DOPA treated rats that 
remained non-dyskinetic (Group: F3.144=104.20, p<0.001). 
8.3.4.2. Comparison of rats with different levels of AIMs  
To test whether AIMs magnitude, rather than LID onset, impaired LCRT task performance, 
lesion L-DOPA treated rats were divided into four groups depending on what quartile their 
AIMs scores fell into. This created four lesion L-DOPA treated groups; 13 rats with AIMs 
<1
st
 quartile (median: 1, range: 0-2.5); 13 rats with AIMs between the 1
st
 and 2
nd
 quartile 
(median: 8.5, range: 3-52.5), 13 rats with AIMs between the 2
nd
 and 3
rd
 quartile (median: 
85.5, range: 58-105), and 12 rats with AIMs >3
rd
 quartile (median: 131.5, range 111 to 
154.5). It should be noted that 9 out of the 13 rats in the AIMs <1
st
 quartile group were 
classified as non-dyskinetic in the analysis described in the previous section (8.3.4.1). 
Lesion effects. As previously stated, the lesion induced a significant loss of 
dopaminergic cell bodies in the ipsilateral SNc (Figure 8.8A; t92=-29.74, p<0.001) and VTA 
(t92=-33.83, p<0.001). An further analysis comparing the percentage dopamine loss observed 
in the groups‟ ipsilateral SNc and VTA confirmed that the lesion groups did not differ in the 
extent of their dopamine loss (Group: F4,88=0.54, n.s.) which, for both groups, was more 
pronounced in the SNc than in the VTA (Region: F1,88=33.07; Region x Group: F4,88=0.52, 
n.s.). All groups showed a strong ipsilateral bias on the spontaneous rotation and cylinder 
tests. Lesion L-DOPA rats whose AIMs scores were >3
rd
 quartile showed a significantly 
greater bias in their spontaneous rotations than lesion L-DOPA treated rats whose AIMs were 
below <1
st
 quartile. None of the other groups‟ spontaneous rotations differed from each other 
(Figure 8.8B; Group: F4,88=3.06, p<0.05). There was no difference in the ipsilateral bias the 
lesion groups exhibited on the cylinder test (Figure 8.8C; H=8.26, df=4, n.s.). 
LCRT task movement time. An initial analysis including both ipsilateral and 
contralateral performance was conducted. Intact rats took were faster than lesion rats at 
executing responses to visual cues. However, there was no overall difference between the 
movement time of the four lesion groups (Figure 8.9A; Group: F5,143=12.13, p<0.001). 
Because movement times were significantly longer when responding to cues presented on the  
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Figure 8.8. Surviving dopaminergic cell bodies in the lesion SNc and VTA, expressed as a 
percentage of the intact side (A), together with the net ipsilateral bias of spontaneous 
rotations (B), and ipsilateral bias on the cylinder test (C) of lesion rats treated with saline 
(n=42) as well as lesion L-DOPA treated rats whose AIMs were below the 1st quartile 
(n=13), between the 1st and 2nd quartile (n=13), between the 2nd and 3rd quartile (n=13), 
and above the 3rd quartile mark (n=12). The bar charts (A, B) show the mean and the 
error bars the standard error of the mean. The box plot (C) shows the median and 
interquartile ranges with circles representing outliers. AIMs=Abnormal involuntary 
movements, SNc=Substantia nigra pars compacta, TH=Tyrosine hydroxylase, 
VTA=Ventral tegmental area. *p<0.05 (versus AIMs <1st quartile group), **p<0.01  
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Figure 8.9. The ipsilateral and contralateral movement time (A-B) and accuracy (C-D) of 
intact (n=56), 6-OHDA + saline treated (n=42) and lesion L-DOPA treated rats whose 
AIMs were <1st quartile (n=13), between the 1st and 2nd quartile (n=13), between the 2nd 
and 3rd quartile (n=13), and above the 3rd quartile (n=12). The line charts show the mean 
response at each testing days, and the error bars show the standard error of the mean. 
AIMs=Abnormal involuntary movements. 
 
contralateral side (Side: F1,143=17.40, p<0.001), a second analysis restricted to contralateral 
movement time was conducted.  
While intact rats movement times was stable over the five days of testing  there was a 
gradual increase in the contralateral movement time of all lesion groups (Figure 8.9B; Day x  
Group: F20,572=2.55, p<0.001; Simple Effect: min.F4,140=2.59, p<0.01). The intact rats were, 
overall, faster at responding to contralateral cues than lesion rats, but there was no difference 
between the four lesion, L-DOPA treated groups (Group: F5,143=9.71, p<0.001). 
LCRT task accuracy. An initial analysis including both ipsilateral and contralateral 
accuracy was conducted. In this analysis, all lesion groups were less accurate than intact 
controls but did not differ from each other (Figure 8.9C-D; Group: F5,143=40.49, p<0.001). 
The lesion induced deficit specifically manifested itself on when rats were required to 
respond to contralateral cues (Side x Group: F5,143=42.54, p<0.001; Simple Effect: 
min.F1,143=74.02, p<0.001). 
A second analysis, that was restricted to the contralateral side, was therefore 
conducted. When responding to cues presented on the contralateral side, the lesion groups‟ 
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performance decreased over the five-testing days whereas the intact rats‟ accuracy remained 
stable (Figure 8.9D; Day x Group: F20,572=8.68, p<0.001; Simple Effect: min.F4,140=5.32, 
p<0.05). The lesion saline treated group had greater contralateral accuracy than all lesion     
L-DOPA treated groups apart from the groups whose AIMs fell below the first quartile and 
predominantly consisted of non-dyskinetic rats (Group: F5,143=123.81, p<0.001).  
8.3.4. Discussion 
The aim of the analysis was to determine whether there was a dissociation between the LCRT 
task performance of lesion L-DOPA rats that did, or did not, develop LID. The data 
confirmed that these groups did differ significantly from each other. When comparing 
dyskinetic and non-dyskinetic rats, a further decrease in contralateral accuracy only occurred 
in lesion rats that developed LID following L-DOPA treatment. Importantly, when 
comparing lesion L-DOPA treated rat with different levels of AIMs magnitude, only the 
performance of lesion L-DOPA treated group whose AIMs were <1
st
 quartile, and 
predominantly consisted of non-dyskinetic rats, aligned with the lesion saline treated rats‟ 
LCRT task performance. All other L-DOPA treated groups showed an exacerbation of the 
lesion induced contralateteral accuracy deficit. This suggests that the L-DOPA deficit only 
manifested itself in rats that developed LID, and that once rats had developed LID the 
magnitude of their AIMs did not further impact on LCRT task performance. 
All lesion groups showed an equal dopamine denervation, and the dissociation 
between dyskinetic and non-dyskinetic rats‟ LCRT task performance could therefore not be 
explained in terms of lesion extent. It is, however, worthwhile to mention that higher AIMs 
scores were associated with a greater ipsilateral bias in rats‟ spontaneous rotations (Figure 
8.8). This is in line with previous findings of a significant correlation between spontaneous 
rotations and AIMs (discussed in Experiment 2) but is unlikely to have impacted on the 
accuracy of LCRT task responding as previous publications have demonstrated that the 
accuracy deficit in the LCRT task is not driven by a motor impairment (Dowd & Dunnett, 
2005a,b).  
8.4. Chapter discussion & conclusions 
The purpose of this chapter was to test whether the previously observed effect of chronic     
L-DOPA on LCRT task performance (Chapter 7) was due to chronic L-DOPA exposure or 
the onset of LID. The pooling of data from two LCRT task experiments demonstrated that an 
exacerbation of the lesion induced accuracy decline only occurred in lesion L-DOPA rats that 
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developed LID, whereas their non-dyskinetic counterparts did not differ from saline treated 
controls. Thus, the data suggest that the impairment was linked to molecular or cellular 
changes associated with LID onset.  
The LCRT task accuracy deficit has previously been suggested to reflect extinction 
(Dowd & Dunnett, 2004, 2007). Based on data showing that a role of hippocampal LTP 
induction in fear extinction (Farinelli et al, 2006) it was hypothesised that the restored ability 
for cortico-striatal LTP that is observed following chronic L-DOPA treatment to lesion rats 
enhanced extinction learning - and that this was the cause of the exacerbation of the 
contralateral accuracy deficit observed in Chapter 7. In addition to restored cortico-striatal 
LTP, chronic L-DOPA also abolishes the ability for depotentiation in rats that develop LID in 
response to the L-DOPA treatment, but not in rats that remain non-dyskinetic (Picconi et al, 
2003). The induction of depotentiation has previously been demonstrated to disrupt extinction 
learning (Farinelli et al, 2006). One may thus hypothesise that the non-dyskinetic rats, in 
which the ability for cortico-striatal depotentiation is retained (Picconi et al, 2003), would 
show less marked extinction than their dyskinetic counterparts. The current data supported 
this hypothesis by showing a greater decrease in the contralateral accuracy of the dyskinetic 
than the non-dyskinetic lesion cohort. However, it is acknowledged that, while the findings 
presented in this chapter support the hypothesis, it was beyond the scope of the presented 
experiments to fully determine the nature of the LCRT task deficit or directly test the 
mechanism underlying the phenomenon. Thus, while the depotentiation/extinction hypothesis 
may explain the difference in dyskinetic and non-dyskinetic rats‟ LCRT task accuracy it 
requires further testing.  
To test the validity of the hypothesis, and to increase understanding of the nature of 
the observed LCRT task deficit, future experiments should directly test effect of LID onset on 
lesion rats‟ extinction rates. This could, for example, be conducted in an extinction study in 
which four groups of rats (intact; lesion, drug naive; lesion, L-DOPA treated and dyskinetic; 
lesion, L-DOPA treated and non-dyskinetic) first undergo an acquisition period during which 
they learn to that perform nose pokes in an operant chamber when a light cue is present in 
exchange for the delivery of a sucrose pellet. Once the CS-US association has been acquired, 
a subset of the each group should undergo an extinction period during which the light cue is 
no longer predictive of a sucrose reward. Thereafter, the success of the extinction learning 
should be tested during a retention trial, during which all rats are re-tested on the task in the 
same environment as they first learned the CS-US association. Successful extinction learning 
should cause the subgroup of rats that have undergone extinction training to make fewer lever 
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presses during the retention trial than control rats. Furthermore, if LID onset increases 
extinction learning as previously hypothesised, it is predicted that lesion dyskinetic rats that 
have undergone extinction testing (i) show a faster rate of extinction, and (ii) make fewer 
responses during the retention trial than lesion L-DOPA treated, non-dyskinetic rats that have 
also undergone extinction testing. Assuming such an effect was to occur, further tests should 
be conducted to determine whether the behaviour meet the criteria for extinction. This 
includes demonstrating (i) that extinguished rats show spontaneous recovery, i.e. exhibit the 
CR when retested in the same environment after a test-free period, (ii) that extinguished rats 
show renewal, i.e. exhibit the CR if the retention test takes place in a different environment 
than the extinction test (e.g. by changing the appearance of the operant chamber by putting 
striped wallpaper on its walls), and (iii) that extinguished rats show reinstatement, i.e. exhibit 
the CR during a retention trial if they are exposed to the US between the extinction and 
retention trials.   
The main finding of the data presented in this chapter was that LID onset is associated 
with the development of non-motor symptoms in the rat 6-OHDA model of PD. Current 
literature predominantly considers LID to be a motor complication that manifest itself when 
patients are on dopaminergic medication (e.g. Jenner, 2008). However, preclinical and 
clinical data demonstrating that LID onset is also associated with sensitisation of striatal 
dopamine receptors (Konradi et al, 2004; Aubert et al, 2005) and disrupted synaptic plasticity 
(e.g. Picconi et al, 2003, Huang et al, 2011) suggest that LID onset may also affect non-
motor behaviour mediated by the striatal circuitry, and that these effects may be independent 
of the acute effects of L-DOPA. The data presented in this chapter and the previous chapter 
builds on these earlier studies by demonstrating that LID onset does affect non-motor 
behaviour in a rat PD model. Hence, the data challenge the view of LID as a pure motor 
complication and suggest that long-term L-DOPA treatment affects a wider range of 
behaviours than previously recognised. Furthermore, the data show that unlike dyskinetic 
movements, the effect of LID onset on non-motor behaviour is present even when lesion rats 
are off medication. While acute L-DOPA is already known to both improve motor function 
(Birkmayer & Hornykiewicz, 1961) and impacting on non-motor function such as visual 
attention (Schneider et al, 2013; Keri et al, 2013) and learning (e.g. Cools et al, 2006), the 
current data shows that chronic L-DOPA also affect both motor and non-motor functions. 
The clinical implications of these findings and suggestions for future research to be 
conducted in this field are further discussed in Chapter 9.   
 272 
9. General discussion 
L-DOPA is the gold standard treatment for PD but long-term use is associated with the 
development of adverse motor side effects. While acute L-DOPA is known to affect both 
motor and non-motor function, little is known about the effects of long-term L-DOPA on 
non-motor behaviour. The aim of this thesis was to explore the effects of long-term L-DOPA 
treatment on motor and non-motor function to determine whether, like acute L-DOPA, 
chronic treatment has dissociable effects on motor and non-motor behaviour. 
 To inform the design of subsequent experiments, the experiments presented in 
Chapters 3 to 4 aimed to (i) identify non-pharmacological lesion screening tests that would 
not risk sensitising the dopaminergic system, and thereby potentially confounding later data 
on the interaction between L-DOPA and behaviour, and (ii) determine acute L-DOPA doses 
that could be administered to lesion, food restricted rats with a history of chronic L-DOPA 
treatment prior to testing in operant chambers without the presence of interfering dyskinesias. 
Together, these experiments provided data to guide methodological decisions in later 
experiments. 
A subsequent series of experiments tested the hypotheses that chronic L-DOPA 
affects (i) the acquisition of novel motor skills using the staircase task (Chapter 6), and (ii) 
non-motor functions measured in the LCRT task (Chapters 7 and 8). After identifying an 
effect of chronic L-DOPA on LCRT task performance, the effects of chronic versus acute 
administration of L-DOPA and a D2 agonist were compared. Having established that the 
effect on non-motor function was only observed in lesion rats treated with L-DOPA, the 
effect of LID onset on non-motor function was explored using an anti-dyskinetic compound 
and by pooling data from earlier experiments. Together, these data demonstrated (i) that 
chronic treatment with L-DOPA but not with a D2 agonist affects non-motor function, and 
(ii) that the observed effects of chronic L-DOPA on non-motor function only occurs in lesion 
rats that develop LID as a result of the treatment. 
9.1. Nutritional issues in PD 
Diet is known to affect the pharmacokinetics of L-DOPA, with dietary neutral amino acids 
competing with L-DOPA for transport across both the wall of the small intestine and the 
BBB (reviewed in del Amo et al, 2008). Some patients suffering from L-DOPA induced 
motor complications are therefore recommended special diets to reduce these motor 
complications. While early stage PD patients have been encouraged to continue consuming 
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normal protein intake (15% of the total energy), a 5% reduction in protein consumption has 
been recommended for late stage PD patients suffering from L-DOPA induced motor 
complications. In addition, late stage patients have been recommended to redistribute their 
protein intake to consume less protein during breakfast and lunch and more protein during 
dinner, as well as taking their medication approximately 30 min prior to meals (Barichella et 
al, 2009; Cereda et al, 2010).  
Based on literature showing that LAT mediated transport of L-DOPA is affected by 
the levels of dietary amino acids competing for transport (Kageyama et al, 2000), it was 
therefore hypothesised that lesion food restricted rats would show a greater motor response to 
acute L-DOPA than ad libitum controls (Chapter 4). The data showed increased motor 
response to acute L-DOPA in food restricted rats with intra-striatal, but not MFB, lesions. To 
determine the mechanism underlying this phenomenon, a microdialysis study was conducted 
(Experiment 5). Contrary to what had been hypothesised, the microdialysis data did not 
demonstrate increased influx of L-DOPA in food restricted rats. However, the data did 
suggest that food restriction affected the serotonergic system. In particular, there were 
increased 5HIAA levels in the lesion striata of 6-OHDA MFB lesion rats relative to their ad 
libitum controls. This suggested an increased serotonergic activity following food restriction 
in a rat model of late stage PD. The data were in line with earlier reports of an increased 
serotonin turnover in intact male rats following food restriction (Schweiger et al, 1989) and 
therefore expanded on current knowledge by demonstrating a similar effect in the ipsilateral 
striata of rats with near complete dopamine loss.  
Interestingly, a systematic review has reported that while protein redistribution diets 
improve PD patients‟ motor function and decrease off-time, some patients on these diets 
require a decrease in their L-DOPA dose due to a worsening of their dyskinesias (Cereda et 
al, 2010). Preclinical data have linked dyskinesias to the uptake, and subsequent uncontrolled 
release, of L-DOPA by serotonergic neurons (Carta et al, 2006; Carlsson et al, 2007). A role 
of serotonin in LID has also been demonstrated by the anti-dyskinetic effects of 5HT1A/B 
antagonists (Bézdard et al, 2013), and the ability of 5HT1 agonists to reduce the magnitude 
of AIMs as well as the development of LID in rodent and primate models of PD (Lundblad et 
al, 2005; Eskow et al, 2007; Muñoz et al, 2008) and to reduce AIMs in patients (Bonifati et 
al, 1994). Against this background, it could be queried whether food restriction could 
indirectly affect AIMs magnitude via increases in serotonergic activity. Future studies may 
wish to explore this by replicating the finding of increased 5HIAA levels presented in 
Chapter 5, while extending on the data by also measuring serotonin levels and doing 
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systematic AIMs scoring of food restricted and ad libitum rats following acute L-DOPA 
injection. 
In addition to AIMs, serotonin affects a range of other motor and non-motor 
behaviours. For example, co-administering a 5HT2 agonist with a D1 agonist enhances 
dopamine agonist-induced locomotion in 6-OHDA lesion rats (Bishop & Walker, 2003). This 
effect is likely linked to the stimulation of 5HT2C receptors, as intra-striatal antagonism of 
5HT2C receptors decreases baseline levels of striatal dopamine (Lucas et al, 2000). Serotonin 
also affects non-motor behaviour, as demonstrated by e.g. data showing impaired inhibition 
of incorrect responding on a visual discrimination following striatal and extrastriatal 
serotonin loss (Harrison et al, 1999). Hence, while food restriction is often required in 
operant paradigms, the data in Chapter 5 suggest it may impact on performance in tasks that 
are reliant on the serotonergic system and highlights the importance of consistent food 
restriction protocols in such experiments.  
9.2. Effects of acute dopaminergic treatment on motor and non-motor 
function 
Acute L-DOPA is known to affect motor and non-motor behaviour differently. While it 
improves motor symptoms of PD (Birkmayer & Hornykiewicz, 1998; Miyasaki et al, 2002), 
it also interferes with a number of non-motor functions in patients and animal models of PD.  
For example, Decamp & Schneider (2009) demonstrated that acute L-DOPA impairs 
MPTP lesion rhesus monkey‟s performance on a delayed response task which was designed 
to measure executive and attentional function. These findings have since been replicated in 
MPTP lesion macaques (Schneider et al, 2013) and have been hypothesised to be caused by 
overdosing of the frontal cortex, which is less affected by MPTP lesions than the striatum 
(Decamp & Schneider, 2009). Similar effects have been observed in patients. Cools and 
colleagues (2010) compared the performance of PD patients tested on or off dopaminergic 
medication on a delayed response task in which patients were shown visual stimuli that they 
were instructed to recall, immediately followed by visual distractors that were either 
congruent or incongruent with the stimuli. For the majority (87%) of patients, their 
medication consisted of L-DOPA while the remaining patients received dopamine agonists. 
Patients tested off medication were less affected by the presentation of congruent distractors 
than healthy controls, but their performance aligned with that of controls when tested on 
medication (Cools et al, 2007). Hence, dopaminergic medication increased the interfering 
effect of congruent distractors, thereby making patients‟ performance similar to that of 
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healthy participants when tested on medication. The same delayed response task has 
previously been associated with neural activity in the striatum and prefrontal cortex (Cools et 
al, 2007), and it was hypothesised that the effect of PD on performance was due to an 
imbalance between striatal and frontal cortical dopamine levels, which resulted in abnormal 
resistance to distractors (Cools et al, 2010). An interesting study, related to Cools and 
colleagues‟ (2010) hypothesis, was conducted by Keri and colleagues (2013) who described 
the effects of a dopamine agonist and L-DOPA treatment on PD patients‟ ability to recall 
pictures associated, or not associated, with a target letter. Prior to testing, participants were 
told they would be shown a series of photos with different backgrounds and instructed to 
remember a white target letter, that would be superimposed on one of these photos, while 
ignoring and forgetting a black distractor letter that would be superimposed on another photo. 
Immediately after a target letter recall test, patients were shown two photos, of which only 
one had been presented to them during the task, and asked which of the photos they had seen 
before. When on medication, patients were better than healthy controls at identifying photos 
that had been shown at the same time as either the target or distractor letter. Crucially, there 
was no difference between participants‟ ability to identify photos that had been shown in the 
absence of a target or distractor letter, suggesting that the phenomenon was not due to 
enhanced memory per se (Keri et al, 2013). Instead, Keri and colleagues (2013) hypothesised 
that the dopaminergic medication provided an „attentional boost‟ that helped direct attention 
to items associated with a cue. Together, these studies suggest that acute dopaminergic 
medication interferes with PD patients‟ performance on delayed response tasks by affecting 
the stimuli which patients attend to (Cools et al, 2010; Keri et al, 2013). This may sometimes 
impair patients‟ performance by focusing their attention on irrelevant stimuli (e.g. Cools et al, 
2010), and has been hypothesised to be caused by overdosing of the prefrontal cortex 
(Decamp & Schneider, 2009; Cools et al, 2007) 
In addition, acute dopaminergic medication also affects learning. Acute L-DOPA has 
been shown to increase learning from positive feedback while decreasing learning from 
negative feedback (e.g. Cools et al, 2006; Frank et al, 2004). It has also been demonstrated 
that patients tested on medication (a combination of L-DOPA and dopamine agonists) 
perform worse than unmedicated patients in terms of the reversal, but not the acquisition, of a 
discrimination rule (Swainson, et al, 2000). The impairing effect of dopaminergic medication 
(L-DOPA and agonists, with or without a MAO inhibitor) on reversal learning has also been 
demonstrated by other groups (Cools et al, 2001). Performance on reversal learning tasks has 
been shown to rely on the prefrontal cortex, ventral striatum, and orbito-frontal cortex 
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(Kehagia et al, 2010). Because motor symptoms of PD are primarily due to dopamine loss in 
the dorsal striatum, it has been hypothesised that the L-DOPA doses required to replace the 
lost dopamine in the dorsal striatum simultaneously over-stimulate the ventral striatum 
(Cools, 2006). This, in turn, has been hypothesised to increase reward-like signals and 
decrease error-like signals in the ventral striatum, which is believed to hinder learning from 
negative feedback and thereby impair reversal learning (Cools, 2006). Similar to the 
interfering effect of L-DOPA on visual attention, the effect of the drug on learning is thus 
believed to stem from the fact that the doses required to restore dopamine levels in the dorsal 
striatum overdose other, less denervated, structures.   
9.3. Effects of chronic dopaminergic treatment on motor and non-motor 
function  
It has long been known that chronic L-DOPA treatment induces motor side effects in the 
form of dyskinesias and “off” periods (Marsden & Parkes, 1977). However, less is known 
about the effects of long-term dopaminergic treatment on non-motor function.  
One group of side effects that have received a lot of attention are impulse control 
disorders (ICDs) which are defined in the American Psychiatric Association‟s Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV) as being characterised by an inability, or 
severe difficulty, in resisting impulses that will result in negative consequences. The 
prevalence of diagnosed ICDs differs across countries, between approximately one tenth and 
one quarter of PD patients, with the largest study to date (DOMINION study, n=3090) 
reporting a prevalence of 13.6% in North American PD patients. ICDs may occur following 
L-DOPA therapy but are predominantly linked to dopamine agonist use (Weintraub et al, 
2010; Perez-Lloret et al, 2012; Poletti et al, 2013). As many other non-motor effects of 
dopaminergic medication, the development of ICDs has been hypothesised to be due to 
overdosing of the ventral striatum (Voon et al, 2011). In addition, personality traits such as 
novelty seeking and impulsive behaviour are known to increase the risk for ICDs (Voon et al, 
2010) which suggest that ICDs in PD may arise from an interaction between a genetic or 
biological predisposition, and exposure to dopaminergic medication. Furthermore, the type of 
ICD expressed by patients (e.g. hypersexuality versus compulsive shopping) appears to differ 
between men and women (Weintraub et al, 2010) suggesting that cultural or biological 
factors also affect the expression of ICDs.  
While several longitudinal studies on PD patients have been conducted, these have 
revealed little on the long-term effects of L-DOPA on non-motor function. For example, 
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Kulisevsky and colleagues (2000) tested a group of newly diagnosed PD patients with a 
battery of neuropsychological tests both prior to their first dopaminergic medication and 24 
months later. Half of the patients received L-DOPA as a monotherapy throughout the study 
while the remaining half received a dopamine agonist during the first 6 months, after which 
L-DOPA was added to their daily medication and co-administered throughout the remainder 
of the study. Relative to baseline, patients treated with L-DOPA showed decreased 
performance on the Wechsler Adult Intelligence Scale and a verbal learning task at the end of 
the study (Kulisevsky et al, 2000). However, because there was no treatment naive control 
group, it is difficult to infer whether the decrease in performance was due to the 
dopaminergic treatment or disease progression. Furthermore, while one patient developed 
dyskinesia and another patient was reported to show „mild dyskinesia‟ at the end of the study 
the sample size did not allow a comparison between dyskinetic and non-dyskinetic patients, 
and the data was not segmented according to presence of dyskinesia. Considering that 
approximately half of PD patients develop LID after 5 years of L-DOPA treatment (Nutt, 
2005), a longer follow-up time and segmentation of the data according to presence of 
dyskinesia would be needed to determine whether LID onset affected neuropsychological 
performance in Kulivesky and colleagues‟ (2000) study.  
A similar problem is encountered when attempting to infer the effect of chronic        
L-DOPA from other published studies. For example, Relja and colleagues (2006) compared 
neuropsychological test performance of 25 PD patients treated with L-DOPA at two time 
points, 6 months apart. However, while patients had been diagnosed with PD approximately 5 
years prior to the first test session, suggesting that a subsample of the patients would have 
developed LID during or prior to the study, the data was not stratified according to the 
presence of dyskinesias. Hence, while an effect of chronic L-DOPA on non-motor function 
may be present in patients, no clinical studies specifically designed to test this hypothesis 
have to my knowledge been reported. Therefore, based on currently published data it cannot 
be determined whether or not the findings of a LID effect on non-motor behaviour presented 
in Chapters 7 and 8 are representative of a phenomenon also present in PD patients. 
While clinical data is ultimately essential for understanding the relevance of the data 
presented in this thesis to PD patients, there is a theoretical ground for hypothesising that the 
findings will translate to the clinic. The expression of AIMs in the 6-OHDA MFB rat model 
used in the thesis project correlates with molecular markers associated with LID in patients 
such as FosB, prodynorphin, and preproenkephalin (Andersson et al, 1999, Winkler et al, 
2002). The model has also been shown sensitive to the clinically available anti-dyskinetic 
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drug Amantadine (Lundblad et al, 2002; Breger et al, 2013). Hence, while the 6-OHDA 
lesion model does not capture the full PD pathology, it is phenotypically and behaviourally 
similar to the dyskinesia observed in PD patients.  
It is recognised that LID may also be induced in other species, such as mice (e.g. 
Lundblad et al, 2005) and primates (e.g. Bédard et al, 1986), and that these models were 
deliberately not used in this project. It could be argued that a mouse model would be more 
clinically valid as e.g. mice over-expressing alpha synuclein (Masliah et al, 2000) or 
transgenic LRRK2 mice (Li et al, 2009) bear similarities to the human condition that are not 
captured in the 6-OHDA rat model. However, the rat model was preferred because (i) the 
primary aim with the presented experiments was to test the hypothesis that LID induction 
affects non-motor function, rather than studying the interaction between chronic L-DOPA 
and genetic predispositions for PD, and (ii) the rat model has been more extensively studied, 
for example in terms of the altered synaptic plasticity associated with PD and LID (Picconi et 
al, 2002). In terms of primate models, it is recognised that these, due to their closer 
evolutionary relationship with humans, are better preclinical models than the 6-OHDA rat. 
However, due to the ethical implications and the high cost involved in primate research, these 
studies are restricted in terms of the number of animals that may be utilised in individual 
experiments. If a primate model of PD and LID had been used, it would thus not have been 
possible to conduct the large scale experiments that were required to include the necessary 
experimental and control groups in this project.  
 While it is hypothesised that the findings presented here will translate to patients it is 
also recognised that this requires much further testing. Ultimately, to test the hypothesis it 
will be necessary to conduct clinical studies that compare neuropsychological performance of 
dyskinetic and non-dyskinetic PD patients who are matched on other disease parameters, 
socio-demographic parameters, and preferably also their medication. When comparing such 
cohorts it will be crucial to utilise an appropriate neuropsychological test. One task of interest 
could be the Wisconsin Card Sorting Task in which participants are required to match test 
cards to reference cards depending on their characteristics (e.g. colour, shape, or number of 
stimuli present on the cards). Participants receive feedback after each trial, indicating whether 
they matched the test card correctly. Once a participant has learned the rule governing the 
matching of test and reference cards, the rule is changed without prior notification and the 
participant is required to use the feedback provided after each trial to learn the new matching 
rule. In healthy participants, data from fMRI experiments have demonstrated that both the 
prefrontal cortex and the basal ganglia are activated when participants receive feedback 
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indicating that a new rule should be learned and during subsequent trials in which participants 
apply the new rule (Monchi et al, 2001). With preclinical studies showing impaired 
depotentiation in the cortico-striatal circuitry after LID onset (Picconi et al, 2003) as well as a 
role of depotentiation in extinction (Farinelli et al, 2003) which reflects relearning of a 
previously learned association (Myers & Davis, 2002), it is possible that the Wisconsin Card 
Sorting Task could be sensitive to the non-motor effects of LID induction and therefore 
useful in clinical studies designed to test the effect of LID onset on patients‟ non-motor 
function.  
9.4. LID: more than just a motor side effect?  
The findings presented in this thesis suggest that the effects of chronic L-DOPA extend 
beyond merely inducing motor side effects to also affect non-motor function. The 
phenomenon was present both following overnight withdrawal (Experiment 10), which is the 
withdrawal period used to study “off” behaviour in clinical studies (e.g. Cools et al, 2001; 
Kulisevsky et al, 1996), and following several weeks of L-DOPA withdrawal (Chapter 7). 
Hence, unlike dyskinesias, the effect was observed even after L-DOPA treatment ceased, 
suggesting that the reported phenomenon may be of a chronic nature. Should the 
phenomenon be replicated in clinical studies it will raise the question of whether or not 
patients will prefer L-DOPA to other anti-Parkinsonian treatments that are less effective in 
treating motor symptoms, but that hold a lower risk of inducing non-motor side effects. 
Furthermore, it will suggest a greater need for anti-dyskinetic drugs that do not only reduce 
the expression of dyskinesias but that prevent the molecular and cellular changes associated 
with the onset of LID. The only clinically available anti-dyskinetic drug today is the NMDA 
antagonist Amantadine. While successfully reducing the severity of AIMs exhibited by 
patients (e.g. Sawada et al, 2010) it is not indicated for the prevention of LID onset. If, as 
hypothesised, it is the pathological changes associated with the onset of LID that underlies 
the non-motor deficit demonstrated in Chapters 7 and 8, Amantadine is thus unlikely to 
alleviate the non-motor effects of chronic L-DOPA treatment.  
9.5. Conclusions  
This thesis demonstrated a dissociation between the acute and chronic effects of 
dopaminergic medication in the rat 6-OHDA model of PD. The main finding was a decreased 
LCRT task performance in lesion rats that developed LID following L-DOPA treatment, but 
not in rats that remained non-dyskinetic. This is to my knowledge the first data to show an 
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effect of LID onset on non-motor function. As such, the data suggest that the neurobiological 
changes associated with LID onset affect a wider range of behaviour than previously 
recognised, and therefore extends our understanding of the side effects induced by L-DOPA 
treatment. It is hoped that future experiments will further investigate this phenomenon: both 
by identifying the exact neuropsychological mechanisms underlying the LID-induced deficit, 
and by determining whether non-motor effects of LID onset are also observed in patients.    
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Appendix I 
The following section provides an overview of the statistical analysis supporting the decision 
to pool the intact groups in section 7.4. The data were analysed using a repeated measures 
ANOVA with Day as within subject factor and Group as a between subject factor. Significant 
between-subject differences were analysed using a Scheffe post-hoc test. The analysis 
included six experimental groups (intact /lesion with saline/L-DOPA/bromocriptine).  
Usable trials: There was an increase in the number of usable trials made by intact rats 
over the five days of testing, while the number of usable trials made by lesion rats decreased 
over the same period of testing (Day: F4,316=117.06, p<0.01; Day x Group: F20,316=2.84, 
p<0.001: Simple Effect: min.F4,76=5.66, p<0.001). However, there was no difference between 
the number of usable trials made by intact rats treated with saline, L-DOPA, or bromocriptine 
(Group: F5,79=17.46, p<0.001).  
Reaction time: While there were some fluctuations in the recorded reaction time over 
the course of testing this was independent of lesion and drug treatments, as well as of what 
side the CS was presented on (Day: F4,316=3.39, p<0.05; Day x Group: F20,316=1.31, n.s.; Side 
x Day: F4,316=1.71, n.s.; Side x Day x Group: F20,316=1.16, n.s.; Side: F1,79=2.47, n.s.; Side x 
Group: F5,79=0.75, n.s.). There was no difference in the ipsilateral reaction time exhibited by 
the six groups (Group: F5,79=0.93, n.s.) 
Movement time: Lesion rats were slowed than intact controls, but there was no 
difference in the performance of the three intact groups (Group: F5,79=12.29, p<0.01). Lesion 
rats treated with bromocriptine showed longer movement times when responding to 
contralateral than ipsilateral cues on all days of testing apart from day 4, while lesion rats 
treated with L-DOPA and saline showed an ipsilateral bias on all, apart from the second and 
fourth, day of testing. Intact rats treated with bromocriptine took marginally longer to 
respond to ipsilateral than contralateral cues on the first day of testing but did not show a bias 
on any of the remaining testing days. No ipsilateral bias was observed in intact rats treated 
with saline or L-DOPA (Side x Day x Group: F20,316=2.21, p<0.01; Simple Effect: 
min.F1,79=4.20, p<0.05).  
Accuracy: While all intact groups were more accurate when responding to 
contralateral than ipsilateral cues on the first day of testing, they did not exhibit a side bias on 
any of the other testing days. Conversely, lesion rats treated with saline or L-DOPA were 
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consistently less accurate when responding to contralateral than ipsilateral cues. A similar 
ipsilateral bias in responding was observed in lesion rats treated with bromocriptine on all 
apart from the first day of testing (Side x Day x Group: F20,316=7.55, p<0.001; Simple Effect: 
min.F1,79=5.10, p<0.05). Overall there was a difference between the accuracy of intact and 
lesion groups, but not difference in the accuracy with which the three intact groups responded 
to cues (F5,79=16.19, p<0.001). 
Appendix II 
The following section provides an overview of the statistical analysis supporting the decision 
to pool the intact groups in section 8.2.The data was analysed using a repeated measures 
ANOVA with Day as a within-subject factor and Lesion, TAT/SDV and L-DOPA/saline as 
between-subject factors. 
Usable trials: There was no difference in the usable trials made by rats treated with 
the TAT2A peptide or the inactive SDV vehicle (TAT: F1,81=0.14, n.s.; TAT x Lesion: F 
1,81=1.23, n.s.; TAT x L-DOPA: F 1,81=0.18, n.s.; TAT x Lesion x L-DOPA: F 1,81=0.25, n.s.; 
TAT x Day: F 4,324=0.90, n.s.) 
Ipsilateral reaction time: The reaction time observed following presentation of cues 
ipsilaterally to the lesion was not similar for all groups (TAT: F1,81=0.50, n.s.; TAT x Lesion: 
F1,81=2.06, n.s.; TAT x L-DOPA: F1,81=1.34, n.s.; TAT x Lesion x L-DOPA: F1,81= 0.88, n.s.; 
TAT x Day: F 4,324=0.21, n.s.) 
Contralateral reaction time: TAT treatment did not impact on the reaction time 
observed following presentation of contralateral cues (TAT: F1,81=0.69, n.s.; TAT x Lesion: 
F1,81=1.39, n.s.; TAT x L-DOPA: F1,81=1.05, n.s.; TAT x Lesion x L-DOPA: F1,81= 1.32, n.s.; 
TAT x Day: F 4,324=1.78, n.s.). 
Ipsilateral movement time: TAT treatment did not impact on the time taken for rats 
to execute responses to ipsilateral cues (TAT: F1,81=1.00, n.s.; TAT x Lesion: F1,81=0.27, n.s.; 
TAT x L-DOPA: F1,81=0.73, n.s.; TAT x Lesion x L-DOPA: F1,81= 0.76, n.s.; TAT x Day: F 
4,324=0.68, n.s.) 
Contralateral movement time: TAT treatment did not impact on the time taken for 
rats to execute responses to contralateral cues (TAT: F1,81=0.32, n.s.; TAT x Lesion: 
F1,81=0.00, n.s.; TAT x L-DOPA: F1,81=0.08, n.s.; TAT x Lesion x L-DOPA: F1,81=0.06, n.s.; 
TAT x Day: F 4,324=0.75, n.s.) 
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Ipsilateral accuracy: The accuracy with which rats responded to cues presented 
ipsilateral to the lesion was not affected by TAT2A treatment (TAT: F1,81=0.78, n.s.; TAT x 
Lesion: F1,81: 3.39, n.s.; TAT x L-DOPA: F1,81=0.77, n.s.; TAT x Lesion x L-DOPA: 
F1,81=0.21, n.s.; TAT x Day: F 4,324=0.50, n.s.) 
Contralateral accuracy: The accuracy with which rats responded to cues presented 
contralateral to the lesion was not affected by TAT2A treatment (TAT: F1,81=0.06, n.s.; TAT 
x Lesion: F1,81=0.57, n.s.; TAT x L-DOPA: F1,81=0.51, n.s.; TAT x Lesion x L-DOPA: 
F1,81=0.15, n.s.; TAT x Day: F 4,324=1.19, n.s.). 
 
 
 
 
 
 
 
 
